onvo-10q_20181231.htm

0001564590-19-002298.txt : 20190207 0001564590-19-002298.hdr.sgml : 20190207 20190207163326 ACCESSION NUMBER: 0001564590-19-002298 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 51 CONFORMED PERIOD OF REPORT: 20181231 FILED AS OF DATE: 20190207 DATE AS OF CHANGE: 20190207 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ORGANOVO HOLDINGS, INC. CENTRAL INDEX KEY: 0001497253 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 271488943 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35996 FILM NUMBER: 19575572 BUSINESS ADDRESS: STREET 1: 6275 NANCY RIDGE DRIVE STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-224-1000 MAIL ADDRESS: STREET 1: 6275 NANCY RIDGE DRIVE STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: REAL ESTATE RESTORATION & RENTAL, INC. DATE OF NAME CHANGE: 20100722 10-Q 1 onvo-10q_20181231.htm FORM 10-Q onvo-10q_20181231.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2018

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-35996

Organovo Holdings, Inc.

(Exact name of registrant as specified in its charter)

Delaware		27-1488943
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

6275 Nancy Ridge Drive, Suite 110, San Diego, CA 92121		(858) 224-1000
(Address of principal executive offices and zip code)		(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☒

Non-accelerated filer	☐	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of February 1, 2019, a total of 119,493,341 shares of the registrant’s Common Stock, $0.001 par value, were outstanding.

ORGANOVO HOLDINGS, INC.

INDEX

PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements	3
	Condensed Consolidated Balance Sheets as of December 31, 2018 (Unaudited) and March 31, 2018	3
	Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss for the Three and Nine Months Ended December 31, 2018 and 2017	4
	Unaudited Condensed Consolidated Statement of Stockholders’ Equity for the Nine Months Ended December 31, 2018	5
	Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended December 31, 2018 and 2017	6
	Notes to Unaudited Condensed Consolidated Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	20
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	26
Item 4.	Controls and Procedures	26
PART II. OTHER INFORMATION
Item 1.	Legal Proceedings	28
Item 1A.	Risk Factors	28
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	28
Item 3.	Defaults Upon Senior Securities	28
Item 4.	Mine Safety Disclosure	28
Item 5.	Other Information	28
Item 6.	Exhibits	29

PART I—FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

Organovo Holdings, Inc.

Condensed Consolidated Balance Sheets

(in thousands except for share data)

	December 31, 2018			March 31, 2018
	(Unaudited)
Assets
Current Assets
Cash and cash equivalents	$	35,224		$	43,726
Accounts receivable		547			883
Grant receivable		124			145
Inventory, net		1,049			842
Prepaid expenses and other current assets		527			1,164
Total current assets		37,471			46,760
Fixed assets, net		1,946			2,788
Restricted cash		127			127
Other assets, net		141			152
Total assets	$	39,685		$	49,827
Liabilities and Stockholders’ Equity
Current Liabilities
Accounts payable	$	647		$	464
Accrued expenses		2,156			3,341
Deferred revenue		580			668
Deferred rent		27			185
Total current liabilities		3,410			4,658
Deferred revenue, net of current portion		—			19
Deferred rent, net of current portion		600			564
Total liabilities		4,010			5,241
Commitments and Contingencies
Stockholders’ Equity
Common stock, $0.001 par value; 200,000,000 shares authorized, 117,769,919 and 111,032,957 shares issued and outstanding at December 31, 2018 and March 31, 2018, respectively		118			111
Additional paid-in capital		289,329			278,595
Accumulated deficit		(253,772	)		(234,120	)
Total stockholders’ equity		35,675			44,586
Total Liabilities and Stockholders’ Equity	$	39,685		$	49,827

The accompanying notes are an integral part of these condensed consolidated financial statements.

Organovo Holdings, Inc.

Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss

(in thousands except share and per share data)

	Three Months Ended			Three Months Ended			Nine Months Ended			Nine Months Ended
	December 31, 2018			December 31, 2017			December 31, 2018			December 31, 2017
Revenues
Products and services	$	670		$	832		$	1,709		$	2,722
Collaborations and licenses		43			61			128			367
Grants		66			260			574			409
Total Revenues		779			1,153			2,411			3,498
Cost of revenues		136			192			381			747
Research and development expenses		3,782			4,005			10,348			13,982
Selling, general and administrative expenses		3,387			4,865			11,794			16,457
Total costs and expenses		7,305			9,062			22,523			31,186
Loss from Operations		(6,526	)		(7,909	)		(20,112	)		(27,688	)
Other Income (Expense)
Gain (loss) on fixed asset disposals		(65	)		—			(63	)		—
Interest income		192			118			526			334
Total Other Income		127			118			463			334
Income Tax Expense		—			—			(3	)		—
Net Loss	$	(6,399	)	$	(7,791	)	$	(19,652	)	$	(27,354	)
Currency Translation Adjustment	$	—		$	(2	)	$	—		$	(2	)
Comprehensive Loss	$	(6,399	)	$	(7,793	)	$	(19,652	)	$	(27,356	)
Net loss per common share—basic and diluted	$	(0.06	)	$	(0.07	)	$	(0.17	)	$	(0.26	)
Weighted average shares used in computing net loss per common share—basic and diluted		116,256,561			107,345,623			113,991,794			106,107,721

The accompanying notes are an integral part of these condensed consolidated financial statements.

Organovo Holdings, Inc.

Unaudited Condensed Consolidated Statement of Stockholders’ Equity

(in thousands)

					Additional						Accumulated Other
	Common Stock				Paid-in			Accumulated			Comprehensive
	Shares		Amount		Capital			Deficit			Income (Loss)		Total
Balance at March 31, 2018		111,033	$	111	$	278,595		$	(234,120	)	$	—	$	44,586
Stock option exercises		622		1		49			—			—		50
Issuance of common stock under employee and director stock option, RSU, and purchase plans		554		1		(136	)		—			—		(135	)
Issuance of common stock from public offering		5,561		5		6,910			—			—		6,915
Stock-based compensation expense		—		—		3,911			—			—		3,911
Net loss		—		—		—			(19,652	)		—		(19,652	)
Balance at December 31, 2018 (Unaudited)		117,770	$	118	$	289,329		$	(253,772	)	$	—	$	35,675

The accompanying notes are an integral part of these condensed consolidated financial statements.

Organovo Holdings, Inc.

Unaudited Condensed Consolidated Statements of Cash Flows

(in thousands)

	Nine Months Ended			Nine Months Ended
	Decemeber 31, 2018			December 31, 2017
Cash Flows From Operating Activities
Net loss	$	(19,652	)	$	(27,354	)
Adjustments to reconcile net loss to net cash used in operating activities:
(Gain) loss on disposal of fixed assets		63			—
Depreciation and amortization		824			962
Stock-based compensation		3,911			5,600
Increase (decrease) in cash resulting from changes in:
Accounts receivable		336			(527	)
Grants receivable		21			(260	)
Inventory		(207	)		(55	)
Prepaid expenses and other assets		637			253
Accounts payable		183			(719	)
Accrued expenses		(1,185	)		(1,293	)
Deferred revenue		(107	)		260
Deferred rent		(122	)		(113	)
Net cash used in operating activities		(15,298	)		(23,246	)
Cash Flows From Investing Activities
Purchases of fixed assets		(37	)		(90	)
Proceeds from disposals of fixed assets		3			—
Purchases of intangible assets		—			(70	)
Net cash used in investing activities		(34	)		(160	)
Cash Flows From Financing Activities
Proceeds from issuance of common stock and exercise of warrants, net		6,916			7,243
Employee taxes paid related to net share settlement of equity awards		(136	)		(74	)
Proceeds from exercise of stock options		50			826
Net cash provided by financing activities		6,830			7,995
Effect of currency exchange rate changes on cash and cash equivalents		—			(2	)
Net decrease in cash, cash equivalents, and restricted cash		(8,502	)		(15,413	)
Cash, cash equivalents, and restricted cash at beginning of period		43,853			62,878
Cash, cash equivalents, and restricted cash at end of period	$	35,351		$	47,465
Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	$	35,224		$	47,338
Restricted cash		127			127
Total cash, cash equivalent and restricted cash	$	35,351		$	47,465
Supplemental Disclosure of Cash Flow Information:
Income taxes paid	$	3		$	23

The accompanying notes are an integral part of these condensed consolidated financial statements.

Organovo Holdings, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

Note 1. Description of Business

Nature of operations

Organovo Holdings, Inc., (“Organovo Holdings,” and collectively with its subsidiaries, “the Company”) is a biotechnology company pioneering a unique set of therapeutic and drug profiling capabilities based on its revolutionary ability to 3D bioprint liver tissues that emulate human biology and disease. The Company is developing its in vivo liver tissues to treat end-stage liver disease and a select group of life-threatening, orphan diseases, for which there are limited treatment options other than organ transplantation. The Company’s program focused on an orphan disease known as Alpha-1-antitrypsin deficiency (“A1AT”), received the U.S. Food and Drug Administration’s (“FDA”) orphan drug designation in December 2017. The Company’s first Investigational New Drug Application (“IND”) filing is targeted for calendar-year 2020. Organovo Holdings is also capitalizing on its foundational ability to characterize highly specialized human cells and to build robust, functional human tissues by creating a range of novel in vitro disease modeling platforms, including a broad set of non-alcoholic fatty liver disease (“NAFLD”) and non-alcoholic steatohepatitis (“NASH”) conditions.

Except where specifically noted or the context otherwise requires, references to “Organovo Holdings,” “the Company,” “we,” “our,” and “us” in these notes to the condensed consolidated financial statements refers to Organovo Holdings, Inc. and its wholly owned subsidiaries, Organovo, Inc., Samsara Sciences, Inc., and Organovo U.K., Ltd. In March 2018, the U.K. operations were combined with Organovo, Inc.’s operations.

Note 2. Summary of Significant Accounting Policies

Basis of presentation and principles of consolidation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not necessarily include all information and notes required by GAAP for complete financial statements. The balance sheet at March 31, 2018 is derived from the Company’s audited balance sheet at that date.

The condensed consolidated financial statements include the accounts of Organovo Holdings and its wholly owned subsidiaries. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal and recurring, necessary for a fair statement of the Company’s financial position, results of operations, stockholders’ equity and cash flows. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2018, as filed with the Securities and Exchange Commission (“SEC”). Operating results for interim periods are not necessarily indicative of operating results for the Company’s fiscal year ending March 31, 2019.

Reclassification of prior year presentation

As a result of the adoption of the new accounting standard associated with clarifying presentation and classification in the statement of cash flows, certain reclassifications have been made to the prior period financial statements to conform with the current period presentation. These reclassifications did not have any effect on previously reported cash flows, net loss, or financial position.

Liquidity

As of December 31, 2018, the Company had cash and cash equivalents of approximately $35.2 million and restricted cash of $0.1 million. The restricted cash was pledged as collateral for two letters of credit the Company is required to maintain as security deposits under the terms of the leases of its facilities. The Company had an accumulated deficit of approximately $253.8 million at December 31, 2018. The Company also had negative cash flows from operations of approximately $15.3 million during the nine months ended December 31, 2018.

Through December 31, 2018, the Company has financed its operations primarily through the sale of convertible notes, warrants, the private placement of equity securities, the sale of common stock through public and at-the-market (“ATM”) offerings, and through revenue derived from product and research service-based agreements, collaborative agreements, licenses, and grants. During the nine months ended December 31, 2018, the Company issued 5,560,514 shares of its common stock through its ATM facility and received net proceeds of approximately $6.9 million.

Based on its current operating plan and available cash resources, the Company has sufficient resources to fund its business for at least the next twelve months from the financial statement issuance date.

The Company will need additional capital to further fund the development of its therapeutic tissues focusing on critical unmet medical needs in the liver disease space and to fund the development and commercialization of its proprietary platform to produce and study living tissues that emulate key aspects of human biology and disease that can be used to facilitate drug discovery and development. The Company intends to cover its future operating expenses through cash on hand, through revenue derived from research service agreements, product sales, collaborative agreements, grants and license payments, and through the issuance of additional equity or debt securities. Depending on market conditions, the Company cannot be sure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to it or to its stockholders.

Having insufficient funds may require the Company to delay, scale back, or eliminate some or all of its development programs or relinquish rights to its technology on less favorable terms than it would otherwise choose. Failure to obtain adequate financing could eventually adversely affect its ability to operate as a going concern. If the Company continues to raise additional funds from the issuance of equity securities, there will be substantial dilution to its existing stockholders. If the Company raises additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict its ability to operate its business.

Use of estimates

The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Actual results could differ from those estimates. Significant estimates used in preparing the condensed consolidated financial statements include those assumed in revenue recognition, the valuation of stock-based compensation expense, and the valuation allowance on deferred tax assets. On an ongoing basis, management reviews these estimates and assumptions.

Revenue recognition

The Company generates revenues from payments received from research service agreements, product sales, collaborative agreements with partners including pharmaceutical and biotechnology companies and academic institutions, licenses, and grants from the National Institutes of Health (“NIH”) and private not-for-profit organizations.

Billings to customers or payments received from customers are included in deferred revenue on the balance sheet until all revenue recognition criteria are met. As of December 31, 2018 and March 31, 2018, the Company had approximately $580,000 and $687,000, respectively, in deferred revenue related to its research service agreements, collaborative agreements, and licenses within the scope of Topic 606. In the nine months ended December 31, 2018 the Company recognized revenue on approximately $136,000 that had been recorded as deferred revenue at March 31, 2018.

Effective April 1, 2018, the Company adopted the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), Topic 606, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, the Company recognizes revenue when (or as) the promised services are transferred to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those services. To determine revenue recognition for arrangements the Company concludes are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) the performance obligation(s) are satisfied. At contract inception, the Company assesses the goods or services promised within each contract, assesses whether each promised good or service is distinct and identifies those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

Service revenues

The Company’s service-based business, Organovo, Inc., utilizes its NovoGen® bioprinting platform to provide customers access to its highly specialized tissues that model human biology and disease, and to in vitro testing services based on that technology. These contracts with customers contain multiple performance obligations including: (i) bioprinting tissues for the customer, (ii) reporting the results of tests performed on the printed tissues pursuant to the agreed upon work plan through exposure of the tissue to various factors (including the customer’s proprietary compound), and (iii) delivering specific byproduct study materials, which are satisfied, respectively, at each of the following points in time: (i) upon completion of manufacturing of the bioprinted tissue for the customer, (ii) upon delivery of the report on tests performed on the tissue, and (iii) upon making certain study materials generated from the aforementioned testing process available to the customer. The customer does not have access or control of any performance obligation prior to the point in time of full completion of the corresponding performance satisfying event as defined above. Furthermore, although the service can be customized for each customer, it is not so highly customized as to not have an alternative use either to other customers or to the Company without significant economic consequences or rework. Accordingly, the Company’s service-based business utilizes point-in-time recognition under Topic 606.

For service contracts, the Company allocates the transaction price to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. The transaction price for service business contracts is a fixed consideration.

Product sales, net

The Company’s product-based business, Samsara Sciences, Inc., produces high-quality cell-based products for use in Organovo’s 3D tissue manufacturing and for use by life science customers. The Company recognizes product revenue when the performance obligation is satisfied, which is at the point in time the customer obtains control of the Company’s product, typically upon delivery. Product revenues are recorded at the transaction price, net of any estimates for variable consideration under Topic 606. The Company’s process for estimating variable consideration does not differ materially from its historical practices. Variable consideration is estimated using the expected value method which considers the sum of probability-weighted amounts in a range of possible amounts under the contract. Product revenue reflects the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the individual contracts. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results vary materially from the Company’s estimates, the Company will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted.

The Company provides no right of return to its customers except in cases where a customer obtains authorization from the Company for the return. To date, there have been no product returns. The Company will continue to assess its estimates of variable consideration as it accumulates additional historical data and will adjust its estimates accordingly.

Collaborative research, development, and licenses

The Company enters into collaborative agreements with partners that typically include one or more of the following: (i) non-exclusive license fees; (ii) non-refundable up-front fees; (iii) payments for reimbursement of research costs; (iv) payments associated with achieving specific development milestones; and (v) royalties based on specified percentages of net product sales, if any. At the initiation of an agreement, the Company analyzes whether it results in a contract with a customer under Topic 606 or in an arrangement with a collaborator subject to guidance under ASC 808, Collaborative Arrangements (“Topic 808”).

The Company considers a variety of factors in determining the appropriate estimates and assumptions under these arrangements, such as whether the elements are distinct performance obligations, whether there are determinable stand-alone prices, and whether any licenses are functional or symbolic. The Company evaluates each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, non-exclusive license fees, non-refundable upfront fees, and funding of research activities are considered fixed, while milestone payments are identified as variable consideration which must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.

The Company’s collaborative agreements that were not completed at the implementation of Topic 606 on April 1, 2018, consisted of research collaboration and limited technology access licenses. These agreements provide the licensee with a non-exclusive, non-transferable, limited, royalty-free technology license, including access to Organovo’s proprietary bioprinter platform, training, and continued support by means of consumables and consultation throughout the duration of the contract. The Company has determined the intellectual property license is not distinct from the continued support promised under the agreement and is therefore a single combined performance obligation. The Company recognizes revenue for these combined performance obligations over time for the duration of the license period, as the combined performance obligation will not be fully satisfied until the end of the contract.

For the nine months ended December 31, 2018, all collaborations and licenses revenue was within the scope of Topic 606 and recognized accordingly. See “Note 4. Collaborative Research, Development, and License Agreements” for more information on the Company’s collaborative agreements.

Grant revenue

In July 2017, the National Institutes of Health (“NIH”) awarded the Company a “Research and Development” grant totaling approximately $1,657,000 of funding over three years. The Company has concluded this government grant is not within the scope of Topic 606, as government entities do not meet the definition of a “customer” as defined by Topic 606, as there is not considered to be a transfer of control of goods or services to the government entity funding the grant. Additionally, the Company has concluded this government grant does meet the definition of a contribution and is a non-reciprocal transaction, however, Subtopic 958-605, Not-for-Profit-Entities-Revenue Recognition does not apply, as the Company is a business entity and the grant is with a governmental agency.

Revenues from this grant are based upon internal costs incurred that are specifically covered by the grant, plus an additional rate that provides funding for overhead expenses. Revenue is recognized as the Company incurs expenses that are related to the grant. The Company believes this policy is consistent with the overarching premise in Topic 606, to ensure that it recognizes revenues to reflect the transfer of promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services, even though there is no “exchange” as defined in the ASC. The Company believes the recognition of revenue as costs are incurred and amounts become earned/realizable is analogous to the concept of transfer of control of a service over time under ASC 606.

Revenue recognized under this grant was approximately $66,000 and $574,000 for the three and nine months ended December 31, 2018, respectively. Revenue recognized under this grant was approximately $260,000 and $409,000 for the three and nine months ended December 31, 2017, respectively.

Cost of revenues

The Company reported approximately $0.1 million and $0.4 million in cost of revenues for the three and nine months ended December 31, 2018, respectively. The Company reported approximately $0.2 million and $0.7 million in cost of revenues for the three and nine months ended December 31, 2017, respectively. Cost of revenues consists of costs related to manufacturing and delivering product and service revenue.

Net loss per share

Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The weighted-average number of shares used to compute diluted loss per share excludes any assumed exercise of stock options and warrants, shares reserved for purchase under the Company’s 2016 Employee Stock Purchase Plan, the assumed release of restriction of restricted stock units, and shares subject to repurchase as the effect would be anti-dilutive. No dilutive effect was calculated for the three and nine months ended December 31, 2018 or 2017, as the Company reported a net loss for each respective period and the effect would have been anti-dilutive.

Common stock equivalents excluded from computing diluted net loss per share were approximately 15.6 million at December 31, 2018, and 14.0 million at December 31, 2017.

Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies. Unless otherwise stated, the Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its consolidated financial position or results of operations upon adoption.

Adoption of New Accounting Pronouncements

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which supersedes most existing revenue recognition guidance in GAAP, including most industry-specific guidance. The standard requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The new standard was originally effective for public companies for annual reporting periods beginning after December 15, 2016, with no early application permitted. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers, which deferred by one year the effective date for all entities, with application permitted as of the original effective date. The standard allows for either a full retrospective or modified retrospective method of adoption. The Company adopted this standard on its effective date, April 1, 2018, under the modified retrospective method of adoption. Under this method, entities recognize the cumulative impact of applying the new standard at the date of adoption without restatement of prior periods presented. The cumulative effect of applying the new standard to contracts that were not completed as of April 1, 2018 did not have a material impact on the Company’s consolidated financial position, results of operations, or cash flows. The new standard also requires enhanced disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. See “Note 2. Summary of Significant Accounting Policies” for further discussion. Topic 606 supersedes the revenue recognition requirements in ASC Topic 605, Revenue Recognition (“Topic 605”). While results for reporting periods beginning after April 1, 2018 are presented under Topic 606, all prior period amounts are not adjusted and continue to be reported under the accounting standards in effect during these prior periods. The accounting policies for revenue recognition for periods prior to April 1, 2018 are described in “Note 1. Description of Business and Summary of Significant Accounting Policies” of the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2018. Adoption of this ASC did not have a material impact on the Company’s financial statements. Refer to the revenue recognition disclosure above.

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. The standard clarifies the presentation of restricted cash and cash equivalents and requires companies to include restricted cash and cash equivalents in the beginning and ending balances of cash and cash equivalents on the statement of cash flows. The standard also requires additional disclosures to describe the amount and detail of the restriction by balance sheet line item. The new standard was effective for the Company on April 1, 2018. The Company adopted this standard using the retrospective transition method by restating its condensed consolidated statements of cash flows to include restricted cash of $0.1 million in the beginning and ending cash, cash equivalents, and restricted cash balance. Net cash flows for the nine months ended December 31, 2017, did not change as a result of including restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period amounts presented on the statements of cash flows.

In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting, which provides clarity and guidance around which changes to the terms or conditions of a stock-based payment award require an entity to apply modification accounting. The new standard was effective for annual reporting periods beginning after April 1, 2018, and interim periods within those annual reporting periods. The adoption of this guidance had no impact on the Company’s financial statements.

In December 2017, the United States (“U.S.”) enacted the Tax Cuts and Jobs Act (the “2017 Act”), which changes existing U.S. tax law and includes various provisions that are expected to affect public companies. The 2017 Act (i) changes U.S. corporate tax rates, (ii) generally reduces a company’s ability to utilize accumulated net operating losses, and (iii) requires the calculation of a one-time transition tax on certain previously unrepatriated foreign earnings and profits (“E&P”). The 2017 Act will also impact estimates of a company’s deferred tax assets and liabilities. The Company has evaluated the financial statement impact of the 2017 Act and expects significant adjustments to its gross deferred tax assets and liabilities; however, it also expects to record a corresponding offset to its estimated full valuation allowance against its net deferred tax assets, which should result in minimal net effect to its provision for income taxes. In accordance with SEC issued guidance under Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”), the Company anticipates a minimal impact to its financial statements.

Recent Accounting Pronouncements Not Yet Adopted

In February 2016, the FASB issued ASU 2016-02, Leases, which requires an entity to recognize lease assets and lease liabilities on the balance sheet for leases with terms of more than 12 months and to disclose key information about leasing arrangements. This new guidance is effective for the Company on April 1, 2019, with early adoption permitted in any interim or annual period. The Company is currently evaluating the impact that this guidance will have on its financial statements and related disclosures.

In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. These amendments simplify the accounting for certain financial instruments with down round features. The amendments require companies to disregard the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or equity classification. Companies that provide earnings per share (EPS) data will adjust their basic EPS calculation for the effect of the feature when triggered (i.e., when the exercise price of the related equity-linked financial instrument is adjusted downward because of the down round feature) and will also recognize the effect of the trigger within equity. This standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The adoption of this guidance will have no impact on the Company’s financial statements as the Company’s only derivative liabilities were all exercised or expired as of March 31, 2017.

In February 2018, the FASB issued ASU No. 2018-02, Income Statement – Reporting Comprehensive Income (“Topic 220”), which allows stranded tax effects resulting from the Tax Cuts and Jobs Act to be reclassified from accumulated other comprehensive income to retained earnings. The amendment only relates to the reclassification of the income tax effects of the Tax Cuts and Jobs Act; thus, the underlying guidance relating to the effect of a change in tax laws be included in income from continuing operations is not affected. The amendments in Topic 220 are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. This new guidance is effective for the Company on April 1, 2019. The requirements of ASU 2018-02 are not expected to have a significant impact on the Company’s financial statements.

In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting, which aligns the measurement and classification guidance for share-based payment to non-employees with the guidance for share-based payments to employees. Under the new guidance, the measurement period for equity-classified non-employee awards will be fixed at the grant date. This update is effective for annual periods beginning after December 15, 2018, and interim periods within those periods and early adoption is permitted. This new guidance is effective for the Company on April 1, 2019. The requirements of ASU 2018-07 are not expected to have a significant impact on the Company’s financial statements.

In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606, which provides guidance on whether certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606. The amendments in this update provide more comparability in the presentation of revenue for certain transactions between collaborative arrangement participants. The key improvements to GAAP for collaborative arrangements resulting from this amendment are to (i) clarify that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit-of-account, (ii) add unit-of-account guidance in Topic 808 to align with the guidance in Topic 606, and (iii) require that in a transaction with a collaborative arrangement participant that is not directly related to sales to third parties, presenting the transaction together with revenue recognized under Topic 606 is precluded if the collaborative arrangement participant is not a customer. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years with early adoption permitted. This new guidance is effective for us on April 1, 2020. The Company is currently evaluating the impact that this guidance will have on its financial statements.

Note 3. Stockholders’ Equity

Stock-based compensation expense and valuation information

Stock-based awards include (i) stock options and (ii) restricted stock units under the 2012 Equity Incentive Plan (“2012 Plan”), (iii) stock options, (iv) restricted stock units, and (v) performance-based restricted stock units under an Incentive Award Performance-Based Restricted Stock Unit Agreement, and (vi) rights to purchase stock under the 2016 Employee Stock Purchase Plan (“ESPP”). The Company calculates the grant date fair value of all stock-based awards in determining the stock-based compensation expense.

Stock-based compensation expense for all stock-based awards consists of the following (in thousands):

	Three Months Ended		Three Months Ended		Nine Months Ended		Nine Months Ended
	December 31, 2018		December 31, 2017		December 31, 2018		December 31, 2017
Research and development	$	249	$	210	$	679	$	925
General and administrative	$	1,109	$	1,040	$	3,232	$	4,675
Total	$	1,358	$	1,250	$	3,911	$	5,600

The total unrecognized compensation cost related to unvested stock option grants as of December 31, 2018 was approximately $8,315,000 and the weighted average period over which these grants are expected to vest is 2.92 years.

The total unrecognized compensation cost related to unvested restricted stock units (not including performance-based restricted stock units) as of December 31, 2018 was approximately $3,660,000, which will be recognized over a weighted average period of 2.67 years.

The total unrecognized compensation cost related to unvested performance-based restricted stock units as of December 31, 2018 was approximately $144,000, which will be recognized over a weighted average period of 4.31 years.

The total unrecognized stock-based compensation cost related to unvested employee stock purchase plan shares as of December 31, 2018 was approximately $6,000, which will be recognized over a period of 2 months.

The Company uses the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method. The fair value of stock options was estimated at the grant date using the following weighted average assumptions:

	Three Months Ended			Three Months Ended			Nine Months Ended			Nine Months Ended
	December 31, 2018			December 31, 2017			December 31, 2018			December 31, 2017
Dividend yield		—			—			—			—
Volatility		73.07	%		80.71	%		72.99	%		76.86	%
Risk-free interest rate		2.79	%		2.15	%		2.75	%		1.81	%
Expected life of options	6 years			6 years			6 years			6 years
Weighted average grant date fair value	$	0.67		$	1.04		$	0.84		$	1.73

The assumed dividend yield was based on the Company’s expectation of not paying dividends in the foreseeable future. Considering the expected life of these options, the Company determined that a blend of historical volatility and implied volatility of comparable companies whose share prices are publicly available is more reflective of market conditions and a better indicator of expected volatility than using purely Company-specific historical volatility. The risk-free interest rate assumption was based on U.S. Treasury rates. The weighted average expected life of options was estimated using the average of the contractual term and the weighted average vesting term of the options. Certain options granted to consultants are subject to variable accounting treatment and are required to be revalued until vested.

The fair value of each restricted stock unit and performance-based restricted stock unit is recognized as stock-based compensation expense over the vesting term of the award. The fair value is based on the closing stock price on the date of the grant.

The Company uses the Black-Scholes valuation model to calculate the fair value of shares issued pursuant to the Company’s ESPP. Stock-based compensation expense is recognized over the purchase period using the straight-line method. The fair value of ESPP shares was estimated at the purchase period commencement date using the following assumptions:

	Three Months Ended			Three Months Ended			Nine Months Ended		Nine Months Ended
	December 31, 2018			December 31, 2017			December 31, 2018		December 31, 2017
Dividend yield		—			—			—		—
Volatility		80.23	%		43.03	%	61.35-80.23%		43.03 - 74.70%
Risk-free interest rate		2.29	%		1.10	%	1.85-2.29%		0.79 - 1.10%
Expected term	6 months			6 months			6 months		6 months
Grant date fair value	$	0.45		$	0.52		$0.30 - $0.45		$0.52 - $1.04

The assumed dividend yield was based on the Company’s expectation of not paying dividends in the foreseeable future. For the first full year of ESPP offering periods, beginning September 1, 2016, the Company determined that a blend of historical volatility and implied volatility of comparable companies whose share prices are publicly available was more reflective of market conditions and a better indicator of expected volatility than using purely Company-specific historical volatility. As of September 1, 2017 and the beginning of the second year of ESPP offering periods, the Company is using the Company-specific historical volatility rate as the 6-month historical volatility is now a better indicator of expected volatility. The risk-free interest rate assumption was based on U.S. Treasury rates. The expected life is the 6-month purchase period.

Preferred stock

The Company is authorized to issue 25,000,000 shares of preferred stock. There are no shares of preferred stock currently outstanding, and the Company has no current plans to issue shares of preferred stock.

Common stock

In December 2014, the Company entered into an equity offering sales agreement (the “2014 Sales Agreement”) with an investment banking firm. In July 2016, the Company registered the sale of up to $26.6 million of common stock under the 2014 Sales Agreement pursuant to its shelf registration statement on Form S-3 (File No. 333-202382) filed with the SEC on February 27, 2015 (the “2015 Shelf”) that expired on March 17, 2018. Prior to its expiration, the Company sold an aggregate of 7,304,286 shares of common stock in at-the-market offerings under the 2014 Sales Agreement, with net proceeds of approximately $19.9 million.

The Company has an effective shelf registration statement on Form S-3 (File No. 333-222929) and the related prospectus previously declared effective by the Securities and Exchange Commission (the “SEC”) on February 22, 2018, as supplemented by a prospectus supplement, dated March 16, 2018 (the “2018 Shelf”), that expires on February 22, 2021.

On March 16, 2018, the Company entered into a Sales Agreement (“2018 Sales Agreement”) with H.C. Wainwright & Co., LLC and Jones Trading Institutional Services LLC (each an “Agent” and together, the “Agents”), pursuant to which the Company may offer and sell, from time to time through the Agents, shares of its common stock in “at the market” sales transactions issued pursuant to the Company’s 2018 Shelf.

On July 26, 2018, the Company filed an amendment to its certificate of incorporation to increase the number of authorized shares of common stock to 200,000,000 shares.

During the three and nine months ended December 31, 2018, the Company issued 1,798,384 and 5,560,514 shares of common stock, respectively, for net proceeds of $1.9 million and $6.9 million, respectively, in at-the-market offerings under the 2018 Sales Agreement. During the three and nine months ended December 31, 2017, the Company issued 2,255,541 and 3,793,758 shares of common stock, respectively, for net proceeds of $3.1 million and $7.1 million, respectively, under the 2014 Sales Agreement.

As of December 31, 2018, the Company has sold an aggregate of 5,560,514 shares of common stock in at-the-market offerings under the 2018 Sales Agreement, with net proceeds of approximately $6.9 million. Based on these sales, the Company cannot raise more than an aggregate of $92.9 million in future offerings under the 2018 Shelf, including the $42.9 million remaining available for future issuance through its at-the-market program under the 2018 Sales Agreement. The Company intends to use the net proceeds raised through any at-the-market sales for general corporate purposes, general administrative expenses, and working capital and capital expenditures.

Restricted stock units

On August 15, 2018, in connection with the appointment of a new Chief Medical Officer (“CMO”), the Company allocated 160,714 Restricted Stock Units (“RSUs”) outside of the 2012 Plan. The Company intends for these to be “inducement awards” within the meaning of NASDAQ Marketplace Rule 5635(c)(4). While outside the Company’s 2012 Plan, the terms and conditions of these awards are consistent with awards granted to the Company’s executive officers pursuant to the 2012 Plan.

A summary of the Company’s restricted stock unit (not including performance-based restricted stock units) activity from March 31, 2018 through December 31, 2018 is as follows:

	Number of Shares			Weighted Average Price
Unvested at March 31, 2018		2,035,345		$	2.89
Granted		1,906,402		$	1.18
Vested		(595,163	)	$	2.48
Cancelled / forfeited		(1,080,456	)	$	2.35
Unvested at December 31, 2018		2,266,128		$	1.82

Performance-based restricted stock units

to profitability goal measured as Negative Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) achievable at any point between the grant date and the end of fiscal year 2020 (20 percent). The number of units that could ultimately vest for each tranche ranged from 0 percent to 120 percent of the target amount, not to exceed 208,822 in aggregate. Based on changes to the Company’s strategy, on December 12, 2018, the Board of Directors formally approved an amendment to the vesting criteria for the PBRSUs. As of December 31, 2018, 100% of the Negative Adjusted EBITDA tranche, or 41,764 shares had vested and 8,352 units had been forfeited. Based on the amendment to the vesting criteria, the remaining 158,706 units eligible to vest upon future performance were divided into three separate but equal tranches with independent vesting criteria based on the achievement of certain regulatory milestones. As of December 31, 2018, no tranches are currently expected to vest in fiscal year 2019.

Based on the amended PBRSU vesting terms, the modified grant date fair value of the PBRSUs is $165,000 of which one-third is being recognized over the expected service period of each tranche ending on April 23, 2023. The Company began recording stock-based compensation expense for the initial performance tranches after the August 23, 2017 grant date when the initial financial performance goals were established and approved and has modified its recording of compensation expense in accordance with the amended performance tranches beginning on December 12, 2018.

A summary of the Company’s performance-based restricted stock unit activity from March 31, 2018 through December 31, 2018 is as follows:

	Number of Shares			Weighted Average Price
Unvested at March 31, 2018		200,470		$	1.88
Granted		—		$	—
Vested		(41,764	)	$	1.88
Cancelled / forfeited		—		$	—
Unvested at December 12, 2018		158,706		$	1.88
Impact of modification		—		$	(0.74	)
Unvested at December 31, 2018		158,706		$	1.04

Stock options

On April 24, 2017, in connection with the appointment of a new CEO, the Company granted 2,088,212 stock options outside of the 2012 Plan. The Company intends for these to be “inducement awards” within the meaning of NASDAQ Marketplace Rule 5635(c)(4). While granted outside the Company’s 2012 Plan, the terms and conditions of these awards are consistent with awards granted to the Company’s executive officers pursuant to the 2012 Plan. On August 15, 2018, in connection with the appointment of a new CMO, the Company allocated 974,694 stock options outside of the 2012 Plan. The Company intends for these to be “inducement awards” within the meaning of NASDAQ Marketplace Rule 5635(c)(4). While outside the Company’s 2012 Plan, the terms and conditions of these awards are consistent with awards granted to the Company’s executive officers pursuant to the 2012 Plan. These stock options vest over a four-year period, with a quarter of the option shares vesting on the one-year anniversary of the vesting commencement date and the remaining options shares vesting in equal quarterly installments over the next 12 quarterly periods.

A summary of the Company’s stock option activity from March 31, 2018 to December 31, 2018 is as follows:

	Options Outstanding			Weighted Average Exercise Price		Aggregate Intrinsic Value
Outstanding at March 31, 2018		10,132,312		$	4.01	$	591,082
Options granted		8,024,194		$	1.29	$	—
Options cancelled / forfeited		(4,496,763	)	$	4.21	$	—
Options exercised		(622,192	)	$	0.08	$	561,591
Outstanding at December 31, 2018		13,037,551		$	2.45	$	—
Vested and Exercisable at December 31, 2018		4,481,218		$	4.06	$	—

The weighted average remaining contractual term of options exercisable and outstanding at December 31, 2018 was approximately 5.55 years.

Employee Stock Purchase Plan

The Company reserved 1,500,000 shares of common stock for issuance under the ESPP. The ESPP permits employees after five months of service to purchase common stock through payroll deductions, limited to 15 percent of each employee’s compensation up to the lower of $25,000 per employee per year or 10,000 shares per employee per six-month purchase period. Shares under the ESPP are purchased at 85 percent of the fair market value at the lower of (i) the closing price on the first trading day of the six-month purchase period or (ii) the closing price on the last trading day of the six-month purchase period. The initial offering period commenced in September 2016. At December 31, 2018, there were 1,230,735 shares available for purchase under the ESPP.

Warrants

The following table summarizes warrant activity for the nine months ended December 31, 2018:

	Warrants			Weighted Average Exercise Price
Balance at March 31, 2018		220,000		$	7.19
Granted		—		$	—
Exercised		—		$	—
Cancelled		(75,000	)	$	7.36
Balance at December 31, 2018		145,000		$	7.11

The warrants outstanding at December 31, 2018 are exercisable at prices between $6.84 and $7.62 per share and have a weighted average remaining term of approximately 0.78 years.

Common stock reserved for future issuance

Common stock reserved for future issuance consisted of the following at December 31, 2018:

Common stock warrants outstanding			145,000
Common stock options outstanding and reserved under the 2012 Plan			9,974,645
Common stock reserved under the 2012 Plan			12,452,052
Common stock reserved under the 2016 Employee Stock Purchase Plan			1,230,735
Restricted stock units outstanding under the 2012 Plan			2,105,414
Common stock options outstanding and reserved under the Incentive Award Agreement			3,062,906
Restricted stock units outstanding under the Incentive Award Agreement			160,714
Performance-based restricted stock units outstanding under the Incentive Award Agreement			158,706
Total at December 31, 2018			29,290,172

Note 4. Collaborative Research, Development, and License Agreements

In April 2015, the Company entered into a research collaboration agreement with a third party to develop custom tissue models for fixed fees. No revenue was recorded under this agreement during the three and nine months ended December 31, 2018. Collaboration revenue of $0 and $150,000 was recorded for the three and nine months ended December 31, 2017, respectively. The Company completed its obligations under this agreement in September 2017.

Also in April 2015, the Company entered into a multi-year research agreement with a third party to develop multiple custom tissue models for use in drug development. No revenue was recorded under this agreement during the three and nine months ended December 31, 2018 and 2017.

In June 2016, the Company entered into a collaborative non-exclusive research affiliation with a university medical school and a non-profit medical charity, under which the Company received a one-time grant from the charity towards the placement of a NovoGen® Bioprinter at the university for the purpose of developing bioprinted tissues for skeletal disease research. The Company received an up-front payment in June 2016, which was initially recorded as deferred revenue. No revenue was recorded under this agreement during the three and nine months ended December 31, 2018. Revenue of $18,000 and $53,000 was recorded under this agreement during the three and nine months ended December 31, 2017, respectively. The Company does not anticipate recording any further revenue under this agreement.

In December 2016, the Company signed another collaborative non-exclusive research affiliation with a university medical school and a non-profit medical charity, under which the Company received a one-time grant from the charity towards the placement of a NovoGen® Bioprinter at the university for the purpose of developing an architecturally correct kidney for potential therapeutic applications. The Company received up-front payments in January and March 2017, which were initially recorded as deferred revenue. Revenue of $10,000 and $29,000 was recorded under this agreement for the three and nine months ended December 31, 2018, respectively. Revenue of $10,000 and $29,000 has been recorded under this agreement for the three and nine months ended December 31, 2017, respectively.

In April 2017, the Company signed a collaborative non-exclusive research affiliation with a university, under which the Company received a one-time non-refundable payment toward the placement of a NovoGen® Bioprinter at the university for the purpose of specific research projects mutually agreed upon by the university and the Company in the field of volumetric muscle loss. The Company received an up-front payment in May 2017, which was initially recorded as deferred revenue. Revenue of approximately $14,000 and $43,000 has been recorded under this agreement for the three and nine months ended December 31, 2018, respectively. Revenue of approximately $14,000 and $28,000 has been recorded under this agreement for the three and nine months ended December 31, 2017, respectively, beginning subsequent to the installation of the printer in July 2017. In addition, during April 2017, the Company signed a non-exclusive patent license agreement with the university including an annual fee of $75,000 for each of the two years for the license to the Company patents for research use limited to the field of volumetric muscle loss. The Company received the first annual payment of $75,000 in April 2017 and the second annual payment of $75,000 in April 2018, which were initially recorded as deferred revenue. Revenue of $18,000 and $56,000 has been recorded under this agreement for the three and nine months ended December 31, 2018 and 2017, respectively.

In September 2017, the Company entered into an agreement with a company, under which the Company received a one-time non-refundable payment of $50,000 for limited use of a Company patent in reference to four bioprinters developed and placed at research and academic facilities. The Company recorded no revenue under this agreement for the three and nine months ended December 31, 2018. The Company recorded $0 and $50,000 for the three and nine months ended December 31, 2017, respectively.

Note 5. Commitments and Contingencies

Operating leases

Since July 2012, the Company has leased its main facilities at 6275 Nancy Ridge Drive, San Diego, California 92121. The lease, as amended in 2013, 2015 and 2016, consists of approximately 45,580 rentable square feet containing laboratory, clean room and office space. Monthly rental payments are currently approximately $120,000 per month with 3% annual escalators. The lease for 14,685 of the total rentable square footage was amended to accelerate the expiration date from December 15, 2018 to October 31, 2018. On November 30, 2018, the Company agreed to extend the term for the remainder of the total rentable square footage under the lease from September 1, 2021 to September 1, 2024 in exchange for $500,000 of landlord funded tenant improvements and a rescission of its option to terminate the lease on or after September 1, 2019 with 9 months prior written notice.

The Company also previously leased a second facility from February 1, 2015 through January 31, 2018, consisting of 5,803 rentable square feet of office and lab space located at 6310 Nancy Ridge Drive, San Diego, California 92121, with a monthly rent of approximately $12,000 commencing on April 1, 2015, which increased be 3% each 12-month anniversary of the 36 month lease.

The Company records rent expense on a straight-line basis over the life of the leases and records the excess of expense over the amounts paid as deferred rent. In addition, one of the leases provides for certain improvements made for the Company’s benefit to be funded by the landlord. Such costs, totaling approximately $518,000 to date, have been capitalized as fixed assets and included in deferred rent. As a result of the Company’s lease amendment, which extends the term of the lease from August 31, 2021 to August 31, 2024, the landlord agreed to fund up to $500,000 in additional tenant improvements, which have not been capitalized or included in deferred rent.

Rent expense was approximately $264,000 and $915,000 for the three and nine months ended December 31, 2018, respectively, and $362,000 and $1,094,000 for the three and nine months ended December 31, 2017, respectively.

Future minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of December 31, 2018, are as follows (in thousands):

Fiscal year ended March 31, 2019	$	264,222
Fiscal year ended March 31, 2020		1,073,027
Fiscal year ended March 31, 2021		1,104,070
Fiscal year ended March 31, 2022		1,145,861
Fiscal year ended March 31, 2023		1,183,092
Thereafter		1,732,566
Total	$	6,502,838

Legal matters

In addition to commitments and obligations in the ordinary course of business, the Company may be subject, from time to time, to various claims and pending and potential legal actions arising out of the normal conduct of its business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. Because litigation is inherently unpredictable and unfavorable resolutions could occur, assessing litigation contingencies is highly subjective and requires judgments about future events. When evaluating contingencies, the Company may be unable to provide a meaningful estimate due to a number of factors, including the procedural status of the matter in question, the presence of complex or novel legal theories, and/or the ongoing discovery and development of information important to the matters. In addition, damage amounts claimed in litigation against it may be unsupported, exaggerated or unrelated to possible outcomes, and as such are not meaningful indicators of its potential liability.

The Company regularly reviews contingencies to determine the adequacy of its accruals and related disclosures. During the period presented, the Company has not recorded any accrual for loss contingencies associated with such claims or legal proceedings; determined that an unfavorable outcome is probable or reasonably possible; or determined that the amount or range of any possible loss is reasonably estimable. However, the outcome of legal proceedings and claims brought against the Company is subject to significant uncertainty. Therefore, although management considers the likelihood of such an outcome to be remote, if one or more of these legal matters were resolved against the Company in a reporting period, the Company’s consolidated financial statements for that reporting period could be materially adversely affected.

Note 6. Concentrations

Credit risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of temporary cash investments. The Company maintains cash balances at various financial institutions primarily located within the United States. Accounts at these institutions are secured by the Federal Deposit Insurance Corporation. Balances may exceed federally insured limits. The Company has not experienced losses in such accounts and management believes that the Company is not exposed to any significant credit risk with respect to its cash and cash equivalents.

The Company is also potentially subject to concentrations of credit risk in its revenues and accounts receivable. The Company’s revenues to date have been derived from a relatively small number of customers and collaborators. However, the Company has not historically experienced any accounts receivable write-downs and management does not believe significant credit risk exists as of December 31, 2018.

Note 7. Related Parties

From time to time, the Company will enter into an agreement with a related party in the ordinary course of its business and on terms and conditions it believes are as fair as those it offers and receives from independent third parties. These agreements are ratified by the Company’s Board of Directors or a committee thereof pursuant to its related party transaction policy.

In August 2017, the Company entered into a services agreement with Cirius Therapeutics, Inc. (“Cirius”), an entity for which Robert Baltera, Jr., a director of the Company, serves as Chief Executive Officer. Under this agreement and its amendments, the Company has provided ExVive™ Liver Tissue Services for Cirius in the amount of $281,000 to date, of which $26,000 and $120,000 was recognized as revenue in the three and nine months ended December 31, 2018, respectively. The Company has provided ExVive™ Liver Tissue Services for Cirius in the amount of $44,000 and $94,000 in the three and nine months ended December 31, 2017, respectively.

2018, of which $0 and $2,000 was recognized as revenue in the three and nine months ended December 31, 2018. In November 2018, Viscient executed a Quote to purchase research services from Organovo in the amount of $142,000, which will be recognized in the first quarter of Fiscal 2020. Viscient also purchased primary human cell-based products from our subsidiary, Samsara, in the amount of $91,000 to date, pursuant to the terms of multiple Quotes entered into throughout the fiscal year, of which $88,000 and $91,000 was recognized as revenue in the three and nine months ended December 31, 2018, respectively. There were no sales to Viscient during the three and nine months ended December 31, 2017. In October 2018, Viscient executed a Quote to purchase additional primary human cell-based products from Samsara in the amount of $55,000 which will be recognized in the fourth quarter of Fiscal 2019 or the first quarter of Fiscal 2020.

Note 8. Subsequent Events

Between January 1, 2019 and the date of filing, the Company issued 1,723,422 shares of its common stock pursuant to its ATM facility for net proceeds of approximately $1.8 million.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following management’s discussion and analysis of financial condition and results of operations should be read in conjunction with the Company’s historical consolidated financial statements and the related notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2018. This discussion and analysis contains forward-looking statements, such as statements related to our plans, objectives, expectations and intentions. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions such as “will,” “may,” “could,” “should,” or similar expressions, identify certain of these forward-looking statements. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to risks and uncertainties, including those described in this Quarterly Report on Form 10-Q, as well as the risk factors disclosed in our Annual Report on the Form 10-K for the fiscal year ended March 31, 2018, filed with the Securities and Exchange Commission on May 31, 2018, that could cause our actual results or events to differ materially from those expressed or implied by such forward-looking statements. Except to the limited extent required by applicable law, the Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this Quarterly Report.

Basis of Presentation

The condensed consolidated financial statements included in this Form 10-Q have been prepared in accordance with the Securities and Exchange Commission (the “SEC”) instructions to Quarterly Reports on Form 10-Q. Accordingly, the condensed consolidated financial statements presented elsewhere in this Form 10-Q and discussed below are unaudited and do not contain all the information required by U.S. generally accepted accounting principles (“GAAP”) to be included in a full set of financial statements. The audited financial statements for the year ended March 31, 2018, filed with the SEC on Form 10-K on May 31, 2018 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year.

Overview

We are a biotechnology company pioneering a unique set of therapeutic and drug profiling capabilities based on our revolutionary ability to 3D bioprint liver tissues that emulate human biology and disease. We are developing our in vivo liver tissues to treat end-stage liver disease and a select group of life-threatening, orphan diseases, for which there are limited treatment options other than organ transplantation. Our program focused on an orphan disease known as Alpha-1-antitrypsin deficiency (“A1AT”), received the U.S. Food and Drug Administration’s (“FDA”) orphan drug designation in December 2017. Our first Investigational New Drug Application (“IND”) filing is targeted for calendar-year 2020. We are also capitalizing on our foundational ability to characterize highly specialized human cells and to build robust, functional human tissues by creating a range of novel in vitro disease modeling platforms, including a broad set of non-alcoholic fatty liver disease (“NAFLD”) and non-alcoholic steatohepatitis (“NASH”) conditions.

We aim to generate revenue through product sales and fee-based service agreements and collaborations for our in vitro tissues to provide a portion of the required cash flow to support our therapeutics development program. Our in vitro and in vivo tissues are both built upon the same proprietary 3D bioprinting technology and our highly specialized primary human cells, providing valuable synergies in advancing each of our businesses. We are striving to change the face of medicine by enabling more relevant and translational drug discovery and by launching novel approaches to treating disease.

In the near-term, we will focus on several value-driving inflection points including:

•

Holding a pre-IND meeting with the FDA for our first liver therapeutic tissue indication and commencing IND-enabling studies in calendar-year 2019;

•

Complete proof-of-concept and preclinical studies supporting the use and further development of our therapeutic liver tissue to treat multiple end-stage liver diseases and a select group of life-threatening orphan diseases;

•

Generating revenue to support our therapeutic research mission through client agreements aimed at developing our NASH profiling platform and other applications of our in vitro tissue platform;

•

Growing our Samsara division’s cell-based product revenue, as well as continuing to generate revenue from grant and licensing agreements; and

•

Continuing to present and publish major scientific findings of our tissue platform.

Over the long-term, we will focus on achieving the following key milestones:

•

One or more successful IND submissions, leading to the initiation of Phase I clinical studies involving implantation and functional evaluation of our liver therapeutic tissue patch in target disease patients;

•

Achieving key FDA designations associated with tissue-based approaches that address serious unmet medical needs in end-stage liver disease and orphan disease indications, which can include Regenerative Medicine Advanced Therapy (“RMAT”), Orphan Disease, Fast Track and Breakthrough designations;

•

Achieving operational breakeven profitability for our commercial business by securing significant revenue-generating fee-based service agreements and collaborations and creating business opportunities which may lead to valuable spin-out and/or partnering opportunities; and

•

Continuing academic, partner and internal research programs to generate additional, high value tissue applications and therapeutics pipeline opportunities in other organ and disease areas.

Critical Accounting Policies, Estimates, and Judgments

Our financial statements are prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. We continually evaluate our estimates and judgments, the most critical of which are those related to revenue recognition, stock-based compensation expense, and the valuation allowance on deferred tax assets. We base our estimates and judgments on historical experience and other factors that we believe to be reasonable under the circumstances. Materially different results can occur as circumstances change and additional information becomes known. Besides the estimates identified above that are considered critical, we make many other accounting estimates in preparing our financial statements and related disclosures. All estimates, whether or not deemed critical, affect reported amounts of assets, liabilities, revenues and expenses, as well as disclosures of contingent assets and liabilities. These estimates and judgments are also based on historical experience and other factors that are believed to be reasonable under the circumstances. Materially different results can occur as circumstances change and additional information becomes known, even for estimates and judgments that are not deemed critical.

There have been no significant changes to our critical accounting policies since March 31, 2018, with the exception of changes made upon adoption of ASU No. 2014-09 and the related supplemental ASUs. For a description of critical accounting policies that affect our significant judgments and estimates used in the preparation of our consolidated financial statements, refer to Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Note 1. Description of Business and Summary of Significant Accounting Policies” in the Notes to Consolidated Financial Statements contained in our Annual Report on Form 10-K for the year ended March 31, 2018, filed with the SEC on May 31, 2018. For a description of accounting policy changes resulting from the adoption of ASU No. 2014-09 and the related supplemental ASUs, refer to Note 2 to our condensed financial statements contained in this quarterly report on Form 10-Q.

Results of Operations

Comparison of the three months ended December 31, 2018 and 2017

The following table summarizes our results of operations for the three months ended December 31, 2018 and 2017 (in thousands):

	Three months ended
	December 31,				Increase (decrease)
	2018		2017		$			%
Revenues	$	779	$	1,153	$	(374	)		(32	%)
Cost of revenues	$	136	$	192	$	(56	)		(29	%)
Research and development	$	3,782	$	4,005	$	(223	)		(6	%)
Selling, general and administrative	$	3,387	$	4,865	$	(1,478	)		(30	%)
Other income	$	127	$	118	$	9			8	%

Revenues

For the three months ended December 31, 2018, total revenue was $0.8 million, a decrease of $0.4 million, or 32%, from the three months ended December 31, 2017. Product and service revenues of approximately $0.7 million for the three months ended December 31, 2018 decreased 19% from the prior year period. These decreases were primarily driven by fewer contracts for liver tissue research services, which was partially offset by increased revenue from sales of primary human liver cells and related products. Collaboration revenue and licensing revenue of less than $0.1 million for the three months ended December 31, 2018 decreased 29% from the prior year period due to the absence of revenue from a collaboration agreement that concluded in the prior year. Grant revenue decreased by approximately $0.2 million for the three months ended December 31, 2018 due to a lower level of activity under our National Institutes of Health (“NIH”) grant during the third quarter of fiscal 2019.

Costs and Expenses

Cost of Revenues

Cost of product and service revenues, which reflects expenses related to manufacturing our products and delivering services was $0.1 million for the three months ended December 31, 2018, compared to $0.2 million for the three months ended December 31, 2017. The decrease was primarily due to lower sales from liver tissue research services versus the prior year period.

Research and Development Expenses

The following table summarizes our research and development expenses for the three months ended December 31, 2018 and 2017 (in thousands):

	Three months ended					Three months ended					Increase (decrease)
	December 31, 2018		% of total			December 31, 2017		% of total			$			%
Research and development	$	3,397		89	%	$	3,632		91	%	$	(235	)		(6	%)
Non-cash stock-based compensation		249		7	%		211		5	%		38			18	%
Depreciation and amortization		136		4	%		162		4	%		(26	)		(16	%)
Total research and development expenses	$	3,782		100	%	$	4,005		100	%	$	(223	)		(6	%)

Research and development expenses were approximately $3.8 million, a decrease of $0.2 million, or 6%, from the prior year period. The decrease was primarily due to a $0.2 million decrease in personnel related costs, which was driven by a reduction in staffing from the Company’s restructuring. The Company’s average full-time research and development staff decreased from an average of sixty-five full-time employees for the three months ended December 31, 2017 to an average of forty-six full-time employees for the three months ended December 31, 2018.

Selling, General and Administrative Expenses

The following table summarizes our selling, general and administrative expenses for the three months ended December 31, 2018 and 2017 (in thousands):

	Three months ended					Three months ended					Increase (decrease)
	December 31, 2018		% of total			December 31, 2017		% of total			$			%
Selling, general and administrative	$	2,161		64	%	$	3,671		76	%	$	(1,510	)		(41	%)
Non-cash stock-based compensation		1,109		33	%		1,040		21	%		69			7	%
Depreciation and amortization		117		3	%		154		3	%		(37	)		(24	%)
Total selling, general and administrative expenses	$	3,387		100	%	$	4,865		100	%	$	(1,478	)		(30	%)

For the three months ended December 31, 2018, selling, general and administrative expenses were approximately $3.4 million, a decrease of $1.5 million, or 30%, over the prior year period of approximately $4.9 million. This decrease was largely due to a $0.9 million decrease in personnel related costs, and a $0.4 million decrease in consulting costs. The decrease in personnel related costs was driven by a reduction in staffing from our restructuring. Our average selling, general and administrative headcount was twenty-two full-time employees for the three months ended December 31, 2018 compared to thirty-two full-time employees in the prior year period.

Other Income (Expense)

Other income was approximately $0.1 million for the three months ended December 31, 2018 and consisted of $0.2 million of interest income, which was offset by a $0.1 million loss on disposal of fixed assets. For the three months ended December 31, 2017, other income of approximately $0.1 million consisted primarily of interest income. Interest income increased from the same period of fiscal 2018 due to higher average yields on short-term investment balances.

Comparison of the nine months ended December 31, 2018 and 2017

The following table summarizes our results of operations for the nine months ended December 31, 2018 and 2017 (in thousands):

	Nine months ended
	December 31,				Increase (decrease)
	2018		2017		$			%
Revenues	$	2,411	$	3,498	$	(1,087	)		(31	%)
Cost of revenues	$	381	$	747	$	(366	)		(49	%)
Research and development	$	10,348	$	13,982	$	(3,634	)		(26	%)
Selling, general and administrative	$	11,794	$	16,457	$	(4,663	)		(28	%)
Other income	$	463	$	334	$	129			39	%

Revenues

For the nine months ended December 31, 2018, total revenue was $2.4 million, a decrease of $1.1 million, or 31%, from the nine months ended December 31, 2017. Product and service revenues of approximately $1.7 million for the nine months ended December 31, 2018 decreased 37% from the prior year period. These decreases were primarily driven by fewer contracts for liver tissue research services, which was partially offset by higher sales of primary human liver cells. Collaboration revenue and licensing revenue of $0.1 million for the nine months ended December 31, 2018 decreased 65% from the prior year period due to the absence of revenue from both a collaboration agreement that concluded, and a one-time license fee that was recorded during the second quarter of fiscal 2018. Grant revenue increased by approximately $0.2 million for the nine months ended December 31, 2018 due to a higher level of activity under our National Institutes of Health (“NIH”) grant during the second quarter of fiscal 2019.

Costs and Expenses

Cost of Revenues

Cost of product and service revenues, which reflects expenses related to manufacturing our products and delivering services was $0.4 million for the nine months ended December 31, 2018, compared to $0.7 million for the nine months ended December 31, 2017. The decrease was primarily due to lower sales from liver tissue research services versus the prior year period.

Research and Development Expenses

The following table summarizes our research and development expenses for the nine months ended December 31, 2018 and 2017 (in thousands):

	Nine months ended					Nine months ended					Increase (decrease)
	December 31, 2018		% of total			December 31, 2017		% of total			$			%
Research and development	$	9,250		89	%	$	12,559		90	%	$	(3,309	)		(26	%)
Non-cash stock-based compensation		679		7	%		926		7	%		(247	)		(27	%)
Depreciation and amortization		419		4	%		497		3	%		(78	)		(16	%)
Total research and development expenses	$	10,348		100	%	$	13,982		100	%	$	(3,634	)		(26	%)

Research and development expenses were approximately $10.3 million, a decrease of $3.6 million, or 26%, from the prior year period. The decrease was primarily due to a $2.0 million decrease in personnel related costs, a $1.0 million decrease in lab services and supply costs, a $0.5 million decrease in facilities and allocated overhead costs, and a $0.1 million decrease in all other costs. The decrease in personnel related costs was driven by a reduction in staffing from our restructuring and a reduction of stock-based compensation. Our average full-time research and development staff decreased from an average of seventy-four full-time employees for the nine months ended December 31, 2017 to an average of forty-seven full-time employees for the nine months ended December 31, 2018.

Selling, General and Administrative Expenses

The following table summarizes our selling, general and administrative expenses for the nine months ended December 31, 2018 and 2017 (in thousands):

	Nine months ended					Nine months ended					Increase (decrease)
	December 31, 2018		% of total			December 31, 2017		% of total			$			%
Selling, general and administrative	$	8,158		70	%	$	11,316		69	%	$	(3,158	)		(28	%)
Non-cash stock-based compensation		3,232		27	%		4,675		28	%		(1,443	)		(31	%)
Depreciation and amortization		404		3	%		466		3	%		(62	)		(13	%)
Total selling, general and administrative expenses	$	11,794		100	%	$	16,457		100	%	$	(4,663	)		(28	%)

For the nine months ended December 31, 2018, selling, general and administrative expenses were approximately $11.8 million, a decrease of $4.7 million, or 28%, over the prior year period of approximately $16.5 million. This decrease was largely due to a $3.7 million decrease in personnel related costs, a $1.0 million decrease in consulting costs, and a $0.4 million decrease in all other costs, which offset a $0.4 million increase in facilities and allocated overhead costs. The decrease in personnel related costs was driven by a reduction in staffing from our restructuring. Our average selling, general and administrative headcount was twenty-three full-time employees for the nine months ended December 31, 2018 compared to thirty-five full-time employees in the prior year period.

Other Income (Expense)

Other income was approximately $0.5 million for the nine months ended December 31, 2018 and consisted primarily of interest income. For the nine months ended December 31, 2017, other income of approximately $0.3 million consisted primarily of interest income. Interest income increased from the same period of fiscal 2018 due to higher average yields on short-term investment balances.

Financial Condition, Liquidity and Capital Resources

We have primarily devoted our efforts to developing and commercializing a platform technology to produce and study living tissues that emulate key aspects of human biology and disease, raising capital and building infrastructure.

As of December 31, 2018, we had cash and cash equivalents of approximately $35.2 million and an accumulated deficit of $253.8 million. We also had negative cash flow from operations of $15.3 million during the nine months ended December 31, 2018. At March 31, 2018, we had cash and cash equivalents of approximately $43.7 million and an accumulated deficit of $234.1 million.

At December 31, 2018, we had total current assets of approximately $37.5 million and current liabilities of approximately $3.4 million, resulting in working capital of $34.1 million. At March 31, 2018, we had total current assets of approximately $46.8 million and current liabilities of approximately $4.7 million, resulting in working capital of $42.1 million.

The following table sets forth a summary of the primary sources and uses of cash for the nine months ended December 31, 2018 and 2017 (in thousands):

	Nine months ended
	December 31,
	2018			2017
Net cash (used in) provided by:
Operating activities	$	(15,298	)	$	(23,246	)
Investing activities		(34	)		(160	)
Financing activities		6,830			7,995
Effect of currency exchange rate		—			(2	)
Net decrease in cash, cash equivalents, and restricted cash	$	(8,502	)	$	(15,413	)

Operating activities

Net cash used by operating activities for the nine months ended December 31, 2018 was approximately $15.3 million as compared to $23.2 million used in operating activities for the nine months ended December 31, 2017. This $7.9 million decrease in operating cash usage can be attributed primarily to a $5.9 million improvement in the net loss less depreciation and amortization and stock-based compensation, resulting from the Company’s restructuring and reduction of headcount, combined with a $2.0 million reduction in the change in working capital.

Investing activities

Net cash used in investing activities was less than $0.1 million and $0.2 million for the nine months ended December 31, 2018 and 2017, respectively. This slight decrease can be attributed to reduced capital spending, combined with the absence of an investment in patent related intangible assets during the nine months ended December 31, 2018.

Financing activities

Net cash provided by financing activities was approximately $6.8 million during the nine months ended December 31, 2018 compared to $8.0 million during the nine months ended December 31, 2017. Financing in both periods was driven by the sale of common stock through at-the-market (“ATM”) offerings.

Operations funding requirements

Through December 31, 2018, we have financed our operations primarily through the sale of convertible notes, the private placement of equity securities, the sale of common stock through public and ATM offerings, and from revenue derived from grants and royalty payments, collaborative agreements, product sales and research-based services. Based on our current operating plan and available cash resources, we have sufficient resources to fund our ongoing operations as currently planned for at least the next twelve months.

We will need additional capital to further fund the development of our therapeutic tissues and the implementation of our business plan. We intend to cover our future operating expenses through cash on hand, revenue derived from research service agreements, product sales, grants, and collaborative research agreements and through the issuance of additional equity or debt securities. Depending on market conditions, we cannot be sure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders. We have an effective shelf registration statement on Form S-3 (File No. 333-222929), or the 2018 Shelf, that registered $100,000,000 of common stock, preferred stock, warrants and units, or any combination of the foregoing, which expires on February 22, 2021. On March 16, 2018, we filed a prospectus supplement to the 2018 Shelf to register the sale of up to $50.0 million of shares of our common stock that may be issued in at-the-market offerings pursuant to an equity offering sales agreement we entered into with two investment banking firms as of the same date. During the nine months ended December 31, 2018, we sold 5,560,514 shares of common stock in at-the-market offerings, with net proceeds of approximately $6.9 million under the 2018 Shelf. Based on our use of the 2018 Shelf through December 31, 2018, we can offer an aggregate of $92.9 million in future offerings under the 2018 Shelf, including the $42.9 million remaining available for future issuance through its at-the-market program, prior to its expiration date on February 22, 2021.

Having insufficient funds may require us to delay, scale back, or eliminate some or all of our development programs or relinquish rights to our technology on less favorable terms than we would otherwise choose. Failure to obtain adequate financing could eventually adversely affect our ability to operate as a going concern. If we continue to raise additional funds from the issuance of equity securities, there will be substantial dilution to our existing stockholders. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business.

As of December 31, 2018, we had 117,769,919 total issued and outstanding shares of common stock, and five-year warrants to purchase an additional 145,000 shares of common stock at exercise prices between $6.84 and $7.62 per share.

In addition, our 2008 Equity Incentive Plan provides for the issuance of up to 896,256 shares of our outstanding common stock and the 2012 Equity Incentive Plan, as amended, provides for the issuance of up to 28,553,986 shares of our common stock, of which 12,452,052 shares remain available for issuance as of December 31, 2018, to executive officers, directors, advisory board members, employees and consultants. We have also issued time-based and performance-based inducement awards under the Incentive Award Agreements for up to 3,382,326 shares of our common stock. Additionally, 1,500,000 shares of common stock have been reserved for issuance under our 2016 Employee Stock Purchase Plan. In aggregate, issued and outstanding common stock, shares underlying outstanding warrants, and shares issuable under outstanding equity awards or reserved for future issuance under the 2008 and 2012 Equity Incentive Plans and the 2016 Employee Stock Purchase Plan total 147,060,091 shares of common stock out of the 200,000,000 shares of common stock authorized for issuance as of December 31, 2018.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements, including unrecorded derivative instruments that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources. We have certain warrants and options outstanding but we do not expect to receive sufficient proceeds from the exercise of these instruments unless and until the underlying securities are registered, and/or all restrictions on trading, if any, are removed, and in either case the trading price of our common stock is significantly greater than the applicable exercise prices of the options and warrants.

Effect of Inflation and Changes in Prices

Management does not believe that inflation and changes in price will have a material effect on our operations.

Contractual Obligations

In the normal course of business, we enter into contracts and commitments that obligate us to make payments in the future. The table below sets forth our significant contractual obligations and related scheduled payments as of December 31, 2018 (in thousands):

	Less than 1 year		1-3 years		3-5 years		More than 5 years
Operating lease obligations (A)	$	264,222	$	2,177,097	$	2,328,953	$	1,732,566
Total	$	264,222	$	2,177,097	$	2,328,953	$	1,732,566

(A)	Operating lease obligations are primarily comprised of remaining payments due under our facility leases.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The primary objective of our investment activities is to preserve our capital for the purpose of funding our operations. To achieve this objective, our investment policy allows us to maintain a portfolio of cash, cash equivalents, and short-term investments in a variety of securities, including money market funds. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because the majority of our investments are comprised of cash and cash equivalents. We currently do not hedge interest rate exposure. Due to the nature of our short-term investments, we believe that we are not subject to any material market risk exposure. We have limited foreign currency risk exposure as our business operates primarily in U.S. dollars. We do not have any significant foreign currency or other derivative financial instruments.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”) is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial and accounting officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the quarterly period covered by this report were designed and operating effectively.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during the fiscal quarter to which this report relates that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

Our management, including our Chief Executive Officer and our Chief Financial Officer, do not expect that our disclosure controls or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

PART II—OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

See Note 5 of the Notes to the Unaudited Condensed Consolidated Financial Statements within this Form 10-Q for a discussion of our legal proceedings and contingencies.

ITEM 1A. RISK FACTORS

In evaluating the Company and an investment in our common stock, we urge you to carefully consider the risks and other information in this Quarterly Report on Form 10-Q as well as the risk factors disclosed in our Annual Report on Form 10-K for the fiscal year ended March 31, 2018, filed with the Securities and Exchange Commission on May 31, 2018. There have been no material changes from the risk factors as previously disclosed in our Annual Report on Form 10-K. Any of the risks discussed in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K, as well as additional risks and uncertainties not currently known to us or that we currently deem immaterial, could materially and adversely affect our results of operations or financial condition.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURE

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

The following exhibit index shows those exhibits filed with this report and those incorporated herein by reference:

Exhibit No.		Description


3.1		Certificate of Incorporation of Organovo Holdings, Inc. (Delaware) (incorporated by reference from Exhibit 3.1 to the February 2012 Form 8-K).

3.2		Bylaws of Organovo Holdings, Inc. (Delaware) (incorporated by reference from Exhibit 3.2 to the February 2012 Form 8-K).

3.3		Certificate of Amendment of Certificate of Incorporation of Organovo Holdings, Inc. (incorporated by reference from Exhibit 3.1 to the Company’s Current Report on Form 8-K, as filed with the SEC on July 27, 2018).

31.1		Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

31.2		Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

32.1		Certification pursuant to 18 U.S.C. Section 1350.*

101		Interactive Data File*

*	Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ORGANOVO HOLDINGS, INC.

Date: February 7, 2019	By:	/s/ Taylor Crouch
	Name:	Taylor Crouch
	Title:	Chief Executive Officer and President (Principal Executive Officer)


Date: February 7, 2019	By:	/s/ Craig Kussman
	Name:	Craig Kussman
	Title:	Chief Financial Officer (Principal Financial Officer)

EX-31 2 onvo-ex311_8.htm EX-31.1 onvo-ex311_8.htm

Exhibit 31.1

CERTIFICATION

I, Taylor Crouch, Chief Executive Officer and President of Organovo Holdings, Inc. (the “Registrant”), certify that:

1. I have reviewed this quarterly report on Form 10-Q of the Registrant;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4. The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

5. The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting

Dated: February 7, 2019

/s/ Taylor Crouch

Taylor Crouch

Chief Executive Officer and President

(Principal Executive Officer)

EX-31 3 onvo-ex312_6.htm EX-31.2 onvo-ex312_6.htm

Exhibit 31.2

CERTIFICATION

I, Craig Kussman, Chief Financial Officer of Organovo Holdings, Inc. (the “Registrant”), certify that:

1. I have reviewed this quarterly report on Form 10-Q of the Registrant;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting

Dated: February 7, 2019

/s/ Craig Kussman

Craig Kussman

Chief Financial Officer

(Principal Financial Officer)

EX-32 4 onvo-ex321_7.htm EX-32.1 onvo-ex321_7.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Organovo Holdings, Inc. (the “Company”) for the period ended December 31, 2018, as filed with the Securities and Exchange Commission (the “Report”), I, Taylor Crouch, Chief Executive Officer and President and I, Craig Kussman, Chief Financial Officer of the Company hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

•

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

•

The information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: February 7, 2019

/s/ Taylor Crouch

Taylor Crouch

Chief Executive Officer and President

(Principal Executive Officer)

/s/ Craig Kussman

Craig Kussman

Chief Financial Officer

(Principal Financial Officer)

A signed original of this written statement required by Section 906 has been provided to Organovo Holdings, Inc. and will be retained by Organovo Holdings, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission, and is not to be incorporated by reference into any filing of Organovo Holdings, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

EX-101.INS 5 onvo-20181231.xml XBRL INSTANCE DOCUMENT shares iso4217:USD iso4217:USD shares pure onvo:Tranche utr:sqft 0001497253 2018-04-01 2018-12-31 0001497253 2019-02-01 0001497253 2018-12-31 0001497253 2018-03-31 0001497253 onvo:ProductsAndServicesMember 2018-10-01 2018-12-31 0001497253 onvo:ProductsAndServicesMember 2017-10-01 2017-12-31 0001497253 onvo:ProductsAndServicesMember 2018-04-01 2018-12-31 0001497253 onvo:ProductsAndServicesMember 2017-04-01 2017-12-31 0001497253 us-gaap:LicenseAndServiceMember 2018-10-01 2018-12-31 0001497253 us-gaap:LicenseAndServiceMember 2017-10-01 2017-12-31 0001497253 us-gaap:LicenseAndServiceMember 2018-04-01 2018-12-31 0001497253 us-gaap:LicenseAndServiceMember 2017-04-01 2017-12-31 0001497253 us-gaap:GrantMember 2018-10-01 2018-12-31 0001497253 us-gaap:GrantMember 2017-10-01 2017-12-31 0001497253 us-gaap:GrantMember 2018-04-01 2018-12-31 0001497253 us-gaap:GrantMember 2017-04-01 2017-12-31 0001497253 2018-10-01 2018-12-31 0001497253 2017-10-01 2017-12-31 0001497253 2017-04-01 2017-12-31 0001497253 us-gaap:CommonStockMember 2018-03-31 0001497253 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001497253 us-gaap:RetainedEarningsMember 2018-03-31 0001497253 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0001497253 us-gaap:CommonStockMember 2018-04-01 2018-12-31 0001497253 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-12-31 0001497253 us-gaap:RetainedEarningsMember 2018-04-01 2018-12-31 0001497253 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-01 2018-12-31 0001497253 us-gaap:CommonStockMember 2018-12-31 0001497253 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001497253 us-gaap:RetainedEarningsMember 2018-12-31 0001497253 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001497253 2017-03-31 0001497253 2017-12-31 0001497253 us-gaap:RestrictedStockUnitsRSUMember 2018-04-01 2018-12-31 0001497253 onvo:PerformanceBasedRestrictedStockUnitsMember 2018-04-01 2018-12-31 0001497253 onvo:AtTheMarketFacilityMember 2018-12-31 0001497253 onvo:AtTheMarketFacilityMember 2018-04-01 2018-12-31 0001497253 us-gaap:ResearchAndDevelopmentArrangementMember 2018-12-31 0001497253 us-gaap:ResearchAndDevelopmentArrangementMember 2018-03-31 0001497253 us-gaap:ProductMember 2018-04-01 2018-12-31 0001497253 onvo:NationalInstituteOfHealthResearchGrantTwoMember 2017-07-01 2017-07-31 0001497253 us-gaap:GrantMember onvo:NationalInstituteOfHealthResearchGrantTwoMember 2018-10-01 2018-12-31 0001497253 us-gaap:GrantMember onvo:NationalInstituteOfHealthResearchGrantTwoMember 2018-04-01 2018-12-31 0001497253 us-gaap:GrantMember onvo:NationalInstituteOfHealthResearchGrantTwoMember 2017-10-01 2017-12-31 0001497253 us-gaap:GrantMember onvo:NationalInstituteOfHealthResearchGrantTwoMember 2017-04-01 2017-12-31 0001497253 us-gaap:AccountingStandardsUpdate201618Member 2016-11-01 0001497253 us-gaap:ResearchAndDevelopmentExpenseMember 2018-10-01 2018-12-31 0001497253 us-gaap:ResearchAndDevelopmentExpenseMember 2017-10-01 2017-12-31 0001497253 us-gaap:ResearchAndDevelopmentExpenseMember 2018-04-01 2018-12-31 0001497253 us-gaap:ResearchAndDevelopmentExpenseMember 2017-04-01 2017-12-31 0001497253 us-gaap:GeneralAndAdministrativeExpenseMember 2018-10-01 2018-12-31 0001497253 us-gaap:GeneralAndAdministrativeExpenseMember 2017-10-01 2017-12-31 0001497253 us-gaap:GeneralAndAdministrativeExpenseMember 2018-04-01 2018-12-31 0001497253 us-gaap:GeneralAndAdministrativeExpenseMember 2017-04-01 2017-12-31 0001497253 us-gaap:EmployeeStockOptionMember 2018-04-01 2018-12-31 0001497253 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0001497253 onvo:PerformanceBasedRestrictedStockUnitsMember 2018-12-31 0001497253 onvo:EmployeeStockPurchasePlanMember 2018-12-31 0001497253 onvo:EmployeeStockPurchasePlanMember 2018-04-01 2018-12-31 0001497253 onvo:EmployeeStockPurchasePlanTwoThousandSixteenMember 2018-10-01 2018-12-31 0001497253 onvo:EmployeeStockPurchasePlanTwoThousandSixteenMember 2017-10-01 2017-12-31 0001497253 onvo:EmployeeStockPurchasePlanTwoThousandSixteenMember 2018-04-01 2018-12-31 0001497253 onvo:EmployeeStockPurchasePlanTwoThousandSixteenMember srt:MinimumMember 2018-04-01 2018-12-31 0001497253 onvo:EmployeeStockPurchasePlanTwoThousandSixteenMember srt:MaximumMember 2018-04-01 2018-12-31 0001497253 onvo:EmployeeStockPurchasePlanTwoThousandSixteenMember 2017-04-01 2017-12-31 0001497253 onvo:EmployeeStockPurchasePlanTwoThousandSixteenMember srt:MinimumMember 2017-04-01 2017-12-31 0001497253 onvo:EmployeeStockPurchasePlanTwoThousandSixteenMember srt:MaximumMember 2017-04-01 2017-12-31 0001497253 onvo:EquityOfferingSalesAgreementMember srt:MaximumMember 2016-07-31 0001497253 onvo:EquityOfferingSalesAgreementMember 2016-07-01 2016-07-31 0001497253 onvo:EquityOfferingSalesAgreementMember 2018-03-17 0001497253 onvo:EquityOfferingSalesAgreementMember 2016-07-20 2018-03-17 0001497253 onvo:TwoThousandEighteenSalesAgreementMember 2018-04-01 2018-12-31 0001497253 onvo:CertificateOfAmendmentMember 2018-07-26 0001497253 onvo:TwoThousandEighteenSalesAgreementMember onvo:AtTheMarketFacilityMember 2018-10-01 2018-12-31 0001497253 onvo:TwoThousandEighteenSalesAgreementMember onvo:AtTheMarketFacilityMember 2018-04-01 2018-12-31 0001497253 onvo:EquityOfferingSalesAgreementMember 2017-10-01 2017-12-31 0001497253 onvo:EquityOfferingSalesAgreementMember 2017-04-01 2017-12-31 0001497253 onvo:TwoThousandEighteenSalesAgreementMember 2018-12-31 0001497253 onvo:TwoThousandEighteenSalesAgreementMember srt:MaximumMember 2018-12-31 0001497253 onvo:TwoThousandEighteenSalesAgreementMember onvo:AtTheMarketFacilityMember 2018-12-31 0001497253 onvo:ChiefMedicalOfficerMember us-gaap:RestrictedStockUnitsRSUMember 2018-08-15 0001497253 us-gaap:RestrictedStockUnitsRSUMember 2018-03-31 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember us-gaap:ChiefExecutiveOfficerMember 2017-04-24 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember 2017-08-22 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2017-08-22 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2017-08-22 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2017-08-22 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember onvo:ShareBasedCompensationAwardTrancheFourMember 2017-08-22 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember onvo:ShareBasedCompensationAwardTrancheFiveMember 2017-08-22 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember us-gaap:ShareBasedCompensationAwardTrancheOneMember srt:MinimumMember 2017-08-22 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember us-gaap:ShareBasedCompensationAwardTrancheOneMember srt:MaximumMember 2017-08-22 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember srt:MinimumMember 2017-08-22 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember srt:MaximumMember 2017-08-22 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember srt:MinimumMember 2017-08-22 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember srt:MaximumMember 2017-08-22 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember onvo:ShareBasedCompensationAwardTrancheFourMember srt:MinimumMember 2017-08-22 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember onvo:ShareBasedCompensationAwardTrancheFourMember srt:MaximumMember 2017-08-22 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember onvo:ShareBasedCompensationAwardTrancheFiveMember srt:MinimumMember 2017-08-22 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember onvo:ShareBasedCompensationAwardTrancheFiveMember srt:MaximumMember 2017-08-22 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember srt:MaximumMember 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember 2018-04-01 2018-12-31 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember onvo:ShareBasedCompensationAwardTrancheFiveMember 2018-04-01 2018-12-31 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember onvo:ShareBasedCompensationAwardTrancheFiveMember 2018-12-31 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember 2018-12-31 0001497253 onvo:PerformanceBasedRestrictedStockUnitsMember 2018-03-31 0001497253 onvo:PerformanceBasedRestrictedStockUnitsMember 2018-04-01 2018-12-12 0001497253 onvo:PerformanceBasedRestrictedStockUnitsMember 2018-12-12 0001497253 onvo:PerformanceBasedRestrictedStockUnitsMember 2018-12-13 2018-12-31 0001497253 onvo:InducementAwardAgreementMember us-gaap:ChiefExecutiveOfficerMember 2017-04-23 2017-04-24 0001497253 onvo:InducementAwardAgreementMember 2017-04-23 2017-04-24 0001497253 onvo:InducementAwardAgreementMember 2018-04-01 2018-12-31 0001497253 onvo:InducementAwardAgreementMember onvo:ChiefMedicalOfficerMember 2018-08-14 2018-08-15 0001497253 us-gaap:WarrantMember 2018-03-31 0001497253 us-gaap:WarrantMember 2018-04-01 2018-12-31 0001497253 us-gaap:WarrantMember 2018-12-31 0001497253 srt:MinimumMember 2018-12-31 0001497253 srt:MaximumMember 2018-12-31 0001497253 onvo:EquityIncentivePlanTwoThousandTwelveMember us-gaap:EmployeeStockOptionMember 2018-12-31 0001497253 onvo:EquityIncentivePlanTwoThousandTwelveMember 2018-12-31 0001497253 onvo:EmployeeStockPurchasePlanTwoThousandSixteenMember us-gaap:EmployeeStockOptionMember 2018-12-31 0001497253 onvo:EquityIncentivePlanTwoThousandTwelveMember us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0001497253 onvo:InducementAwardAgreementMember us-gaap:EmployeeStockOptionMember 2018-12-31 0001497253 onvo:InducementAwardAgreementMember us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0001497253 onvo:InducementAwardAgreementMember onvo:PerformanceBasedRestrictedStockUnitsMember 2018-12-31 0001497253 onvo:AprilTwoThousandFifteenResearchCollaborationAgreementMember us-gaap:LicenseAndServiceMember 2018-10-01 2018-12-31 0001497253 onvo:AprilTwoThousandFifteenResearchCollaborationAgreementMember us-gaap:LicenseAndServiceMember 2018-04-01 2018-12-31 0001497253 onvo:AprilTwoThousandFifteenResearchCollaborationAgreementMember us-gaap:LicenseAndServiceMember 2017-10-01 2017-12-31 0001497253 onvo:AprilTwoThousandFifteenResearchCollaborationAgreementMember us-gaap:LicenseAndServiceMember 2017-04-01 2017-12-31 0001497253 onvo:AprilTwoThousandFifteenMultiYearResearchAgreementMember us-gaap:LicenseAndServiceMember 2018-10-01 2018-12-31 0001497253 onvo:AprilTwoThousandFifteenMultiYearResearchAgreementMember us-gaap:LicenseAndServiceMember 2018-04-01 2018-12-31 0001497253 onvo:AprilTwoThousandFifteenMultiYearResearchAgreementMember us-gaap:LicenseAndServiceMember 2017-10-01 2017-12-31 0001497253 onvo:AprilTwoThousandFifteenMultiYearResearchAgreementMember us-gaap:LicenseAndServiceMember 2017-04-01 2017-12-31 0001497253 onvo:JuneTwoThousandSixteenNonExclusiveResearchAffiliationCollaborativeMember us-gaap:LicenseAndServiceMember 2018-10-01 2018-12-31 0001497253 onvo:JuneTwoThousandSixteenNonExclusiveResearchAffiliationCollaborativeMember us-gaap:LicenseAndServiceMember 2018-04-01 2018-12-31 0001497253 onvo:JuneTwoThousandSixteenNonExclusiveResearchAffiliationCollaborativeMember us-gaap:LicenseAndServiceMember 2017-10-01 2017-12-31 0001497253 onvo:JuneTwoThousandSixteenNonExclusiveResearchAffiliationCollaborativeMember us-gaap:LicenseAndServiceMember 2017-04-01 2017-12-31 0001497253 onvo:DecemberTwoThousandSixteenNonExclusiveResearchAffiliationCollaborativeMember us-gaap:LicenseAndServiceMember 2018-10-01 2018-12-31 0001497253 onvo:DecemberTwoThousandSixteenNonExclusiveResearchAffiliationCollaborativeMember us-gaap:LicenseAndServiceMember 2018-04-01 2018-12-31 0001497253 onvo:DecemberTwoThousandSixteenNonExclusiveResearchAffiliationCollaborativeMember us-gaap:LicenseAndServiceMember 2017-10-01 2017-12-31 0001497253 onvo:DecemberTwoThousandSixteenNonExclusiveResearchAffiliationCollaborativeMember us-gaap:LicenseAndServiceMember 2017-04-01 2017-12-31 0001497253 onvo:AprilTwoThousandSeventeenNonExclusiveResearchAffiliationCollaborativeMember us-gaap:LicenseAndServiceMember us-gaap:TimeAndMaterialsContractMember 2018-10-01 2018-12-31 0001497253 onvo:AprilTwoThousandSeventeenNonExclusiveResearchAffiliationCollaborativeMember us-gaap:LicenseAndServiceMember us-gaap:TimeAndMaterialsContractMember 2018-04-01 2018-12-31 0001497253 onvo:AprilTwoThousandSeventeenNonExclusiveResearchAffiliationCollaborativeMember us-gaap:LicenseAndServiceMember us-gaap:TimeAndMaterialsContractMember 2017-10-01 2017-12-31 0001497253 onvo:AprilTwoThousandSeventeenNonExclusiveResearchAffiliationCollaborativeMember us-gaap:LicenseAndServiceMember us-gaap:TimeAndMaterialsContractMember 2017-04-01 2017-12-31 0001497253 onvo:AprilTwoThousandSeventeenNonExclusiveResearchAffiliationCollaborativeMember us-gaap:LicenseMember 2017-04-01 2017-04-30 0001497253 onvo:AprilTwoThousandSeventeenNonExclusiveResearchAffiliationCollaborativeMember 2017-04-01 2017-04-30 0001497253 onvo:AprilTwoThousandSeventeenNonExclusiveResearchAffiliationCollaborativeMember 2018-04-01 2018-04-30 0001497253 onvo:AprilTwoThousandSeventeenNonExclusiveResearchAffiliationCollaborativeMember us-gaap:LicenseAndServiceMember 2018-10-01 2018-12-31 0001497253 onvo:AprilTwoThousandSeventeenNonExclusiveResearchAffiliationCollaborativeMember us-gaap:LicenseAndServiceMember 2018-04-01 2018-12-31 0001497253 onvo:AprilTwoThousandSeventeenNonExclusiveResearchAffiliationCollaborativeMember us-gaap:LicenseAndServiceMember 2017-10-01 2017-12-31 0001497253 onvo:AprilTwoThousandSeventeenNonExclusiveResearchAffiliationCollaborativeMember us-gaap:LicenseAndServiceMember 2017-04-01 2017-12-31 0001497253 onvo:SeptemberTwoThousandSeventeenAgreementMember us-gaap:LicenseAndServiceMember 2017-09-01 2017-09-30 0001497253 onvo:SeptemberTwoThousandSeventeenAgreementMember us-gaap:LicenseAndServiceMember 2018-10-01 2018-12-31 0001497253 onvo:SeptemberTwoThousandSeventeenAgreementMember us-gaap:LicenseAndServiceMember 2018-04-01 2018-12-31 0001497253 onvo:SeptemberTwoThousandSeventeenAgreementMember us-gaap:LicenseAndServiceMember 2017-10-01 2017-12-31 0001497253 onvo:SeptemberTwoThousandSeventeenAgreementMember us-gaap:LicenseAndServiceMember 2017-04-01 2017-12-31 0001497253 onvo:LeaseTermForFourteenThousandSixHundredAndEightyFiveOfRentableSquareFootageMember 2018-04-01 2018-12-31 0001497253 onvo:LeaseTermForRemainderOfRentableSquareFootageMember 2018-04-01 2018-12-31 0001497253 2018-11-30 2018-11-30 0001497253 2018-01-31 0001497253 2015-02-01 2018-01-31 0001497253 2012-07-01 2018-12-31 0001497253 onvo:LeaseAmendmentMember 2018-04-01 2018-12-31 0001497253 srt:MaximumMember onvo:LeaseAmendmentMember 2018-12-31 0001497253 onvo:CiriusTherapeuticsIncorporationMember 2018-04-01 2018-12-31 0001497253 onvo:CiriusTherapeuticsIncorporationMember 2017-10-01 2017-12-31 0001497253 onvo:CiriusTherapeuticsIncorporationMember 2017-04-01 2017-12-31 0001497253 onvo:CiriusTherapeuticsIncorporationMember 2018-10-01 2018-12-31 0001497253 onvo:ViscientBiosciencesMember onvo:StudyMaterialsMember 2018-04-01 2018-12-31 0001497253 onvo:ViscientBiosciencesMember onvo:StudyMaterialsMember 2018-10-01 2018-12-31 0001497253 onvo:ViscientBiosciencesMember onvo:ResearchServicesMember us-gaap:ScenarioForecastMember 2019-04-01 2019-06-30 0001497253 onvo:ViscientBiosciencesMember onvo:SamsaraSciencesIncMember onvo:PrimaryHumanCellBasedProductsMember 2018-04-01 2018-12-31 0001497253 onvo:ViscientBiosciencesMember onvo:SamsaraSciencesIncMember onvo:PrimaryHumanCellBasedProductsMember 2018-10-01 2018-12-31 0001497253 onvo:ViscientBiosciencesMember 2017-10-01 2017-12-31 0001497253 onvo:ViscientBiosciencesMember 2017-04-01 2017-12-31 0001497253 onvo:ViscientBiosciencesMember onvo:SamsaraSciencesIncMember onvo:PrimaryHumanCellBasedProductsMember us-gaap:ScenarioForecastMember 2019-01-01 2019-03-31 0001497253 onvo:ViscientBiosciencesMember onvo:SamsaraSciencesIncMember onvo:PrimaryHumanCellBasedProductsMember us-gaap:ScenarioForecastMember 2019-04-01 2019-06-30 0001497253 us-gaap:SubsequentEventMember onvo:AtTheMarketFacilityMember 2019-02-07 0001497253 us-gaap:SubsequentEventMember onvo:AtTheMarketFacilityMember 2019-01-01 2019-02-07 10-Q false 2018-12-31 2019 Q3 ONVO ORGANOVO HOLDINGS, INC. 0001497253 --03-31 Accelerated Filer true false 119493341

35224000

43726000

547000

883000

124000

145000

1049000

842000

527000

1164000

37471000

46760000

1946000

2788000

127000

141000

152000

39685000

49827000

647000

464000

2156000

3341000

580000

668000

27000

185000

3410000

4658000

19000

600000

564000

4010000

5241000

118000

111000

289329000

278595000

-253772000

-234120000

35675000

44586000

39685000

49827000

0.001

200000000

117769919

111032957

117769919

111032957

670000

832000

1709000

2722000

43000

61000

128000

367000

66000

260000

574000

409000

779000

1153000

2411000

3498000

136000

192000

381000

747000

3782000

4005000

10348000

13982000

3387000

4865000

11794000

16457000

7305000

9062000

22523000

31186000

-6526000

-7909000

-20112000

-27688000

-65000

-63000

192000

118000

526000

334000

127000

118000

463000

334000

3000

-6399000

-7791000

-19652000

-27354000

-2000

-6399000

-7793000

-19652000

-27356000

-0.06

-0.07

-0.17

-0.26

116256561

107345623

113991794

106107721

111033000

111000

278595000

-234120000

44586000

622000

1000

49000

50000

554000 1000 -136000 0 0 -135000 5561000 5000 6910000 0 0 6915000

3911000

-19652000

117770000

118000

289329000

-253772000

35675000

-27354000

-63000

824000

962000

3911000

5600000

-336000

527000

-21000 260000

207000

55000

-637000

-253000

183000

-719000

-1185000

-1293000

-107000

260000

-122000 -113000

-15298000

-23246000

37000

90000

3000

70000

-34000

-160000

6916000 7243000

136000

74000

50000

826000

6830000

7995000

-2000

-8502000

-15413000

43853000

62878000

35351000

47465000

47338000

127000

3000

23000

Note 1. Description of Business Nature of operations Organovo Holdings, Inc., (“Organovo Holdings,” and collectively with its subsidiaries, “the Company”) is a biotechnology company pioneering a unique set of therapeutic and drug profiling capabilities based on its revolutionary ability to 3D bioprint liver tissues that emulate human biology and disease. The Company is developing its in vivo liver tissues to treat end-stage liver disease and a select group of life-threatening, orphan diseases, for which there are limited treatment options other than organ transplantation. The Company’s program focused on an orphan disease known as Alpha-1-antitrypsin deficiency (“A1AT”), received the U.S. Food and Drug Administration’s (“FDA”) orphan drug designation in December 2017. The Company’s first Investigational New Drug Application (“IND”) filing is targeted for calendar-year 2020. Organovo Holdings is also capitalizing on its foundational ability to characterize highly specialized human cells and to build robust, functional human tissues by creating a range of novel in vitro disease modeling platforms, including a broad set of non-alcoholic fatty liver disease (“NAFLD”) and non-alcoholic steatohepatitis (“NASH”) conditions. Except where specifically noted or the context otherwise requires, references to “Organovo Holdings,” “the Company,” “we,” “our,” and “us” in these notes to the condensed consolidated financial statements refers to Organovo Holdings, Inc. and its wholly owned subsidiaries, Organovo, Inc., Samsara Sciences, Inc., and Organovo U.K., Ltd. In March 2018, the U.K. operations were combined with Organovo, Inc.’s operations.

Note 2. Summary of Significant Accounting Policies Basis of presentation and principles of consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not necessarily include all information and notes required by GAAP for complete financial statements. The balance sheet at March 31, 2018 is derived from the Company’s audited balance sheet at that date. The condensed consolidated financial statements include the accounts of Organovo Holdings and its wholly owned subsidiaries. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal and recurring, necessary for a fair statement of the Company’s financial position, results of operations, stockholders’ equity and cash flows. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2018, as filed with the Securities and Exchange Commission (“SEC”). Operating results for interim periods are not necessarily indicative of operating results for the Company’s fiscal year ending March 31, 2019. Reclassification of prior year presentation As a result of the adoption of the new accounting standard associated with clarifying presentation and classification in the statement of cash flows, certain reclassifications have been made to the prior period financial statements to conform with the current period presentation. These reclassifications did not have any effect on previously reported cash flows, net loss, or financial position. Liquidity As of December 31, 2018, the Company had cash and cash equivalents of approximately $35.2 million and restricted cash of $0.1 million. The restricted cash was pledged as collateral for two letters of credit the Company is required to maintain as security deposits under the terms of the leases of its facilities. The Company had an accumulated deficit of approximately $253.8 million at December 31, 2018. The Company also had negative cash flows from operations of approximately $15.3 million during the nine months ended December 31, 2018. Through December 31, 2018, the Company has financed its operations primarily through the sale of convertible notes, warrants, the private placement of equity securities, the sale of common stock through public and at-the-market (“ATM”) offerings, and through revenue derived from product and research service-based agreements, collaborative agreements, licenses, and grants. During the nine months ended December 31, 2018, the Company issued 5,560,514 shares of its common stock through its ATM facility and received net proceeds of approximately $6.9 million. Based on its current operating plan and available cash resources, the Company has sufficient resources to fund its business for at least the next twelve months from the financial statement issuance date. The Company will need additional capital to further fund the development of its therapeutic tissues focusing on critical unmet medical needs in the liver disease space and to fund the development and commercialization of its proprietary platform to produce and study living tissues that emulate key aspects of human biology and disease that can be used to facilitate drug discovery and development. The Company intends to cover its future operating expenses through cash on hand, through revenue derived from research service agreements, product sales, collaborative agreements, grants and license payments, and through the issuance of additional equity or debt securities. Depending on market conditions, the Company cannot be sure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to it or to its stockholders. Having insufficient funds may require the Company to delay, scale back, or eliminate some or all of its development programs or relinquish rights to its technology on less favorable terms than it would otherwise choose. Failure to obtain adequate financing could eventually adversely affect its ability to operate as a going concern. If the Company continues to raise additional funds from the issuance of equity securities, there will be substantial dilution to its existing stockholders. If the Company raises additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict its ability to operate its business. Use of estimates The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Actual results could differ from those estimates. Significant estimates used in preparing the condensed consolidated financial statements include those assumed in revenue recognition, the valuation of stock-based compensation expense, and the valuation allowance on deferred tax assets. On an ongoing basis, management reviews these estimates and assumptions. Revenue recognition The Company generates revenues from payments received from research service agreements, product sales, collaborative agreements with partners including pharmaceutical and biotechnology companies and academic institutions, licenses, and grants from the National Institutes of Health (“NIH”) and private not-for-profit organizations. Billings to customers or payments received from customers are included in deferred revenue on the balance sheet until all revenue recognition criteria are met. As of December 31, 2018 and March 31, 2018, the Company had approximately $580,000 and $687,000, respectively, in deferred revenue related to its research service agreements, collaborative agreements, and licenses within the scope of Topic 606. In the nine months ended December 31, 2018 the Company recognized revenue on approximately $136,000 that had been recorded as deferred revenue at March 31, 2018. Effective April 1, 2018, the Company adopted the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), Topic 606, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, the Company recognizes revenue when (or as) the promised services are transferred to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those services. To determine revenue recognition for arrangements the Company concludes are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) the performance obligation(s) are satisfied. At contract inception, the Company assesses the goods or services promised within each contract, assesses whether each promised good or service is distinct and identifies those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Service revenues The Company’s service-based business, Organovo, Inc., utilizes its NovoGen® bioprinting platform to provide customers access to its highly specialized tissues that model human biology and disease, and to in vitro testing services based on that technology. These contracts with customers contain multiple performance obligations including: (i) bioprinting tissues for the customer, (ii) reporting the results of tests performed on the printed tissues pursuant to the agreed upon work plan through exposure of the tissue to various factors (including the customer’s proprietary compound), and (iii) delivering specific byproduct study materials, which are satisfied, respectively, at each of the following points in time: (i) upon completion of manufacturing of the bioprinted tissue for the customer, (ii) upon delivery of the report on tests performed on the tissue, and (iii) upon making certain study materials generated from the aforementioned testing process available to the customer. The customer does not have access or control of any performance obligation prior to the point in time of full completion of the corresponding performance satisfying event as defined above. Furthermore, although the service can be customized for each customer, it is not so highly customized as to not have an alternative use either to other customers or to the Company without significant economic consequences or rework. Accordingly, the Company’s service-based business utilizes point-in-time recognition under Topic 606. For service contracts, the Company allocates the transaction price to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. The transaction price for service business contracts is a fixed consideration. Product sales, net The Company’s product-based business, Samsara Sciences, Inc., produces high-quality cell-based products for use in Organovo’s 3D tissue manufacturing and for use by life science customers. The Company recognizes product revenue when the performance obligation is satisfied, which is at the point in time the customer obtains control of the Company’s product, typically upon delivery. Product revenues are recorded at the transaction price, net of any estimates for variable consideration under Topic 606. The Company’s process for estimating variable consideration does not differ materially from its historical practices. Variable consideration is estimated using the expected value method which considers the sum of probability-weighted amounts in a range of possible amounts under the contract. Product revenue reflects the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the individual contracts. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results vary materially from the Company’s estimates, the Company will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. The Company provides no right of return to its customers except in cases where a customer obtains authorization from the Company for the return. To date, there have been no product returns. The Company will continue to assess its estimates of variable consideration as it accumulates additional historical data and will adjust its estimates accordingly. Collaborative research, development, and licenses The Company enters into collaborative agreements with partners that typically include one or more of the following: (i) non-exclusive license fees; (ii) non-refundable up-front fees; (iii) payments for reimbursement of research costs; (iv) payments associated with achieving specific development milestones; and (v) royalties based on specified percentages of net product sales, if any. At the initiation of an agreement, the Company analyzes whether it results in a contract with a customer under Topic 606 or in an arrangement with a collaborator subject to guidance under ASC 808, Collaborative Arrangements (“Topic 808”). The Company considers a variety of factors in determining the appropriate estimates and assumptions under these arrangements, such as whether the elements are distinct performance obligations, whether there are determinable stand-alone prices, and whether any licenses are functional or symbolic. The Company evaluates each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, non-exclusive license fees, non-refundable upfront fees, and funding of research activities are considered fixed, while milestone payments are identified as variable consideration which must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. The Company’s collaborative agreements that were not completed at the implementation of Topic 606 on April 1, 2018, consisted of research collaboration and limited technology access licenses. These agreements provide the licensee with a non-exclusive, non-transferable, limited, royalty-free technology license, including access to Organovo’s proprietary bioprinter platform, training, and continued support by means of consumables and consultation throughout the duration of the contract. The Company has determined the intellectual property license is not distinct from the continued support promised under the agreement and is therefore a single combined performance obligation. The Company recognizes revenue for these combined performance obligations over time for the duration of the license period, as the combined performance obligation will not be fully satisfied until the end of the contract. For the nine months ended December 31, 2018, all collaborations and licenses revenue was within the scope of Topic 606 and recognized accordingly. See “Note 4. Collaborative Research, Development, and License Agreements” for more information on the Company’s collaborative agreements. Grant revenue In July 2017, the National Institutes of Health (“NIH”) awarded the Company a “Research and Development” grant totaling approximately $1,657,000 of funding over three years. The Company has concluded this government grant is not within the scope of Topic 606, as government entities do not meet the definition of a “customer” as defined by Topic 606, as there is not considered to be a transfer of control of goods or services to the government entity funding the grant. Additionally, the Company has concluded this government grant does meet the definition of a contribution and is a non-reciprocal transaction, however, Subtopic 958-605, Not-for-Profit-Entities-Revenue Recognition does not apply, as the Company is a business entity and the grant is with a governmental agency. Revenues from this grant are based upon internal costs incurred that are specifically covered by the grant, plus an additional rate that provides funding for overhead expenses. Revenue is recognized as the Company incurs expenses that are related to the grant. The Company believes this policy is consistent with the overarching premise in Topic 606, to ensure that it recognizes revenues to reflect the transfer of promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services, even though there is no “exchange” as defined in the ASC. The Company believes the recognition of revenue as costs are incurred and amounts become earned/realizable is analogous to the concept of transfer of control of a service over time under ASC 606. Revenue recognized under this grant was approximately $66,000 and $574,000 for the three and nine months ended December 31, 2018, respectively. Revenue recognized under this grant was approximately $260,000 and $409,000 for the three and nine months ended December 31, 2017, respectively. Cost of revenues The Company reported approximately $0.1 million and $0.4 million in cost of revenues for the three and nine months ended December 31, 2018, respectively. The Company reported approximately $0.2 million and $0.7 million in cost of revenues for the three and nine months ended December 31, 2017, respectively. Cost of revenues consists of costs related to manufacturing and delivering product and service revenue. Net loss per share Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The weighted-average number of shares used to compute diluted loss per share excludes any assumed exercise of stock options and warrants, shares reserved for purchase under the Company’s 2016 Employee Stock Purchase Plan, the assumed release of restriction of restricted stock units, and shares subject to repurchase as the effect would be anti-dilutive. No dilutive effect was calculated for the three and nine months ended December 31, 2018 or 2017, as the Company reported a net loss for each respective period and the effect would have been anti-dilutive. Common stock equivalents excluded from computing diluted net loss per share were approximately 15.6 million at December 31, 2018, and 14.0 million at December 31, 2017. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies. Unless otherwise stated, the Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its consolidated financial position or results of operations upon adoption. Adoption of New Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which supersedes most existing revenue recognition guidance in GAAP, including most industry-specific guidance. The standard requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The new standard was originally effective for public companies for annual reporting periods beginning after December 15, 2016, with no early application permitted. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers, which deferred by one year the effective date for all entities, with application permitted as of the original effective date. The standard allows for either a full retrospective or modified retrospective method of adoption. The Company adopted this standard on its effective date, April 1, 2018, under the modified retrospective method of adoption. Under this method, entities recognize the cumulative impact of applying the new standard at the date of adoption without restatement of prior periods presented. The cumulative effect of applying the new standard to contracts that were not completed as of April 1, 2018 did not have a material impact on the Company’s consolidated financial position, results of operations, or cash flows. The new standard also requires enhanced disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. See “Note 2. Summary of Significant Accounting Policies” for further discussion. Topic 606 supersedes the revenue recognition requirements in ASC Topic 605, Revenue Recognition (“Topic 605”). While results for reporting periods beginning after April 1, 2018 are presented under Topic 606, all prior period amounts are not adjusted and continue to be reported under the accounting standards in effect during these prior periods. The accounting policies for revenue recognition for periods prior to April 1, 2018 are described in “Note 1. Description of Business and Summary of Significant Accounting Policies” of the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2018. Adoption of this ASC did not have a material impact on the Company’s financial statements. Refer to the revenue recognition disclosure above. In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. The standard clarifies the presentation of restricted cash and cash equivalents and requires companies to include restricted cash and cash equivalents in the beginning and ending balances of cash and cash equivalents on the statement of cash flows. The standard also requires additional disclosures to describe the amount and detail of the restriction by balance sheet line item. The new standard was effective for the Company on April 1, 2018. The Company adopted this standard using the retrospective transition method by restating its condensed consolidated statements of cash flows to include restricted cash of $0.1 million in the beginning and ending cash, cash equivalents, and restricted cash balance. Net cash flows for the nine months ended December 31, 2017, did not change as a result of including restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period amounts presented on the statements of cash flows. In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting, which provides clarity and guidance around which changes to the terms or conditions of a stock-based payment award require an entity to apply modification accounting. The new standard was effective for annual reporting periods beginning after April 1, 2018, and interim periods within those annual reporting periods. The adoption of this guidance had no impact on the Company’s financial statements. In December 2017, the United States (“U.S.”) enacted the Tax Cuts and Jobs Act (the “2017 Act”), which changes existing U.S. tax law and includes various provisions that are expected to affect public companies. The 2017 Act (i) changes U.S. corporate tax rates, (ii) generally reduces a company’s ability to utilize accumulated net operating losses, and (iii) requires the calculation of a one-time transition tax on certain previously unrepatriated foreign earnings and profits (“E&P”). The 2017 Act will also impact estimates of a company’s deferred tax assets and liabilities. The Company has evaluated the financial statement impact of the 2017 Act and expects significant adjustments to its gross deferred tax assets and liabilities; however, it also expects to record a corresponding offset to its estimated full valuation allowance against its net deferred tax assets, which should result in minimal net effect to its provision for income taxes. In accordance with SEC issued guidance under Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”), the Company anticipates a minimal impact to its financial statements. Recent Accounting Pronouncements Not Yet Adopted In February 2016, the FASB issued ASU 2016-02, Leases, which requires an entity to recognize lease assets and lease liabilities on the balance sheet for leases with terms of more than 12 months and to disclose key information about leasing arrangements. This new guidance is effective for the Company on April 1, 2019, with early adoption permitted in any interim or annual period. The Company is currently evaluating the impact that this guidance will have on its financial statements and related disclosures. In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. These amendments simplify the accounting for certain financial instruments with down round features. The amendments require companies to disregard the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or equity classification. Companies that provide earnings per share (EPS) data will adjust their basic EPS calculation for the effect of the feature when triggered (i.e., when the exercise price of the related equity-linked financial instrument is adjusted downward because of the down round feature) and will also recognize the effect of the trigger within equity. This standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The adoption of this guidance will have no impact on the Company’s financial statements as the Company’s only derivative liabilities were all exercised or expired as of March 31, 2017. In February 2018, the FASB issued ASU No. 2018-02, Income Statement – Reporting Comprehensive Income (“Topic 220”), which allows stranded tax effects resulting from the Tax Cuts and Jobs Act to be reclassified from accumulated other comprehensive income to retained earnings. The amendment only relates to the reclassification of the income tax effects of the Tax Cuts and Jobs Act; thus, the underlying guidance relating to the effect of a change in tax laws be included in income from continuing operations is not affected. The amendments in Topic 220 are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. This new guidance is effective for the Company on April 1, 2019. The requirements of ASU 2018-02 are not expected to have a significant impact on the Company’s financial statements. In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting, which aligns the measurement and classification guidance for share-based payment to non-employees with the guidance for share-based payments to employees. Under the new guidance, the measurement period for equity-classified non-employee awards will be fixed at the grant date. This update is effective for annual periods beginning after December 15, 2018, and interim periods within those periods and early adoption is permitted. This new guidance is effective for the Company on April 1, 2019. The requirements of ASU 2018-07 are not expected to have a significant impact on the Company’s financial statements. In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606, which provides guidance on whether certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606. The amendments in this update provide more comparability in the presentation of revenue for certain transactions between collaborative arrangement participants. The key improvements to GAAP for collaborative arrangements resulting from this amendment are to (i) clarify that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit-of-account, (ii) add unit-of-account guidance in Topic 808 to align with the guidance in Topic 606, and (iii) require that in a transaction with a collaborative arrangement participant that is not directly related to sales to third parties, presenting the transaction together with revenue recognized under Topic 606 is precluded if the collaborative arrangement participant is not a customer. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years with early adoption permitted. This new guidance is effective for us on April 1, 2020. The Company is currently evaluating the impact that this guidance will have on its financial statements.

Note 3. Stockholders’ Equity Stock-based compensation expense and valuation information Stock-based awards include (i) stock options and (ii) restricted stock units under the 2012 Equity Incentive Plan (“2012 Plan”), (iii) stock options, (iv) restricted stock units, and (v) performance-based restricted stock units under an Incentive Award Performance-Based Restricted Stock Unit Agreement, and (vi) rights to purchase stock under the 2016 Employee Stock Purchase Plan (“ESPP”). The Company calculates the grant date fair value of all stock-based awards in determining the stock-based compensation expense. Stock-based compensation expense for all stock-based awards consists of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.56%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.56%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">210</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">679</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">925</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.56%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,109</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,040</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,232</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,675</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,358</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,250</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,911</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,600</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table>  </div> The total unrecognized compensation cost related to unvested stock option grants as of December 31, 2018 was approximately $8,315,000 and the weighted average period over which these grants are expected to vest is 2.92 years. The total unrecognized compensation cost related to unvested restricted stock units (not including performance-based restricted stock units) as of December 31, 2018 was approximately $3,660,000, which will be recognized over a weighted average period of 2.67 years. The total unrecognized compensation cost related to unvested performance-based restricted stock units as of December 31, 2018 was approximately $144,000, which will be recognized over a weighted average period of 4.31 years. The total unrecognized stock-based compensation cost related to unvested employee stock purchase plan shares as of December 31, 2018 was approximately $6,000, which will be recognized over a period of 2 months. The Company uses the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method. The fair value of stock options was estimated at the grant date using the following weighted average assumptions:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.86%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73.07</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80.71</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72.99</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76.86</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.79</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.15</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.75</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.81</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life of options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6 years</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6 years</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6 years</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6 years</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average grant <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   date fair value</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.67</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.04</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.84</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.73</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   The assumed dividend yield was based on the Company’s expectation of not paying dividends in the foreseeable future. Considering the expected life of these options, the Company determined that a blend of historical volatility and implied volatility of comparable companies whose share prices are publicly available is more reflective of market conditions and a better indicator of expected volatility than using purely Company-specific historical volatility. The risk-free interest rate assumption was based on U.S. Treasury rates. The weighted average expected life of options was estimated using the average of the contractual term and the weighted average vesting term of the options. Certain options granted to consultants are subject to variable accounting treatment and are required to be revalued until vested. The fair value of each restricted stock unit and performance-based restricted stock unit is recognized as stock-based compensation expense over the vesting term of the award. The fair value is based on the closing stock price on the date of the grant. The Company uses the Black-Scholes valuation model to calculate the fair value of shares issued pursuant to the Company’s ESPP. Stock-based compensation expense is recognized over the purchase period using the straight-line method. The fair value of ESPP shares was estimated at the purchase period commencement date using the following assumptions:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80.23</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43.03</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61.35-80.23%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43.03 - 74.70%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.29</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.10</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.85-2.29%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.79 - 1.10%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6 months</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6 months</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6 months</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6 months</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant date fair value</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.45</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.52</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.30 - $0.45</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.52 - $1.04</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   The assumed dividend yield was based on the Company’s expectation of not paying dividends in the foreseeable future. For the first full year of ESPP offering periods, beginning September 1, 2016, the Company determined that a blend of historical volatility and implied volatility of comparable companies whose share prices are publicly available was more reflective of market conditions and a better indicator of expected volatility than using purely Company-specific historical volatility. As of September 1, 2017 and the beginning of the second year of ESPP offering periods, the Company is using the Company-specific historical volatility rate as the 6-month historical volatility is now a better indicator of expected volatility. The risk-free interest rate assumption was based on U.S. Treasury rates. The expected life is the 6-month purchase period. Preferred stock The Company is authorized to issue 25,000,000 shares of preferred stock. There are no shares of preferred stock currently outstanding, and the Company has no current plans to issue shares of preferred stock. Common stock In December 2014, the Company entered into an equity offering sales agreement (the “2014 Sales Agreement”) with an investment banking firm. In July 2016, the Company registered the sale of up to $26.6 million of common stock under the 2014 Sales Agreement pursuant to its shelf registration statement on Form S-3 (File No. 333-202382) filed with the SEC on February 27, 2015 (the “2015 Shelf”) that expired on March 17, 2018. Prior to its expiration, the Company sold an aggregate of 7,304,286 shares of common stock in at-the-market offerings under the 2014 Sales Agreement, with net proceeds of approximately $19.9 million.   The Company has an effective shelf registration statement on Form S-3 (File No. 333-222929) and the related prospectus previously declared effective by the Securities and Exchange Commission (the “SEC”) on February 22, 2018, as supplemented by a prospectus supplement, dated March 16, 2018 (the “2018 Shelf”), that expires on February 22, 2021. On March 16, 2018, the Company entered into a Sales Agreement (“2018 Sales Agreement”) with H.C. Wainwright & Co., LLC and Jones Trading Institutional Services LLC (each an “Agent” and together, the “Agents”), pursuant to which the Company may offer and sell, from time to time through the Agents, shares of its common stock in “at the market” sales transactions issued pursuant to the Company’s 2018 Shelf. On July 26, 2018, the Company filed an amendment to its certificate of incorporation to increase the number of authorized shares of common stock to 200,000,000 shares. During the three and nine months ended December 31, 2018, the Company issued 1,798,384 and 5,560,514 shares of common stock, respectively, for net proceeds of $1.9 million and $6.9 million, respectively, in at-the-market offerings under the 2018 Sales Agreement. During the three and nine months ended December 31, 2017, the Company issued 2,255,541 and 3,793,758 shares of common stock, respectively, for net proceeds of $3.1 million and $7.1 million, respectively, under the 2014 Sales Agreement. As of December 31, 2018, the Company has sold an aggregate of 5,560,514 shares of common stock in at-the-market offerings under the 2018 Sales Agreement, with net proceeds of approximately $6.9 million. Based on these sales, the Company cannot raise more than an aggregate of $92.9 million in future offerings under the 2018 Shelf, including the $42.9 million remaining available for future issuance through its at-the-market program under the 2018 Sales Agreement. The Company intends to use the net proceeds raised through any at-the-market sales for general corporate purposes, general administrative expenses, and working capital and capital expenditures. Restricted stock units On August 15, 2018, in connection with the appointment of a new Chief Medical Officer (“CMO”), the Company allocated 160,714 Restricted Stock Units (“RSUs”) outside of the 2012 Plan. The Company intends for these to be “inducement awards” within the meaning of NASDAQ Marketplace Rule 5635(c)(4). While outside the Company’s 2012 Plan, the terms and conditions of these awards are consistent with awards granted to the Company’s executive officers pursuant to the 2012 Plan. A summary of the Company’s restricted stock unit (not including performance-based restricted stock units) activity from March 31, 2018 through December 31, 2018 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at March 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,035,345</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.89</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,906,402</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.18</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(595,163</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.48</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled / forfeited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,080,456</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.35</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,266,128</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.82</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table>   Performance-based restricted stock units On April 24, 2017, in connection with the appointment of a new Chief Executive Officer (“CEO”), the Company allocated 208,822 Performance-Based Restricted Stock Units (“PBRSUs”) outside of the 2012 Plan. The Company intends for these to be “inducement awards” within the meaning of NASDAQ Marketplace Rule 5635(c)(4). While outside the Company’s 2012 Plan, the terms and conditions of these awards are generally consistent with awards granted to the Company’s executive officers pursuant to the 2012 Plan. On August 23, 2017, the Board of Directors formally approved the vesting criteria for the PBRSUs allocated by the Company on April 24, 2017. The units were initially divided into five separate tranches each with independent vesting criteria. The first four tranches had performance criteria related to annual revenue goals with measurement at the end of fiscal year 2018 (20 percent), fiscal year 2019 (20 percent), fiscal year 2020 (20 percent), and fiscal year 2021 (20 percent). The fifth tranche had a performance metric related to a path to profitability goal measured as Negative Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) achievable at any point between the grant date and the end of fiscal year 2020 (20 percent). The number of units that could ultimately vest for each tranche ranged from 0 percent to 120 percent of the target amount, not to exceed 208,822 in aggregate. Based on changes to the Company’s strategy, on December 12, 2018, the Board of Directors formally approved an amendment to the vesting criteria for the PBRSUs. As of December 31, 2018, 100% of the Negative Adjusted EBITDA tranche, or 41,764 shares had vested and 8,352 units had been forfeited. Based on the amendment to the vesting criteria, the remaining 158,706 units eligible to vest upon future performance were divided into three separate but equal tranches with independent vesting criteria based on the achievement of certain regulatory milestones. As of December 31, 2018, no tranches are currently expected to vest in fiscal year 2019. Based on the amended PBRSU vesting terms, the modified grant date fair value of the PBRSUs is $165,000 of which one-third is being recognized over the expected service period of each tranche ending on April 23, 2023. The Company began recording stock-based compensation expense for the initial performance tranches after the August 23, 2017 grant date when the initial financial performance goals were established and approved and has modified its recording of compensation expense in accordance with the amended performance tranches beginning on December 12, 2018. </div> A summary of the Company’s performance-based restricted stock unit activity from March 31, 2018 through December 31, 2018 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at March 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,470</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.88</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,764</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.88</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled / forfeited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 12, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158,706</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.88</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impact of modification</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.74</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158,706</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.04</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Stock options On April 24, 2017, in connection with the appointment of a new CEO, the Company granted 2,088,212 stock options outside of the 2012 Plan. The Company intends for these to be “inducement awards” within the meaning of NASDAQ Marketplace Rule 5635(c)(4). While granted outside the Company’s 2012 Plan, the terms and conditions of these awards are consistent with awards granted to the Company’s executive officers pursuant to the 2012 Plan. On August 15, 2018, in connection with the appointment of a new CMO, the Company allocated 974,694 stock options outside of the 2012 Plan. The Company intends for these to be “inducement awards” within the meaning of NASDAQ Marketplace Rule 5635(c)(4). While outside the Company’s 2012 Plan, the terms and conditions of these awards are consistent with awards granted to the Company’s executive officers pursuant to the 2012 Plan. These stock options vest over a four-year period, with a quarter of the option shares vesting on the one-year anniversary of the vesting commencement date and the remaining options shares vesting in equal quarterly installments over the next 12 quarterly periods. A summary of the Company’s stock option activity from March 31, 2018 to December 31, 2018 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at March 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,132,312</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.01</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">591,082</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,024,194</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.29</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options cancelled / forfeited</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,496,763</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.21</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(622,192</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.08</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">561,591</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,037,551</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.45</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and Exercisable at December 31, 2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,481,218</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.06</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   The weighted average remaining contractual term of options exercisable and outstanding at December 31, 2018 was approximately 5.55 years. Employee Stock Purchase Plan The Company reserved 1,500,000 shares of common stock for issuance under the ESPP. The ESPP permits employees after five months of service to purchase common stock through payroll deductions, limited to 15 percent of each employee’s compensation up to the lower of $25,000 per employee per year or 10,000 shares per employee per six-month purchase period. Shares under the ESPP are purchased at 85 percent of the fair market value at the lower of (i) the closing price on the first trading day of the six-month purchase period or (ii) the closing price on the last trading day of the six-month purchase period. The initial offering period commenced in September 2016. At December 31, 2018, there were 1,230,735 shares available for purchase under the ESPP. Warrants The following table summarizes warrant activity for the nine months ended December 31, 2018:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at March 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.19</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75,000</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.36</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.11</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   The warrants outstanding at December 31, 2018 are exercisable at prices between $6.84 and $7.62 per share and have a weighted average remaining term of approximately 0.78 years. Common stock reserved for future issuance Common stock reserved for future issuance consisted of the following at December 31, 2018:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants outstanding</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options outstanding and reserved under the 2012 Plan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,974,645</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved under the 2012 Plan</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,452,052</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved under the 2016 Employee Stock Purchase Plan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,230,735</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units outstanding under the 2012 Plan</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,105,414</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options outstanding and reserved under the Incentive <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   Award Agreement</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,062,906</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units outstanding under the Incentive Award Agreement</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160,714</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Performance-based restricted stock units outstanding under the Incentive Award <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   Agreement</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158,706</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total at December 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,290,172</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

Note 4. Collaborative Research, Development, and License Agreements In April 2015, the Company entered into a research collaboration agreement with a third party to develop custom tissue models for fixed fees. No revenue was recorded under this agreement during the three and nine months ended December 31, 2018. Collaboration revenue of $0 and $150,000 was recorded for the three and nine months ended December 31, 2017, respectively. The Company completed its obligations under this agreement in September 2017. Also in April 2015, the Company entered into a multi-year research agreement with a third party to develop multiple custom tissue models for use in drug development. No revenue was recorded under this agreement during the three and nine months ended December 31, 2018 and 2017.   In June 2016, the Company entered into a collaborative non-exclusive research affiliation with a university medical school and a non-profit medical charity, under which the Company received a one-time grant from the charity towards the placement of a NovoGen® Bioprinter at the university for the purpose of developing bioprinted tissues for skeletal disease research. The Company received an up-front payment in June 2016, which was initially recorded as deferred revenue. No revenue was recorded under this agreement during the three and nine months ended December 31, 2018. Revenue of $18,000 and $53,000 was recorded under this agreement during the three and nine months ended December 31, 2017, respectively. The Company does not anticipate recording any further revenue under this agreement. In December 2016, the Company signed another collaborative non-exclusive research affiliation with a university medical school and a non-profit medical charity, under which the Company received a one-time grant from the charity towards the placement of a NovoGen® Bioprinter at the university for the purpose of developing an architecturally correct kidney for potential therapeutic applications. The Company received up-front payments in January and March 2017, which were initially recorded as deferred revenue. Revenue of $10,000 and $29,000 was recorded under this agreement for the three and nine months ended December 31, 2018, respectively. Revenue of $10,000 and $29,000 has been recorded under this agreement for the three and nine months ended December 31, 2017, respectively. In April 2017, the Company signed a collaborative non-exclusive research affiliation with a university, under which the Company received a one-time non-refundable payment toward the placement of a NovoGen® Bioprinter at the university for the purpose of specific research projects mutually agreed upon by the university and the Company in the field of volumetric muscle loss. The Company received an up-front payment in May 2017, which was initially recorded as deferred revenue. Revenue of approximately $14,000 and $43,000 has been recorded under this agreement for the three and nine months ended December 31, 2018, respectively. Revenue of approximately $14,000 and $28,000 has been recorded under this agreement for the three and nine months ended December 31, 2017, respectively, beginning subsequent to the installation of the printer in July 2017. In addition, during April 2017, the Company signed a non-exclusive patent license agreement with the university including an annual fee of $75,000 for each of the two years for the license to the Company patents for research use limited to the field of volumetric muscle loss. The Company received the first annual payment of $75,000 in April 2017 and the second annual payment of $75,000 in April 2018, which were initially recorded as deferred revenue. Revenue of $18,000 and $56,000 has been recorded under this agreement for the three and nine months ended December 31, 2018 and 2017, respectively. In September 2017, the Company entered into an agreement with a company, under which the Company received a one-time non-refundable payment of $50,000 for limited use of a Company patent in reference to four bioprinters developed and placed at research and academic facilities. The Company recorded no revenue under this agreement for the three and nine months ended December 31, 2018. The Company recorded $0 and $50,000 for the three and nine months ended December 31, 2017, respectively.

Note 5. Commitments and Contingencies Operating leases Since July 2012, the Company has leased its main facilities at 6275 Nancy Ridge Drive, San Diego, California 92121. The lease, as amended in 2013, 2015 and 2016, consists of approximately 45,580 rentable square feet containing laboratory, clean room and office space. Monthly rental payments are currently approximately $120,000 per month with 3% annual escalators. The lease for 14,685 of the total rentable square footage was amended to accelerate the expiration date from December 15, 2018 to October 31, 2018. On November 30, 2018, the Company agreed to extend the term for the remainder of the total rentable square footage under the lease from September 1, 2021 to September 1, 2024 in exchange for $500,000 of landlord funded tenant improvements and a rescission of its option to terminate the lease on or after September 1, 2019 with 9 months prior written notice. The Company also previously leased a second facility from February 1, 2015 through January 31, 2018, consisting of 5,803 rentable square feet of office and lab space located at 6310 Nancy Ridge Drive, San Diego, California 92121, with a monthly rent of approximately $12,000 commencing on April 1, 2015, which increased be 3% each 12-month anniversary of the 36 month lease. The Company records rent expense on a straight-line basis over the life of the leases and records the excess of expense over the amounts paid as deferred rent. In addition, one of the leases provides for certain improvements made for the Company’s benefit to be funded by the landlord. Such costs, totaling approximately $518,000 to date, have been capitalized as fixed assets and included in deferred rent. As a result of the Company’s lease amendment, which extends the term of the lease from August 31, 2021 to August 31, 2024, the landlord agreed to fund up to $500,000 in additional tenant improvements, which have not been capitalized or included in deferred rent. Rent expense was approximately $264,000 and $915,000 for the three and nine months ended December 31, 2018, respectively, and $362,000 and $1,094,000 for the three and nine months ended December 31, 2017, respectively. Future minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of December 31, 2018, are as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fiscal year ended March 31, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">264,222</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fiscal year ended March 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,073,027</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fiscal year ended March 31, 2021</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,104,070</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fiscal year ended March 31, 2022</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,145,861</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fiscal year ended March 31, 2023</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,183,092</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,732,566</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,502,838</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table>  </div> Legal matters In addition to commitments and obligations in the ordinary course of business, the Company may be subject, from time to time, to various claims and pending and potential legal actions arising out of the normal conduct of its business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. Because litigation is inherently unpredictable and unfavorable resolutions could occur, assessing litigation contingencies is highly subjective and requires judgments about future events. When evaluating contingencies, the Company may be unable to provide a meaningful estimate due to a number of factors, including the procedural status of the matter in question, the presence of complex or novel legal theories, and/or the ongoing discovery and development of information important to the matters. In addition, damage amounts claimed in litigation against it may be unsupported, exaggerated or unrelated to possible outcomes, and as such are not meaningful indicators of its potential liability. The Company regularly reviews contingencies to determine the adequacy of its accruals and related disclosures. During the period presented, the Company has not recorded any accrual for loss contingencies associated with such claims or legal proceedings; determined that an unfavorable outcome is probable or reasonably possible; or determined that the amount or range of any possible loss is reasonably estimable. However, the outcome of legal proceedings and claims brought against the Company is subject to significant uncertainty. Therefore, although management considers the likelihood of such an outcome to be remote, if one or more of these legal matters were resolved against the Company in a reporting period, the Company’s consolidated financial statements for that reporting period could be materially adversely affected.

Note 6. Concentrations Credit risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of temporary cash investments. The Company maintains cash balances at various financial institutions primarily located within the United States. Accounts at these institutions are secured by the Federal Deposit Insurance Corporation. Balances may exceed federally insured limits. The Company has not experienced losses in such accounts and management believes that the Company is not exposed to any significant credit risk with respect to its cash and cash equivalents. The Company is also potentially subject to concentrations of credit risk in its revenues and accounts receivable. The Company’s revenues to date have been derived from a relatively small number of customers and collaborators. However, the Company has not historically experienced any accounts receivable write-downs and management does not believe significant credit risk exists as of December 31, 2018.

Note 7. Related Parties From time to time, the Company will enter into an agreement with a related party in the ordinary course of its business and on terms and conditions it believes are as fair as those it offers and receives from independent third parties. These agreements are ratified by the Company’s Board of Directors or a committee thereof pursuant to its related party transaction policy. In August 2017, the Company entered into a services agreement with Cirius Therapeutics, Inc. (“Cirius”), an entity for which Robert Baltera, Jr., a director of the Company, serves as Chief Executive Officer. Under this agreement and its amendments, the Company has provided ExVive™ Liver Tissue Services for Cirius in the amount of $281,000 to date, of which $26,000 and $120,000 was recognized as revenue in the three and nine months ended December 31, 2018, respectively. The Company has provided ExVive™ Liver Tissue Services for Cirius in the amount of $44,000 and $94,000 in the three and nine months ended December 31, 2017, respectively. During the fiscal year, the Company sold study materials and products to Viscient Biosciences (“Viscient”), an entity which Keith Murphy, a former director and Chief Executive Officer of the Company, serves as Chief Executive Officer. Viscient purchased study materials from Organovo in the amount of $2,000 to date, pursuant to the terms of a Quote which was entered into on September 11, 2018, of which $0 and $2,000 was recognized as revenue in the three and nine months ended December 31, 2018. In November 2018, Viscient executed a Quote to purchase research services from Organovo in the amount of $142,000, which will be recognized in the first quarter of Fiscal 2020. Viscient also purchased primary human cell-based products from our subsidiary, Samsara, in the amount of $91,000 to date, pursuant to the terms of multiple Quotes entered into throughout the fiscal year, of which $88,000 and $91,000 was recognized as revenue in the three and nine months ended December 31, 2018, respectively. There were no sales to Viscient during the three and nine months ended December 31, 2017. In October 2018, Viscient executed a Quote to purchase additional primary human cell-based products from Samsara in the amount of $55,000 which will be recognized in the fourth quarter of Fiscal 2019 or the first quarter of Fiscal 2020.

Note 8. Subsequent Events Between January 1, 2019 and the date of filing, the Company issued 1,723,422 shares of its common stock pursuant to its ATM facility for net proceeds of approximately $1.8 million.

Basis of presentation and principles of consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not necessarily include all information and notes required by GAAP for complete financial statements. The balance sheet at March 31, 2018 is derived from the Company’s audited balance sheet at that date. The condensed consolidated financial statements include the accounts of Organovo Holdings and its wholly owned subsidiaries. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal and recurring, necessary for a fair statement of the Company’s financial position, results of operations, stockholders’ equity and cash flows. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2018, as filed with the Securities and Exchange Commission (“SEC”). Operating results for interim periods are not necessarily indicative of operating results for the Company’s fiscal year ending March 31, 2019.

Revenue recognition The Company generates revenues from payments received from research service agreements, product sales, collaborative agreements with partners including pharmaceutical and biotechnology companies and academic institutions, licenses, and grants from the National Institutes of Health (“NIH”) and private not-for-profit organizations. Billings to customers or payments received from customers are included in deferred revenue on the balance sheet until all revenue recognition criteria are met. As of December 31, 2018 and March 31, 2018, the Company had approximately $580,000 and $687,000, respectively, in deferred revenue related to its research service agreements, collaborative agreements, and licenses within the scope of Topic 606. In the nine months ended December 31, 2018 the Company recognized revenue on approximately $136,000 that had been recorded as deferred revenue at March 31, 2018. Effective April 1, 2018, the Company adopted the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), Topic 606, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, the Company recognizes revenue when (or as) the promised services are transferred to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those services. To determine revenue recognition for arrangements the Company concludes are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) the performance obligation(s) are satisfied. At contract inception, the Company assesses the goods or services promised within each contract, assesses whether each promised good or service is distinct and identifies those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Service revenues The Company’s service-based business, Organovo, Inc., utilizes its NovoGen® bioprinting platform to provide customers access to its highly specialized tissues that model human biology and disease, and to in vitro testing services based on that technology. These contracts with customers contain multiple performance obligations including: (i) bioprinting tissues for the customer, (ii) reporting the results of tests performed on the printed tissues pursuant to the agreed upon work plan through exposure of the tissue to various factors (including the customer’s proprietary compound), and (iii) delivering specific byproduct study materials, which are satisfied, respectively, at each of the following points in time: (i) upon completion of manufacturing of the bioprinted tissue for the customer, (ii) upon delivery of the report on tests performed on the tissue, and (iii) upon making certain study materials generated from the aforementioned testing process available to the customer. The customer does not have access or control of any performance obligation prior to the point in time of full completion of the corresponding performance satisfying event as defined above. Furthermore, although the service can be customized for each customer, it is not so highly customized as to not have an alternative use either to other customers or to the Company without significant economic consequences or rework. Accordingly, the Company’s service-based business utilizes point-in-time recognition under Topic 606. For service contracts, the Company allocates the transaction price to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. The transaction price for service business contracts is a fixed consideration. Product sales, net The Company’s product-based business, Samsara Sciences, Inc., produces high-quality cell-based products for use in Organovo’s 3D tissue manufacturing and for use by life science customers. The Company recognizes product revenue when the performance obligation is satisfied, which is at the point in time the customer obtains control of the Company’s product, typically upon delivery. Product revenues are recorded at the transaction price, net of any estimates for variable consideration under Topic 606. The Company’s process for estimating variable consideration does not differ materially from its historical practices. Variable consideration is estimated using the expected value method which considers the sum of probability-weighted amounts in a range of possible amounts under the contract. Product revenue reflects the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the individual contracts. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results vary materially from the Company’s estimates, the Company will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. The Company provides no right of return to its customers except in cases where a customer obtains authorization from the Company for the return. To date, there have been no product returns. The Company will continue to assess its estimates of variable consideration as it accumulates additional historical data and will adjust its estimates accordingly. Collaborative research, development, and licenses The Company enters into collaborative agreements with partners that typically include one or more of the following: (i) non-exclusive license fees; (ii) non-refundable up-front fees; (iii) payments for reimbursement of research costs; (iv) payments associated with achieving specific development milestones; and (v) royalties based on specified percentages of net product sales, if any. At the initiation of an agreement, the Company analyzes whether it results in a contract with a customer under Topic 606 or in an arrangement with a collaborator subject to guidance under ASC 808, Collaborative Arrangements (“Topic 808”). The Company considers a variety of factors in determining the appropriate estimates and assumptions under these arrangements, such as whether the elements are distinct performance obligations, whether there are determinable stand-alone prices, and whether any licenses are functional or symbolic. The Company evaluates each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, non-exclusive license fees, non-refundable upfront fees, and funding of research activities are considered fixed, while milestone payments are identified as variable consideration which must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. The Company’s collaborative agreements that were not completed at the implementation of Topic 606 on April 1, 2018, consisted of research collaboration and limited technology access licenses. These agreements provide the licensee with a non-exclusive, non-transferable, limited, royalty-free technology license, including access to Organovo’s proprietary bioprinter platform, training, and continued support by means of consumables and consultation throughout the duration of the contract. The Company has determined the intellectual property license is not distinct from the continued support promised under the agreement and is therefore a single combined performance obligation. The Company recognizes revenue for these combined performance obligations over time for the duration of the license period, as the combined performance obligation will not be fully satisfied until the end of the contract. For the nine months ended December 31, 2018, all collaborations and licenses revenue was within the scope of Topic 606 and recognized accordingly. See “Note 4. Collaborative Research, Development, and License Agreements” for more information on the Company’s collaborative agreements. Grant revenue In July 2017, the National Institutes of Health (“NIH”) awarded the Company a “Research and Development” grant totaling approximately $1,657,000 of funding over three years. The Company has concluded this government grant is not within the scope of Topic 606, as government entities do not meet the definition of a “customer” as defined by Topic 606, as there is not considered to be a transfer of control of goods or services to the government entity funding the grant. Additionally, the Company has concluded this government grant does meet the definition of a contribution and is a non-reciprocal transaction, however, Subtopic 958-605, Not-for-Profit-Entities-Revenue Recognition does not apply, as the Company is a business entity and the grant is with a governmental agency. Revenues from this grant are based upon internal costs incurred that are specifically covered by the grant, plus an additional rate that provides funding for overhead expenses. Revenue is recognized as the Company incurs expenses that are related to the grant. The Company believes this policy is consistent with the overarching premise in Topic 606, to ensure that it recognizes revenues to reflect the transfer of promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services, even though there is no “exchange” as defined in the ASC. The Company believes the recognition of revenue as costs are incurred and amounts become earned/realizable is analogous to the concept of transfer of control of a service over time under ASC 606. Revenue recognized under this grant was approximately $66,000 and $574,000 for the three and nine months ended December 31, 2018, respectively. Revenue recognized under this grant was approximately $260,000 and $409,000 for the three and nine months ended December 31, 2017, respectively.

Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies. Unless otherwise stated, the Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its consolidated financial position or results of operations upon adoption. Adoption of New Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which supersedes most existing revenue recognition guidance in GAAP, including most industry-specific guidance. The standard requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The new standard was originally effective for public companies for annual reporting periods beginning after December 15, 2016, with no early application permitted. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers, which deferred by one year the effective date for all entities, with application permitted as of the original effective date. The standard allows for either a full retrospective or modified retrospective method of adoption. The Company adopted this standard on its effective date, April 1, 2018, under the modified retrospective method of adoption. Under this method, entities recognize the cumulative impact of applying the new standard at the date of adoption without restatement of prior periods presented. The cumulative effect of applying the new standard to contracts that were not completed as of April 1, 2018 did not have a material impact on the Company’s consolidated financial position, results of operations, or cash flows. The new standard also requires enhanced disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. See “Note 2. Summary of Significant Accounting Policies” for further discussion. Topic 606 supersedes the revenue recognition requirements in ASC Topic 605, Revenue Recognition (“Topic 605”). While results for reporting periods beginning after April 1, 2018 are presented under Topic 606, all prior period amounts are not adjusted and continue to be reported under the accounting standards in effect during these prior periods. The accounting policies for revenue recognition for periods prior to April 1, 2018 are described in “Note 1. Description of Business and Summary of Significant Accounting Policies” of the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2018. Adoption of this ASC did not have a material impact on the Company’s financial statements. Refer to the revenue recognition disclosure above. In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. The standard clarifies the presentation of restricted cash and cash equivalents and requires companies to include restricted cash and cash equivalents in the beginning and ending balances of cash and cash equivalents on the statement of cash flows. The standard also requires additional disclosures to describe the amount and detail of the restriction by balance sheet line item. The new standard was effective for the Company on April 1, 2018. The Company adopted this standard using the retrospective transition method by restating its condensed consolidated statements of cash flows to include restricted cash of $0.1 million in the beginning and ending cash, cash equivalents, and restricted cash balance. Net cash flows for the nine months ended December 31, 2017, did not change as a result of including restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period amounts presented on the statements of cash flows. In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting, which provides clarity and guidance around which changes to the terms or conditions of a stock-based payment award require an entity to apply modification accounting. The new standard was effective for annual reporting periods beginning after April 1, 2018, and interim periods within those annual reporting periods. The adoption of this guidance had no impact on the Company’s financial statements. In December 2017, the United States (“U.S.”) enacted the Tax Cuts and Jobs Act (the “2017 Act”), which changes existing U.S. tax law and includes various provisions that are expected to affect public companies. The 2017 Act (i) changes U.S. corporate tax rates, (ii) generally reduces a company’s ability to utilize accumulated net operating losses, and (iii) requires the calculation of a one-time transition tax on certain previously unrepatriated foreign earnings and profits (“E&P”). The 2017 Act will also impact estimates of a company’s deferred tax assets and liabilities. The Company has evaluated the financial statement impact of the 2017 Act and expects significant adjustments to its gross deferred tax assets and liabilities; however, it also expects to record a corresponding offset to its estimated full valuation allowance against its net deferred tax assets, which should result in minimal net effect to its provision for income taxes. In accordance with SEC issued guidance under Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”), the Company anticipates a minimal impact to its financial statements. Recent Accounting Pronouncements Not Yet Adopted In February 2016, the FASB issued ASU 2016-02, Leases, which requires an entity to recognize lease assets and lease liabilities on the balance sheet for leases with terms of more than 12 months and to disclose key information about leasing arrangements. This new guidance is effective for the Company on April 1, 2019, with early adoption permitted in any interim or annual period. The Company is currently evaluating the impact that this guidance will have on its financial statements and related disclosures. In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. These amendments simplify the accounting for certain financial instruments with down round features. The amendments require companies to disregard the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or equity classification. Companies that provide earnings per share (EPS) data will adjust their basic EPS calculation for the effect of the feature when triggered (i.e., when the exercise price of the related equity-linked financial instrument is adjusted downward because of the down round feature) and will also recognize the effect of the trigger within equity. This standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The adoption of this guidance will have no impact on the Company’s financial statements as the Company’s only derivative liabilities were all exercised or expired as of March 31, 2017. In February 2018, the FASB issued ASU No. 2018-02, Income Statement – Reporting Comprehensive Income (“Topic 220”), which allows stranded tax effects resulting from the Tax Cuts and Jobs Act to be reclassified from accumulated other comprehensive income to retained earnings. The amendment only relates to the reclassification of the income tax effects of the Tax Cuts and Jobs Act; thus, the underlying guidance relating to the effect of a change in tax laws be included in income from continuing operations is not affected. The amendments in Topic 220 are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. This new guidance is effective for the Company on April 1, 2019. The requirements of ASU 2018-02 are not expected to have a significant impact on the Company’s financial statements. In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting, which aligns the measurement and classification guidance for share-based payment to non-employees with the guidance for share-based payments to employees. Under the new guidance, the measurement period for equity-classified non-employee awards will be fixed at the grant date. This update is effective for annual periods beginning after December 15, 2018, and interim periods within those periods and early adoption is permitted. This new guidance is effective for the Company on April 1, 2019. The requirements of ASU 2018-07 are not expected to have a significant impact on the Company’s financial statements. In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606, which provides guidance on whether certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606. The amendments in this update provide more comparability in the presentation of revenue for certain transactions between collaborative arrangement participants. The key improvements to GAAP for collaborative arrangements resulting from this amendment are to (i) clarify that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit-of-account, (ii) add unit-of-account guidance in Topic 808 to align with the guidance in Topic 606, and (iii) require that in a transaction with a collaborative arrangement participant that is not directly related to sales to third parties, presenting the transaction together with revenue recognized under Topic 606 is precluded if the collaborative arrangement participant is not a customer. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years with early adoption permitted. This new guidance is effective for us on April 1, 2020. The Company is currently evaluating the impact that this guidance will have on its financial statements.

Stock-based compensation expense for all stock-based awards consists of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.56%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.56%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">210</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">679</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">925</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.56%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,109</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,040</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,232</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,675</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,358</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,250</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,911</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,600</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The fair value of stock options was estimated at the grant date using the following weighted average assumptions:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.86%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73.07</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80.71</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72.99</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76.86</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.79</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.15</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.75</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.81</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life of options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6 years</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6 years</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6 years</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6 years</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average grant <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   date fair value</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.67</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.04</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.84</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.73</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The fair value of ESPP shares was estimated at the purchase period commencement date using the following assumptions:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80.23</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43.03</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61.35-80.23%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43.03 - 74.70%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.29</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.10</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.85-2.29%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.79 - 1.10%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6 months</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6 months</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6 months</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6 months</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant date fair value</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.45</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.52</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.30 - $0.45</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.52 - $1.04</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

A summary of the Company’s restricted stock unit (not including performance-based restricted stock units) activity from March 31, 2018 through December 31, 2018 is as follows: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at March 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,035,345</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.89</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,906,402</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.18</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(595,163</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.48</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled / forfeited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,080,456</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.35</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,266,128</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.82</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

A summary of the Company’s performance-based restricted stock unit activity from March 31, 2018 through December 31, 2018 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at March 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,470</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.88</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,764</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.88</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled / forfeited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 12, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158,706</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.88</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impact of modification</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.74</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158,706</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.04</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

A summary of the Company’s stock option activity from March 31, 2018 to December 31, 2018 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at March 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,132,312</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.01</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">591,082</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,024,194</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.29</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options cancelled / forfeited</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,496,763</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.21</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(622,192</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.08</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">561,591</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,037,551</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.45</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and Exercisable at December 31, 2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,481,218</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.06</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The following table summarizes warrant activity for the nine months ended December 31, 2018:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at March 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.19</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75,000</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.36</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.11</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

Common stock reserved for future issuance consisted of the following at December 31, 2018:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants outstanding</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options outstanding and reserved under the 2012 Plan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,974,645</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved under the 2012 Plan</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,452,052</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved under the 2016 Employee Stock Purchase Plan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,230,735</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units outstanding under the 2012 Plan</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,105,414</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options outstanding and reserved under the Incentive <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   Award Agreement</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,062,906</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units outstanding under the Incentive Award Agreement</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160,714</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Performance-based restricted stock units outstanding under the Incentive Award <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   Agreement</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158,706</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total at December 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,290,172</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

Future minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of December 31, 2018, are as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fiscal year ended March 31, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">264,222</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fiscal year ended March 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,073,027</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fiscal year ended March 31, 2021</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,104,070</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fiscal year ended March 31, 2022</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,145,861</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fiscal year ended March 31, 2023</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,183,092</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,732,566</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,502,838</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

5560514

6900000

580000

687000

136000

0 1657000 P3Y

66000

574000

260000

409000

100000

400000

200000

700000

15600000

14000000

100000

249000

210000

679000

925000

1109000

1040000

3232000

4675000

1358000

1250000

8315000

P2Y11M1D

3660000

144000

P2Y8M1D

P4Y3M21D

6000

P2M

0.00

0.7307

0.8071

0.7299

0.7686

0.0279

0.0215

0.0275

0.0181

P6Y

0.67

1.04

0.84

1.73

0.00

0.8023

0.4303

0.6135

0.4303

0.8023

0.7470

0.0229

0.0110

0.0185

0.0079

0.0229

0.0110

P6M

0.45

0.52

0.30

0.45

0.52

1.04

25000000

26600000

2018-03-17

7304286

19900000

2021-02-22

200000000

1798384

5560514

1900000

6900000

2255541

3793758

3100000

7100000

5560514

6900000

92900000 42900000

160714

2035345

1906402

595163

1080456

2266128

2.89

1.18

2.48

2.35

1.82

208822

0.20

2018

0.20

2019

0.20

2020

0.20

2021

0.20

2020

0.00

1.20

0.00

1.20

0.00

1.20

0.00

1.20

0.00

1.20

208822

1.00

41764

8352

158706

Based on the amendment to the vesting criteria, the remaining 158,706 units eligible to vest upon future performance were divided into three separate but equal tranches with independent vesting criteria based on the achievement of certain regulatory milestones.

0 165000

200470

41764

158706

1.88

-0.74

1.04

2088212

P4Y

These stock options vest over a four-year period, with a quarter of the option shares vesting on the one-year anniversary of the vesting commencement date and the remaining options shares vesting in equal quarterly installments over the next 12 quarterly periods.

0.25

974694

10132312

8024194

4496763

622192

13037551

4481218

4.01

1.29

4.21

0.08

2.45

4.06

591082

561591

P5Y6M18D

1500000

0.15

25000

10000

0.85

P6M 2016-09

Shares under the ESPP are purchased at 85 percent of the fair market value at the lower of (i) the closing price on the first trading day of the six-month purchase period or (ii) the closing price on the last trading day of the six-month purchase period.

P6M

1230735

220000

75000

145000

7.19

7.36

7.11

6.84

7.62

P9M10D

145000

9974645

12452052

1230735

2105414

3062906

160714

158706

29290172

150000

18000

53000

10000

29000

10000

29000

14000

43000

14000

28000

75000

P2Y

75000

18000

56000

18000

56000

50000

120000

0.03

45580 14685

2024-09-01

2018-10-31

500000 option to terminate the lease on or after September 1, 2019 with 9 months prior written notice. 5803

P36M

2015-02-01 2018-01-31 12000

0.03

518000

2024-08-31

500000

264000

362000

915000

1094000

264222000

1073027000

1104070000

1145861000

1183092000

1732566000

6502838000

281000

44000

94000

120000

26000

2000

142000

91000

88000

91000

55000

1723422

1800000

EX-101.SCH 6 onvo-20181231.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Unaudited Condensed Consolidated Statement of Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - Description of Business link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Collaborative Research, Development, and License Agreements link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Concentrations link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Related Parties link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Stockholders' Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Commitments and Contingencies (Tables) link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Stockholders' Equity - Schedule of Stock-based Compensation Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Stockholders' Equity - Stock-based Compensation Expense and Valuation Information - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Stockholders' Equity - Fair Value of Employee Stock Options (Detail) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Stockholders' Equity - Fair Value of Employee Stock Purchase Plan (Detail) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Stockholders' Equity - Preferred Stock - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Stockholders' Equity - Common Stock - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Stockholders' Equity - Restricted Stock Awards, Restricted Stock Units and Performance-Based Restricted Stock Units - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Stockholders' Equity - Summary of Company's Restricted Stock Unit Activity and Performance-Based Restricted Stock Unit Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Stockholders' Equity - Stock Options and Employee Stock Purchase Plan - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Stockholders' Equity - Summary of Warrant Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Stockholders' Equity - Warrants - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Stockholders' Equity - Common Stock Reserved for Future Issuance (Detail) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Collaborative Research, Development, and License Agreements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Commitments and Contingencies - Future Minimum Annual Operating Lease Payments (Detail) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Related Parties - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Subsequent Events - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 onvo-20181231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 onvo-20181231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 onvo-20181231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Document and entity information. Document And Entity Information [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current Assets Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Accounts receivable Accounts Receivable Net Current Grant receivable Grants Receivable Inventory, net Inventory Net Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Fixed assets, net Property Plant And Equipment Net Restricted cash Restricted Cash Noncurrent Other assets, net Other Assets Noncurrent Total assets Assets Liabilities and Stockholders’ Equity Liabilities And Stockholders Equity [Abstract] Current Liabilities Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued expenses Accrued Liabilities Current Deferred revenue Contract With Customer Liability Current Deferred rent Deferred Rent Credit Current Total current liabilities Liabilities Current Deferred revenue, net of current portion Contract With Customer Liability Noncurrent Deferred rent, net of current portion Deferred Rent Credit Noncurrent Total liabilities Liabilities Commitments and Contingencies Commitments And Contingencies Stockholders’ Equity Stockholders Equity [Abstract] Common stock, $0.001 par value; 200,000,000 shares authorized, 117,769,919 and 111,032,957 shares issued and outstanding at December 31, 2018 and March 31, 2018, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders’ equity Stockholders Equity Total Liabilities and Stockholders’ Equity Liabilities And Stockholders Equity Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Income Statement [Abstract] Statement [Table] Statement [Table] Product and Service Product Or Service [Axis] Product and Service Products And Services [Domain] Products and services. Products and Services [Member] Products And Services [Member] Collaborations and Licenses [Member] License And Service [Member] Grants [Member] Grant [Member] Statement [Line Items] Statement [Line Items] Revenues Disaggregation Of Revenue [Abstract] Total Revenues Revenue From Contract With Customer Excluding Assessed Tax Cost of revenues Cost Of Goods And Services Sold Research and development expenses Research And Development Expense Selling, general and administrative expenses Selling General And Administrative Expense Total costs and expenses Costs And Expenses Loss from Operations Operating Income Loss Other Income (Expense) Nonoperating Income Expense [Abstract] Gain (loss) on fixed asset disposals Gain Loss On Disposition Of Assets Interest income Investment Income Interest Total Other Income Nonoperating Income Expense Income Tax Expense Income Tax Expense Benefit Net Loss Net Income Loss Currency Translation Adjustment Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax Comprehensive Loss Comprehensive Income Net Of Tax Net loss per common share—basic and diluted Earnings Per Share Basic And Diluted Weighted average shares used in computing net loss per common share—basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Stock issued during period shares under employee and director stock option RSU and purchase plans. Stock issued during period value under employee and director stock option RSU and purchase plans. Stock issued during period shares public offering. Stock issued during period value public offering. Statement Of Stockholders Equity [Abstract] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Additional Paid In Capital [Member] Accumulated Deficit [Member] Retained Earnings [Member] Accumulated Other Comprehensive Income (Loss) [Member] Accumulated Other Comprehensive Income [Member] Beginning balance Stockholders Equity Including Portion Attributable To Noncontrolling Interest Beginning balance, Shares Shares Outstanding Stock option exercises Stock Issued During Period Value Stock Options Exercised Stock option exercises, Shares Stock Issued During Period Shares Stock Options Exercised Issuance of common stock under employee and director stock option, RSU, and purchase plans Stock Issued During Period Value Under Employee And Director Stock Option R S U And Purchase Plans Issuance of common stock under employee and director stock option, RSU, and purchase plans, Shares Stock Issued During Period Shares Under Employee And Director Stock Option R S U And Purchase Plans Issuance of common stock from public offering Stock Issued During Period Value Public Offering Issuance of common stock from public offering, Shares Stock Issued During Period Shares Public Offering Stock-based compensation expense Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Net loss Profit Loss Ending balance Ending balance, Shares Increase decrease in grants receivable. Increase decrease in deferred rent. Proceeds from issuance of common stock and warrants. Statement Of Cash Flows [Abstract] Cash Flows From Operating Activities Net Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] (Gain) loss on disposal of fixed assets Gain Loss On Sale Of Property Plant Equipment Depreciation and amortization Depreciation Depletion And Amortization Stock-based compensation Allocated Share Based Compensation Expense Increase (decrease) in cash resulting from changes in: Increase Decrease In Operating Capital [Abstract] Accounts receivable Increase Decrease In Accounts Receivable Grants receivable Increase Decrease In Grants Receivable Inventory Increase Decrease In Inventories Prepaid expenses and other assets Increase Decrease In Prepaid Deferred Expense And Other Assets Accounts payable Increase Decrease In Accounts Payable Accrued expenses Increase Decrease In Accrued Liabilities Deferred revenue Increase Decrease In Contract With Customer Liability Deferred rent Increase Decrease In Deferred Rent Net cash used in operating activities Net Cash Provided By Used In Operating Activities Cash Flows From Investing Activities Net Cash Provided By Used In Investing Activities [Abstract] Purchases of fixed assets Payments To Acquire Property Plant And Equipment Proceeds from disposals of fixed assets Proceeds From Sale Of Productive Assets Purchases of intangible assets Payments To Acquire Intangible Assets Net cash used in investing activities Net Cash Provided By Used In Investing Activities Cash Flows From Financing Activities Net Cash Provided By Used In Financing Activities [Abstract] Proceeds from issuance of common stock and exercise of warrants, net Proceeds From Issuance Of Common Stock And Warrants Employee taxes paid related to net share settlement of equity awards Payments Related To Tax Withholding For Share Based Compensation Proceeds from exercise of stock options Proceeds From Stock Options Exercised Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Effect of currency exchange rate changes on cash and cash equivalents Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations Net decrease in cash, cash equivalents, and restricted cash Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Cash, cash equivalents, and restricted cash at beginning of period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations Cash, cash equivalents, and restricted cash at end of period Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract] Cash and cash equivalents Restricted cash Supplemental Disclosure of Cash Flow Information: Supplemental Cash Flow Information [Abstract] Income taxes paid Income Taxes Paid Organization Consolidation And Presentation Of Financial Statements [Abstract] Description of Business Nature Of Operations Accounting Policies [Abstract] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Equity [Abstract] Stockholders' Equity Shareholders Equity And Share Based Payments [Text Block] Collaborative Research, Development, and License Agreements Collaborative Arrangement Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments Disclosure [Text Block] Risks And Uncertainties [Abstract] Concentrations Concentration Risk Disclosure [Text Block] Related Party Transactions [Abstract] Related Parties Related Party Transactions Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Basis of presentation and principles of consolidation. Basis of presentation and principles of consolidation Basis Of Presentation And Principles Of Consolidation Policy [Text Block] Reclassification of prior year presentation Prior Period Reclassification Adjustment Description Liquidity policy. Liquidity Liquidity Policy [Text Block] Use of estimates Use Of Estimates Revenue recognition Revenue From Contract With Customer Policy [Text Block] Cost of revenues Cost Of Sales Policy [Text Block] Net loss per share Earnings Per Share Policy [Text Block] Recent Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Schedule Of Stock By Class [Table] Schedule Of Stock By Class [Table] Award Type Award Type [Axis] Equity Award Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Restricted stock units (RSUs) [Member] Restricted Stock Units R S U [Member] Performance based restricted stock units. Performance-Based Restricted Stock Units [Member] Performance Based Restricted Stock Units [Member] Class Of Stock [Line Items] Class Of Stock [Line Items] Schedule of Stock-based Compensation Expense Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Fair Value of Employee Stock Options Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block] Fair Value of Employee Stock Purchase Plan Schedule Of Share Based Payment Award Employee Stock Purchase Plan Valuation Assumptions Table [Text Block] Summary of Company's Restricted Stock Unit Activity and Performance Based Restricted Stock Unit Activity Schedule Of Sharebased Compensation Restricted Stock And Restricted Stock Units Activity Table [Text Block] Summary of Stock Option Activity Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Summary of Warrant Activity Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block] Common stock capital shares reserved for future issuance. Common Stock Reserved for Future Issuance Common Stock Capital Shares Reserved For Future Issuance Table [Text Block] Future Minimum Annual Operating Lease Payments Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block] Summary of significant accounting policies. Schedule of summary of significant accounting policy. Schedule Of Summary Of Significant Accounting Policy [Table] Schedule Of Summary Of Significant Accounting Policy [Table] Sale of Stock Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] At-the-market facility. At-The-Market Facility [Member] At The Market Facility [Member] Category of Item Purchased Long Term Purchase Commitment By Category Of Item Purchased [Axis] Long-term Purchase Commitment, Category of Item Purchased Long Term Purchase Commitment Category Of Item Purchased [Domain] Research and Development Services [Member] Research And Development Arrangement [Member] Product [Member] Product [Member] Research and Development Arrangement, Contract to Perform for Others, Type Research And Development Arrangement Contract To Perform For Others By Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type Research And Development Arrangement Contract To Perform For Others Type [Domain] National Institute of Health research grant two. NIH Research Grants Two [Member] National Institute Of Health Research Grant Two [Member] Adjustments for New Accounting Pronouncements Adjustments For New Accounting Pronouncements [Axis] Type of Adoption Type Of Adoption [Member] Accounting Standards Update 2016-18 [Member] Accounting Standards Update201618 [Member] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Cash and cash equivalents Restricted cash Cash flow from operations Issuance of common stock Gross proceeds from sale of common stock shares Proceeds From Issuance Of Common Stock Deferred revenue Revenue recognized Contract With Customer Liability Revenue Recognized Contract with customer liability sales returns. Product return revenue Contract With Customer Liability Sales Returns Grant revenue funding period. Research grant. Revenue recognized under grants Research Grant Grant revenue funding period Grant Revenue Funding Period Revenue recognized under grants Cost of revenues Cost Of Revenue Dilutive effect Dilutive Securities Common stock equivalents excluded from computing diluted net loss per share Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Research and development Research And Development Expense [Member] General and administrative General And Administrative Expense [Member] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Total stock-based compensation expense Stock options [Member] Employee Stock Option [Member] Plan Name Plan Name [Axis] EX-101.PRE 10 onvo-20181231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Dec. 31, 2018	Feb. 01, 2019
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Trading Symbol	ONVO
Entity Registrant Name	ORGANOVO HOLDINGS, INC.
Entity Central Index Key	0001497253
Current Fiscal Year End Date	--03-31
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		119,493,341

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Mar. 31, 2018
Current Assets
Cash and cash equivalents	$ 35,224	$ 43,726
Accounts receivable	547	883
Grant receivable	124	145
Inventory, net	1,049	842
Prepaid expenses and other current assets	527	1,164
Total current assets	37,471	46,760
Fixed assets, net	1,946	2,788
Restricted cash	127	127
Other assets, net	141	152
Total assets	39,685	49,827
Current Liabilities
Accounts payable	647	464
Accrued expenses	2,156	3,341
Deferred revenue	580	668
Deferred rent	27	185
Total current liabilities	3,410	4,658
Deferred revenue, net of current portion	0	19
Deferred rent, net of current portion	600	564
Total liabilities	4,010	5,241
Commitments and Contingencies	0	0
Stockholders’ Equity
Common stock, $0.001 par value; 200,000,000 shares authorized, 117,769,919 and 111,032,957 shares issued and outstanding at December 31, 2018 and March 31, 2018, respectively	118	111
Additional paid-in capital	289,329	278,595
Accumulated deficit	(253,772)	(234,120)
Total stockholders’ equity	35,675	44,586
Total Liabilities and Stockholders’ Equity	$ 39,685	$ 49,827

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2018	Mar. 31, 2018
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	117,769,919	111,032,957
Common stock, shares outstanding	117,769,919	111,032,957

XML 14 R4.htm IDEA: XBRL DOCUMENT

Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Revenues
Total Revenues	$ 779	$ 1,153	$ 2,411	$ 3,498
Cost of revenues	136	192	381	747
Research and development expenses	3,782	4,005	10,348	13,982
Selling, general and administrative expenses	3,387	4,865	11,794	16,457
Total costs and expenses	7,305	9,062	22,523	31,186
Loss from Operations	(6,526)	(7,909)	(20,112)	(27,688)
Other Income (Expense)
Gain (loss) on fixed asset disposals	(65)	0	(63)	0
Interest income	192	118	526	334
Total Other Income	127	118	463	334
Income Tax Expense	0	0	(3)	0
Net Loss	(6,399)	(7,791)	(19,652)	(27,354)
Currency Translation Adjustment	0	(2)	0	(2)
Comprehensive Loss	$ (6,399)	$ (7,793)	$ (19,652)	$ (27,356)
Net loss per common share—basic and diluted	$ (0.06)	$ (0.07)	$ (0.17)	$ (0.26)
Weighted average shares used in computing net loss per common share—basic and diluted	116,256,561	107,345,623	113,991,794	106,107,721
Products and Services [Member]
Revenues
Total Revenues	$ 670	$ 832	$ 1,709	$ 2,722
Collaborations and Licenses [Member]
Revenues
Total Revenues	43	61	128	367
Grants [Member]
Revenues
Total Revenues	$ 66	$ 260	$ 574	$ 409

XML 15 R5.htm IDEA: XBRL DOCUMENT

Unaudited Condensed Consolidated Statement of Stockholders' Equity - 9 months ended Dec. 31, 2018 - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Beginning balance at Mar. 31, 2018	$ 44,586	$ 111	$ 278,595	$ (234,120)	$ 0
Beginning balance, Shares at Mar. 31, 2018		111,033,000
Stock option exercises	$ 50	$ 1	49	0	0
Stock option exercises, Shares	622,192	622,000
Issuance of common stock under employee and director stock option, RSU, and purchase plans	$ (135)	$ 1	(136)	0	0
Issuance of common stock under employee and director stock option, RSU, and purchase plans, Shares		554,000
Issuance of common stock from public offering	6,915	$ 5	6,910	0	0
Issuance of common stock from public offering, Shares		5,561,000
Stock-based compensation expense	3,911	$ 0	3,911	0	0
Net loss	(19,652)	0	0	(19,652)	0
Ending balance at Dec. 31, 2018	$ 35,675	$ 118	$ 289,329	$ (253,772)	$ 0
Ending balance, Shares at Dec. 31, 2018		117,770,000

XML 16 R6.htm IDEA: XBRL DOCUMENT

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash Flows From Operating Activities
Net loss	$ (19,652)	$ (27,354)
Adjustments to reconcile net loss to net cash used in operating activities:
(Gain) loss on disposal of fixed assets	63	0
Depreciation and amortization	824	962
Stock-based compensation	3,911	5,600
Increase (decrease) in cash resulting from changes in:
Accounts receivable	336	(527)
Grants receivable	21	(260)
Inventory	(207)	(55)
Prepaid expenses and other assets	637	253
Accounts payable	183	(719)
Accrued expenses	(1,185)	(1,293)
Deferred revenue	(107)	260
Deferred rent	(122)	(113)
Net cash used in operating activities	(15,298)	(23,246)
Cash Flows From Investing Activities
Purchases of fixed assets	(37)	(90)
Proceeds from disposals of fixed assets	3	0
Purchases of intangible assets	0	(70)
Net cash used in investing activities	(34)	(160)
Cash Flows From Financing Activities
Proceeds from issuance of common stock and exercise of warrants, net	6,916	7,243
Employee taxes paid related to net share settlement of equity awards	(136)	(74)
Proceeds from exercise of stock options	50	826
Net cash provided by financing activities	6,830	7,995
Effect of currency exchange rate changes on cash and cash equivalents	0	(2)
Net decrease in cash, cash equivalents, and restricted cash	(8,502)	(15,413)
Cash, cash equivalents, and restricted cash at beginning of period	43,853	62,878
Cash, cash equivalents, and restricted cash at end of period	35,351	47,465
Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	35,224	47,338
Restricted cash	127	127
Cash, cash equivalents, and restricted cash at end of period	35,351	47,465
Supplemental Disclosure of Cash Flow Information:
Income taxes paid	$ 3	$ 23

XML 17 R7.htm IDEA: XBRL DOCUMENT

Description of Business

9 Months Ended

Dec. 31, 2018

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Description of Business

Note 1. Description of Business

Nature of operations

XML 18 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

9 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2. Summary of Significant Accounting Policies

Basis of presentation and principles of consolidation

Reclassification of prior year presentation

Liquidity

Use of estimates

Revenue recognition

Service revenues

Product sales, net

Collaborative research, development, and licenses

Grant revenue

Cost of revenues

Net loss per share

Common stock equivalents excluded from computing diluted net loss per share were approximately 15.6 million at December 31, 2018, and 14.0 million at December 31, 2017.

Recent Accounting Pronouncements

Adoption of New Accounting Pronouncements

Recent Accounting Pronouncements Not Yet Adopted

XML 19 R9.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

9 Months Ended

Dec. 31, 2018

Equity [Abstract]

Stockholders' Equity

Note 3. Stockholders’ Equity

Stock-based compensation expense and valuation information

Stock-based compensation expense for all stock-based awards consists of the following (in thousands):

	Three Months Ended		Three Months Ended		Nine Months Ended		Nine Months Ended
	December 31, 2018		December 31, 2017		December 31, 2018		December 31, 2017
Research and development	$	249	$	210	$	679	$	925
General and administrative	$	1,109	$	1,040	$	3,232	$	4,675
Total	$	1,358	$	1,250	$	3,911	$	5,600

	Three Months Ended			Three Months Ended			Nine Months Ended			Nine Months Ended
	December 31, 2018			December 31, 2017			December 31, 2018			December 31, 2017
Dividend yield		—			—			—			—
Volatility		73.07	%		80.71	%		72.99	%		76.86	%
Risk-free interest rate		2.79	%		2.15	%		2.75	%		1.81	%
Expected life of options	6 years			6 years			6 years			6 years
Weighted average grant date fair value	$	0.67		$	1.04		$	0.84		$	1.73

	Three Months Ended			Three Months Ended			Nine Months Ended		Nine Months Ended
	December 31, 2018			December 31, 2017			December 31, 2018		December 31, 2017
Dividend yield		—			—			—		—
Volatility		80.23	%		43.03	%	61.35-80.23%		43.03 - 74.70%
Risk-free interest rate		2.29	%		1.10	%	1.85-2.29%		0.79 - 1.10%
Expected term	6 months			6 months			6 months		6 months
Grant date fair value	$	0.45		$	0.52		$0.30 - $0.45		$0.52 - $1.04

Preferred stock

Common stock

On July 26, 2018, the Company filed an amendment to its certificate of incorporation to increase the number of authorized shares of common stock to 200,000,000 shares.

Restricted stock units

A summary of the Company’s restricted stock unit (not including performance-based restricted stock units) activity from March 31, 2018 through December 31, 2018 is as follows:

	Number of Shares			Weighted Average Price
Unvested at March 31, 2018		2,035,345		$	2.89
Granted		1,906,402		$	1.18
Vested		(595,163	)	$	2.48
Cancelled / forfeited		(1,080,456	)	$	2.35
Unvested at December 31, 2018		2,266,128		$	1.82

Performance-based restricted stock units

On April 24, 2017, in connection with the appointment of a new Chief Executive Officer (“CEO”), the Company allocated 208,822 Performance-Based Restricted Stock Units (“PBRSUs”) outside of the 2012 Plan. The Company intends for these to be “inducement awards” within the meaning of NASDAQ Marketplace Rule 5635(c)(4). While outside the Company’s 2012 Plan, the terms and conditions of these awards are generally consistent with awards granted to the Company’s executive officers pursuant to the 2012 Plan. On August 23, 2017, the Board of Directors formally approved the vesting criteria for the PBRSUs allocated by the Company on April 24, 2017. The units were initially divided into five separate tranches each with independent vesting criteria. The first four tranches had performance criteria related to annual revenue goals with measurement at the end of fiscal year 2018 (20 percent), fiscal year 2019 (20 percent), fiscal year 2020 (20 percent), and fiscal year 2021 (20 percent). The fifth tranche had a performance metric related to a path to profitability goal measured as Negative Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) achievable at any point between the grant date and the end of fiscal year 2020 (20 percent). The number of units that could ultimately vest for each tranche ranged from 0 percent to 120 percent of the target amount, not to exceed 208,822 in aggregate. Based on changes to the Company’s strategy, on December 12, 2018, the Board of Directors formally approved an amendment to the vesting criteria for the PBRSUs. As of December 31, 2018, 100% of the Negative Adjusted EBITDA tranche, or 41,764 shares had vested and 8,352 units had been forfeited. Based on the amendment to the vesting criteria, the remaining 158,706 units eligible to vest upon future performance were divided into three separate but equal tranches with independent vesting criteria based on the achievement of certain regulatory milestones. As of December 31, 2018, no tranches are currently expected to vest in fiscal year 2019.

A summary of the Company’s performance-based restricted stock unit activity from March 31, 2018 through December 31, 2018 is as follows:

	Number of Shares			Weighted Average Price
Unvested at March 31, 2018		200,470		$	1.88
Granted		—		$	—
Vested		(41,764	)	$	1.88
Cancelled / forfeited		—		$	—
Unvested at December 12, 2018		158,706		$	1.88
Impact of modification		—		$	(0.74	)
Unvested at December 31, 2018		158,706		$	1.04

Stock options

A summary of the Company’s stock option activity from March 31, 2018 to December 31, 2018 is as follows:

	Options Outstanding			Weighted Average Exercise Price		Aggregate Intrinsic Value
Outstanding at March 31, 2018		10,132,312		$	4.01	$	591,082
Options granted		8,024,194		$	1.29	$	—
Options cancelled / forfeited		(4,496,763	)	$	4.21	$	—
Options exercised		(622,192	)	$	0.08	$	561,591
Outstanding at December 31, 2018		13,037,551		$	2.45	$	—
Vested and Exercisable at December 31, 2018		4,481,218		$	4.06	$	—

The weighted average remaining contractual term of options exercisable and outstanding at December 31, 2018 was approximately 5.55 years.

Employee Stock Purchase Plan

Warrants

The following table summarizes warrant activity for the nine months ended December 31, 2018:

	Warrants			Weighted Average Exercise Price
Balance at March 31, 2018		220,000		$	7.19
Granted		—		$	—
Exercised		—		$	—
Cancelled		(75,000	)	$	7.36
Balance at December 31, 2018		145,000		$	7.11

The warrants outstanding at December 31, 2018 are exercisable at prices between $6.84 and $7.62 per share and have a weighted average remaining term of approximately 0.78 years.

Common stock reserved for future issuance

Common stock reserved for future issuance consisted of the following at December 31, 2018:

Common stock warrants outstanding			145,000
Common stock options outstanding and reserved under the 2012 Plan			9,974,645
Common stock reserved under the 2012 Plan			12,452,052
Common stock reserved under the 2016 Employee Stock Purchase Plan			1,230,735
Restricted stock units outstanding under the 2012 Plan			2,105,414
Common stock options outstanding and reserved under the Incentive Award Agreement			3,062,906
Restricted stock units outstanding under the Incentive Award Agreement			160,714
Performance-based restricted stock units outstanding under the Incentive Award Agreement			158,706
Total at December 31, 2018			29,290,172

XML 20 R10.htm IDEA: XBRL DOCUMENT

Collaborative Research, Development, and License Agreements

9 Months Ended

Dec. 31, 2018

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Collaborative Research, Development, and License Agreements

Note 4. Collaborative Research, Development, and License Agreements

XML 21 R11.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Dec. 31, 2018

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 5. Commitments and Contingencies

Operating leases

Future minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of December 31, 2018, are as follows (in thousands):

Fiscal year ended March 31, 2019	$	264,222
Fiscal year ended March 31, 2020		1,073,027
Fiscal year ended March 31, 2021		1,104,070
Fiscal year ended March 31, 2022		1,145,861
Fiscal year ended March 31, 2023		1,183,092
Thereafter		1,732,566
Total	$	6,502,838

Legal matters

XML 22 R12.htm IDEA: XBRL DOCUMENT

Concentrations

9 Months Ended

Dec. 31, 2018

Risks And Uncertainties [Abstract]

Concentrations

Note 6. Concentrations

Credit risk

XML 23 R13.htm IDEA: XBRL DOCUMENT

Related Parties

9 Months Ended

Dec. 31, 2018

Related Parties

Note 7. Related Parties

During the fiscal year, the Company sold study materials and products to Viscient Biosciences (“Viscient”), an entity which Keith Murphy, a former director and Chief Executive Officer of the Company, serves as Chief Executive Officer. Viscient purchased study materials from Organovo in the amount of $2,000 to date, pursuant to the terms of a Quote which was entered into on September 11, 2018, of which $0 and $2,000 was recognized as revenue in the three and nine months ended December 31, 2018. In November 2018, Viscient executed a Quote to purchase research services from Organovo in the amount of $142,000, which will be recognized in the first quarter of Fiscal 2020. Viscient also purchased primary human cell-based products from our subsidiary, Samsara, in the amount of $91,000 to date, pursuant to the terms of multiple Quotes entered into throughout the fiscal year, of which $88,000 and $91,000 was recognized as revenue in the three and nine months ended December 31, 2018, respectively. There were no sales to Viscient during the three and nine months ended December 31, 2017. In October 2018, Viscient executed a Quote to purchase additional primary human cell-based products from Samsara in the amount of $55,000 which will be recognized in the fourth quarter of Fiscal 2019 or the first quarter of Fiscal 2020.

XML 24 R14.htm IDEA: XBRL DOCUMENT

Subsequent Events

9 Months Ended

Dec. 31, 2018

Subsequent Events [Abstract]

Subsequent Events

Note 8. Subsequent Events

Between January 1, 2019 and the date of filing, the Company issued 1,723,422 shares of its common stock pursuant to its ATM facility for net proceeds of approximately $1.8 million.

XML 25 R15.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2018
Accounting Policies [Abstract]
Basis of presentation and principles of consolidation	Basis of presentation and principles of consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not necessarily include all information and notes required by GAAP for complete financial statements. The balance sheet at March 31, 2018 is derived from the Company’s audited balance sheet at that date. The condensed consolidated financial statements include the accounts of Organovo Holdings and its wholly owned subsidiaries. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal and recurring, necessary for a fair statement of the Company’s financial position, results of operations, stockholders’ equity and cash flows. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2018, as filed with the Securities and Exchange Commission (“SEC”). Operating results for interim periods are not necessarily indicative of operating results for the Company’s fiscal year ending March 31, 2019.
Reclassification of prior year presentation	Reclassification of prior year presentation As a result of the adoption of the new accounting standard associated with clarifying presentation and classification in the statement of cash flows, certain reclassifications have been made to the prior period financial statements to conform with the current period presentation. These reclassifications did not have any effect on previously reported cash flows, net loss, or financial position.
Liquidity	Liquidity As of December 31, 2018, the Company had cash and cash equivalents of approximately $35.2 million and restricted cash of $0.1 million. The restricted cash was pledged as collateral for two letters of credit the Company is required to maintain as security deposits under the terms of the leases of its facilities. The Company had an accumulated deficit of approximately $253.8 million at December 31, 2018. The Company also had negative cash flows from operations of approximately $15.3 million during the nine months ended December 31, 2018. Through December 31, 2018, the Company has financed its operations primarily through the sale of convertible notes, warrants, the private placement of equity securities, the sale of common stock through public and at-the-market (“ATM”) offerings, and through revenue derived from product and research service-based agreements, collaborative agreements, licenses, and grants. During the nine months ended December 31, 2018, the Company issued 5,560,514 shares of its common stock through its ATM facility and received net proceeds of approximately $6.9 million. Based on its current operating plan and available cash resources, the Company has sufficient resources to fund its business for at least the next twelve months from the financial statement issuance date. The Company will need additional capital to further fund the development of its therapeutic tissues focusing on critical unmet medical needs in the liver disease space and to fund the development and commercialization of its proprietary platform to produce and study living tissues that emulate key aspects of human biology and disease that can be used to facilitate drug discovery and development. The Company intends to cover its future operating expenses through cash on hand, through revenue derived from research service agreements, product sales, collaborative agreements, grants and license payments, and through the issuance of additional equity or debt securities. Depending on market conditions, the Company cannot be sure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to it or to its stockholders. Having insufficient funds may require the Company to delay, scale back, or eliminate some or all of its development programs or relinquish rights to its technology on less favorable terms than it would otherwise choose. Failure to obtain adequate financing could eventually adversely affect its ability to operate as a going concern. If the Company continues to raise additional funds from the issuance of equity securities, there will be substantial dilution to its existing stockholders. If the Company raises additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict its ability to operate its business.
Use of estimates	Use of estimates The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Actual results could differ from those estimates. Significant estimates used in preparing the condensed consolidated financial statements include those assumed in revenue recognition, the valuation of stock-based compensation expense, and the valuation allowance on deferred tax assets. On an ongoing basis, management reviews these estimates and assumptions.
Revenue recognition	Revenue recognition The Company generates revenues from payments received from research service agreements, product sales, collaborative agreements with partners including pharmaceutical and biotechnology companies and academic institutions, licenses, and grants from the National Institutes of Health (“NIH”) and private not-for-profit organizations. Billings to customers or payments received from customers are included in deferred revenue on the balance sheet until all revenue recognition criteria are met. As of December 31, 2018 and March 31, 2018, the Company had approximately $580,000 and $687,000, respectively, in deferred revenue related to its research service agreements, collaborative agreements, and licenses within the scope of Topic 606. In the nine months ended December 31, 2018 the Company recognized revenue on approximately $136,000 that had been recorded as deferred revenue at March 31, 2018. Effective April 1, 2018, the Company adopted the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), Topic 606, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, the Company recognizes revenue when (or as) the promised services are transferred to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those services. To determine revenue recognition for arrangements the Company concludes are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) the performance obligation(s) are satisfied. At contract inception, the Company assesses the goods or services promised within each contract, assesses whether each promised good or service is distinct and identifies those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Service revenues The Company’s service-based business, Organovo, Inc., utilizes its NovoGen® bioprinting platform to provide customers access to its highly specialized tissues that model human biology and disease, and to in vitro testing services based on that technology. These contracts with customers contain multiple performance obligations including: (i) bioprinting tissues for the customer, (ii) reporting the results of tests performed on the printed tissues pursuant to the agreed upon work plan through exposure of the tissue to various factors (including the customer’s proprietary compound), and (iii) delivering specific byproduct study materials, which are satisfied, respectively, at each of the following points in time: (i) upon completion of manufacturing of the bioprinted tissue for the customer, (ii) upon delivery of the report on tests performed on the tissue, and (iii) upon making certain study materials generated from the aforementioned testing process available to the customer. The customer does not have access or control of any performance obligation prior to the point in time of full completion of the corresponding performance satisfying event as defined above. Furthermore, although the service can be customized for each customer, it is not so highly customized as to not have an alternative use either to other customers or to the Company without significant economic consequences or rework. Accordingly, the Company’s service-based business utilizes point-in-time recognition under Topic 606. For service contracts, the Company allocates the transaction price to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. The transaction price for service business contracts is a fixed consideration. Product sales, net The Company’s product-based business, Samsara Sciences, Inc., produces high-quality cell-based products for use in Organovo’s 3D tissue manufacturing and for use by life science customers. The Company recognizes product revenue when the performance obligation is satisfied, which is at the point in time the customer obtains control of the Company’s product, typically upon delivery. Product revenues are recorded at the transaction price, net of any estimates for variable consideration under Topic 606. The Company’s process for estimating variable consideration does not differ materially from its historical practices. Variable consideration is estimated using the expected value method which considers the sum of probability-weighted amounts in a range of possible amounts under the contract. Product revenue reflects the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the individual contracts. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results vary materially from the Company’s estimates, the Company will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. The Company provides no right of return to its customers except in cases where a customer obtains authorization from the Company for the return. To date, there have been no product returns. The Company will continue to assess its estimates of variable consideration as it accumulates additional historical data and will adjust its estimates accordingly. Collaborative research, development, and licenses The Company enters into collaborative agreements with partners that typically include one or more of the following: (i) non-exclusive license fees; (ii) non-refundable up-front fees; (iii) payments for reimbursement of research costs; (iv) payments associated with achieving specific development milestones; and (v) royalties based on specified percentages of net product sales, if any. At the initiation of an agreement, the Company analyzes whether it results in a contract with a customer under Topic 606 or in an arrangement with a collaborator subject to guidance under ASC 808, Collaborative Arrangements (“Topic 808”). The Company considers a variety of factors in determining the appropriate estimates and assumptions under these arrangements, such as whether the elements are distinct performance obligations, whether there are determinable stand-alone prices, and whether any licenses are functional or symbolic. The Company evaluates each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, non-exclusive license fees, non-refundable upfront fees, and funding of research activities are considered fixed, while milestone payments are identified as variable consideration which must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. The Company’s collaborative agreements that were not completed at the implementation of Topic 606 on April 1, 2018, consisted of research collaboration and limited technology access licenses. These agreements provide the licensee with a non-exclusive, non-transferable, limited, royalty-free technology license, including access to Organovo’s proprietary bioprinter platform, training, and continued support by means of consumables and consultation throughout the duration of the contract. The Company has determined the intellectual property license is not distinct from the continued support promised under the agreement and is therefore a single combined performance obligation. The Company recognizes revenue for these combined performance obligations over time for the duration of the license period, as the combined performance obligation will not be fully satisfied until the end of the contract. For the nine months ended December 31, 2018, all collaborations and licenses revenue was within the scope of Topic 606 and recognized accordingly. See “Note 4. Collaborative Research, Development, and License Agreements” for more information on the Company’s collaborative agreements. Grant revenue In July 2017, the National Institutes of Health (“NIH”) awarded the Company a “Research and Development” grant totaling approximately $1,657,000 of funding over three years. The Company has concluded this government grant is not within the scope of Topic 606, as government entities do not meet the definition of a “customer” as defined by Topic 606, as there is not considered to be a transfer of control of goods or services to the government entity funding the grant. Additionally, the Company has concluded this government grant does meet the definition of a contribution and is a non-reciprocal transaction, however, Subtopic 958-605, Not-for-Profit-Entities-Revenue Recognition does not apply, as the Company is a business entity and the grant is with a governmental agency. Revenues from this grant are based upon internal costs incurred that are specifically covered by the grant, plus an additional rate that provides funding for overhead expenses. Revenue is recognized as the Company incurs expenses that are related to the grant. The Company believes this policy is consistent with the overarching premise in Topic 606, to ensure that it recognizes revenues to reflect the transfer of promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services, even though there is no “exchange” as defined in the ASC. The Company believes the recognition of revenue as costs are incurred and amounts become earned/realizable is analogous to the concept of transfer of control of a service over time under ASC 606. Revenue recognized under this grant was approximately $66,000 and $574,000 for the three and nine months ended December 31, 2018, respectively. Revenue recognized under this grant was approximately $260,000 and $409,000 for the three and nine months ended December 31, 2017, respectively.
Cost of revenues	Cost of revenues The Company reported approximately $0.1 million and $0.4 million in cost of revenues for the three and nine months ended December 31, 2018, respectively. The Company reported approximately $0.2 million and $0.7 million in cost of revenues for the three and nine months ended December 31, 2017, respectively. Cost of revenues consists of costs related to manufacturing and delivering product and service revenue.
Net loss per share	Net loss per share Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The weighted-average number of shares used to compute diluted loss per share excludes any assumed exercise of stock options and warrants, shares reserved for purchase under the Company’s 2016 Employee Stock Purchase Plan, the assumed release of restriction of restricted stock units, and shares subject to repurchase as the effect would be anti-dilutive. No dilutive effect was calculated for the three and nine months ended December 31, 2018 or 2017, as the Company reported a net loss for each respective period and the effect would have been anti-dilutive. Common stock equivalents excluded from computing diluted net loss per share were approximately 15.6 million at December 31, 2018, and 14.0 million at December 31, 2017.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies. Unless otherwise stated, the Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its consolidated financial position or results of operations upon adoption. Adoption of New Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which supersedes most existing revenue recognition guidance in GAAP, including most industry-specific guidance. The standard requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The new standard was originally effective for public companies for annual reporting periods beginning after December 15, 2016, with no early application permitted. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers, which deferred by one year the effective date for all entities, with application permitted as of the original effective date. The standard allows for either a full retrospective or modified retrospective method of adoption. The Company adopted this standard on its effective date, April 1, 2018, under the modified retrospective method of adoption. Under this method, entities recognize the cumulative impact of applying the new standard at the date of adoption without restatement of prior periods presented. The cumulative effect of applying the new standard to contracts that were not completed as of April 1, 2018 did not have a material impact on the Company’s consolidated financial position, results of operations, or cash flows. The new standard also requires enhanced disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. See “Note 2. Summary of Significant Accounting Policies” for further discussion. Topic 606 supersedes the revenue recognition requirements in ASC Topic 605, Revenue Recognition (“Topic 605”). While results for reporting periods beginning after April 1, 2018 are presented under Topic 606, all prior period amounts are not adjusted and continue to be reported under the accounting standards in effect during these prior periods. The accounting policies for revenue recognition for periods prior to April 1, 2018 are described in “Note 1. Description of Business and Summary of Significant Accounting Policies” of the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2018. Adoption of this ASC did not have a material impact on the Company’s financial statements. Refer to the revenue recognition disclosure above. In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. The standard clarifies the presentation of restricted cash and cash equivalents and requires companies to include restricted cash and cash equivalents in the beginning and ending balances of cash and cash equivalents on the statement of cash flows. The standard also requires additional disclosures to describe the amount and detail of the restriction by balance sheet line item. The new standard was effective for the Company on April 1, 2018. The Company adopted this standard using the retrospective transition method by restating its condensed consolidated statements of cash flows to include restricted cash of $0.1 million in the beginning and ending cash, cash equivalents, and restricted cash balance. Net cash flows for the nine months ended December 31, 2017, did not change as a result of including restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period amounts presented on the statements of cash flows. In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting, which provides clarity and guidance around which changes to the terms or conditions of a stock-based payment award require an entity to apply modification accounting. The new standard was effective for annual reporting periods beginning after April 1, 2018, and interim periods within those annual reporting periods. The adoption of this guidance had no impact on the Company’s financial statements. In December 2017, the United States (“U.S.”) enacted the Tax Cuts and Jobs Act (the “2017 Act”), which changes existing U.S. tax law and includes various provisions that are expected to affect public companies. The 2017 Act (i) changes U.S. corporate tax rates, (ii) generally reduces a company’s ability to utilize accumulated net operating losses, and (iii) requires the calculation of a one-time transition tax on certain previously unrepatriated foreign earnings and profits (“E&P”). The 2017 Act will also impact estimates of a company’s deferred tax assets and liabilities. The Company has evaluated the financial statement impact of the 2017 Act and expects significant adjustments to its gross deferred tax assets and liabilities; however, it also expects to record a corresponding offset to its estimated full valuation allowance against its net deferred tax assets, which should result in minimal net effect to its provision for income taxes. In accordance with SEC issued guidance under Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”), the Company anticipates a minimal impact to its financial statements. Recent Accounting Pronouncements Not Yet Adopted In February 2016, the FASB issued ASU 2016-02, Leases, which requires an entity to recognize lease assets and lease liabilities on the balance sheet for leases with terms of more than 12 months and to disclose key information about leasing arrangements. This new guidance is effective for the Company on April 1, 2019, with early adoption permitted in any interim or annual period. The Company is currently evaluating the impact that this guidance will have on its financial statements and related disclosures. In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. These amendments simplify the accounting for certain financial instruments with down round features. The amendments require companies to disregard the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or equity classification. Companies that provide earnings per share (EPS) data will adjust their basic EPS calculation for the effect of the feature when triggered (i.e., when the exercise price of the related equity-linked financial instrument is adjusted downward because of the down round feature) and will also recognize the effect of the trigger within equity. This standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The adoption of this guidance will have no impact on the Company’s financial statements as the Company’s only derivative liabilities were all exercised or expired as of March 31, 2017. In February 2018, the FASB issued ASU No. 2018-02, Income Statement – Reporting Comprehensive Income (“Topic 220”), which allows stranded tax effects resulting from the Tax Cuts and Jobs Act to be reclassified from accumulated other comprehensive income to retained earnings. The amendment only relates to the reclassification of the income tax effects of the Tax Cuts and Jobs Act; thus, the underlying guidance relating to the effect of a change in tax laws be included in income from continuing operations is not affected. The amendments in Topic 220 are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. This new guidance is effective for the Company on April 1, 2019. The requirements of ASU 2018-02 are not expected to have a significant impact on the Company’s financial statements. In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting, which aligns the measurement and classification guidance for share-based payment to non-employees with the guidance for share-based payments to employees. Under the new guidance, the measurement period for equity-classified non-employee awards will be fixed at the grant date. This update is effective for annual periods beginning after December 15, 2018, and interim periods within those periods and early adoption is permitted. This new guidance is effective for the Company on April 1, 2019. The requirements of ASU 2018-07 are not expected to have a significant impact on the Company’s financial statements. In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606, which provides guidance on whether certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606. The amendments in this update provide more comparability in the presentation of revenue for certain transactions between collaborative arrangement participants. The key improvements to GAAP for collaborative arrangements resulting from this amendment are to (i) clarify that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit-of-account, (ii) add unit-of-account guidance in Topic 808 to align with the guidance in Topic 606, and (iii) require that in a transaction with a collaborative arrangement participant that is not directly related to sales to third parties, presenting the transaction together with revenue recognized under Topic 606 is precluded if the collaborative arrangement participant is not a customer. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years with early adoption permitted. This new guidance is effective for us on April 1, 2020. The Company is currently evaluating the impact that this guidance will have on its financial statements.

XML 26 R16.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

9 Months Ended

Dec. 31, 2018

Class Of Stock [Line Items]

Schedule of Stock-based Compensation Expense

Stock-based compensation expense for all stock-based awards consists of the following (in thousands):

	Three Months Ended		Three Months Ended		Nine Months Ended		Nine Months Ended
	December 31, 2018		December 31, 2017		December 31, 2018		December 31, 2017
Research and development	$	249	$	210	$	679	$	925
General and administrative	$	1,109	$	1,040	$	3,232	$	4,675
Total	$	1,358	$	1,250	$	3,911	$	5,600

Fair Value of Employee Stock Options

The fair value of stock options was estimated at the grant date using the following weighted average assumptions:

	Three Months Ended			Three Months Ended			Nine Months Ended			Nine Months Ended
	December 31, 2018			December 31, 2017			December 31, 2018			December 31, 2017
Dividend yield		—			—			—			—
Volatility		73.07	%		80.71	%		72.99	%		76.86	%
Risk-free interest rate		2.79	%		2.15	%		2.75	%		1.81	%
Expected life of options	6 years			6 years			6 years			6 years
Weighted average grant date fair value	$	0.67		$	1.04		$	0.84		$	1.73

Fair Value of Employee Stock Purchase Plan

The fair value of ESPP shares was estimated at the purchase period commencement date using the following assumptions:

	Three Months Ended			Three Months Ended			Nine Months Ended		Nine Months Ended
	December 31, 2018			December 31, 2017			December 31, 2018		December 31, 2017
Dividend yield		—			—			—		—
Volatility		80.23	%		43.03	%	61.35-80.23%		43.03 - 74.70%
Risk-free interest rate		2.29	%		1.10	%	1.85-2.29%		0.79 - 1.10%
Expected term	6 months			6 months			6 months		6 months
Grant date fair value	$	0.45		$	0.52		$0.30 - $0.45		$0.52 - $1.04

Summary of Stock Option Activity

A summary of the Company’s stock option activity from March 31, 2018 to December 31, 2018 is as follows:

	Options Outstanding			Weighted Average Exercise Price		Aggregate Intrinsic Value
Outstanding at March 31, 2018		10,132,312		$	4.01	$	591,082
Options granted		8,024,194		$	1.29	$	—
Options cancelled / forfeited		(4,496,763	)	$	4.21	$	—
Options exercised		(622,192	)	$	0.08	$	561,591
Outstanding at December 31, 2018		13,037,551		$	2.45	$	—
Vested and Exercisable at December 31, 2018		4,481,218		$	4.06	$	—

Summary of Warrant Activity

The following table summarizes warrant activity for the nine months ended December 31, 2018:

	Warrants			Weighted Average Exercise Price
Balance at March 31, 2018		220,000		$	7.19
Granted		—		$	—
Exercised		—		$	—
Cancelled		(75,000	)	$	7.36
Balance at December 31, 2018		145,000		$	7.11

Common Stock Reserved for Future Issuance

Common stock reserved for future issuance consisted of the following at December 31, 2018:

Common stock warrants outstanding			145,000
Common stock options outstanding and reserved under the 2012 Plan			9,974,645
Common stock reserved under the 2012 Plan			12,452,052
Common stock reserved under the 2016 Employee Stock Purchase Plan			1,230,735
Restricted stock units outstanding under the 2012 Plan			2,105,414
Common stock options outstanding and reserved under the Incentive Award Agreement			3,062,906
Restricted stock units outstanding under the Incentive Award Agreement			160,714
Performance-based restricted stock units outstanding under the Incentive Award Agreement			158,706
Total at December 31, 2018			29,290,172

Restricted stock units (RSUs) [Member]

Class Of Stock [Line Items]

Summary of Company's Restricted Stock Unit Activity and Performance Based Restricted Stock Unit Activity

A summary of the Company’s restricted stock unit (not including performance-based restricted stock units) activity from March 31, 2018 through December 31, 2018 is as follows:

	Number of Shares			Weighted Average Price
Unvested at March 31, 2018		2,035,345		$	2.89
Granted		1,906,402		$	1.18
Vested		(595,163	)	$	2.48
Cancelled / forfeited		(1,080,456	)	$	2.35
Unvested at December 31, 2018		2,266,128		$	1.82

Performance-Based Restricted Stock Units [Member]

Class Of Stock [Line Items]

Summary of Company's Restricted Stock Unit Activity and Performance Based Restricted Stock Unit Activity

A summary of the Company’s performance-based restricted stock unit activity from March 31, 2018 through December 31, 2018 is as follows:

	Number of Shares			Weighted Average Price
Unvested at March 31, 2018		200,470		$	1.88
Granted		—		$	—
Vested		(41,764	)	$	1.88
Cancelled / forfeited		—		$	—
Unvested at December 12, 2018		158,706		$	1.88
Impact of modification		—		$	(0.74	)
Unvested at December 31, 2018		158,706		$	1.04

XML 27 R17.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

9 Months Ended

Dec. 31, 2018

Commitments And Contingencies Disclosure [Abstract]

Future Minimum Annual Operating Lease Payments

Future minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of December 31, 2018, are as follows (in thousands):

Fiscal year ended March 31, 2019	$	264,222
Fiscal year ended March 31, 2020		1,073,027
Fiscal year ended March 31, 2021		1,104,070
Fiscal year ended March 31, 2022		1,145,861
Fiscal year ended March 31, 2023		1,183,092
Thereafter		1,732,566
Total	$	6,502,838

XML 28 R18.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Mar. 31, 2018	Nov. 01, 2016
Summary Of Significant Accounting Policies [Line Items]
Cash and cash equivalents		$ 35,224,000	$ 47,338,000	$ 35,224,000	$ 47,338,000	$ 43,726,000
Restricted cash		127,000	127,000	127,000	127,000	127,000
Accumulated deficit		$ (253,772,000)		(253,772,000)		$ (234,120,000)
Cash flow from operations				$ 15,298,000	23,246,000
Issuance of common stock		117,769,919		117,769,919		111,032,957
Deferred revenue		$ 580,000		$ 580,000		$ 668,000
Revenue recognized				136,000
Revenue recognized under grants		779,000	1,153,000	2,411,000	3,498,000
Cost of revenues		100,000	200,000	400,000	700,000
Dilutive effect		0	0	$ 0	$ 0
Common stock equivalents excluded from computing diluted net loss per share				15,600,000	14,000,000
Accounting Standards Update 2016-18 [Member]
Summary Of Significant Accounting Policies [Line Items]
Restricted cash							$ 100,000
NIH Research Grants Two [Member]
Summary Of Significant Accounting Policies [Line Items]
Revenue recognized under grants	$ 1,657,000
Grant revenue funding period	3 years
Product [Member]
Summary Of Significant Accounting Policies [Line Items]
Product return revenue				$ 0
Grants [Member]
Summary Of Significant Accounting Policies [Line Items]
Revenue recognized under grants		66,000	260,000	574,000	$ 409,000
Grants [Member] \| NIH Research Grants Two [Member]
Summary Of Significant Accounting Policies [Line Items]
Revenue recognized under grants		66,000	$ 260,000	574,000	$ 409,000
Research and Development Services [Member]
Summary Of Significant Accounting Policies [Line Items]
Deferred revenue		$ 580,000		$ 580,000		$ 687,000
At-The-Market Facility [Member]
Summary Of Significant Accounting Policies [Line Items]
Issuance of common stock		5,560,514		5,560,514
Gross proceeds from sale of common stock shares				$ 6,900,000

XML 29 R19.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Schedule of Stock-based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 1,358	$ 1,250	$ 3,911	$ 5,600
Research and development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	249	210	679	925
General and administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 1,109	$ 1,040	$ 3,232	$ 4,675

XML 30 R20.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Stock-based Compensation Expense and Valuation Information - Additional Information (Detail)	9 Months Ended
	Dec. 31, 2018 USD ($)
Class Of Stock [Line Items]
Total unrecognized compensation cost related to unvested stock option grants	$ 8,315,000
Employee Stock Purchase Plan [Member]
Class Of Stock [Line Items]
Total unrecognized compensation cost related, weighted average period	2 months
Unrecognized stock-based compensation expense	$ 6,000
Stock options [Member]
Class Of Stock [Line Items]
Total unrecognized compensation cost related, weighted average period	2 years 11 months 1 day
Restricted stock units (RSUs) [Member]
Class Of Stock [Line Items]
Total unrecognized compensation cost related, weighted average period	2 years 8 months 1 day
Unrecognized stock-based compensation expense	$ 3,660,000
Performance-Based Restricted Stock Units [Member]
Class Of Stock [Line Items]
Total unrecognized compensation cost related, weighted average period	4 years 3 months 21 days
Unrecognized stock-based compensation expense	$ 144,000

XML 31 R21.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Fair Value of Employee Stock Options (Detail) - $ / shares	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Dividend yield	0.00%	0.00%	0.00%	0.00%
Volatility	73.07%	80.71%	72.99%	76.86%
Risk-free interest rate	2.79%	2.15%	2.75%	1.81%
Expected life of options	6 years	6 years	6 years	6 years
Weighted average grant date fair value	$ 0.67	$ 1.04	$ 0.84	$ 1.73

XML 32 R22.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Fair Value of Employee Stock Purchase Plan (Detail) - $ / shares	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield	0.00%	0.00%	0.00%	0.00%
Volatility	73.07%	80.71%	72.99%	76.86%
Risk-free interest rate	2.79%	2.15%	2.75%	1.81%
Expected term	6 years	6 years	6 years	6 years
Grant date fair value	$ 0.67	$ 1.04	$ 0.84	$ 1.73
2016 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield	0.00%	0.00%	0.00%	0.00%
Volatility	80.23%	43.03%
Volatility, Minimum			61.35%	43.03%
Volatility, Maximum			80.23%	74.70%
Risk-free interest rate	2.29%	1.10%
Risk-free interest rate, Minimum			1.85%	0.79%
Risk-free interest rate, Maximum			2.29%	1.10%
Expected term	6 months	6 months	6 months	6 months
Grant date fair value	$ 0.45	$ 0.52
2016 Employee Stock Purchase Plan [Member] \| Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield			0.00%
Grant date fair value			$ 0.45	$ 1.04
2016 Employee Stock Purchase Plan [Member] \| Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield			0.00%
Grant date fair value			$ 0.30	$ 0.52

XML 33 R23.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Preferred Stock - Additional Information (Detail)	Dec. 31, 2018 shares
Equity [Abstract]
Preferred stock, shares authorized	25,000,000
Preferred stock, shares outstanding	0

XML 34 R24.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Common Stock - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended		20 Months Ended
	Jul. 31, 2016	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Mar. 17, 2018	Jul. 26, 2018	Mar. 31, 2018
Class Of Stock [Line Items]
Common stock reserved for future issuance		29,290,172		29,290,172
Issuance of common stock		117,769,919		117,769,919				111,032,957
Common stock, shares authorized		200,000,000		200,000,000				200,000,000
At-The-Market Facility [Member]
Class Of Stock [Line Items]
Issuance of common stock		5,560,514		5,560,514
Certificate of Amendment [Member]
Class Of Stock [Line Items]
Common stock, shares authorized							200,000,000
Equity Offering Sales Agreement [Member]
Class Of Stock [Line Items]
Equity sales agreement expiration date	Mar. 17, 2018
Issuance of common stock						7,304,286
Value of shares sold under equity distribution agreement			$ 3,100,000		$ 7,100,000	$ 19,900,000
Issuance of common stock from stock options exercises, net, Shares			2,255,541		3,793,758
Equity Offering Sales Agreement [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Common stock reserved for future issuance	26,600,000
2018 Sales Agreement [Member]
Class Of Stock [Line Items]
Equity sales agreement expiration date				Feb. 22, 2021
Issuance of common stock		5,560,514		5,560,514
Value of shares sold under equity distribution agreement				$ 6,900,000
2018 Sales Agreement [Member] \| At-The-Market Facility [Member]
Class Of Stock [Line Items]
Value of shares sold under equity distribution agreement		$ 1,900,000		$ 6,900,000
Issuance of common stock from stock options exercises, net, Shares		1,798,384		5,560,514
Common stock value reserved for future issuance		$ 42,900,000		$ 42,900,000
2018 Sales Agreement [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Common stock value reserved for future issuance		$ 92,900,000		$ 92,900,000

XML 35 R25.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Restricted Stock Awards, Restricted Stock Units and Performance-Based Restricted Stock Units - Additional Information (Detail)		9 Months Ended
	Aug. 23, 2017 USD ($) Tranche shares	Dec. 31, 2018 Tranche shares	Aug. 15, 2018 shares	Mar. 31, 2018 shares	Apr. 24, 2017 shares
Restricted stock units (RSUs) [Member]
Class Of Stock [Line Items]
Number of shares allocated		2,266,128		2,035,345
Share based compensation arrangement, number of shares vested		595,163
Restricted stock units (RSUs) [Member] \| CMO [Member]
Class Of Stock [Line Items]
Number of shares allocated			160,714
Inducement Award Performance-Based Restricted Stock Units [Member]
Class Of Stock [Line Items]
Number of tranches \| Tranche	5
Award vesting percentage		100.00%
Number of tranches expected to vest \| Tranche		0
Grant date fair values of tranches \| $	$ 165,000
Inducement Award Performance-Based Restricted Stock Units [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Number of shares allocated	208,822
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share-based Compensation Award, Tranche One [Member]
Class Of Stock [Line Items]
Award vesting percentage	20.00%
Stock units vesting year	2018
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share-based Compensation Award, Tranche One [Member] \| Minimum [Member]
Class Of Stock [Line Items]
Award vesting percentage	0.00%
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share-based Compensation Award, Tranche One [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Award vesting percentage	120.00%
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share-based Compensation Award, Tranche Two [Member]
Class Of Stock [Line Items]
Award vesting percentage	20.00%
Stock units vesting year	2019
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share-based Compensation Award, Tranche Two [Member] \| Minimum [Member]
Class Of Stock [Line Items]
Award vesting percentage	0.00%
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share-based Compensation Award, Tranche Two [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Award vesting percentage	120.00%
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share-based Compensation Award, Tranche Three [Member]
Class Of Stock [Line Items]
Award vesting percentage	20.00%
Stock units vesting year	2020
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share-based Compensation Award, Tranche Three [Member] \| Minimum [Member]
Class Of Stock [Line Items]
Award vesting percentage	0.00%
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share-based Compensation Award, Tranche Three [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Award vesting percentage	120.00%
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share Based Compensation Award Tranche Four [Member]
Class Of Stock [Line Items]
Award vesting percentage	20.00%
Stock units vesting year	2021
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share Based Compensation Award Tranche Four [Member] \| Minimum [Member]
Class Of Stock [Line Items]
Award vesting percentage	0.00%
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share Based Compensation Award Tranche Four [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Award vesting percentage	120.00%
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share Based Compensation Award Tranche Five [Member]
Class Of Stock [Line Items]
Award vesting percentage	20.00%
Stock units vesting year	2020
Share based compensation arrangement, number of shares vested		41,764
Share based compensation arrangement, number of shares forfeited		8,352
Share based compensation arrangement, number of shares eligible to vest upon future performance		158,706
Share based compensation arrangement amendment description and terms		Based on the amendment to the vesting criteria, the remaining 158,706 units eligible to vest upon future performance were divided into three separate but equal tranches with independent vesting criteria based on the achievement of certain regulatory milestones.
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share Based Compensation Award Tranche Five [Member] \| Minimum [Member]
Class Of Stock [Line Items]
Award vesting percentage	0.00%
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share Based Compensation Award Tranche Five [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Award vesting percentage	120.00%
Inducement Award Performance-Based Restricted Stock Units [Member] \| CEO [Member]
Class Of Stock [Line Items]
Number of shares allocated					208,822

XML 36 R26.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Summary of Company's Restricted Stock Unit Activity and Performance-Based Restricted Stock Unit Activity (Detail) - $ / shares	1 Months Ended	8 Months Ended	9 Months Ended
	Dec. 31, 2018	Dec. 12, 2018	Dec. 31, 2018
Restricted stock units (RSUs) [Member]
Class Of Stock [Line Items]
Beginning balance, Unvested, Number of Shares		2,035,345	2,035,345
Granted, Number of Shares			1,906,402
Vested, Number of Shares			(595,163)
Canceled / forfeited, Number of Shares			(1,080,456)
Ending balance, Unvested, Number of Shares	2,266,128		2,266,128
Beginning balance, Unvested, Weighted Average Price		$ 2.89	$ 2.89
Granted, Weighted Average Price			1.18
Vested, Weighted Average Price			2.48
Canceled / forfeited, Weighted Average Price			2.35
Ending balance, Unvested, Weighted Average Price	$ 1.82		$ 1.82
Performance-Based Restricted Stock Units [Member]
Class Of Stock [Line Items]
Beginning balance, Unvested, Number of Shares	158,706	200,470	200,470
Impact of modification, Number of Shares	0
Granted, Number of Shares		0
Vested, Number of Shares		(41,764)
Canceled / forfeited, Number of Shares		0
Ending balance, Unvested, Number of Shares	158,706	158,706	158,706
Beginning balance, Unvested, Weighted Average Price	$ 1.88	$ 1.88	$ 1.88
Impact of modification, Weighted Average Price	(0.74)
Granted, Weighted Average Price		0
Vested, Weighted Average Price		1.88
Canceled / forfeited, Weighted Average Price		0
Ending balance, Unvested, Weighted Average Price	$ 1.04	$ 1.88	$ 1.04

XML 37 R27.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Stock Options and Employee Stock Purchase Plan - Additional Information (Detail) - USD ($)			3 Months Ended		9 Months Ended
	Aug. 15, 2018	Apr. 24, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Class Of Stock [Line Items]
Weighted-average remaining contractual term of options exercisable					5 years 6 months 18 days
Weighted-average remaining contractual term of options outstanding					5 years 6 months 18 days
Number of common stock shares approved under ESPP			29,290,172		29,290,172
Expected life of options			6 years	6 years	6 years	6 years
Inducement Award Agreement [Member]
Class Of Stock [Line Items]
Period for vesting schedule over start date		4 years
Award vesting conditions					These stock options vest over a four-year period, with a quarter of the option shares vesting on the one-year anniversary of the vesting commencement date and the remaining options shares vesting in equal quarterly installments over the next 12 quarterly periods.
Award vesting percentage					25.00%
Inducement Award Agreement [Member] \| CEO [Member]
Class Of Stock [Line Items]
Stock options granted		2,088,212
Inducement Award Agreement [Member] \| CMO [Member]
Class Of Stock [Line Items]
Stock options granted	974,694
Employee Stock Purchase Plan [Member]
Class Of Stock [Line Items]
Number of common stock shares approved under ESPP			1,500,000		1,500,000
Employee subscription rate			15.00%		15.00%
Compensation amount per employee					$ 25,000
Number of shares per employee					10,000
Fair market value at discount					85.00%
Purchase period					6 months
Initial offering period					2016-09
Description of plan					Shares under the ESPP are purchased at 85 percent of the fair market value at the lower of (i) the closing price on the first trading day of the six-month purchase period or (ii) the closing price on the last trading day of the six-month purchase period.
Expected life of options					6 months
Shares remaining available for purchase under ESPP			1,230,735		1,230,735

XML 38 R28.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Summary of Stock Option Activity (Detail)	9 Months Ended
	Dec. 31, 2018 USD ($) $ / shares shares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options Outstanding, Beginning balance \| shares	10,132,312
Granted, Options Outstanding \| shares	8,024,194
Cancelled / forfeited, Options Outstanding \| shares	(4,496,763)
Exercised, Options Outstanding \| shares	(622,192)
Options Outstanding, Ending balance \| shares	13,037,551
Vested and Exercisable, Options Outstanding \| shares	4,481,218
Weighted-Average Exercise Price, Options Beginning balance \| $ / shares	$ 4.01
Options granted, Weighted-Average Exercise Price \| $ / shares	1.29
Options cancelled / forfeited, Weighted-Average Exercise Price \| $ / shares	4.21
Options exercised, Weighted-Average Exercise Price \| $ / shares	0.08
Weighted-Average Exercise Price, Options Ending balance \| $ / shares	2.45
Vested and Exercisable, Weighted-Average Exercise Price \| $ / shares	$ 4.06
Aggregate Intrinsic Value, Options Beginning balance \| $	$ 591,082
Options Exercised, Aggregate Intrinsic Value \| $	561,591
Aggregate Intrinsic Value, Options \| $	0
Vested and Exercisable, Aggregate Intrinsic Value \| $	$ 0

XML 39 R29.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Summary of Warrant Activity (Detail)	9 Months Ended
	Dec. 31, 2018 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options Outstanding, Beginning balance \| shares	10,132,312
Granted, Options Outstanding \| shares	8,024,194
Exercised, Options Outstanding \| shares	(622,192)
Options Outstanding, Ending balance \| shares	13,037,551
Weighted-Average Exercise Price, Options Beginning balance \| $ / shares	$ 4.01
Granted, Weighted-Average Exercise Price \| $ / shares	1.29
Exercised, Weighted-Average Exercise Price \| $ / shares	0.08
Weighted-Average Exercise Price, Options Ending balance \| $ / shares	$ 2.45
Warrants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options Outstanding, Beginning balance \| shares	220,000
Granted, Options Outstanding \| shares	0
Exercised, Options Outstanding \| shares	0
Cancelled, Options Outstanding \| shares	(75,000)
Options Outstanding, Ending balance \| shares	145,000
Weighted-Average Exercise Price, Options Beginning balance \| $ / shares	$ 7.19
Granted, Weighted-Average Exercise Price \| $ / shares	0
Exercised, Weighted-Average Exercise Price \| $ / shares	0
Cancelled, Weighted-Average Exercise Price \| $ / shares	7.36
Weighted-Average Exercise Price, Options Ending balance \| $ / shares	$ 7.11

XML 40 R30.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Warrants - Additional Information (Detail)	9 Months Ended
	Dec. 31, 2018 $ / shares
Class Of Stock [Line Items]
Weighted-average remaining contractual term of options exercisable	5 years 6 months 18 days
Minimum [Member]
Class Of Stock [Line Items]
Warrants exercisable price, per share	$ 6.84
Maximum [Member]
Class Of Stock [Line Items]
Warrants exercisable price, per share	$ 7.62
Warrants [Member]
Class Of Stock [Line Items]
Weighted-average remaining contractual term of options exercisable	9 months 10 days

XML 41 R31.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Common Stock Reserved for Future Issuance (Detail)	Dec. 31, 2018 shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	29,290,172
Equity Incentive Plan 2012 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	12,452,052
Warrants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	145,000
Stock options [Member] \| Equity Incentive Plan 2012 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	9,974,645
Stock options [Member] \| 2016 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	1,230,735
Stock options [Member] \| Inducement Award Agreement [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	3,062,906
Restricted stock units (RSUs) [Member] \| Equity Incentive Plan 2012 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	2,105,414
Restricted stock units (RSUs) [Member] \| Inducement Award Agreement [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	160,714
Performance-Based Restricted Stock Units [Member] \| Inducement Award Agreement [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	158,706

XML 42 R32.htm IDEA: XBRL DOCUMENT

Collaborative Research, Development, and License Agreements - Additional Information (Detail) - USD ($)	1 Months Ended			3 Months Ended		9 Months Ended
	Apr. 30, 2018	Sep. 30, 2017	Apr. 30, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Collaborative Arrangements and Noncollaborative Arrangement Transactions [Line Items]
Total Revenues				$ 779,000	$ 1,153,000	$ 2,411,000	$ 3,498,000
Non-exclusive patent license agreement annual fee				136,000	192,000	381,000	747,000
April 2017 Non-exclusive Research Affiliation Collaborative [Member]
Collaborative Arrangements and Noncollaborative Arrangement Transactions [Line Items]
Non-exclusive patent license agreement term			2 years
Proceeds from Non-exclusive patent annual license fee	$ 75,000		$ 75,000
Collaborations and Licenses [Member]
Collaborative Arrangements and Noncollaborative Arrangement Transactions [Line Items]
Total Revenues				43,000	61,000	128,000	367,000
Collaborations and Licenses [Member] \| April 2015 Research Collaboration Agreement [Member]
Collaborative Arrangements and Noncollaborative Arrangement Transactions [Line Items]
Total Revenues				0	0	0	150,000
Collaborations and Licenses [Member] \| April 2015 Multi-year Research Agreement [Member]
Collaborative Arrangements and Noncollaborative Arrangement Transactions [Line Items]
Total Revenues				0	0	0	0
Collaborations and Licenses [Member] \| June 2016 Non-exclusive Research Affiliation Collaborative [Member]
Collaborative Arrangements and Noncollaborative Arrangement Transactions [Line Items]
Total Revenues				0	18,000	0	53,000
Collaborations and Licenses [Member] \| December 2016 Non-exclusive Research Affiliation Collaborative [Member]
Collaborative Arrangements and Noncollaborative Arrangement Transactions [Line Items]
Total Revenues				10,000	10,000	29,000	29,000
Collaborations and Licenses [Member] \| April 2017 Non-exclusive Research Affiliation Collaborative [Member]
Collaborative Arrangements and Noncollaborative Arrangement Transactions [Line Items]
Total Revenues				18,000	18,000	56,000	56,000
Collaborations and Licenses [Member] \| April 2017 Non-exclusive Research Affiliation Collaborative [Member] \| Up-front Payment Received [Member]
Collaborative Arrangements and Noncollaborative Arrangement Transactions [Line Items]
Total Revenues				14,000	14,000	43,000	28,000
Collaborations and Licenses [Member] \| September 2017 Agreement [Member]
Collaborative Arrangements and Noncollaborative Arrangement Transactions [Line Items]
Total Revenues		$ 50,000		$ 0	$ 0	$ 0	$ 50,000
License [Member] \| April 2017 Non-exclusive Research Affiliation Collaborative [Member]
Collaborative Arrangements and Noncollaborative Arrangement Transactions [Line Items]
Non-exclusive patent license agreement annual fee			$ 75,000

XML 43 R33.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Detail)		3 Months Ended		9 Months Ended		36 Months Ended	78 Months Ended
	Nov. 30, 2018 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2018 USD ($) ft²	Dec. 31, 2017 USD ($)	Jan. 31, 2018 USD ($) ft²	Dec. 31, 2018 USD ($)
Commitments And Contingencies [Line Items]
Rent expense per month				$ 120,000
Base rent escalators		3.00%		3.00%		3.00%	3.00%
Office space under lease agreement \| ft²				45,580
Landlord tenant improvements funded amount	$ 500,000
Area of leased office space \| ft²						5,803
Lease term						36 months
Lease rental period start date						Feb. 01, 2015
Lease rental period end date						Jan. 31, 2018
Base rent under the lease						$ 12,000
Leasehold improvements							$ 518,000
Rent expense		$ 264,000	$ 362,000	$ 915,000	$ 1,094,000
Lease Term For Remainder of Total Rentable Square Footage [Member]
Commitments And Contingencies [Line Items]
Lease expiration date				Sep. 01, 2024
Lease option termination description				option to terminate the lease on or after September 1, 2019 with 9 months prior written notice.
Lease For 14,685 of Total Rentable Square Footage [Member]
Commitments And Contingencies [Line Items]
Office space under lease agreement \| ft²				14,685
Lease expiration date				Oct. 31, 2018
Lease Amendment
Commitments And Contingencies [Line Items]
Lease expiration date				Aug. 31, 2024
Lease Amendment \| Maximum [Member]
Commitments And Contingencies [Line Items]
Tenant improvements		$ 500,000		$ 500,000			$ 500,000

XML 44 R34.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Future Minimum Annual Operating Lease Payments (Detail) $ in Thousands	Dec. 31, 2018 USD ($)
Commitments And Contingencies Disclosure [Abstract]
Fiscal year ended March 31, 2019	$ 264,222
Fiscal year ended March 31, 2020	1,073,027
Fiscal year ended March 31, 2021	1,104,070
Fiscal year ended March 31, 2022	1,145,861
Fiscal year ended March 31, 2023	1,183,092
Thereafter	1,732,566
Total	$ 6,502,838

XML 45 R35.htm IDEA: XBRL DOCUMENT

Related Parties - Additional Information (Detail) - USD ($)	3 Months Ended				9 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Cirius Therapeutics, Inc., [Member]
Related Party Transaction [Line Items]
Amount of transactions with related party for providing services				$ 44,000	$ 281,000	$ 94,000
Revenue recognized from related parties agreement			$ 26,000		120,000
Viscient Biosciences [Member]
Related Party Transaction [Line Items]
Amount of transactions with related party for providing services				$ 0		$ 0
Viscient Biosciences [Member] \| Study Materials [Member]
Related Party Transaction [Line Items]
Amount of transactions with related party for providing services					2,000
Revenue recognized from related parties agreement			0		2,000
Viscient Biosciences [Member] \| Research Services [Member] \| Scenario, Forecast [Member]
Related Party Transaction [Line Items]
Amount of transactions with related party for providing services	$ 142,000
Viscient Biosciences [Member] \| Samsara [Member] \| Primary Human Cell-based Products [Member]
Related Party Transaction [Line Items]
Amount of transactions with related party for providing services					91,000
Revenue recognized from related parties agreement			$ 88,000		$ 91,000
Viscient Biosciences [Member] \| Samsara [Member] \| Primary Human Cell-based Products [Member] \| Scenario, Forecast [Member]
Related Party Transaction [Line Items]
Amount of transactions with related party for providing services	$ 55,000	$ 55,000

XML 46 R36.htm IDEA: XBRL DOCUMENT

Subsequent Events - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended	9 Months Ended
	Feb. 07, 2019	Dec. 31, 2018	Mar. 31, 2018
Subsequent Event [Line Items]
Common stock, shares issued		117,769,919	111,032,957
At-The-Market Facility [Member]
Subsequent Event [Line Items]
Common stock, shares issued		5,560,514
Net proceeds from sale of common stock		$ 6.9
Subsequent Event [Member] \| At-The-Market Facility [Member]
Subsequent Event [Line Items]
Common stock, shares issued	1,723,422
Net proceeds from sale of common stock	$ 1.8

EXCEL 47 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 48 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 49 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 179 211 1 false 54 0 false 6 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.organovo.com/20181231/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.organovo.com/20181231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.organovo.com/20181231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss Sheet http://www.organovo.com/20181231/taxonomy/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss Statements 4 false false R5.htm 100040 - Statement - Unaudited Condensed Consolidated Statement of Stockholders' Equity Sheet http://www.organovo.com/20181231/taxonomy/role/StatementUnauditedCondensedConsolidatedStatementOfStockholdersEquity Unaudited Condensed Consolidated Statement of Stockholders' Equity Statements 5 false false R6.htm 100050 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows Sheet http://www.organovo.com/20181231/taxonomy/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows Unaudited Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 100060 - Disclosure - Description of Business Sheet http://www.organovo.com/20181231/taxonomy/role/DisclosureDescriptionOfBusiness Description of Business Notes 7 false false R8.htm 100070 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.organovo.com/20181231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 100080 - Disclosure - Stockholders' Equity Sheet http://www.organovo.com/20181231/taxonomy/role/DisclosureStockholdersEquity Stockholders' Equity Notes 9 false false R10.htm 100090 - Disclosure - Collaborative Research, Development, and License Agreements Sheet http://www.organovo.com/20181231/taxonomy/role/DisclosureCollaborativeResearchDevelopmentAndLicenseAgreements Collaborative Research, Development, and License Agreements Notes 10 false false R11.htm 100100 - Disclosure - Commitments and Contingencies Sheet http://www.organovo.com/20181231/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 11 false false R12.htm 100110 - Disclosure - Concentrations Sheet http://www.organovo.com/20181231/taxonomy/role/DisclosureConcentrations Concentrations Notes 12 false false R13.htm 100120 - Disclosure - Related Parties Sheet http://www.organovo.com/20181231/taxonomy/role/DisclosureRelatedParties Related Parties Notes 13 false false R14.htm 100130 - Disclosure - Subsequent Events Sheet http://www.organovo.com/20181231/taxonomy/role/DisclosureSubsequentEvents Subsequent Events Notes 14 false false R15.htm 100140 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.organovo.com/20181231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.organovo.com/20181231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies 15 false false R16.htm 100150 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.organovo.com/20181231/taxonomy/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.organovo.com/20181231/taxonomy/role/DisclosureStockholdersEquity 16 false false R17.htm 100160 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.organovo.com/20181231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.organovo.com/20181231/taxonomy/role/DisclosureCommitmentsAndContingencies 17 false false R18.htm 100170 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.organovo.com/20181231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 18 false false R19.htm 100180 - Disclosure - Stockholders' Equity - Schedule of Stock-based Compensation Expense (Detail) Sheet http://www.organovo.com/20181231/taxonomy/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetail Stockholders' Equity - Schedule of Stock-based Compensation Expense (Detail) Details 19 false false R20.htm 100190 - Disclosure - Stockholders' Equity - Stock-based Compensation Expense and Valuation Information - Additional Information (Detail) Sheet http://www.organovo.com/20181231/taxonomy/role/DisclosureStockholdersEquityStockBasedCompensationExpenseAndValuationInformationAdditionalInformationDetail Stockholders' Equity - Stock-based Compensation Expense and Valuation Information - Additional Information (Detail) Details 20 false false R21.htm 100200 - Disclosure - Stockholders' Equity - Fair Value of Employee Stock Options (Detail) Sheet http://www.organovo.com/20181231/taxonomy/role/DisclosureStockholdersEquityFairValueOfEmployeeStockOptionsDetail Stockholders' Equity - Fair Value of Employee Stock Options (Detail) Details 21 false false R22.htm 100210 - Disclosure - Stockholders' Equity - Fair Value of Employee Stock Purchase Plan (Detail) Sheet http://www.organovo.com/20181231/taxonomy/role/DisclosureStockholdersEquityFairValueOfEmployeeStockPurchasePlanDetail Stockholders' Equity - Fair Value of Employee Stock Purchase Plan (Detail) Details 22 false false R23.htm 100220 - Disclosure - Stockholders' Equity - Preferred Stock - Additional Information (Detail) Sheet http://www.organovo.com/20181231/taxonomy/role/DisclosureStockholdersEquityPreferredStockAdditionalInformationDetail Stockholders' Equity - Preferred Stock - Additional Information (Detail) Details 23 false false R24.htm 100230 - Disclosure - Stockholders' Equity - Common Stock - Additional Information (Detail) Sheet http://www.organovo.com/20181231/taxonomy/role/DisclosureStockholdersEquityCommonStockAdditionalInformationDetail Stockholders' Equity - Common Stock - Additional Information (Detail) Details 24 false false R25.htm 100240 - Disclosure - Stockholders' Equity - Restricted Stock Awards, Restricted Stock Units and Performance-Based Restricted Stock Units - Additional Information (Detail) Sheet http://www.organovo.com/20181231/taxonomy/role/DisclosureStockholdersEquityRestrictedStockAwardsRestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsAdditionalInformationDetail Stockholders' Equity - Restricted Stock Awards, Restricted Stock Units and Performance-Based Restricted Stock Units - Additional Information (Detail) Details 25 false false R26.htm 100250 - Disclosure - Stockholders' Equity - Summary of Company's Restricted Stock Unit Activity and Performance-Based Restricted Stock Unit Activity (Detail) Sheet http://www.organovo.com/20181231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanySRestrictedStockUnitActivityAndPerformanceBasedRestrictedStockUnitActivityDetail Stockholders' Equity - Summary of Company's Restricted Stock Unit Activity and Performance-Based Restricted Stock Unit Activity (Detail) Details 26 false false R27.htm 100260 - Disclosure - Stockholders' Equity - Stock Options and Employee Stock Purchase Plan - Additional Information (Detail) Sheet http://www.organovo.com/20181231/taxonomy/role/DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail Stockholders' Equity - Stock Options and Employee Stock Purchase Plan - Additional Information (Detail) Details 27 false false R28.htm 100270 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Detail) Sheet http://www.organovo.com/20181231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail Stockholders' Equity - Summary of Stock Option Activity (Detail) Details 28 false false R29.htm 100280 - Disclosure - Stockholders' Equity - Summary of Warrant Activity (Detail) Sheet http://www.organovo.com/20181231/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityDetail Stockholders' Equity - Summary of Warrant Activity (Detail) Details 29 false false R30.htm 100290 - Disclosure - Stockholders' Equity - Warrants - Additional Information (Detail) Sheet http://www.organovo.com/20181231/taxonomy/role/DisclosureStockholdersEquityWarrantsAdditionalInformationDetail Stockholders' Equity - Warrants - Additional Information (Detail) Details 30 false false R31.htm 100300 - Disclosure - Stockholders' Equity - Common Stock Reserved for Future Issuance (Detail) Sheet http://www.organovo.com/20181231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetail Stockholders' Equity - Common Stock Reserved for Future Issuance (Detail) Details 31 false false R32.htm 100310 - Disclosure - Collaborative Research, Development, and License Agreements - Additional Information (Detail) Sheet http://www.organovo.com/20181231/taxonomy/role/DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail Collaborative Research, Development, and License Agreements - Additional Information (Detail) Details 32 false false R33.htm 100320 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.organovo.com/20181231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 33 false false R34.htm 100330 - Disclosure - Commitments and Contingencies - Future Minimum Annual Operating Lease Payments (Detail) Sheet http://www.organovo.com/20181231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumAnnualOperatingLeasePaymentsDetail Commitments and Contingencies - Future Minimum Annual Operating Lease Payments (Detail) Details 34 false false R35.htm 100340 - Disclosure - Related Parties - Additional Information (Detail) Sheet http://www.organovo.com/20181231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail Related Parties - Additional Information (Detail) Details 35 false false R36.htm 100350 - Disclosure - Subsequent Events - Additional Information (Detail) Sheet http://www.organovo.com/20181231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail Subsequent Events - Additional Information (Detail) Details 36 false false All Reports Book All Reports onvo-20181231.xml onvo-20181231.xsd onvo-20181231_cal.xml onvo-20181231_def.xml onvo-20181231_lab.xml onvo-20181231_pre.xml http://fasb.org/srt/2018-01-31 http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true ZIP 53 0001564590-19-002298-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-19-002298-xbrl.zip M4$L#!!0 ( %2$1TX_Q0%0]N, *]C#@ 1 ;VYV;RTR,#$X,3(S,2YX M;6SLO6MSVTB2*/K]1)S_@./MV7#'I6B^2=G=]79?WT?[_/7>.!!:'C>S^_ MZ+8[+PSF6;[M>/<_OXC#"S.T'.>%$4:F9YNN[[&?7SRQ\,7__>O__E\__9^+ M"^/=AUOCRHJK5X^-CVYZ&EM^V_/FKJ>/!=8[I7H0L>' L%KXR+B[D2ZX#9D8 H/'. MC)A!_[TV>IWNY46G=]$9?>V.7W<'KWN#=O>R,^ETQ_]?I_.ZTU$>\ =?H*'\ M]]KHM_OMT>5PW.X/N_V1QYS7?9D?) K;1F__GK=-JY< MU_B"%X?&%X:+9W9;/.O[7> :0!\O?!U'P<\O%,SA3VT_N'_5ZW0N7\&O+\2% M3N@/>MWQRHO[K\05XH9U%PKBR4?[WH.?N1RN-#W_@5,0ECGI]OI=>34^RUWS M=-?QOMV98?+T[_A%YOK'/EW=O;R\?$6_RDL]0&8\+WZV'06OHJ<%>P477"V^")]Z:Y*'P5_E#\IL)W%%QJ,R>[XI!9[7O_X17\4'"YY<=>%#P5 MWR)^Q-O&N=OB( !%L^H^\6O!C>R[-2N^"7\I -#Q'E@8%=_"?\.;^CE\18N@ M^!;\I0C!CK7B>L?"R[O9RSW3L<+B&^BG@H43OSF%S#CBS.B\ *UA&*0WW->A M-6-S\PN;&B0\KY&;?GX1.O.%BT)'WYF!%?@N*R>F=, MVCM(<7D%\8HO*_:A[^&7.3+0[?^5?__1*?J;;7N%] M2T\06O#WVW=+3Q$_O8;?MGQ4'B[;>7!L)CZ)FSZABC$C/TB^+O-JNNI5\?WT MV'?,\^=@6E8\N @SZ3.7;_[IE0+[BG4OX$%+R,,O2V$-6>AK /9EMOP0_.VU M^+'4P\ AG].HZ4'P?>O\8?5#[%\+V+?^7.N_]GI=+J#RW%OV/\G.79XJ?P-S:_8P&G>N%ZWO!5>7*U?XTZO"1RLF( O-EFJHVWEF-;0S MF<>2S&--YBW)/"Y'YG$=R/S,5ON4R'P$IV)W:99DUM*\O327(O-S2+/(6/P* MG[V0I6@X'>,L5OAZQ1+/Q3IO)G33S?,Q"5TC^UQ"HAMNH(\KT;6QT"4DNN$F M^K@273<;_4L \?GIV65E66=FBW,$/17[^UP$K9_-S4OHB=C9YY/0NMG6O(2> MB#U]/@E]=AOZ_(:Q[D;H^2U+W;7X\TMRW:5&*(;;")Z#PO[^SQB@O?;G"]^# MCZ&J$^';N>_=1K[U335USU'7VE$A2K6W=GFI=EQ:8-4Z\D#EMVV(>&7;#C;T MF>Z-Z=@?O6MSX42F>YH$7;O8$R3N%Q:9CL?L]V;@.=Y]>)I4+5[E"9+SRK+B M>>S"E?;G:,8"O"I@,T3; _OH6?ZQZ0WB0&VM/TGR!-'$X5?;G]OJL.<6:.J<]>L\D2= MXBRYJ56=!5,_F.-V^;=FR.PBK)P(X7GC>NGUGB@+W,9WH6,[9O!T:[KL\Y26 MG;##5?1UQGXS@V\L^F!:C@OK:9H]7K4^P0 K5]@0PUL!&1LEQ+6A9TWD]U?? MN__*@OE-'%@ST& 8X3L1KN/MTS6\XMX/GCY//X)/*J^P<[:=F?#]%0#$'ICK M+_#6JR PO7MR8QLF[CNB(^,&E$%(L[3#,S))$^JF)\$DA]]O+E8K?FN:P=C< MOIE9V(F:AXV<>@T/"$PK^BI=_P]^0!F)\.U3)C+X9/(\(XY"'I?J@X3+GK\=O Y\ M>H9;@+1@U'TG4RT$XT0LO1:,NKLK#1.,,]QCJ 6C[ELE:R$8Y[>U3PO&,?=: M7=G_BD/*W82 JD_L\"TP7<'-ESQW/"<&5QQ-ESL&[*+7V\_4O2K/& M"7H8QV>-6OL8Y;7&Z7D9QV>-6OL9Y;7&Z7D:QV>-(R:UBMKPW\\7KO_$&'4\ M?EX@QIJJ&U:TX*]*P/95[[YUH(!F/O&7BL 2]<4WO MDSE/Z9E11[(3%*]J&!'5A0D:;EC:&1"N4?;R^!2LB<4L3^JOC_[7F1^'IF?? M.M\CQC)2VZ3TRS;$7[7J$TV\5,,.S4JYU)X=CI=LJ4@[G*QI.))V.$8SX1=L MJ"$^@ ^_.9XSC^?9-BG-+(=AEC+P8/]50J$7?\6/&1J=/$.:WS5#UITA51J= M&D-6ZS\U*OE<>X-YG!.3GLM@:F9IG,&L T,>SF!JAFRQQ<$E[=!RPW.V'4A%W216N4C+AQE4WDO$S'NM@B75WN>G^6 MX&F54;H_\J,(]\M4PP*33[XXUW7>M177Z%]UQO>2YU]%TK4:>>YW- M(;5@@&>09\4;>^_Q*TN!V:S'/A**FS2NXQ,XSP+@WJCO="Y'6S% MI#4=%WFLBGD=V%E;MY-CYV.9V#W=[69U?M37W3Y>R\>^#-"HY&^=&>!86R4J MB;<:3OPCA5D'ZNK=+]6NR7YB2?<#-(S7P0G6O+AK0.\-ZS#V4\-&/A?/^)5?1CZ\FY$$)68SWVCW[;8G+A6G8@?2>;>?V=6 MC'NREW0*Q%6]0<.X@G3)SEBK4M>L4';RYS6X/R#34HC7&]25:8GI)KV>_*.O MN:_"X'YRT>N5.$ +NL?]GRZO;7:'W"%X]VKNNQV9@;\=CR%$^C$IU'0NP-X M](Q]]IAFLXJ5G$*(5+5M00K-\@=E^=Q49\WRQV/Y9QOA?.XL/PN8UO-U8?J4 M&)KM=V%[?.!F-'_PXT"S_"%9GL#:AA":W0_([A P:W:O [LGA#@U=B^UE[(N M+H\.;&OC\)0.;,O 2UT6NB>6^B>Z:*TM7*,MG!:X5'-V=95EW-/:V'D-9,UP,AK=J^,W367GPR7/_D MD: UDFD@:+_1UK@V,HVT[=?AY,:8 I^4I MO;V-[)I,>CH>NVIV.Q]"-ROU5B]"U^CHX'T,4*D9I8/&#"NMH^W9;U+JODP* M##@H<1@7'VE:'9-^<#QP$1W3_0B^=Q 3^A6'YQ]F$)BYT_3JKX%6+"IU+S++ M:E:V8GN"-]6"+UW%#&>[YLHM9X)36>9C:MV0["XBJ?TP9FBORY?<.V[KGGG![R'NHB;.PU* M^E>"-GG$Y>Z(JVJ;6A$#I:IZ!0L=N@FKS.'C598R3D60&E4]TX)T>C7!$Q&D ML;1(8RU(6I"ZXW(6::P%J:#I4PN2%J1,@ZH6)(4??HO=R/D?>$?R)AT?;12B M34@[70'2L=%. J3C(BU .B;:78!T/*0%2,="^PB0CH.T )U]#/3WV&/+;5V? M?._]=\N-0^>!)>^:3AW7H>!8B92S/4;G&A15A<73%;$SCI(J%;&S#9NTB.DX MZEE$['P#*RUB.M)Z'A$[V]!+BYB.Q5:*V#MFT9-U/+:OF%6)R=,5M3..R2H7 MM;.-R[2HZ=CL647M?.,S+6HZ1GM>43O;.$V+VDG&:I(#_N%$L^LXC/PY"]Z: MH1-^GMX$@)WL<>1? ?_PI-\ Y, QW5#>_5S%[%MXG*?#O_T+W'L@LM;"NPU^ MR[%^"M)ZYM=QZ?FJE;,-=;5::;A::5@,?E9JY7S#>JU6&JU6&I=O."^UO) MM*63+=4Q;5VJL+J,TSQ>;VX-MG'%DOH*FBYL:$$[H?)!;05-I_JUH)U20KV^ M@J:3WUK0&IAB/KR@W;)%M-3@*7FD<%C,IOC.CWP8\#I(FRM_)OL6<'S 9,O7?N9]'3!^>!?9Y^ M@:>8=RZ[_3,V _;!]R/SOK$EFU7H$=Q;-8).S779ELF^L+GI>#8+SI>-RJ'@ MU!B%"-GM=Y(_#D[1;0/D+B6)-F*D6U4NB7B\^PRLO=6IFYUN5:=NPN.&G9YL M":O#0C,4'UYT>N6:H;H5RD"O,WY.K;851@ =X[J:CROXVFYRHJ:,@<@M\M1, M 'CF7W#Y1%GX\)OYW9G'\VR(MALKU)D#,"!)UOWBK_@QL_(J]]+4@,L.>Y#X M%^8"%]HWP+-/7V&9(02A@ $(.]5?$H:Y=@(G#K]"8&HN6!PY5OC1L_Q@(0Z4 M:ZHR*8\%0?A2>#@U?7-@EFE:]K-Q+'.$].*A6:9A6< &LLRQTFP',TP-J]PW MCF5J5!JGPD(4VT_)WN9\^6(K'OO#"2T',/'6\>D/BX5GX_"L7/MA2PR\XE% MPE/SK6K!PJ>M&L^,A6NEA64!5'Q_*"86S[N-X";$W*W%/!,6HI:TY7"ZN 1"J9?)[(W@3,W@Z>_Q7/3NV:N^]8,@:?XU=J/ MJJ40 OE?Y^@O[<\*#G@&T2_!1Z?FS)V"&&I?4(MAPQW2 XC%B>>H=Q:+\\A+ MKV>-T\Y%'XLUGCW_W'3CO6\,W)4Q<%]SL;;[VU*DEF%XMUP8WM[W7NFIALR_J+,(Y<7=$/+?L^1H;ZQ MM]T;U93:RN]7+.81+KQ]L]_K_ M[A>]7'EV^GKP_FS'N[]]FM_YKOK*X7:O_/SIC\_\I9DGIB_BOMT7=N^$$7B< MT2=SGB'Q:,OW??GEZM/G/SX;?_O\Z[N/GWZY;1D?/UVW.0A%[\I#GK[^.@R##$ 7\/MD.@@L9QJU[?AX!'QR7!=?P MP[T?9)9_N=W+KRR+P9,P:C#HF2H6,B_)0W [-\&OCD/'8Z'*[MTM%5D4Q$Q] M:>:Y^9>^G[/@'OCSE\!_C&;7_GQA>NKRN[MKMS4O6.(^?S[W/3)6MS,S8.'G M.$+/!25'!6:#XD,G >"UF07!BAO^_.+CIP\OC-AS^.6__S.DAX.N[UX.+OO] M03?#HFN X GIZN8(6[CQW_>_QD[#V!JO2B\BJ[-('B"J_\PW5AEX.XF?4FX M4^"^Z&? =D)_T.N.?[]]]^*O_6&O-X#;?WJU%31[+F"CQNV77L"@/^Z-]ET M2)D?PT5?F,7@ACN7?6*1$'45[DUJ>PO$#P?C#-3K0-@-V(TZOSR2)Y/^CL#^ M@A9"N4X%<),EV *;W1P3YU];'JB-QJ$\UKJ#X19 ??30AP=%#JA4 =ID,+;! M4F=PF8%(?6UDI+0')7J!O=,6WX+[N:+ ?["NAK-+^C =8 %=URPX 56E/1F,T)^4 MN@E\"":CIQL7)!LGC("]H3D\.:FIT&Z JS'*D74U#+M!6Z'AZ(TGDQVA_<(@ MO' L<'S1DG_R/6N9[I5:D*RDKWK]]D!6:5%V E*1\V((JS0Q@ZPT%[Y[._#Z M%=J<[K"W+7C\5Q6>"NU+_W(T&19HFTT@5&@G!I>3'%<5@B \OAOS"5V791W< MK] HC%;XQMF7;PM@I49BL N $$G;OSKF'29*'59@R/H5&HI>=SC* UD,P YP M5F@B,&[>!4XYWTX]DU3>\U0 @AE0-D/^ IMR&@TV1/X=VS*X&L; M1V-=P[].0?39K]"FY-33RM=O#^6@2M.24^0EP5PK9X,J30V)F0+@)@%;#UF5 M%F@TG&P%V5J6+?0A!A5:I[*RL\JAV 'Z"DU7][*\]*]:P3)K%X-=H36CF&RM M=.T+;(4F;9AS#\H#JW"^"EN%MFO06:T&2L%2H2D:]G*F?R4LF$QWHCDE!J$J3 M8MTM@+JR050=WS/=&].Q/WK7YL*)3%>Y206S0A/3FUSV>UE%O1F6?6"OT,#T MQI/AY7 OV+^PR'0\9K\W P^8.(2(()['U#H)JA3;2538*[0R%W#/>)Q-$6P& M9A_@*[0Z%SUP\7J=O8 G8LQ\UV9!B*FY2"W>#BLT0_WA:)QEDN57;P-:A59I M,!A.1EN!II@MG%B^%M *3=1R\F@3(#N#/:K09BTGG+8#6U$;-V;P.:#F7IO4 M]PT+J-:N0KZM2Z964\'EU>8B/=AK=O M#>*V)FTUB-T.>$'#\;X@%G?_C+:U9ON@[_'Q=9[<$S.ZF:WJ16 MJ%GGT>W!-+NHFOXHWP%S7-2LDKG:2 M\FYW6"N?:K+=]L62JFS0K95[--F0']O-F \N*W9TKOTP^CS]Q?=M-;RY]5TU M0S79F$3;0?*Z_=PNI)60[ +QAIS:;G)TV3L@Q-MM\RS)+Y-\];9*B#>DV';B M\'&ND[4LQ,6G^XJM&RK0&\M).[!R?SS)A_-KH-D-\,L-!:6=.'J S16'!GR[ M':QE-V;U!WE-6#WDFXSQ+@S>[5_NSBRWS'5Q+R_S6&"Z<,.5/7<\VE8>.0^L M8 D;"TJ[L'M_DA72>/+P1'6LLG2[B0D MH\%P?Q9#VX%60_RHMI1=;JQE[1)+]'/:- ] >? VF=9=>/VR,UKV7W8#;[N9 M#"4=^-ZPUZ\$ONZFT3.[^=[=[F398UT-W^<%3J$ GL7#G^;L5S_,@'B(8/9B M-,QM[2\ 8BLH#Q&.7D#(?5DIE(>()R_@^FZO4C /$1%>],:CW([1C6#^8CH> M?OO9>^>$"S^D5L//T_RFN>[&H3L[\F@&VK7 [ CW(8*_ X-\B.CO8M0_.*H/ M$0/N!C).0PBIG9OS_4> *H!O5&@/$?SELP*KX-@:VDUSAW;,!4X.!.TAPKR\ M.:L.VD.$=OW^8 =H/_F>G]782TYV=_, HUT8-]=4NA*0'> ]1*R69]TJX3U$ M0#;(J=\JX3U$T)5GWY+P\I^^FM_%KV\A1)LZ&6$[1+"5D;-""+8&\Q!!UP' M/$3PU<\IKDH@W33[:%_GH!28GUA4Z(UO'GJTDW/;O\R&-IG7EX3L,$'7^+*[ M-V0'";2ZEZ/9HI*78W3T7:3X\>9@'/C:1#!'\7!4-P&H^H M0X2<)X>D0\2W1^"F@L<7K?80\?&R35P#S"Y0;QIWM;.]S&>CJX7Z$/%R@2VM M&NQ#!,YD9_.Y]9)@RXVZ/#+V#G,+O, KK/L("=X^XR"^CMRD+_ !LQ@V^O'B!< MOV>?8FS[_#RE&Y6]:6O6M7.$WEFQ:6[4&XZ&(V7'[&XP5KW.G4/\%>OLC/N# MX:C7K]LZ=\X1K*(GV'#L+ZC9.C>-(ULMCZOH.0*2CGL5\^V:C:K=M1/+Q .2 MT[CX[GZTC;Y'N,'Y)-& M4>#/SJXP G[%#UJ8^C("6_=D#:P1&Q;N9--4L]-/K6>3?;H&_%[)G= M4%DPVZ89V%SG:FV#S?P\F=W06#2IIAEX7.?Q;<65Z1R>5?'R;JAM'$8K'(!4 M9G!/12C@Q0$^B4Y^XO:%?OR\H.,^WW]G@>6$60N_SC.MP"J4#+*EG1SE M]FUOO[92N*%!,AM1L\Z9?3[49-NR2R!G]>(JQ,TZ![AB:[A+:?BR+HA:.UNQ M*D.W7R+YF-BIRCG?TGPU%V';'8U8L@NHP/'9?GG\!.=U^OIW#\S>^_G"]9\8 MHU@N8%;D!\I#O]S^#C_WR4"O?C%>BR?YH MKQ']?$-AVS504'SV*>FX[L[4Z! M+2WCP^/*.#> -_&=ZUB?IU,69-.S:\?/'L.DCS:;GJ(EE>22E7A8.\_V.#:X M).-4C(?*(H*#V,S1I3BLX+G14E7R_@@VKF),5):'KX5-JA@YVYT<7YKG]U % M,JI,.ZC"K_X*X23%>@>VQ49B "6H]^H+ RJ&3L3$= K^PB_,\N\]>DKN?(;N MVIG$Q]&EF;,'#HN(XZ&]*C_\,*J[?YDK.YXN(:IRVP^7^H*=YNW4URB'? M;8F'<*NWP/NZ_K:U8Z+W%_R2>1,\M'0I]<$2LVTC=B+Z7M8.C MJ]6Z^YT[UPQL5N4&KE'V>QXCUPP\5M9GLI5QV:,OH.X873OT>EM'N,29>?NC MH- D;QI67=5^Y%4F.1V<,9!FRZ&8"OYVF=C">35'KOLW?:\NX1 .W:27/V1Y,TS[ MK6+#=J^="'&9&V*X_2JN7->W4-'*C579D'=YVLJF8=(5!>FEP-IW*1LV>NU$ MDF'^K/%=E@)Z.&!PY3O&__WH@4GT8S"37YC%G ?4Q^I"#E*-[O?S\Z8V [7? M,C;D?W:C1VZP4_E54 5E^7(Z3*)X 9O&4N\X>U$IF$9JOW6<0A;?M'M79;@ MIBW7<>TOGQ4C;U=.,>]M&J2](VDV&IJU\%6VN$.:_[W6ML)WD#KP2R;>[6T: MTKTCD<1.MQ*P[ 3T(3P!$/K^=D!+,GUBT;49SB"4?W!L9K]]^AUBEH]>,DK[ MRHJ[I"G\L!5L:C#V/E^;S"J9%%@<60AV_HS=@*62;_@ M-/[EE%!OTT3PW2+XK!8K#U@5"SJ$W;_L5+.@P+<8LT,\E"S)D.%!AI'IW3O@I"W!OFG ^-XU[$VP[ 'Z(6SW M> /_KP=_A4+C0\!7:=M-<\AW3&,MS2PM"5D5*SJ,8<^Y5=LNB1P"59:P0]CT M+) GI9P..NT?9D 9&G5%!VI:5C:W;0-9!0LZA(D?]P;]?1:4E[HOC(JA7_VO MYG=TE;%H!X3]X ?%265U?0<)ZG.IX5WAK'ZUAW %<@VS2, MO8J-Y!OAV0/\0[@%D]QI&%O"OT)G?G \D,Y5ZGS3#/?=E!\ER#:K\P+0JEC2 M07R'R]R8JUV7]'XZ95;T>?K^NS4#;X-] 8'[[.&C\'_H-0U\G6KR#Y(+FFH&*;"73C0>X@SN.B$R[-/?(*_.<@>()GYC;-]38?^+ -'OK]92G= M"$UV 5FT8,\PG=>AVL!-QSUL=1!>KK]KU>M7G-?%0MSXH,)V""]_Q8EB_.6E M(3N$"]S; K1/9A0'[/.T4!XWG<>0P]M?_]=_NM&;A1%&3R[[^<7<#.X=[^+. MCR)__KJSB-Z(;R)_01_QN1>.9P,E7W?^\F8*;[IXI&GDK^]\U^9?A,Z_V>LN M7DX?I^;<<9]>?W7F$/)^8H_&%W]N>N)2?.]KSP\ 0_SA$1X@,X4OX%N/\:L> MS, QX8V&N/#%?]Y';S[Y$4/@\0H)OPJ/>NU_FO/%F__HCCIO$Y7>!E^W6T; M[UAH!0[E* Q_:KR-0\=C86C0=0N\: L,C4ICB):-6WP<:QN<;8DA8A185KI\ M/^&92A>X!<6SU-F7"3X']Z;G/_C&WWC6+VP9(#OM5KKBE_S/2:_7*;@Z^;'[ MQC ]&T3'=1D5LMPGX]&)9H83A488WX6.[9C8K=D//)' MPPG3WTWCS@&>M6:>[_KW3_ NNMY8 #D8GTIBHG[X$PQ+R")D1VPG,Q6!>@-< M^0O:8!EQN5F2R R[$]T8]$Q<(2 @J$S"% M!#/NT;8CREQGRBZB&=[)&CQ3)&4P(HG?';$D5#W@3F']UFQH T] M1 7'^.;YC_!]:%RY\/U%]P*>ZT3!TP(4$2!WZE@.GK)EJ'Q\U;WZJK)9"^B- MS;L(/\#R>_NV;7SP?9M0] YYYLJ>.YX#)IE SD"I/OC#NZL,^TI8\1$V"YU[ M3V3Z/5"<%NW],M#2K<;!U G"R! UL'N3;W(DG<#A6BR )_A#54 ^?GJ7 40P M//!;!-J((:60BA8Z0K897#PQ$R'I==K&DI#C76!_?107XL%_XZ.$H$S]&!X@ MP%+D!")K;(@"L?PW2 .H+- 'X0(W=<#]\'8N(!9SW9"P#+?*Q_%K)UW<@^";ME0QH& O3-?R9SX\W9B:$:P_*V?NO_U;YG;P5?C6U["]F\WM]NIFD]Y_M]@B @V#NH5X!H38=(&! M/!\9UP](2H67QO7+(^ :A)A*^B&*\Y3AX7I<#9:V8%G+).5QU26/;-4O?APL M64;EYSA4?P1>A) 2-"<_*6F5YJW C%MS'H((&[>D/YET#.A1R6M^;_\7?/5K M9+?A5^,W,P";@+YQ2^C1_VH;J<=D/")!P6K?X>9B[AUDWYK1?.F-[92QE5K, MDA>?V\0*RI88QXM$8S/M!W71'H1?@7'>NK[U3?7\MSO(;!O/O[Q?^VR>O]%K M&[?Q?([N#6@Q!5M&BBY#XNL4O'D\S2G$M2Y 13#A?! [HS=G.0N7T<^IO*&E M/PDO'YT+TQ+^,M(U]DPP9A'7+J7US,Q\8,8=8QZB< %>GXW*"Q\N0.1XN.:4?*AJ M' ]\L]CB>@84X0>XPNAV+OZ;KK@*( !P&7R!!/["[F-^PJIQ>_'_VL3O 6I+ M]XGTUI-A^ZB,#0]Z M"HECL,SG18R]5D]EF;YZQMZ&@R45(R$0N-T%66+9Y]UH,8%O@!6 "X DQ)3P MAXQ(DT<3>Z;G^ZHBQ#!B\@A4$**,TB%CBB!B6"@2*X!/B.!P%=RVIA)<+!A3 MX25)\5E0*2R4R@_N Z\!([^06-I,IXFU1&R'49WOD=>%"*>U0)@4!P%%A5(X MGNA5)GB^3I"B6@3?*T(:"?#"#\EW18MDNH[0FI956"3>DG%[;3F5]899K A&F,FPGC\0!Q-#*5>>D MQ'I']=?15R&&Z<0 4BN8MI]DC/&S!^ H[@$-[S(#HT3(WJBIZ;J*IX/$8)Q'G_6+AQZ2'3QHX ME419,Q+WJ4!+;;4,@.V0%N& H#EAO/G")[_KP?'C$$0M(+7![,RJ/##TKA^& MF+0KT+/E['[M1>A7!]2_C0;@--SS*[)[24(P5>V*J@1N$*1.C!Y+*YEXO[E8 M!/YW!ST28(\?^L-VSX 5N%) @J2BR&^'6W[HM+OR&NZ,YB]Z!.L"#JQ]CPY\ M2.E]]'B ITB5/_H&>+<19A]0OL#[=:(,U([B%X. S$'D2.S@62&W4N!M,^+/ M$ RWS;A]@"?.0ZD=7$H[XR=*.)J6R-AG4^F('Y.B$3ES2V1_HP+D0$C?GJ38 MB9:1GWTXI3_Q#1Z[Y^8ME3KNC"MICN77=8?M?O(VFR:8<[WG>)AM]*)9**Q\ M 1PGDM7[.@O\^'ZVF9)BX3*W<0W%W _=#D["UZG,N\# MQH2_3E)YYP><,]5? $ST?\4[[PD9[=2)?+<5*[9RDHWC^(UA:SCJM(;=@<'' M\%0C1J7R:ZZD1DXJU:\T%O'LG2S04]06D7*-A!/V M'?YX9.Y#P@A)FJ' X2$&H/P"911.A"*JTG\$9@.LH+ EXT5E#8SC-*#2)N$6 ML21*N5*U(+K5 K0L8%$Y4Y30+%0Z&/;$WAS8?\YL^N21# @?-EM-"A>@O63) MK/#5O X_G^.&$:RV)6$& @0B!7J011BXR_(6/HFK'/[@,(IM*F*1F*\G5RB'^]&SA9R-& MR!N(>8M&(C.,SY()$YW#?1T/I,.S6^O5;E[59E2IU,EH&=;J7*YE:2U"_1H+ ML=4JJ_HI/2.%"/5=RF7"*H&(VNPN4JP3-MPL1'3L8X1"=B PG M?8A8(F(H;YG*?2N&R5-$\SB 0C:4!3$F =6N<[@\N,@7= 96@@69:7(;.VKH9A2N M*.;I?QM$-40#;HHM!"@;:9\ EUR& 8%IW/O\&2 0 69!IUEN%CVGM*C 1-A4 M9B8T)Q9+%:QB'R]@"=]B7C?"OA%XCNWPOA^).?;="4560F78'&P$3K@,SQU5 M#GC.E,MR@JO67P&F$_4 MCZR=*^:;7&FAS#E+\GAO%5E4EV%'&S^I5QGP]Y#S!! 5/#)"G$H'72U[8S)>H4&G(J'%F1E-',;C4A M?"&MC#]2^@A!>C(*E]D'TXT3+)-:$$&9I>[F%IY(*ZE1IK>!9O0?N7:B'C4: M8&1$YG=\/ZN9QC7B'I>N62A;, [+'4'2.K"3.:8CLEV5"G)#42A/" M2^:\DDSK%=9,.H]IH%R9L\IE'^0F\C"%E_:X+2"6GT.<$?/@!+FJJ/=65IA, M"UR!.1@:+,,[42Q".]!HMT:BTR4392N?D\ MQLSV"F =QB5_LT '4LR*16]Z.$2MH,R+$]A$J$P-KR"GG=5J?3H5M_ M&$W&^('*PPO95MXJ7$? IUA(KVVM=*R.W92@C0N'+"-9X!#A&K_Z"V#S46>4 MU.A+),ZRGB+'Y+^S-,@GC/LCP@+95L02U:/PUL#FF?@E!,C&$25S?"KLS_?F M(JVN0.Q=HY"7J*8H&K@_)'9>Z66[%57%T'CK8W$QT[=]=?LVHV(*[[OV[;3 MF,GUWF8JZ*V435IE.Y*EC2/YE>,DA8*^3L0YTZ^L0I"\,%/)+_GN[&/I4&YU M!87FH:LPA5X<[BISAD\X4X EX)3XP$ZR]@:OSEXM7<+G6*! M-&U30N-J,;SLX4?R57'N?_%%27F\_,M1Q[Z$!R>LM(:35CX5D8]^=CAUF T& M*$I>@.:.+5)G/=$/X%F'/#'(C'L?.UC@30F+)DPK2,I,8#+YS%9Z-\!(25_Z M/;D)GZ<\CEKU*&T@BCB"4 Z]WI=Y45Q$\1)SM4U%ZLQ4\*B3@HN-B/8*R(/O MH?T;XO0&2;#4HJX H2PU\.DI):J--W8-+PILT'861YR,F7CB)Q=M9#JOLI5% MF>Y9WA( ?KU+3(@>UB?XX1>,*"W@N"35*[6P94SZ:@6[ M@S)%!]J.L[K&T)+%D+WV_D1,9/FD0DBV Q(,:>@C^W:LK(U.%X<_8 YD'KL1 M]CBO$O$TW.*Z7T5?6BH2>UW$TUM<[_/TBDQV*+V3N(I0OE""3Y5O:OF4CUW$ M 69'(ZD,R 6VC7B!8N\'WWCE4=8IP,Y2UB;1,O04O!>YS(^I)R/R8>DOTPA2 MA3J_J2\I0&$4B?O'?N0TE&:)"EY$#)G O'M*(EJJ3*%GC,WOU&*7.39I4?TJ]7/R-H)WSTE? ;$ND8XW3F.(-+,H MYRY#@'3T>;5+?3*G-/4!4JE!!$14>H+ [@&K%;PX.X?% Q)=L+I)OXC0[:(J MR5=(6@<)R.U^0D&'K">N&QN N*)2[C!)B2G->O@J%G@\LHPQ->?P[:^^V >; M"=\%0M*",X(99;+^8/D]'U,KZ >S/V.^J8U*/2BIR[L7MM#PJ4(GDER@W4*2 MJ,YPG(T&3J7._T%QUA)-GG,8A+AM$=R125%S)4\$&(<*CK> MQPYMV*6@U%6]W+7>]3))IPI7)$*2&GKTHR%D^R[*"DE4>BI>[TTV:XS]6*?M M^ K)6G)\5^U]%4TRW&6]^#,VJ5R*F]C%(Q)114Y"]0]63GK1F3?WWTFO(>M< M(*O+>^^>:!B#$7(H4M.Q,CB43E(FH"X9NDE/"ID\*K#3JF\@&@!"U?JO,CT" M)E >3PNQC3OC$;6-FRS4/+.2YCJC8OW+^5.X':DR0N01#U"W7"9WE#=EZ^9. M6+)%3CP9:;/BL8EG)*J7TAN#A9(3QD.<$,\JPUK* G4)ST3]4?Q H$!J+WBG M&-D02G?!5P\T.FO.P%FP!='D X0RCN=\5XE_)TKZ0IZ4@BQFW=+A">#@A]0X M*W].6[&E^ENB4S9-5X3'.SP%."6-W/R1I"Q6I_80!3*?ES&DF78)W&T$D276 MD1,EG526Y4J6WH-AF^*0IX(&&CI95GQF#_ 6RNS)/ZR08 MY._A66? MNP\2C<9>;ZBMO':G'HGZTPI4%8-6VJ#7;8J6-6>/,MW_>#U?W3HOQKL MHD[<>B_B11EJLRW5-L 39(EUE_TT& N $& $OI1YX:D6''L#\N:"C7M@2;/L ME+%0U#?P K R.&$(&3M>7("<84NEO 2N24K@4PJ*G?E='(3)]HZD#FSY812* MDD9R2WY_(012#GO(9)[43DL@#P@#K"M4JAC^$X3\F?EAXEYT!UE@X7Z_>RZA M8H.#ZF,[Y+]0 8-;-)#,I+4(TPD2Z;G8%(3WZ=]*.<*)$C-$ECVIAN0*1WDG MR*"-O?2FM.*5W)30'^.B^.Y?:'* +S#>(E>2/PP+7I/.I'2I,RMS5TJE+9N2 M7:YOPEN6ZIN53#&HJS2F?IU)^IU%E$&4^59JA.!%/.DE4G ,#C)6[%;W["7N M'7:\*01H)5&X9"SR/%VYOQU$.:EKK8BM6^JM8CB7,/* MVW#=20\&WJU, D,^?)K?X52:K)5DO+D.[EB7DXG4TJ^#K=0R"YB$07)+DNS1 M4.IM6+'+)R_!'^ S]^8XV4_JP-8:U=9:UFJI4N.8P)]$ICG17V9ZZH49I#:> MFAJ_B^@-'I:H*$7)80N0K#_2@E9X"MR]G*/=QWJZP*A=A#6'0C\TF1L#"#HM:1DEI,D!0>6P8Q)_79\PU1 M8F U:+@%U5[N(%ACII=$B/$<80WEU6A,A=;@"5',S%.3?IQML4X#9%4AS:@D M(:1&SBB"H!,CYIC2 /S9X31*3PC%DZ5A*HTXXA-= M=F7RVJI<\8JL4A)D^M)D;'A2F"K%) [*8RW9&D4A*4TQX8M=^V2Q)X_O:<*R MT9.BN7G7(ADLSUZFSDDJG \"O:6V[YH422K:(,PV/"9I0W-#\^.2D50"0^,6 M)%MMWL5AHTQ*G,J102P?^ZB$[JS3OJ02P MOV!7=4*YTTC7?_260HFLS-%5?X]!^G%X;FO?=O)'DS+-F0!+9>$OB1.&XX!3 M?E7YDKK;P5@A!Z#QRO7SMD9#:F7FY6[AWI&2G*$EQ-$_2_,LPJ39$&$#G7Z/ M=WBDY?GKA,U8*ZND6I4[*:^*;J08P MI.GK,C%<<41(?(6JMJ#[M 3A36'=Y/(57YBW@II)LZFP[;)&L=SV)^J$>?P\ M)42B7Q'9$*,G>;-:1@.5B0P#WGJ1/=,F;^ M(W!BT#)NX[N(L'\YG%R,.L/6>H0NJZL"%'\2NRIN:%?%Q7O!,Q>R2_E+VB&P M+?72>@G("'7G9!ML:>%)\5500VZA2MA>.)XIEC'C?X^#OMM+ %62SBXP^D?3 MCU\R^X,XNQ%B,-3C:2@JLWXK<-R38T#4@-K3.$1_!"=0._@#)7TQ?2 M^+4$KRE/OV.N U"$'%T+S" \R3 68R:9]<(WX I0WXLY8^AK8\2OML3[P)GI MGGK*ON7]9;Y-F=?(TAA8**5,Y_"22GKNYO@E(%K45V6D75-2VZI603YHA540 M%NGJ]CIKV!1*9%N-*&@5J990\*S8O\3YEK)8HJQWQ_"$%ZIP,?M5P&C0!;64 MA)0=]>^Q,3$=IDU5'8P)BBV#F?1]I*%+FMVD:O'9Z!551F6$F:@8C WR@WE& MZ8ZMX7A 'V38Q]T;FHM9)D)1^S93M;$E/+V1LH5LT+G<&:!Q'J"3V$U[#8*E MR-KI];8KN\^SC*%,N^/,T6D/DB]H4WP6,]5P<3G(>GG(QI5#ML3.>4Z0QE"D MQ,(HTT^WW*BD=&JK$\O"[.:)T]B#_DE,UL3$%!]U5B:AU(#QK#@67QR.A)-/ MQ!RVW%(QP*%N!"N0"L_FAY*$6$AM@#1L,=F#A,/9G?D!Q61(6H9&J@>!6F MTH,'T2"^B,$S-$.F)%^+\DX@;R/C_7SA^D\@H'22NW$C;[UQ3;$[34($ZU&![[**=;XYB;"S[D!OOD M/_F&_)!QB M3F2H_;4J*^J0UVQ9C3,^R=!JP:724M;8=(?MT=K1IYRWNH-V9]UEXQ,9)OR% M88M&YM"3P/?@;TL4OD[#/_I J0)JY/7IWU9^ZO8BNVR*O/B,3Y$1P$WR5/&F M,GTRI#MD$=U_Y]LTH.YWC\:+I0/$:-:.G%CQ=).UL\A;N924RG$S^ M,CV9;$N=A^]P7!Q&55 (F>B9^X S4<8RE73NF-%4 MYG0R$D5=PR>0EU3YA3[!A+SUAV2>1NU.+D\W.45\%U'R4F+ M"RSK1]@NC5-@KN)[[)F!FX9K66AX@3Q6)0MEBRV"&,EDF+LGZL&D8R52'PK1 M9=/01C%24A:$Q((+UXE>G-#,$O^YQ^48BB:<"<^.[X T^3;/@$6!GWAY5,RU M>6-2]A>QO8'&H@H%FYW(GHQ[P4TL\K5"HV=!:^7[9%+/?8N7_YYFGOC/K;24 MEA44T6F-#TJ-&A4[DF';*E,+^T+0^- M6/=J?F2%8*V5K4A$^@P*\RI+GLS6GLN-Z=^-!H?T_J6>47JNRG,[XQE2,9HQ3$ZP*CX :.UY5TO>F6HLE=*^ M:BZI[9NK&=7_YXE_L)!N&JNG"4OP.;.C)%UJ&@>85KCS61]>31'D^YO+^']I M5CKKT!'#@:,+/'N:41Y]+14306:27#TMYTU*&> MQ<^FSZ#HPI]>*"E@ $[]1ICSU 7(JXK'VV0KKM6IU1>B M5I'Y,CMVDBOE<7?RX^NR R9O95OB;^H(S=3E*,R%)-U%I*=%%UB2\S #G!PE M][\3;R:.B=@E'JA#1'B3AS*L6X[2I_9/J0VS"1"*G$20*&!.G;E2"JUT_B$7 MHB8C3Y0#-Y,V3YI3ON+!PN7,>T4)VN@0,W]73^ATQ"A1=*DL_>[1KACR3+(' M4^.1UIF68>:9EAPV^]7\;ES'PA?XNW\7X@0"XR7^I#P"7X,_9.?$9KDW2?;1 M$=HX#MXU'P4KB"JFG+A&LA$J\_<#94 $'O QP[05MST0.^ \1DHIGAL[O#I] P),5TJQ(#NO!8I7<],9W M\R9."2521!$RZ9(%JO()58H]1T!Q8IN8B*:"9 %#BRC D\Y*4S$?@4 M<>QOS1+[/?V-_[O)QJT9U/%=\NA'"5'*[,4OQDW!I'^Q 8-CK>!,PU#=AS=; M<1!7IG*20$AV4V1EU8EBRE'/'5R MFS^=ABQ*SE-)1IM0/K#H4 3S'B2P?8W_[_EH:UMQ^9U 0TZD:+[^%A3#XBZQO=XL@ MZ",' C6(\KB/\R0#FV1="Y7,ZLS+[=5;!"2K;#+[&^!5EK/@FX,3I E.$@BK MT +4KLJUL>K["3S>_P$>NN)QQLD4NSZPNR#&],_J<)Y"^4ZO-!?_2N>S%KIP MF^I*O.E%U37TA:)QB@\H0 D6Q\+RKFTY%HBVAM%)5MV>C&S$>%@1V_+#Z]3= M8SPOC(\C=TS9#H_:&-N>@29IK6V+F/52U%1$!4DZ96E9A=J[GQ)/+W48U5XH M96>$."/233:\R\!)2BZOIJL.'QDJ2H2)XLC*D^MEKY]Z3L_I.'RY[6(K Z=N MMS3COY>NQ U:!>RW*4Y?C3H_OBG[S'?%[!I-M MWL/H !7G0>QX_ANS[_.!F'SPI#LLGW][>6,&D?$QF+S%8,@ !T+<9CU;QC$ MX30DX),OS&:,]H.O@!>3EF)!GWQ/N-ERFQ0A5/Z\XK%PE]A^0,F/CZ@!:!*P MV-G$(^;WW\4L^^4T)NI-@,7F\(0X*4">!&!F,2]=XU3PG3SF;<0\#ZBG O,B MD$Q?(2/D3)83=$7 [JF6B#7,I JR-/I*6@LS+%.7^6"^]+(O:VT)^.;#:2@PR20"#MEGOY_N;V M1SX)*S>(S0GH$"Z@\(I#[>]I:]=)ILW8K'2S9QZN!IEGQ;:XED1O;R3:T9DTTYCM3D[9SIR+6M9J[W M/?>)'QS+*^VJM\+[+;&K0I"6CH6 &,D)DE)ZIH15LHVR 6VK.>=RLM;.3K9Q M,$68E):,$G)TWXBZ(7(+TBI@(%LT MBE@SJ?ZO3@')>K+41[)Q5\V'B*'@&9D>#3I*Z'\^][C%F@.<6D*!E1AX:67,#F&F8]6 M%_UP8FJ":"UTL-N:6N26Q"H3,5.*J5TKT4*LZ2K6!<"8DV;6728>&D]*SMC121 ME!$5)=\H/ QD5"8'3R_UUJ0CQ2I8$P>0\GHY/4SG6M-;5CVHP*'#J"IQL4Q^ MY#V5RCBE>1AY'%*DL6.I5_!I*DF#JG(6'P@8]]5P.R'V5@@(1+G/M.W\+YGM M!BE'8[$1K56!7N3Y]OQT7G@^D:)0TRZDL]" M)Q?5"6Q^*Z,#DHDAI="J[X_\>RYL!$BP:@9!2A*'.E&D;SO=CCKDX^8.72J0 M-%1@53NYEULZN>MSV:6,81SF;&"O\VPY;L7:_?0J#B_N37/Q6NF 35TRV?_Z M%83DK0O.WE__]_\RC)^2>]!5FODNSN7EZ=@KSZ8OR<<3+EYZM^'8/[_X\,]. MI]/KCUY(Z?O"IC^_N,9ONX/+<6_8_R<:J,Z@TZ4_NKU^]\5?#[-AOGP6?@^C MC)W"A98V:_OI6G&(X*CS)F,2^^WT!W*Z!=(5QT;DPZO=I'FD$0.W2G.2I88< M8B0226M:+U=*6*=1G537+R(#V6&)UG=YH[XX"[%H?[S2O0_2U)-L\M'#LB]J M(]R"GRF9TV7X;38?Q"U6YMTM/D5^W<9\G RO3# 5BUH+*H"30G=%B=P;Y0D\ M?%2:FWD4BCU+Z:1,^7)$"U*&+%\R$$"^4T',^A$%V;:8VYN"?IAD4+F<%Q#F M@C=C:CJ!.+(&_0W7S33A)71>&F0>;I"&D^GIW"CVTM(7X$T=V$)UA^1HRY?< MA,W?A(C\QRW8>DK\CJHC=X7E/P<\O.B_H M1*T0C#TL)/F\P#9U\9DBY"]EG^\ ?_ CF:O)P#_ MB_2E0?HGJ55Z)$?$"^/NG@9S_?SB/S[0?\E+!!@7+IM&A"#YQ1?BB4Y[/%2^ M_(I8S'[U-D4U!ZL_: ]'*F0)<0CW!-AKOM2"0#Q'+O$Q@2Y+/_SBN*%Z$3_0 M7Y%=$W)TGX\4JV:_39Y?"96D"T ,<@F$Z;TX*HT&[=XS2XSJ$^Y%M[UFG(&= M3UWBWZB]*?W\'DM5-1:KQYD3L0O4Z[C^Q\!<%)'PE C6 &W7[@VTPM,*KY[R MHQ5>PPC6!(7WC Y>T^BBM=TQB?3)\;2R:Q"]FJ#LM'>G]5U=Y4?KNV;1JXQ0 MO5+3JL^<8!GH8_$)>[5^86&76RO&(XI7(DB;625FR=>3,G,]S M3M9N:RVBE*[5)J37GZA-0N9>-(=JAL\_6'#YT/UT?IYSU,9O)HO;Q? M6,AHE D?"?[ 7'^!NQ!VE*V#$Z:X\>/$B+*W@_$<9'@V;58GROQ06X+TT6\H M1Q/%3: =1@>JMAR-2+W!96W)=*9RTP"-5J+-YB2EI0&D.5.AT<:F 43J=3NU M)=.9RDT#--KF!O:3%)8&4.9,94;;F@80:336@4W-2-( C:8#F]J2YDR%1AN; M!A#ILC>L+9G.5&[.9?/&B9'M%W[L'I783!O'8^%,>IP1UK0*]NG3JC:]/>N4 M7YGVD+-4D+LZ%H_K]/76B5&T49O7-D"#T*="( M7BFIY1#%VJ-H2#-5140[=7>BV^H/=QW]HONMSEVI)&&RQML$Y7 +NM MWE#O?*P941J@%?7.Q[I21MLK;:].5P#[KP&S_'L/(,'YS?,%\T(S1;WTS_ 5==0^OC$+## U_:BS-83<>X0=SL0C\[\X<'N0^&3],6OWNL 5L M2'LY(X"$KPV>;#ZPP+QGQH(%CF\;/GPT0$2L&5X6LN1E 3/8]P6S!&0(E^&$ M1J]]V3.>F!F$[91D6Y")^.)TZ!3 /X%CI22+/0>P]]+S 5N>Y<:HEA#7"(GI M6>SBS@Q7WO?C-C3NMT:C#M*X)>CWZ+BN<<<,91%$77,U\:= S]%8TS.A9UE* M;4.H[F"P-YD&[7[W+,A$.!:H+T@R+:B MUJ@ >M-[,N(0WH;VXZUK EUNK9GOPC?@T<6<+'/? M9B[2PS)=*T;JT.53TPGH*H8H4JT9X.EV%8W1X'A .K S>8SC0Y'@0ITB[N,0 M/^ /.*8 ,7#A.AXSYBR:^7;;^+H>#B(^/G%.+&5&]"@R?X:-ZTB?/_5=UW_$ M3TLB:H9A/.>%83$7SZ6P $G) M9^&5TV<1 O#C'A*'7T18X#F[YB)DK^4?;PSNOD\Z:D[CN<>$K&YXZ[\43KO8ZH..OC6OOMRS,\>/SK+&#ZY/$&$4PK/*WP MM,+3"D\KO/J0Y5D57M,(H]7=,8GTR?&TMFL0O;2VT^Z=UG=:WVE]5ZM9S#RC M6K?#H9NG')]O_,EHPQ@&3:_&&3-]G'>)X[QWW?U:^3 -;[06FU(9G6@ VB@M: =2=D;7T[ MK0&?.Z-[^#F1*]MF3VQ+Y#OGP0'(;./)8>ZNY9!GV#*^PG2=T#G%-NL.1 MKJ>Z%GJK>(FM)9->MU=?>NH))W6E3(E(ZW2EIMZDT?:KL:33]DO;KU,A3;TE M38=;=:&$-E>-)9TV5]I,ZT=.1*_HZ(*Y+QY+68LVC#/D+VAW U8[[[LT\Y45AI &6UM%&O3'=:63F<3EU*6F 3CM366D 9;2U2:C5;4]V[0C4$M2,(IK>@%858=Y_7S K8K;A M.E-F^%/#7T2.[X6UK4+KT%.E1*U&-Y^AK1D93\P,ZBLM9VIN&M#VI*,NS4)48KMD:022NV6I)%'_M3=PK]@Y[& M;,-\8(%YSXQ[N#-*J772BU?8,_G+L,V(&5/3"9#_8KV!HCXTJBLESE2Y_U!; M@NCR;T*D3GNTZ_PQ+3CGJ])TN%=;TIRIT&AKTP B==N=06WI=*:"TP"5ID.9 MNE#B3&5$&Y<&$*G3GFCC4C.:-$"EZ5"FMJ0Y4Z'1UJ8!1.JVQ_W:TNFX@L/Q M+M&^CD+'K2:^BLP[ER57V<[##AC*(.0O*@)Z&S"P$N;*(.@\/PV^SIAAAF$\ M9[8!"'4 *MMXT8$UUW[\X7I/25'8HW?A :C'18F[JK M_16>'QD+\PFX/'E::#C\=@"'A8PA#8UI',4!:\,CO1"N"O &O(;E-VS ER&3 MVS9:*AB&S2(6S!T/KHYF9F28!CP9H(>[9DX8^8%CF:[QD)Q!9)CPHS-?N [< MH7P-UUOXR( @HS\]!_#^.//AU>',#)BQ@(?!5_1G?.S =E^YQ0F,. MBS,"-G4!?.>!0 >R?V,1/-"S'0*? H602 U9L !# Q&N3=2MPP:($PX1 M-0M %KQ1K!S4!+.*)+0_Z@ MQWQ%>8E&@CKT/'B/,S?Q5PXY$DS>R,F)" 'VM*(8H$8*$EJBHC<]X-/P(7B5 MN%N\#%B'!9$)K"7?3H5NY 4?WQ#&;@2?.0$(D+^&3L!?]@=?J32,:P);G )+&:W=U( I&5JIP'2\C@QHVG-#.08 MX"S$*/"8]0W6[G $+5B SS4]BUUP]BF^%J0B8)9_[\'* *TA_TW<@F+&O) K M#N0H#\4^XW"0V,J?J!% /(R8Y90H*)5B M',+;<(5O71.0?6O-?!>^061Q7,]]F[DD)*9KQ2[B)%KB %)ZH+A!5P!J0?N$ M,;P5[UIE!][?WMRTC=M-%,[R1$)O>(,U@[N0MQQ?U1W 6";BZL(%16_,633S MEYD (,;W2["S>@@L0]$K #P0>8N1W!-KI"^=^J[K/^*G5%N&KP]@$&5UKL5 MJI-#[H\XM_/G%YT7AL5<;%.T -+DLW RZ;/P:"V&%B#Q7\7!G^ (NN8B9*_E M'V\,[HU..FI\79]-JX--83]?9Q6!2\,C_5JT#U='C54ARZ2>(4N]VH>+NQX/ M)S4"WW>^:^]'N+T,(OB]W#QU1YTWO\&%LS#]_!Y@MFLK6L^8"Z@-P;3&TQI/ M:SRM\;3&JQ%9GE7C-8TP6M\=E4J?'$^KNP;1JPGJKJ<=/*WPZBI 6N$UBUZ' MVBE;%;72G*I(*$NTA[[KV :_RJ#E+LP \*M5XQ%E2_7(-;U.RY2MHZ?$ZMF9 MNW?,8O,[%AC];LOH=;J3>@B@MF3'IT$ME6#3J*558.TIF5>!NV[[UBKP-%7@ MV0F$5FVG0LG:>G=EW0JM H]-JV?-UC:-"EH%UIZ2M?7NM I\[I3NX89W4L[BI.>C5&7U/ES;+J4N@Y17&B6SG([6%O2G*FL-( RVMZD MY!KTVQUM;VI&E.;9FQ,C0",[_\]0>XVZ[?[P@GSF^LK,F2JQ!C@"NOBCU5N= MZ43.F7%AC ?M<4M"":W/ZDH9G;E)R=5K M]RYK2Z@S%:%=?32]L>B,E=J9RDH#**/-34JN;KO;J2VASE2$FF=N3HP E2;2 M#D^5LTVD==N3X04ZS/65F#-580WP G250"NW.M,),'-I7!CHH&GU5C/:Z T$ MM2;/^^\+1@>IX]'GM:VO:6=:5Z5K1*>1,??I0*2ZRHNV-76EC,Y":]569SII MU59/NC18M9TG);0FTYI,:[*&:C*=[]2JK<9TTJJMGG31_="U)L\O<&%DV&;$ MC*GI!(CP6'=#-T!F=.7F&)3YH;8$T5UI:NUS,*PMHNK:D.5.A MT>:F"53JM(>]VA+J3"6G 3I-!S.Z8;!&=/JAT^YWC OC!^T]UX\X35!GND"@ M]5N-Z?0#NFFHW[KMSJ"V4G1<_<8)(/&_CE3'+1*\BLP[ER57V<[##AC*(.0O M*@)Z&S"P$N;*(.@\/PV^SIAAAF$\9[9A9\YQ-A[-T+@S0_C!]XP(KKOVYZ#+ MGI(S"L9O0H-1U[09.7"-/X5'1\;"? (N3YX6&@Z_'N:SPQ,\!'O;^]N8%_IRS IRW@']\.6\8= UQZ^-4M6T3\)'=^ MD/NHI4)IV P;N1T/.[IG9F28!KP8%@>/GCEAY >.9;K&0S(VWC#A1V>^:'S AG9L",!3P,OJ(_XSO7L5QXW(/IN'0/(G(. MBS<"-G4!6\X#PZ<"6WQC$3S1LQW$7T@0 )@L L@!:S9 "'#BM4PVIRN P:H\ M(PX).X!,>*58.J@19CE3QRI>:-NX"O&9>?R-Z?V(PA3'(?#2WDE/="Y#5P(QTG(VZS@<6,]B?,3=G0FV'IHLFZQ[TX1S9["7>+&U[K_,&GVC< MTD57\J+DY^Z;'XU'![0=/-CQ'D"5TC/N3.\;/AO,^;QM 'Q_CX'9EVUS 8F MY."1>8&W($/'"V3S'WJC]L@ )+K"J;!4CH@!^=QG* (0M6\88W,#RDL4@K0P M=RK>%W W!00OXA?#!W! YL;M1=]X^<$!(#[Y;:/?[U_T.KW^I/+)[_F]#0*%B"2.W6[,ENO=]F[_#&Q ^#+F>A= (+18XKB$%7] M@^/'H8M^K>6:R#_I>^^>.'$R6Q:.ERD=8 $NO MN]'&-86//GLY'*U3WDM:[N42+C?IZ;^UK]O&/TS'>Z0T#R<&_@]>V6X9O_YZ M33SS=X Z!)_71,\$%'@8.5&,C S^]RT+'BC,P8M?,M,B[:] MP+RI ?OA?5Q%JDOAUI+(:UH\6B-WS,[ O"I*3OE]QW"@5S?? MX[.T[87LR\TFVBC@1IM85A@UBP41AH#";#F>Y0<+7RA+O,:S,.!B]#@O)M\& MK4WJFJ^P;W!OCSOJBK.^"=M-T1;OXD#&TL#>$,"B $" SD3[,^@+&U"3>(/] M;A%5!,-V6^/+2:L_&=!3AJWAJ-,:@MTO1FP+S!'I>3 T[E,+LSA+OL /W=3X MTT-_&*5?Y!]0UA%94FIM8T>T@>DP/^&DWW0T&]WLV@8 MIU_D'[#>Z=HUEJN=GN"II@V,B8Y4H5>[B3EW9Z9R7JW"QFWCK9(+#7G0DDMZ M6::'"=# =$+&,WZ4H\NOZH?+GB(OL 2>#5T#.UH.E!S+C6TI 3\,U*<$; [& M'7]+\X[(H^+1R/.F9Z76$75Q%G.P\/O G&\4PDS2!-P4S/""\HVESE8Q2IBP MDY?B+=F78"85_@H1Q_(WTY[#&KEO_<#3UKF E,4])W\FZZT'41%.9LP*6T32F1)RIF-+2>:0\@=.)2$E'$QD/0T\AK@ M6US%]W$8&=VA5!<@)9;O>S2N9PZ;&K\QF]+& MGZ?@;@!'JS[S]6^?\X%'RM2FZ_H613%=4#YC4#X*LF\)V;\CLC-/_'+[>YB- MI.(H=&PF,^BPBIYQXYI>L0!->1TD)#?V+N,G U5BB[O]YJ,9V.IK"!&BO#)G MIDS9?[JZ?7?UWQA@@(PM7!/D_DL,"F$XZ@]?6C^^'/P(L< ,0U )Y1K'E8/- M4805%1Y<*E4+OD( G8-':5#X.<0,#P#-TT3\IWO<=\+3JZL+2A#%BA()$2Y< M\K 57)Z*E800>C['0%>P2Q%F@B*1-UZBQ4DMPX(%^$+4]1>\D%%X6_BC@6', M V8$*83BP:@TSXG&7C+0Q?'Z (NE\95BT*4[E8'#S_\XO."P@^ M7&S'L !1R6=1E*?/H@/ HN@[J?>+D^LM6+*Y"-EK^0=*'U;O)QVUL^*YIW9Q M&$;@J4S^\D8L5N(=?"K'-OB%/'9=F%A2.%!K02,Z8]PP*]M>N@!*WJG[UCN#9C141\ M=OI;5GZG9B L_D6YG$)MF^_U!O#:DB:UQ8CB0D.L-X;5DW2]C"NU)_E.711[ MK4Y_V.KK'9AU(TP#!$UO**\+);2U:MX\$VVDMCAD>*(/&:X931I[IM#9!,2_ M\):'(^>,=/1;VZJ!UFG-HPSW&[1;@*OMMBX[H]:@L^LP-"U'YRM'.G:M"R7. M5$9V#4VUB7G>([MW+A]IR6E8Y*E+L551Z \JQ-8V8Z,#S]J21JNTNE)&>P4I MN5X.+X>M[JA?6V*=J1C]6%N"Z'"S+I0X4]&H>R54&Q9>Z!S4MUOQ3"6G[H7. M&FW#K!/9KG$CLHO#@%[A'O-M^C!.@>NWSLW/J/MRE(5Y'3FZM\4RVH=BIJ\A&I/$W[IU9 M1^"S]F4:0-Z2VZ.J(_&IBW2OU1N-6MU>331P>?6K);0&Y-K78&KR/),T[:0I MSU[1[F)"8I-1[Q,%@'_G3HC?P@ M;'&6VY3."61XG'3$R-Q8@$>#3E,C7*&4XF$EB+P\>/PEXJQL/P[2^V>FK8[^ M3QAU\$8[X!+'*_7RY]F?X*?LS\E3NDF[F$KG>*>H#OE1:J9E9ZYRAJ&96:BQ, MO,7'DVBFH+WO^+'1N&2Y6!N/,?B$9_(@1:[L?\64+GUO!BA1H?&6X7GEQD=Q M4G3+^&I^QZ-FWK$%\)3##RS#%5S-_2!R_LV_4!7$^[8_W(&)=IDA(Z1C$Y$+*0&#ET'E5*R/-'T)40>GD\>L&9 M5=U.YR\2 P6L0_26Z 30 V/0;8U'R>%5R+HR*P\4G;3ZPYZ@$_YTAQR0-,EE MSYO:O(J6.#I4'@/5'4Y:X\Y(/)^!=^T@V\'=1/UXX2?G3JG"1+HKH['X26N) MRKJ+(SQ*&/@P43X;]59ZI#HMA82 2:N.)P("S'AL:NSB&>Y/>*@5/ &/HEQ# M#,]/(: C9Y+#M9/CV>5B\8BMG*8ZE7,8EYD$/A(C)U0@ \[98^[;SM2!*Q0E M,S6= ,.O./%;A/%S0N.'[HC./\=?^'F< ,T%N!\@>?#S',SF%T!+IB3LF.]_I9C^D.9,VC]P1T.;G$PE.VX!KF MA5S]BA/!$HD61CC#X2G33",!;!&7S\0W%K0N7!H@S/$\@=DE_:D> MFT1_J8?F-%402AVA5/)TI&K.1MKM<*I#!L?Z<"1].%(]FFYT\[T^-^,\3H[0 MAR/IPY%J?F)&DQ3_&=)&*_G:4U(?CJ0/1SHZ&>K>J:TG&U?:HT'-9'(U5%(7TT4CWI4IN:@=9IS:.,'B2:(Q?V'O7J2R\M276EC(Y> MZT*),Y61ND_;TD9&&YGZDT979&M,(7U&4BW)THB,ME9I]:2,=@Y2]U7GYE4_LPD.33M MR-DN?6;2Z>3U]9E))TQ>?692U:4&/LBV'OJW&:=':/G4)R;5FCS:.M8IX-=& ML7&DKD']75M$790_6;)]G .;TO$$?%J[13/9ZY%\TU7Y$ZI:((H+[9PN:S27 MO,ONSH%)?!8BK0L@S:)7'614U_5K31YM(>N4!]"&L7&D?@E8V75WES:)-=GR MI5L!:D>MPE: F@SKUJT NMBABQT-(*^N>NA6@+/U=VHCG[H5H-;DT=:Q3BD M;10;1^INNW/L^2Z-LHB<&)(6SW= ];:= *_HA.;DJNW/Z,:/&814>))T.0A& M*R!03TM3T.I$P*E6H+P'&- MWH ?7M_" ^,MW_.81E&_=\)KO1 M:W4FDU:OVS/"#-;\. H=F\E#UN&-/>/&-;VV\55Y"KR'>38>A1[@92$S(M^X M8X:LX_4Z;P"!L<4(&O/1#.PP^:W[AH"&9> ;YLSD!]E/C4]7M^^N_AM/3OO& MHH4+RL/X$H-^&8[ZPY?6CR\'/[:-?\P<^$:N0D*[ZCSX!'R.A(@%\] P/3QS MT[,=L>*I6 ('TP -AC^'3A@A$1?\9-\+2QVU1O9=V;%D?. &)PZ%@M"8Q$' M80PWRML4G")UX_LXC(SND.>>MB3O;SGRFJ[K6R;">#D>M$:7@T:2M^ED_4HO MSF(>\XVHAU#4I2K*J6L2>*ZW\!?\Y#^P &@]]>/@XHF9@;%@@>/;+0&_\6=L M!A$=/TTP$<9(1W*3*\DW'-2@*+ASS ]#U82A&;P)&^4EUK^'&@J"&L#(Q%: M\8J S4V'DU*L*/<6(#@#<%P)DXM\%(+*=_%A0!!<"C[) P5H *[2Z_BBPO9. M*IM05RN=?66$\7RN8+>(HU3N,$P0]@C*F@3_/'1V)_+64HC88 M'\R;.,/"DP4'TC47(7LM_T#MA=[NI*/.R3M.V^9PW!X!8[%ZJ%UM^HY/ S)] M9Z<(M4D[%4I>W=\'[-Z,SE2M?_2BP/%"QSK/Y?]ANG%MC%GMFN9K0Z:Z3]%; MJ7E%6O;TLWM*6@0;Y;-UB=IV(*UR7DZ,.*?1X7>6W7L-(%TGXUSN2;Z3;]'K MM+K]7JO?[=66GOK,G+I2ID2L?9)"TP#2:/O5M.YS;;:V(..@W>G6EI+:8-65 M,MI@U98TVF!I@W7"$CB\[+8Z$QUDU8PL=9^!JA.YHKE/[G0X@W8(<+635JT9[N&:T931J@T[2YJ2UISE1HM+EI I7VSWYJ 6I8 M]O,$1ZC6B6PR)%1VA&A'.NHUVMU+W?= M>W+Z8X7J1*Q=TZXULVFG+E.U49-:JIK0+U3:&D3=IJ2-AQU6\/+76N/6LSJIA6/V1B[+C5\QF>&Y\:]+ATZ=^0* MS!J7Y(R)UH@*LS[H_83)6W*$D3[QO?0.TWZKTQ^WAL-C=UHUZMQW+:(5&#.M!/2UCC5*)VH0UBUY:O+0).V%)JT4# MLA:U4^]*/N,LYA\LC)AMF)YMB#-I341%A5GH9RB,GS']:E,'+YN%+DP_ZBQT M<\F[G(4^,(E/W?,9M :3;JM7%X6K_9YF2*B.X!M)+RU>C6T#I;,\V_ U-UL:C&1KF8A'XWYVY&3'WR1BVAT/C MB9E!V#9VPF=WL@*A DMWOFNK.'(B4"36-CC?#IWOYPO7?V+,N(U\ZYMQ$P?6 MS R9<>.:WDX+_/_9>_?FMHUD;_C_4W6^ \IOMBJIHA@ O,K>I$J6[:SWB6T] MEI*\^U<*(H823D" P46RSJ=_IGMF@ %X T&0')!S:L^N+)' 3/^F[SW=0Q4/ MS'4XFSO!"STG,8F>Z,&Q.@/3[%#Q9,2/5#K&<$PFX6P6!G230 CZ9,.+XQ2Z M51LIW4ID)/1![V]O;KK&'?_)F-,3YB7T9'$JTN,RI:?.F'I/Q* /2Q[QR?!2 MCSXG"8VY('#A;8E"WS=A/#L^#]\IFNCW_S.'N#>Z<.R!^ _X&0; M=.=6@38+'XN];Q>XNWP[]-=>Z':-6_:5(L4,^KOLHR[PVKBP$_C<*D#94TPZYQM43^ M=.!M$8@[^E]6Q^Z9G5%O(%!QGAS/1UD&9S5;2>FLGH20^L.)8%IF7$_DJBB1 M/M-CDO\*;1 C3F=T$W2-+Y>UZ/G;B;.2K,,5R ;7(P,S+C]Z97YRH"Y 6"^4F)E_^:&,?Z;F]P@ M54B4&=C<.J9&J>_,8_):_/#&8!;TV)3;81ZG"&$X[%X>O>F6 HZ50B&,[M ^ M-B#*^;V;X:%+IC2A^-BOCIJ"[G7'&_A)D'5]#(/)DB:"& OZYO 71VP6S<$;Y3KP&P;4R/* NFGH*A*C*K=-6IL-[CS*>C3?\"V1*CCZ72?N^JB1,M AK'S+,3-!6 M@%K5ZYJ3VL=)VGM5%IHS99IC7Z326D=KG?9#HQ.R"B/T?L?AP#H!JXH5H.-H MYXN,-@>:- 6>DA:):J)G5[YII@T0V.WWH\$.5__CH/-$?ULW$$',PBJ,L*+.. M3VJ4Q;4\42&;] #]T*=IDE)J9?,<:FU7N3;RU?<["8/8PZG>8MB":#J_]&P> MI2_\(05,:[K,[SV*,#:[YEE E/$0=7EF^Y 9()-H M!U"=,*;FHI85.6L3H6 BB)F!!3^.>EN9G9W/V:(FLUV:EZ=8J:8V(51!0@L_ M59'1)D0.UV7GB]'KM_BQ&S'I6X<PPR)-/!*%6@Z_J <:BWP MHG"!'ES09O0&&QE.]T4L MF'&#<6=T]'"0;O]\"C&B=;;=&7<3O@L3QU>Y^?,2B7G&<+4@#J&;/Y\TO$4; M1C=_WKV*Z+)C7YH=:W3L6TRZ>>8>S)P#-,]KP,5?OH5XSHWS D&)^(Z^YZT?3O[Z^;__RS#^*;Y]#1WEZ)EP M((AS!0W,'C"(\]#[$PP,LV]:^(-E]ZQ7/R^E"5"@/U_&\Y7:/V[!U#NB!_.@60=+&SZU9N0("9Y."BN%113KB_DQ\"XFD>>#_;C MH(/!O^MP-G>"%P-[%A+7\((D-!PL[0+B&).<9F%@.((@QK.7/-+/)8]>Y!I4 MWB0O!OVBRRAI3-*8TL-(H,\D,6:A2_R8]9_TOD$G2D+BKO$YI*]Y(D$*S5%C M^O,$Q%I>3>;%TOO<-(*H)2PY>:2_1)P"+X"G!\EC3#< WUVPD@NHTQV(-X93 MXSN3M5"U!B:TQ2HN A:[[-.(O"$_J]/("*+D=A[JBT< M5E:W=+]>8-R2><*>#\^NVXK55NT07OEQ"-NK>!)GJ9]X%]"--C^458\A?I=2 M??5Y3"F7T[6X4?H@O@7//=#AQ,\AN,NBT2>"-Q4Z_TX#=F-U+=*3@GBF3[T@ MWR9^&L._/8>@C>1U\TCP*IUZ2 M_7U"52O]?(?#20TE^FAY:11OXD%IJV/0W5TDE$S& W0&-:81'"3Z4?X,>MX@ M:Q+C[^8^M;7P2$!397J(GL)?2,"[S8[Z;XRW7DB//>P;?'KXBK1Z(7/F:30/ M8Y11_$S"Z;H77W7Y.68G./Z+4+%"]^1ZE$1Q3JJB^,DW%!CI_(+N@BYRSNP* MX )(D8-./5>X"6>X_LO^?FGOW7)E$019IF000XFR;]*LML:H\Q& 3[H+',G(7P5K$R:PII&](U11J)E2^MN8/:,M:L96D=S MEBBS9]1;9/B8>DAX!$,DB&;XM0Q/.14H0'VX29)&R(;T6-&%)L9?GAL0]OTY M-6X#X%)X$G7Q2$J/(31T]^G&T $J1.]("$_(?W9^>&:ZC9;S=P.< MO1VGPALB,J5?P9[M0J\Q3MT/HP*RWI2R6K8?*G+^AZ(=4[,S29%!\ !I]$= MWK^4'PK'2-X893_LP.\1']OQ/X5^.B-0QT&?2#UY8E!G?A4WKU#KGYR7(@=O MH=4EULGG0\#)A;,A#F\Q](,'!$9(?&?UWQ@(="A M[Z&\C;,WXO0^)G^G[)SB@[T@IH:0 MS1#)Z"9>Q7I8X!Y44,'@6$FU"8ZD4S_]8CJRL? $5QXE.F8IP2C\")B^ 0$1C=0IYSH43/7%<,J/<,W4F5 $G'EED'G;<@G"MTU+OY*UXEXC&2>38U>):%FG? M(E9>#K+/*#AH*&^(JX\;B*NO".Y4GZM4/=JS8V ]'Z4S@%AK1B3$[)I^E6H- M>E[I(6MVN-*11DE]F1,X.U03^A!MV;@IL07%C?I;#T2*L##LHD@$/82[9;%K M&!XFR0Z0+T-[-# ^.\'DQ?CJN0_$>!=1]NH8MU2 OO/(0]@QKBDN="6!YQB7 MMF5;3 S@8SN@'9T98VKZ;+J"'C+T0&BI84=,JHH73;K^H#,8FP:D/%&XQG^G M, &-VB<),B*?=<;9/HRHZ*9& UU9%%+/'MX04D^$;A\SI5WC$\@8U-U!DFO^ M&.>R3=((?@VV?#"2FF+GK_$ 8$B2>.#Z^/I9VCF*,6Z7 \R.PF M+/A9V$Q(?_W PFN"4J"?)A/BPX$D^%WR;>[Q/(<+O\/0128E(=".JI]^\< W0M[!B$D @QYM1Q)Y( M+ITPS37QXIC;VYB8P5X':'/2G7F!("U;(7R.^H=3L,A+:[(N&>*70D=1I4P_ M^QQY"7T_1 @].%PG$M275;@#"9TY-12\,(TI+W!1X0@+FHN*%X;O!W(?88C) MXBQ.-7R8/CQFH:?,L#\Q+T1ETQF9O.9?3OW(6!E@IHS-6IG[!Q$F8!33L M6>:6$JHC++Z9)!"6>90V'CQJ%\Y T<%JN6>0ZT:^6>$E4&D;,2K=$Y 1Z#A9 M]@63'%1BH.<%U.",U!MRJ8+$/>RQ,Q$Q*!JBF*F1DUM3/QR'?*3L78MD9OP+\+" 2JJ<"A1X$++!XK M$G*L:]RFF(JGZJ_#9"JZXL5C.. >).0_Z:\Z;/PG^H\39XYVT?\R1Y0EX9TX M)EP0,O>>*=\B!2H&U2VM0VXL;ET-F^,3>T,X?;W7,RWYC;N*I M(/2!S7:E1HLW2V<+YFM$_DZ]* LBA65')GFD:A(/.0]?&1B0$Z."(8(Q@2N& M/JI?QI# HC&WQ;B(!2F)U1H._G,)NCB>..:39F/C>XQ[4].!HA?_<)0)LRLK M]' %>B:L=#O#ML^AT<,'#[PU=HZ9$&')4'Z(+Y6M_M:-.%1!XDQ;"'RG+""# M[MC6_3?XG09JK-GVL2\T:.9I6?\-;1BL-PSLNK.5=:]/50P#W:/P?)'1%H+4 MVJ%CCGH=TQXIBY;F(R7[.&@;88.-8"EK=6L;014DM&Q3%1EM(\@V@F7VJ9U0 MU^O1?-0R&T''$0YD(]2-S.DX@BJ:2/L_YXN,MA$*-D)_T!D/ZWH]FH]:9B/H M.,*!;(2>LE:WMA%404++-E61T39"P488]SKFI:Y'4 P8U>,(!8- STF0;E5$ M!"\I'=GHUF,L6NK!ZC$6;4:/V19ZC$5U^V/4LSN#H1YDT0:T5 ]]9\!IN"8+L@ M^$,8Q]X][QQ9:J/L3"81-&R"5A[0EI(2CKX(>DPG3L):0G2-MV3BL!Z5":>U MX0&U(?*&[:'28!Y![VEV81Q>G@93YRF,\-\1H9HN952AD$!?R\DDC3I\CT D MZ M4O##B#XV;R'*VIJ&$^)"5VLD:QJ+ \$X%8C_=PK/A<8K[ LDQK:']'-LE,8W MZ$\0A$]$'#/ZL3#"+5!J_,@;0X3!0P@O=;UX EU?V$&01CW@F0MP?C*#<38/ MH\3)N[)RV5%NNNK,H(65Z!^#G,#:?TC .0\.]'0UH!&YH&2:+C8,>4M^)L$'3DT>>-PH(QZ6!)TXQXO&00P#-VOR2*%_ MEP\.F!,J^UQ^'A'&X/LKS(14P\%)L.(4 <]$* MW\##C0Q#@'_B-_EV7-:U YH_2]*%'QF0%$P"PN^@EX<3A\#)+]GI>@._+S\M M[XN$WQ(R$_N0%N2F%\O/9%* _K%K_"M\I@P6,=*(U4!CMO)6D.)\J_?8!BS) MF*;0&CL6P@[0A([&T'H;F#0->-^EA,UEB BE,G04]*&GR,,C9;S 82T^63\Q M&+'%&T?]17SO,0RQJ3#CJB!;+>O'%)%9"*V4/-;7)(3>?I'H @7BOV!=8.]? M%.W8_779/@)LC@0" ,X3.TN=E4V28,'@$>'96*:(>/\;[/!:?"A7*_9SHE,!Y^18_4=:U.RVU1<7H\ZSKXU8O_VM <]?*LFJ,:0^B) M*E'H-)J@7H-I0\\5>PP3SL81JSS]T[/G1APK:K MP@Z?%E;O)=RRI"^D-/>@)2-OA CZA;L$OP78:OH69 E]X]5DPBP9I@!B4GP4 MV!LQH29JWIWN Z&BE+[R'94\,=WK1VK:1+ TNO)HSN>M=?,6B&_%PL$4@GY1 M. @.G^ (SQX=@"NT0!H52A^Q@U\ )H:@T*B*!_PR1WMGRJ4"21?T]%/%5% M<:[9))7"GQG&O)DJ;Y8O5(N,(2IFWC4,/@MF \*!"@Q^ ..;VM2(7RV>4*^A MV%V17*S/YS)NV,0!W)7BO<1Y\U6!&&N7S@R'NQ6*,/LF;VXH]3:D!PB;K:.G MZC#S#?NZ&3'=B"^Y(FP('"AJ!"UK!(XM>0LF2_G@/5+VI:[%!'](Y__9HPQ$ M^/R1%>,0A+_$AB^NCC?)<1T6I@IX^T#&C0'SK&-PEC.I+5H%.A[V$Z0F/2@F M\-FG@H_YM(68"0 @+(2B<*I*-A123#B0YYRPAP.G3+U.F "3Z9-DK,7%:/40#NMF5"L!^NF@1K4 MBHB>/+1?BB?IVHL\:LK/8>-\9P4DYKF-T5*LY^HLJ3;2]V7+ S P_51" %W-*A^ MI]_VX#"_]4+\"8"1F4Y\8!7;L>/W?PBP\:<1>ZN6-HD;X$CTX0?@4+F.E(B/)TEOTGV;C)HS_FX(5D(]0*\BT M4!XH9&6C/GS!L^4TF:) F 01C$[S7,^!41ZWSBQV0,0O+OC2J@AP-B<:R52"E\\G@$3* J_E M&(_':K]@R#$(C9AZGD5FKCOK%D^4& ^RS8$2N1&,\%:"DD.W!+D! M:Q^^\:"%,%IWZ4FS+@V> 5I_&I=Y45OX1$5GZC8;Z?<>?QG M#&,,LI&'C$"G$3Q\2Y)G"$6("29B'HR8)(@1"\B%>C"WH:BAT1YRZ5=&=J_3 MMVTC?G0@A\L])O QJ'Z)$SA$9??BZNZ3-%P%LJ$D$=F5)7.2OK.Z8X/2Q,>X MW))SO_+XLE,>!D_AZ[/+](:EOS#.%6R'+ET3Y*0B@90PT #XYX;.#^9F X&V6+N %+I0O/]!/&)9Y\7_Q$U<1 M]6.I76'A7*JOF*C&K]]>_/\LYHYCXF'*!7T8#)/'T&! 8)H""]WSR2(&Q#++ M"PC06LD&.]R_&+ 3-HT&:R1@!MC2^A4 AF<2J,2!&4I.PJZ7YP([&Q7JQ<4H MZZI B8!VX<$8? =\3\;Y OIM]G7@X[IA-1(B6G0:1XD\Q"!%(L 2[5"XI"!VT_C-_-O8 / M1]A*.!<3EPH#N MG1>'\2A?&D6H/05S,)7GL.!@1NIU,X?R!6/&"NMXV*0B-KF$342A!.DPA4L1 M@&H!Z1F8Y>'%9)CUF<(($Q%;K"?1J8^((S#YGS28Y(/1\=0L4%UZ1BX, MY$%$J^APQ282?L62 7!?A=#Z/QEZY:83BU*APR9)^:)J!;YU"RCQH9 !!('X M@#XL*&!C]F2Q>_O^6I:Z72,?KBE@D06Q.$FB]JDH);'X"2($.9*EYZP^%H4^ M&_"U3X5I'P5CJ0$KJ.@TW,"IXRV3AME3,&$1<9--J]-(S2R9H^:X?#JE*)ZERY&,&RH/ A=2%>6" M,DJYR)N^, .H9(*6J,JE1D&RY*U#M;#OA@$:YQ ODG#*5F=%'$+NP*_"0H* M.A S6-02RZ,$V_*MY$3]ZE$U0L7YRQKWJ'\VK)U1XT1JB:Y6#3XK)H;=6T34\? FV5&&L)G9M3(''TW\\H<@)$GUD_O XI%8 Y%@%0\J MR.?0H#X#UC+F%1REHIG,VZ",*TJ3L"R9Z7[JP[!ZH%@:[YL%6J79F3S L6H& M/=#'01\OG:6\(I=0_O*636"E/)&'-L#AV#!T'B//\(: /#"C(9<&/,JJ++! M:F,T;:E[X$1T>2+%2K_^!(&UN>],,EW%[?,X,T0[I8=*X33QUGEZ3^4;*TJB M%'@D%W19?U&5(-NJ5W>?"A$"K$ AZW#0P'L62+"7_"7>=1;L&TA[<(#XWE9 M0D>J3,*;'=)?Z#+!J^#O?$!B2!5V[[8ZBDOCD(/.8&AV!E9_71Q2;'8A!BG5 M8[B;@I'#[N628&2K>>(M0AFR8C=AP^2^"#VH3'0[3X['IFBBV(&*\32:E._> M/.)=#TAW8NXE^U0VR+9048.^<(+"->'&X3?ZPS/QG[*#D 5OEAAB> P:H-Q MFA-!1!;ZF$8*H.I4RE3Q,;Z,IA'4\3#:LGMDQ4M"6!"<5:<8";(,4'Z2LFMM MU','H0/.9!K,"-S.R>%A4Y[,$L+4Y?B\*!KQI#4KKEI5=3!X-7CI&>P M_X$B: VPFVHYS_"!PW$F88[?W ,V54S^"K>:LD^T5GR]? >C#LBE>KE M=XPP!86/8KDH.6!V,D;.OQSD&:A-S^0P\"BK8>>6#84O MX\71=.D-(E;\QJ_8PJ.0<[%HTS'8S4LL#8\@MCPMGF:\!,>+NB/'*Y80,#)G M&DMFK.4V'A1#\',+T7*XP0D*SO78/5M!.:RJ9M$2^<"6UH;+B1?7-3I]\NEWB#(N"0I7-EVX"(91,9C%(Q!)GY 0,.W)?6- MIC07YNQ(,G]O%2R%R]4+4X7' =PFV42?('/1_7_/[-FJ#G\&PDR-?%+6C,8F>B"&YFE%M*]^#7!Z"R)(N6GPWI]EY$ M"FGN3/8)61LR1[M8A@)),A^-[B4B&1UWJ*? AU/7G>J6Y5%\!*J0'EX2V"^% MN@9C,R\.'HY'K(I:+N?M+-V'U Z$W29:PQVK'5C)8]=3T%5#U3"9&'>*"->)("H29+"YZ=R_-^C MK0-875&V]XVE9PD3OH0I_OR&^E6>\KWE*5]Q24V6,!^N;M\61,S2[UV';I[] M+02\;PO%&9W\F'00 ]B:H/VBWBSH..1?80EP 7V=L3,""D^ K\@KR%Y8*!*I M^.[B8]G=+6D'2T]O7J"/X9+OP4F/?^#)AG#FX1V3[/H:^,Z(-C>\9#'FH>7% M"]IY?PY>],0M2VQ$X@C/E!4^>>R*.[^60QU9O%_C,RE'1#$-*V4!,U.LI4MW M)K6X62;?,#P<82\7T=J@X(FC-&6;6B8BZ&%8I!OU*>&DQ[P4'\Q1.%M3.-1Q M0N;Q:^-[[P=JWL$VIB]BYW@*OJ=TY1=(!=7>T$^7/\Y?P:S&+_,5BN?A ME^FWBXU^"CL#..-GCL H48R<\D\6!P@Y+>!R9#Q>MVF(IP2MQG70SIG@/9 4\ M\![L1R#:6G# _C(00+ZS/]PR\DX!G54?\-> A0,R[R=W)^!?O@ M25;I!*H1A:TF.O1!R Z2-G!(Y.YN,=DODR_/ET6\R(L] MO?&GR+TM>>-"NKA"XT*QZL)AD[-PX$52^>7^P# 4:@FS?@B&B.+>OV0> M;?'>JEP'G4FALK\ V3L0UR)$EZG?>>CQ\!STG:!L$/I9T[OE.H*5 M-@I; :@NB(YWO5+?+Y&@H7O0EN'=-*1?>=$R3/NB=X=59.?5#-'X006@$[&"^<@7#"?!=PZN+%F"TD M?"[0$9(+T%L B6P,IT5OX%2*'3Y(QEHFR4L&(S>9XM66+S,"EQ]Y27_D\6(W MZ[G$*Y!]:)48$PSOL.=F&;',N,PN LOV*N+B,Q98O8HL6;?J;>)TA_?P9"8' M1*D75L=(]V)*K4JR$/C:YR=,8+&&)LRIEF2.?!F&]2:+%Q/[S((.D*\PKPJQ MDB=V"QXSKP^I!_(U(+$A'2J70J,B;)%3W8T=1E^\:S')E7>BI6 M[TTQ:@Q%::=M^'+.6C!\Q67[6][A0QC O%*(F:P7?Z<.YHR7WMF''L78&#"S MH@MO[KT35D/1N("C+KY[#X5(4X@LX"IRU;'2.11&4L&AKNBZ"4O*$VT-2WI: MM@UX%40L:_]5JH>OB0J/ESGO"E>PB+K&37'5O-E4%NM,ELM?=CZYV9$+(R > MG@$L&2S$CLJJ;&4'/6$;H3W G@S8K'AL9AGQ9*K40Y:UV4(71S3%HP^'76 D MZO?E#Z0(Y/J"ECQ M+OZ 4S%,MXR.]W0;$C3B9DX6LE@=VO/B/)Y74*2%FA&XR$8]RY0U MQ6=".DMTBYTLO ?<,AYGS[(F4 ]2S(4OWY&4':>*U2FFU)_ I2FCO_%)2[K( ML7N>Y51SH9<,3_]') ;@CA)I62F%#XSA\9>T CG+V MG2P@>?P!F)25AL&9B B5N%FE4VZ50[/5.4J]B1='GI)3_(E%B6L8Z MUC4&1OKL/*K_ 98$$IB&SY;$N\(MZC_PM:K&(ID!5HR;ZT03PYV"8V>L5RP98@"S3[J*\9[$)?!YY8:$6NJP+RF\^U7%/)*L8GA(2\_P&?(!J M&:J,\&"G\PO*9U!7*CY"/Y.EP*?H%'NS>^BB*0K1LSSP)(R3F*'##DWP5SD$308M9Y8!S*;WG(-K:' M]@LF,)A&HYR953K)+41+OBEEWI?_E=(17I*I(=3L63:DE#@J&T$&WAG'-^49 MK^Q+4MM?N8$Q^%MH2K*'0<)K;(XKISJ+/'L1'2.J8$,&;O5)829>0<%>!( GGO+\#55)P M#E]F]U 45]22?$0/]*-;$Y,I3#?QH)Y<1 $S-TC@]R&?SBGJ+J.:Q^9MT#/-8J[L?DDV4 1W[LI1Z 7W M[>1YMS2<9(4F1=W)&Q,F62.BS.OUX-^SK F!7( $FJ94#L.')Q"WI/FR=_/K MT#@W ',!63T?#^@+OEO2 5ID\=BU+/P8$8JB<-K9 1?E'NR^#']CAZO+%ZK' MH15T_G[^1'GT59XD7!I!D?-(62XFRA*/'0,/)UXVX$VST8(&[P>'2D%X!29" M91YBB@-YLA;;H$RYU"@VM81)7,4TA7"098'TB"D):5@0Z_+C@\>[(&WT(DEN5K6("BMP%]$Y28'S M@9.WTAUF!SU)21K$Q8+'+&SH;"A^7%"2DF-HW%+.EHMWH?=I'T;[R"+P:^9I MO2M[6K_RDW&5R1[)YL/SA"Z%G#H(5_=O6B5Y3\6!_06JJC/D3B-<_S%8<"6* M/(>?^G=*N3]OH;]#.?FS@Y'F@H,E'^&OF1$6N/)YE<\E5K=3904G )17J9ZW M,QQ@*3-+=W/S#H4D]AN&ODQ+!OF(8D-8&Y7I#_"- *4\>QW7&6MY%46K]$V, MJX(9R?LGSJ#@&R4T)-"]S/>4"5 NY( -2REWJDGSUQ5\N.4>87&>KK'V&TN M=[AV$]N7;&%6"NIDQ:9-1#.&Y3>\3I/[E8'PQ- >=]01= M%%=+2/R9WZJXP5L5%^_YF;D05O'(9]!/GXM7 _B!TW) RX>BP,A2DVD3-G MP2]^&Y>(.9A0,<6C7!BWP\X"))ON@D_L4'LZC3$\E >-(U8-["1Y9%UPRY0[ MQ(_0G5'T(X!Y0+R7>[G)>P%X6%XL=S'@JRSE]#DWWE4X:]+3I>%F,.H3K]4) M-Q9\)A'U@C? #D#>\R9P8&N#QR^7Q(?T9.:-!;QDB;W,[FJS'%GN W.A5*@< M7A!)ARZ.7UA$!^NJC+QJ2DA;62N(!ZW0"EPC7=U>%Q6;A$2QU B=5AYJB?F9 MY?>7V+G%*!9/Z]T3'#T*&2[B_A@1[/:!)24Q1D?#!RA,%#5M(=:$HT^P7#-D MLW8DUR6/;F*V^&SDBLRCPL/,1 SX!N7N1-(HG<&(S9X1;M].8QMJKL<>2E?( M^N9E[06MF88C#T#8Y@)O>2!LG'R9WD(J8,U%W]'97/0%>DABX/3*[J5[^L4S M*W4C9.?6[/:S7V#[@")EFF&P:BNSRRL;-;ZR!4XKGP2AIWFT+DX*I7Z+-512 M$;G<42XNWNM8,=%Y%5,6F?<]+ZZX(=$M]'];P\'CL^'@S[P[+,3O6%N\*G&W M%K08AB[6$W[MQ,>Y/L'B5L$/Q*(.".2GQ?(M48%UX8!U28RO*%M]:>4\8Q,;_*H8=)_BK(.$1/O(X^&W64QZB7A>?HH1\:[V=S/WRAPN(67W(COGKC._P2 MGU@1Y7GLK<;R&]B^)[,:=:P5T^BO;M]BZ0+66V2M\&.2X/?O0Q?;+?X68+.\ MO!T>]G!RBZ'/Q:'Q'OW#)+N2'"$J?M8T=_4ZLW@/Q 9?*(^2K.U#EO5CMZRD M@2[\7;R-[/+64Z(U/;LUM62$"8N6B8D!IY(9NI(F(,!C5S+&:?#%Q\#XY&!" MJ-_)3SD_=5>WOU$5WL6_7IB7S7;E* 2&1)5VG,ZA^2.85#/P9;)>BLLZ3F0% M==2?@L9PKG(ZA+%5Y@=F/%PUE$NGSB+YHYHM5 LP,\Z"6P. M'&;FS?9!3+9$$%+9,L%V"B./'B8,/>>MYC"AAQL#D]^\UE,N+DG M]"E8_N9,H0 D4\#6 !7PL,/@"N"Z7L2NC_FBB-@9"U^[E^PF!:'M^16'I +IR5.>8-4D=GC&UZZ3[ SN606]"\] MKG2@L',>MSW955:'W=>-2!*%F1V*67F759@5_\+OJ6"37RY@B_,%LKX]<%&D43'RN!=IY)>X=YV]6HQF6?=J-AB&'ZV5-64(?8&$I4$PRQ3K MZL**MG 96HB+,F\C$& D>V3P$J9 M$A$@4&]X29Z5S&:9A<(T,FIO>.BA%]JFR;>)EE6SV#"==893>^F3Y3:9LHX% MFYR>J7+QBFB=#AM*<9MW/UC9[/,J-G[:W(B\-^ZYU!+OT_XP2\K &!Q,MY\[3;A9ZM38_*DYK5714& M=E'A#.>ZOGA:/LKS*ZC4O 72(FRYF.&-)$[D/ARU;CZ'^>3[X5K[9GAA5;_- M<2OKM&N0K!] LI:$"6-JNV?^\+JZA,HB>O#8P@-+1@H;VN9QH5F8VU8,#:Z> M(L4J&KG6R4U/N!_([S-5>@QG#TGJP35,%L/E/3;C;$[<\G%6:Z?*+5AGLK*4 M:C1D=8GU^TS,R/8_2Y-0#>GGOGH>4J4V9[$GJ(_5_W1-*\SYH@TOAPC*A>I5 M[+\\;EXTZ/# ,U;EMMW]"S>LL,T$BP(L:T4M-: N4'0=Q*4Y86O1A2]T%N#L M+)T_QBF[HC_CNO(XR*_(\[4?3G%H8NYQ+@Q"P_Y6*P\L-AD M&1I,<&9[D407X?1""E+3QH\-P'*IS\N'__3D<<\6C%:*XI'VT0KKN5N MZ!<\FU+X9;%_*!/*(VO\P^NJG4)O17WI)[D7:FYR+(V%9&5B**=Y.5\6\W B M: $F&AG@V2BYKUKI&&\F;UNMC_?L6#NA-: M)L7A]3#VOE#[30)G(KH&WSG?C.N4VP+_#N]C:"5A? ]_DAX!KX$_%!O^%D]O M%NR#]^&8 =]YYD>!YUE%ZSSDC5B:ZQ!)G3[@Y#+7I!P38Z=#K 5O4XN7XSLG M830/6:$F?7O$^D?@G6K6(L['[A>LF8W#'UL:4)]/1.%MP@H#)K'Y2C9Z"M)I MXO8BNY:=&2482.%ITJS&L[:0YM&L"LB23R1**5GJ$@ M;V[!VL%#H7(1[/?X,_S_3=%O+9".M3L .XJS4J&IPG+:+)D@P6_2,*HMF= 9 MRQ,E2MD3K(5HM[D45FY-9PT#E[TL7B((*]987EO\OIQZ X!VY<"OZSY M#FY>;L$73JRO_R6 M;H30GU#[6ELX01_9(D""2(_[.,LBL%G4=:F061UYN;UZ"PLI"IO"117ZJHDW M9[>\,Z+QD\0)UJ &4"[+M3'K^YE:O/^A9^B*^1DGD^SZ0.ZC%,(_J]UY=.5- MN_(I_A6G#2\UX3;EE5A9CBQK\!>2Q%D^:0(XF \Y9N7WHK\3WO'#N6R6+3P; MWN>7^[9L%*-\#9#%A>%Q:(Y)?0U &D/].L4DS[5MX;->\IP*SR )HRQ/JV"= M_DMFZ>4&HURM)5UQX1-/_:QS@7"R;+IL\*&BPD 83XXL':[$W$T^!%J: M_W0Z!E_IWM]*Q\FR*A]\48UCW(!6@'J&KH?G#FZK/?,=,0!A("-C^*G$" M)AO>XV2^I>_IC[=Y#\%).-X3O[K^+^(^E!TQ\>"Q-:@>?_O^QHD2XV-A%@:P MR34WT/(X,=RXC%*I-="[\#F@9P#.1I8F%T-R'\,^"TZ M0IT ,"SX:/9/X,1!6RMZ3KX2EQ"\V+]BO1"TY!OZ' ;^18/#C(T@ ;.G,KZ@QC_G]-SZ48#&,"7*3KL5EZXFAY8,8Z> 4*2],XYSQ MO3+E7: \PSGGDK]8?)5 M@&@#4?&-9)-XX$GHK7=$7>@\Y#/MY=XU0E/@Y%<^M7+BT_=E'GN7RT]/%!N) MCA29(Y#7\WW__N;V!];2K-11SXMPN!O%^.:VX)<(#9"G6]%,EW=//9"'![PC M][W7)=U.WE\SJY1E?62S>"J3PVP[%_1\_%7(E1;IEN6R@/@8RK@G$R>-L\'S84!9V@4Q&&Q<'Q9"<\YKYFEOU?'0(2^60ACT1IL1P/X=W="RL7KBDP)I\.+615 M22BSH\CD19SG)XL",&][*CS>;"OKG,LW]$\I;S,J=0W/F(QU) ?S,RR)#4>D M"KQ !+$@WEE(!O/%\%)K3,!CJ" OKN2W]%D@2]2W2.HHNUE+(63AKV+@5:IL M6A!)FT7,ED)K9T>!;:]0HX$SH7X3S)+5+LA1/I[?EJ,[^PGLMD@&_3L-2"7Y M,VHN0?(:8C;07#Z+JE'SCF374\"VN'B+28<;GG38D/J@[WX(F ::4;\TC?(F M327FSHX;-J''-Q73&SAH(K@0JXGS^^J;OHH;R;Z75\"1PCGO+*R29^FFF45V M(4E >2TL]1)G0\59CWQ>#\?;7_#20@^JK;%$;H&M"AYS,ZPM?LF;(6^X!O;$%HAQO9(X[5GH%:XN3%:A*0Q4I@S%;#2X\ M0FT%7P%/]SFN6_Y+X;I!?J(AV0C::HE>*38_64CR,3IBWV&YS^="%^%U^Q.# M"ED/1&KZ)IE!C+*2-;5'$]6+7/95@I.N\4 *II7?GX0/C-EP(=&J9A(Y)!Y6 MH@C;=KH=.FCCEJ9G+>$T$&!-&[F76QJYZV/9E91A&I=TH&T>+,:]]-;^MG/Q$U]\F4J[B+S"9!H\J'%)YN)5VPT%/WIR_1K=IYND.[0/B!>=A5S M8.ZO"X!R^+[,3WX="/9 MO^=0LLG_C<+WIU>0SB31*[$7]H +%$/SF+P6/[RAO.(FCZ_'=/VO\I=&^8\X M* 8?R0CQRKA_P&Y#/[WZ_S[@_V4OX*O MWN:D9LOJ];N#H;RR#!RD/2[L-=OJ$J.T!!?_9[:Z(G[PB^.:KPK<)L17V]A%R 7(?]/T?.?!F$IP18"Z1=U^YK@:<%GIK\HP5> MRP!K@\ [H('7-ERTM#LF2)^]0 N[%N'5!F&GK3LM[U3E'RWOVH57%:;Z40ZK M'CC"6@BG\G"RH#Q>;C?8!UGF:^Y QD4+QR.R5\9+&JR3TF3KX"P,'3DG;;?0 M%+=MS*<5WK&Q0FM>-5G9-K2TI%0=R(5^/&IPGY:4+9*4"AJ5;0-+"TK5@=0F M9>L@4TY0:I-22\K3!U*;E*V#;%_1YNL/'\P/UT>IY]U/9/)HM;R%6>^N-.N] M'F_M'9CEA1\G!LK.!L8A8#B8-%,)F>^4!:0'=D,U3"0S(8+W[2G;M5[6L1QL? ML%NK8YEU?=W3K^]1"2EE!&;SQ9 GR5G*X*45G%9PYZS@S'[=Q*%6<&DCT(I:*2'E@,3:HFA),55#H)VZ.6%U>H.Z MK5]TO=7Y2D5=W*LL-%IA:85UN@QH=>R!OOFH&"@MD(KZYJ.JR&A]I?75Z3)@ MKW-I6:E"H0)!_R 2P-U!@Y9K_^6,:7SPXSOSU[>21N*E/ODS?S^9^^$+( M+8F>O FY?70B\M:)B7L=SN8DB)W$"X,KWP\G^-.7Z52#\7 M)_$=7>Q;^IF_?O[O_S*,?RZ^)G_NC?,"G4:OGIW(O4WH5[[,X<'Q[XZ?LI?% M<3ICO[L#.F;/-CSWIUG5-?S6ZE^.[$'O3VBG M;O9-"W^P[)[UZN>[1V),'2\"YDF)$4XI#/#$D+W'>'9B@\2)-W,2XAI.8B3T M"P_T?"2&2W]EI#'E!_SE-*2T>(9_L3,&'W\BD?- #"=?^.N#@;VOXXZ#_/*C M@_N1#S(><2[3?WIE4CB(#ZVT)Y0TV;^Y(,%_8'756ZO" 0SAWZJI]UA/F M>MW+,YR5>O<8$3TLM46 :8&G!9X6>%K@:8&G#BP'%7AM T:+NV."]-D+M+1K M$5Y:VFGS3LL[+>^TO%.J?22+J*HVS[)]PO%P-[:'&VZ.:KQ:I\ST!-(VS6K6 MNNS8&"@I ]N&EI: J@.I[ QF+0&/C8$.S&K)UF(@E;7ME.OMH@QD6@*V" 4M M 54'4EG;3DO 0T=T]]_::F79[(G=XGCG/7ET9:[QXA&_;CKD +?<5JBN$T-# M7VK3T.T/.ELV+?3MM@I72\:V9:N+I[Z4K2HR%3RMT^4:M:'1^JNUT&G]I?77 MJ4"C-J=I=TL5)+2Z:BUT6EUI=74JT*C-:=K=4A8:K;]:"YW67UI_G0HT"M\J MT3G(WT/?23S?2UZ.G-'7#K$J%4M:BK4/&;07M#D NQWUNN:QRY,T"Y5 ^8>R M@&C_55EHSI176H",5C<96F-*K+JS S0+:75SF@"T0(:=*6NT !FM77)GAM+B M4EF@SI2%VJ==3IU-6B#4SI176H",5C>YNAEVQT-E@3I3%EJC;O3]O6,"\]6+ M_[J81H08'ESX)7%B1$Y"E$U":]]3%23.5)*U !EM#&1HV=U17==3N M SUCF7:FO-("9+2VD;2--5 6IS/EH/9IFQ,#H 4B[$Q9HP7(:.4BNS):N2B& M2?N4RZES20MDVIGR2@N0T=HF0\OJCNM6!&H.:D<235] :PJ8]]_F9)(0U_"] M*3'"J1'.$R\,8F6ST-KUE)%0JG7S&>J:H?%"G$A=;CE3==."LB?MY6C!IC!, M6K I"4N+!=MY(J'EF)9C6HZ=DAP[=8[1@JT5,&G!IB0L>NR/Z@C]@4\CKN$\ MD.9_:3X3H),::.%\'Y2_4%"G4P4A6),Q7NWRD+B$[_ M9B"9W6'=_F.:<)]FG7.\)?O[GCVE\\> X\]>WDT?BIC[Y,KU]="+RUHF)>^.\S.C> MKYZ=R+U-PLE?7]@-@-\=/W7@IZLX3F?L=W?P^#NZA;<^_>#/__U?AO'/JL]^ M/YO[X0LA^(Z;-)H\TD_<^$ZP^46&Y_[TZL.?% Y[8+\R)I1>]$]?R?2G5]?P M6ZM_.;('O3]MTQJ;?=/"'RR[9[WZ^>Y13FW!!8?WMS)?;WDD M"R?P'_*)L^E?5QX$? N'F+$H$(U/+?OIE4D)17PHTIC0]67_YBR&_^;\/"'0 M/RWC7C[VC+*![\QC\EK\\,9@O#@V9>M"G2L[_4U&#]MG$V*[Y7:.$L53S:&Q M2F"/U138:A5/+:_YV!_7<'K?A[Z[&W [H'3W&!'"YA9:0_/-)_K!QSC_]WNZ M9E=9UCJ@):0,8%KB:8FG)9Z6>%KB*03+025>VX#1\NZH*'WV BWN6H17&\2= MK0T\+?!492 M\-J%U[[N"36%5AY3Y0%E0?8X]#W78)\R<+MS)Z+TU:+QB+PE M6^0:K]-29>OP%%0].W7WCDS([)Y$1L_J&)#M4X,!M28[/@9*"L&VH:5%H/)( MED5@W4MO6@2>I@@\.X;0HNU4D%36NJMJ5F@1>&RL#AJM;1L*6@0JCZ2RUIT6 M@8<.Z>Z_]=/RRMD3N][PSGORZ,I9FK!=#9!<-B1_A._=X72Q./;^5G'D2\O?0=Q+/]Y*7(^?SM3^L2L&2%F'M0X99"]H8@-V.S:Y=MV^DYJ$] M@?(/90'1^4)EH3E37FD!,EK?Y'#U>UU3ZQO%0&F?OCDQ %I9^7^&TFMH=7N# M"[29U>69,Q5B+3 $=/)'BS>5<4+CS+@P1OWNR-0"3C%T] TEI>'YZL5_74PC M0@P/[C.2.#$B)]'SV%O -3K9J9'1D9L-<-E=^U)9H,Z4A>K::/IBT1D+M3/E ME18@H]5-#I?5M4QE@3I3%FJ?NCDQ !H-I.T?E;,-I%G=\> "#&9U.>9,15@+ MK "=)=#"366<*&4NC0L###0MWA3#1E\@4!J>]]_F9 +#JA,2S93-KVEC6F>E M%<)I:,Q"'(BD*K]H7:,J,CH*K46;RCAIT:8F+BT6;>>)A)9D6I)I2=922:;C MG5JT*8R3%FUJXJ+KH96&YQ?ZP<1PG8084\>+@."IKH9N <_HS,TQD/E.64!T M59J<^^P/E 7J3#FG!3)-QZ&5A>9,F4:KFS:@9'8'MK) G2GGM$"F:6=&%PPJ MA--W9K=G&A?&=]IZ5@^<-H@SG2#0\DUAG+X#,PWDF]4U^\IRT7'E&P- T'\= M5,=-$OR8./<^R3[E>D_P\S]_3..+!\>9O[Z=/!(W]VC$Y&W3DS<&^=E M1O=^]>Q$[OO9W ]?"+E-PLE?-VDT>:2?N/&=X'?'3YW$"X.K.$YG<_@IOH-W MW=']O/7IIW_^[_\RC'^N>-$]O.@ZG,U)$.-COI(XB3PH)L97705NZ3>_!5X2 M7TT2[\E+7HIO,CSWIU*RI B#J5S+]Z=4U_-;J7X[H7_[D:\&- MW;W,R=4W+Q:_7/:VK[>_?<*YYW_:IC4V^Z:%/UAVSWKU\Q:GS++IOPNGZA]+ MV?APQ^C*H*#1%;X8X=1('HD!4#C!2S9+8?0F-J*,)'270.:4$L7X/@@3PPLF M?@J,:>)3%/?DS7$(7IPZ-1GC0_ M-KS8<&)C&OI^^!R_SD\]TI^?9R:/X$SPF1D_O3+I.2 ^:)()76;V;RY/\-]< M>$T(]+?)1!4?ND%YWG?F,7DM?GAC,,$S-F6E<.@+!VP-PV'W>61_ /7 M0-SSE/%73R1R'HAQ0_V8NC5>6M2?;T4D]\]./]K^6_!$O7WJZ3M)R:-7-FZH M:U>4A49/K&TM=';!E-H1OE-G1;MC]@:=GDX>JP9,"QA-U\*H@H365NTKQ=1* M:HO^Z&/='UTQ3%K;#NUL'&*\)2B'S8X2,]+>K[)9 RW3VH<,LQNT60"[M3J7 MYK#3-^O>X]!\=+Y\I'U759 X4QZIZYIJ%7/@42EUTT>:>I4;%,(_8Z) M6&4C-MKQ5!8:+=)4149;!3E*:=M%J3#6!>:4WO90GKKBL[KC8\]Y:97..]%NXHTV^3Y. M._'^MNW$P^ IO,E[8F-#]66O/N?&XA5[AC?3,=S(C_:6K+R:L/8&PJYD+MVT M7(56J>VU817+%IZZ':/[V3;!;BJT$M5-RW73_BJ(*%UE9JU"%I%-55VH*X)K_53H^ZP;EG>%$*Z9;F:N"B3,] RK7W( MZ 8_);B@]LA6%R_-2:HBH[U759 X4QY1_1:\5C):R:@/C<[(*HR0[EVN)"RM MB&AKD:8F,MHXR.'ZOF]U1L.^LEB=*1?IUN5:C&G6:&5&5.L5G?!4$Q/5$YX* M7<94"3;=NKRUT+4B=*V;O+87/=WMM:VQ<-WTM54LJ,[M5 V/UF_GD;[5:DVK MM=/D/-7SOKJ7>?5>YI:MQ U=WYDWG6H8C#LCL^XLLK/L MZJKY4WK1U5TP1:B<]"UYMZ$^SM MKD;P36?E3RAK 21>JN=T6J.]\"Z:.WN&^"Q86B= VH67"CRJ\_I*PZ,UI$IQ M *T86P?U]Y0J=6]W:96HR)4O70J@'%IZK'GK(=3)CI/FT!; J[,>NA3@;.T= M9?A3EP(H#8_6CBJ% +12;!W45M<\=G^75FE$/?)\QY'G;\MOPJ=]F<./%0:; M#]8,-C_+H>1L[GB(]-LP>3Q4YHJ(?9+D62:_)5BN3$-Y\F<>($<&K4$#-ZDNWQ,=A5U)\V MRVC)?RI(ZC'FS@,YS\V__T:BB1?K(>[M$*:'57UG)PBU2CL5)*\>'B+RX"1G M*M8_!DGD!;$W.<_M_^[XJ3+*3+GR2&5@4KU?TDK)R\.RIQ_=D$B4!)9S$LH MFVM>9;R<&#BG492N+IYZ.H"HR%7SM MDV2:%D"C]5?;Z@RUVMH"QG[7M)1%4BLL59'1"DM9:+3"T@KKA#EP<&EUS+%V MLA2#1?5N=SJ0RXO[C ?ZA>//F=.A6U72_5J4M0\99C%H@P!V.^Z8=K]C71Z[ M&8[FH_;QD79CE87F3)E&W0YN6N?(-Z_M2V6!.E/.:8%,T^I&66C.E&FTNFD# M2NHTP=8,I M86X:0B'M.G "Z0A#7^-&@WYL2KWX45!>PJF(9Z(3.^2*C380< MKN_[G?[EL#,:]I2%ZTP9:4W[;T5US*GS2@M$VYGRBNHU.EK7L)I16]>,*H9) M"V2:5C?*0G.F3*/531M0VCWZJ1FH9='/$VRAJA)L(B1*>.NG8Q>#ZKZJK4H9,:FYJ@WU M0I4UU_9(G3JGF5VS;K\NS6/G+!*U"FL77IJ]M H[34X;#*W.X+)N[E&SF6I2 M\9B%L>M"PV<\';;4[G5AZ-R1,S!K3)(S!JT5&68]TO>$X:W8PDC/]JU\P[37 M,7NCSF!P[$JK5DWXU2S:D((\=?92#2_-7DH7:JWSV7=$ZM0YS>[V!VJ@IWFL M52)1J[!VX:792ZNP$^8T)0J0-:N=>E7R&4[6V<$Q[$NFG W50$_S6*M$HE9A[<)+LY=682?,:4KT &X5JS%,!"3K MT#MN#/K'!(*=V:=<[PE^_N>/:7SQX#CSU[>31^*F/ODRO7VD5'WKQ,2]#F=S M$L0.-'.X3<+)7[ROP]4D\9Z\Y.4.'GE'E_W6IW_\^;__RS#^N>1Y\,W'T*=( MQN__3NGW/H<)^<.)8$Y8_"7"XQ!GCS$\]Z=7'_ZD!+8'PU?&A%* _NDKF?[T MZAI^:_4O1_:@]R>$:$/EMVS7OV\!=Y#^L\"O/]8RF*'P_/ND3 .M(9P MLGP_?*9LD?\*X3/B=$8W0=<8YW]Y9I3,?^%P>.3G14;R2(S "X@QHVMXC U" M-^XN1KY?&_EYVI)_5M/3WD#/E2<:5\#/*A- 2 8F%WYZ9=+S07P?.)\2*_LW MERGX;RZM)G11),ID$Q-WO>ZXPW\),BZWOQCLJ0)^T_&Y)YJ MR)4&QKB*0MH!2:&-U6"S S8[4P:!4Q-U^W"7V@:6%GS*(_D'KD%N4'=.N[]Z M(I'S0,YS\[P&B!@WD3RSS)2T #J[8#;N"-^IIT]LV^S052@+IFX@KBHR MJW35J7-,"Z#1RDO-NV9:9S4"XZAKU9TRKQ76$:7B,>^6:6_X%\B4''VDA?9] M54F8:!'6/F28F:"M +4*_S0GM8^3M/>J+#1GRC3'KD'76D=KG?9#HQ.R"B/T M?L>YBCH!JXH5H.-HYXN,-@>:- (W><2+-Z!=.U6U3')2VR1,P:L%>%X/2;YA.&M>/U)#ZBH/":YOXN#KL=RG25_-J0= M3YVW5,-+LY?2*>UUGKKN[;WIHJ^E!GKMX+$3;.J]71-NULL[#)["U]?A;,;; M?U\[B/LAC#ZD21J1CW&<@K]:[ HNM_,>G4\[;T8UNG8@ M0<1)94 ?[BD2R_ XM8 BL8>#*<,I-NG.FG\O=?R/TI][;Z4WT)R\M)_6=/O> MNS[E_US $@92UV7R;4/F0$RB3;$ MU0DG:2YJ6;&I-A$*)D+(QA#)%@).=<_L[)3N@DV\H2:S;=SX3J!LR9PV(51! M0@L_59'1)D0.UV7GS^9^^$*(@0E2XR:-)H\.S)32 M(8>C ]@"QU8+/U61T5:$9$5T[)[9&?5TR$$Q8'3(076$OI(XB;P)E/8&P0TR?^&5.(B>AV/]*G)C$JQL:CO?6T!!;\BG5 MT9"1S)@QFAD1$LV8E%6B10*$AH^TM!('JD%]>@\$8,^(/'H5\.( M?FGFT'_23]&77TQP=B"V_,,O&0F)9C']O$&^34@<0X-$ND;CA3B1X> _%TRR MCD%/!_R1=5&,C>_IUY/',(V=P(U_.$KWQ)5FSSYX\80R M )YC0M?H&I^<:/(H#O&ELI:-3C*K@L29IL>.W8-\G=$_MG5NF=OKPW['MH]M MK&OF:5EN61L&ZPT#^]AS8K5AH'X"3EJ 8,#J.H#I"&VR$NI$Y'4=0 M11-I_^=\D=$V0L%&Z \ZXV%=KT?S4Q[S4]0B* :-Z'*%@$.@[P-E]J$<2$6>:D.C(1K>^HMU2#U9?T6XS M>LRVT%>TJ]L?HY[=&0SU)>TVH*5ZX&*=47+&MW[QDO:1#7Q]'[NEWK*^CWVZ M-S+T->S&H!YV!J;=&?<4Z7NA;V'O_Q9VHW=D5Z[KGS\V>D.[>.E;ND'.KH[# M37'BRM>X+]=R2?G.@ODGQP M)I[O)2^?\%YR?OG;<,G$H^C$/[WZ^)E:\] .$-_VVY\Q+NO5SX/!T!Q8_9P: M*Y9>W-]-%$X(<>,/43@3E^"_3*6O2CL=FOO=:?&^N[3EBT%AQUX<]FUK]-OM MNU<_#R^16_)=;]Q0&=^ ,L4D^<-+'J_3F)Y,$OWJ.?>XMNLT @D@D\#:3()? MP^#ACD0S,OEP["7D(HY$-7V8_6&U?>SL#JV,]Y.8\T7@=_CKX3*W2"6=]1? MLZ,X2BB_NNDD^1+=DNC)FQ 97_ZW*B*B+!7E_9M9-Y"*RY>V+([8+_1,%4[W M8//IWG@\Q8+N0MX!%G13\DBB^.W+W@/15*9JP_*<,!._N+6)9+@O_DQ^9!B,UJZ?"\LG.-A MN\CS\TWO/WS;*[=79''Q":IFEIVK]]\F?@K?O8JIA4'EUIWS3:;/J#Y7X +Y M3E0@Y=@R5S#EZI,V+$JD&L1L%(UUG7C:AL9*$;D:C<&HKQ0-@O'=1@G7Z;\,3*AUSD7:P7M&@?),LMV MO_3RBNM:9\G7==SZ#:QK@[&\FO?6K,MN8%WK3-ZUAW#-ND;5U_7.\U,8!W!+ M)FGD)1Z1[?'1.L-U[2';8&*O?OLVJUMG-^[B #2SNG56V]H#=Y#5;>@GN/K8 M-;2ZJR#QW(7/,'E(7"8O9_,T0;']9?K>B:!Y7TRE/,:GKF9A6O"Q1NOL@&WD MC@B168-AB8L:6?)^J3!>IWZWD289%9CHW2\5\GEIUT[\^#D,)@L!HG&%6-J5 M^S]4K8JX[6?R?#69P,O *8O"@/XX09LAEHV._#.W,"S%B=SXM[GK)(02:6B- M,*4;./P80: M&G1O">[]5W@#?=CFR!A_7177;4TXR>X7[:%J>]R5+NMT?>-T66,YK*&+91Z! M+NMLC>;/2YWPXW!TC/-2(3[7X'E9+8-7T^72'AR!+A4"W1C(2A8OD81V:==;<'TM02,I;9/X:466=:[N/4U)$S/;MG'X$T M%=*_C9Z:.J*F/QP=0=9<;K!KR,"F#'K;R?S?WPA1 > M?%O^36J>/E%[E;@X(##&"H/LI<#D8_EC*C3PG\%G[-D.E8P:/%U62O?_K:F&F/U MR>\-2R'^HU%&08 J6.Y%@" 7((U0Q=R,SN4*=__3^^3??*DWT8H57" ;GPG^.S,CN?2=')%QM-_'<"5>[ MQ.#<";>I!J)RTO=4"?=[Z-/'8&ESB70;RC162[G^4L*->N9HSZ0K[N6HQ-M0 M1K):TBTGWM@<6>=#O-I5+BM.'C6'SH=XFXIP5DJ\%<0;CH>G0KRO7OS7AXB0 MCS#0D1JA9=)MFCBZI<2#$IT]D6[93HY(N V52-M*.].V!F=!.&N3)[&EI(/Z MQ?,@W"9/8DLI!Q0^+N'N-[_N?ANA"O<&+9EB&Q-39M&S'_ZG1)"]K/ 8E-BN M+OJ4*;')Q"]'>TZ7$IOL]:(\.2(EZH@E'IO$^Q[QQX"%T_[ C@C$O7HBD?- M\(_OJ&S*%B639Y-%OM(RLE<$;+-R6[,[;,(MK+=%9>A;NW)^(WVMKMG7]-UD MV:^TLRJV^E;(W!I5V@F4CV!<_<P$[JWW M+2$DJ%*">BXAT%405+B T0P$.N^Q"H(*UST:X@*=05D!P3IO*8ZH.TO?B;2G M_^ =I8HWFC5 ^P5H0P>9(D#.-PW0H0&J4+'7D![1VONVI5:D] MNPD#5XD$RV88*I3K[=NF6@Y#OV>>. Q<.H=SR;?FEH,K$4X>%6 YG)N^-;>,^J-]&UB'AF5# M8K9W.(]]ZVH,^SRJ,7H5KLX=Q\8R+6M?[* !(N*O%?A,MW1G&]K?,A2D?VK M\8J0*.V,'[1>[$B0+"KPP[GFVW/)897&<=3W$D@.YZ9OSR6'52*K(=EW34KO M<-[Y0NW7IQ.M\^D=SK5>J"([59KVC^47GS)-C^74'I&F1ZEHW M8:NWN\:HKX!;6P&I@:V1VBHC?8R2@0HX]IHP,EN.XSI?68G* BTY*^&XSL$^ M(#_N4 6JY2K@N&$JSJ'X<:=J7F6JT6\B,B51Q%O^X'OBJS1Y#*/BT+%>?^.U MT(HC"%D_P^(TOG5KV+S>+VD20P]O+WB0%[RI,7S5!6]8J?3VE5,AKYVYES@^ M^P*T"XZ>"'1R81,HQ01":?&##>-4-A]R;,ESG8W*B_/#_G?J)2]?IG0CT/P< M)II=/42D- IO6!X(MA+.8;E=_M;[EL:&L<45%T4])B]"GGA73/$,*KB'NY.! M,3FCQ\]P;B[,WH4UXH/ -B]XRU&AO4$%7VS'78W979O-X(YZ9M^6;[ZO6'Y) M-\"?V1_>I5$V&@VESV?RC'^)Y1U7\&EVQ]$VEVY]73?_R_+Q>993XCG9!]3MGF?ZP!X-!WSJPY*LR4GQ7 M4E3.00M2]$:7O=%@?%BI565B^-X.Q1H.Z95G/QU XJP=!+[O4[%N#&$#M-CL M**T=&MZDO5Q;B^_%6ZHR5'P/;L+^]00?OUX.'N!'J\1,UHX3WRUFTN1I*4YW M$O2JM?F&Z-82JWJ;N;%-T'7G^"R3L#!X.$J1:N4VV5D7Z,\I[%+&I()M7J.! M/O_0G9< \3\&+MQ+3!T_=[,?/3+]1%SJ:/M4-7@3$LD280P=@BIXAT-S9#41 MX=Z6@@H 5\$)J#OYH%?10H6(6B,)/U7)7\QX2-1?.X5\1^IOZ]-3%W38-YO( MUVU)CT.A\#LBOPR%*C-;#X3"X')@#9NX%+8E.1H"@3(8>_S"ZZG2FA(/M%9\ M175O%IZ53<6U,]D/S0XF_![2[D*E1X6 =AM./4\&RI M"[="\U"3P[9CR_Y!T-R2;(="4U*K6T&Y]5"R@T#92$.-1FFFMGK<3R2BIE0= M'\2?4D\]KC$LMPXX0)SG8^"F$Y*]?XM)@&M#2/R/&$5Z_XU,4IA.O1!'&IE] M:-=6)9(Q'MN'15PV6#%VR'[Q97I'7S)Y+$3BQUM'&W8C/9*.$D3\T%M'0PS. MLC53+Y@'0LN;:>A.%_X7*"\O>/@*'!/374WH7RG/R/3:.B[0R%'E"Y,/Z(J# MA.]FI/D2D"I4+XHL<3G7+M^::)JHTOFLS1/R\_]#'%FFC+>.&Z@)%)9K\J/? M&)T.S#-;QPV.!\7=(G+.FV=K=5Q4J M**,V6\XWM::(-PH&/' S$A_"-#ICGMG:(U<1)KQVT')^.8[K70,(ZH6?+[]< M'MA-WP],)Z!?+M?Y_Y5N8*MB"NP4'5CH-K\??CH8JNN"!97*+D\ 5>M04O)@ MJ.X\\$055'>*2IP:K^X\)>4$4#T]7MVJ0XW2O+I;-.34N'7G"PTG@>OI\>M6 M'6R.P*^'B,*<&J^N"\JHP*O[Q_3T^'1=?*=%?+I3].>T^+1O[MQ8J?68'H=/ M#UL6U3>WBC7M&^$U<4RBL/S"E@98\&?\JA$&!A5SAC/C;?>,),1?/+&W&90."95W3@=_&Y&9 M0YTA^GN*<(="C.#'!O&]!X_B M^&;QKIG#YXBIT7C'F^5>.9T%]@73GT>PGP M91$A1DSF3@0]$^_3Q"!_IXYO)*(J^]E+'NEG74(WZ<(2RVLS[@M;F3QZY DI M;8138T*BA*Z9+OTA]9TDC%Z,F>?3)X0!B;L-'-$*AV=-S7DV,R($?.53=N"* MG2KL72@\-U<4GA=WU$0!0+6K=\-! MWN+D:'13P-6K58:SK>M0N?F&VN+#$4S#61E0:[>OZ5NU0@=-@:H, MGYY4(YN^=9 @]J<>BK];/KV(<(4RC+FM@KT"&;P5F >(M*QTGW8B.J%V1WU MC^)+M)Q'#Q$N.=;41O6,W$V17;O.S.E2.F1%/_A=VTCUMN\G9>UMA&I#<,@5 M0^S!E@Q&A8C)MF L$O/GF_Y_&B#3DJWL@4BLK$JF484X1@T:E9/C=X\D)D8, MPL4(V8%@B>V0,JSA&-,PC2Y>X#+R'/?>85EJQ_@[=:*$?B2<8C*:?==@IS1+ M7/-,=1@0]@PG""@71+$3O8@O9CGN<$97RA9ON) A=P*WE(L7"RR]Q0MX)IVO MR7^AOXH3Q_=1-K&MP),"2DS#LJ7/L4TUDAY?1/.PQ8AVA:C*[@=F\TW[M_1T9W$"S%%J9HEO"T[UU?G.] MFMS^Y7#4R&R&JMO98@@?_I$_EYJ@T<2+28$J]'962SRK.Y@UU MQ&6#J[?.BZF5@NIWS?VIV7L!NE^UV[P=.[TX8;/M/BV5L3>YT/L1NQS:ZYC6QM=(='%[R;W($ZPS&: MF*BP5\%;73U6)>,F[Z&&!&BDV&6['>WM-'X,$FJRQMZD'-KO;W0C2HI_=?W[ MX-(R&YD'L6GY>SELN;C >OK5!*OM:*RAW-"BQ&O\M*W=TA&.VK9.RFJ"-9%B MKW'*ZH3_%@5 \35R+J&_K<-2G4)[6?K>2%22D5]%U/R:$B=R)DGJ^'!'JT"[ MC1Y,,5EP,_C/\),U?K<7.E5=?[,$7*VK5RW E@FXG=^R!P+66/_*&?5\KC2+ MSE28NMWOUTDYO)_-_?"%$'SE31I-'NG6\&YAG?I:TS3E%@=;[Z8AD:I%)DZ%BK0FB$-_&EZ8.\_?6;J=IE@T M;UT@$ZA.C5@- C'!0YG0Y74I[V]O;@P'.DCP[[N&DQCC 92G0-6#J)69.EYD MS)"OC"?T%.G'X ]^^,Q*<;[W?L!?3/PPAM*8.<9\>!G.U(OB!-I-@+5HN$Y6 M@Q-[WRZHV90\9@O@A3%&&-%'KGNF[VSYR"9*;23X&O(&LG+$*VH7SH1OPOL[ ME+RF09WJM;I"9O\[.WA/H$&=RK9&O0:[9XX:&:%[F*X]%9+9@PJ>V R/,?]K+$<7AEL-S"D,;-@N89$7;7?'4L%_K?4W3(*M9LL4 M^M[7),&H.[0;)<%Q\_K#_3ME/]]]"A]'6 MC27X+POA.89H\<[;8D"/7R&'^+;WA*&\N^?P[C%,8RIR[YZ)7ZLA]R7<>9.+ M.8])S5K9J/W0Q;+[ ]N4.\T?DS!;]T:H?\Q6Q8TEHMYZWQ)"&HDD'Y.H6S>$ MY+]4S:]2<2OU*GDB0$BB> M$:;N'U[R>)W&23@CT?MO$S\%9_0JC@G]CWOG?)/WM6%ZXTT44CBI.W-+UT)] M&)G=?J7_#F)R174A^V/Q9,#Z':HZZ=_?T37ZX1P/16[;B^7>B6-'=XHM@>*W M+X53>36//%_2$Q^\*:A>\8+KT/>=^Y#=]%IZWLP:A7F2;5V#Q(UBM&$:XTE@ M5*MX4AV,QANF*YX"1B/!1Z-:MR..C="&N8@G@9#@HBT08M7PZL"TSLM3'*9/ MJ9]X_Z'OR-YT>LIHO,YA/ 5\VJZ(UKF?)X#/:B74$GS6.;>G@,]*%=02?#9D MTI3 Y]]I0!9#D9_# #<7>T\D>]=TZOD>V@N2\5 ,LJU22*VPZC9D_4X/KAJW MWA6"JPWAAB;AJN,S48Q5,LC;$'UH%+(:3M2@IQ)DEVT(1KPC$WSR,?68I93K M>]F&"$7CL-709_:E4K"U(6+1-&RU])I:W-:&0$;CL-70;8IQV_[B&\M6\]:) MO?C+%.KWQ'1Y_ND[;P9/^N3@D'4_%M\^E$]^"V0\L+KL*W42]A=).:^34$,# M]]6R=_<7LSFKDU!+J:LE$_87#CJODU#'3F@X;'$=QLF7Z2]AZ,8Y)O%MZ,M7 M8R]W#RBU#A(VDJ *)*-RC?@JBDJ=9&[HD0T2P0PBP/\N94EGF?05RM_;0LV? M;^S_\-8SZ_=?/*+T=$T(<6,XY/P;'PA4;DT(?9MT3BD.IT.L.D=O Z5JD[5" ML;RR9,T-K\.0=2?5.C#;$.90P4E2*7H_,-L0Y5# H1D,E4*MC44UXE^6]NTUI .G.RY-APA'$MW.' MGFOZP=^@83$^-CM3\EXV#6*I+)S3)(K_GB:O?NX/!N,,I8UKJ;WP"M>\V9=S MUBRP'_X1.I+ _59=2R^D-HXKX5M<2IP;_E0_:@4;LEDZC"/>[*)&+]7%SHF[L=$7ZV M3;M_85Y>R%,REZU\N[U5N%Y];/BAI_KXPC(O>I5VCD?@5_IZ/XS<#]!GW+TC M@1,D'V?S*'QB_<=D$FR\$FWUS.R'+?2%8-Y-:Y&7#;MB/1. IE[ -K>L8?O MJM#GZ #',F3K2D(CX2LFK#1X4SIWXQ,41M6QZ /N#2>J=(T+@UL ME1Y#:W7ZV>?(2Q(2&$&84";N"AIN(HQ$Q"O7]>!7CH_?YYM5EM@2]5%17L+$O4V%02$NU-X[5SQW0C[QB< M.%%2'-8QL#?8(@/3%GD B[/MX,*T46!M>,NZI;RG%F)I(1L,AR4+&=-5H/Q8 M^XZ-1MI;_KU%0\W>8 "4UE3=4%MKIY76LS];S=XX+,TZIJV&CW@,?5>6JTS> MOGW!/V:]>N1-;1A@9INC[0/P/):[[;*VTMIV(UK[BO[:71M#X#;'N*+F%9]8 MJV[M^OT-=]K9-D&1\F"U53J[0!)JX[ 3NT0X;)S9NWU^SAX6*Y:6KF'+96Y0 MB76"&;VAW?0R>QO5X?8^\:4U:'R9&]1EK28'YN76J)?D+.O!PWNG\E:4\;N4 M7*=15'0->]OZYQ>]=:?5MHLG8;MUU=K31^C*!A=]90'4VW9FZIIM6>:H9]JC M.OO*UU9W:X_4F5W8W"8]OY&7QD!M9TY2ZL?'U,X-HSGO^+/C MK;EQD6FWV'43Y.I7JH#<#[GJ&&#]0<:S2I/.5NZQ!BDJM._=&REJ.5_U*%&+A>H4T6%B-$G=E^SF1CG] MNA4Q?_?BB4=USELOQ!\F)-Y1B!^0S>J4LQV4?HUUKMF9#>O4D+7MJ.V35>L4 M>\&F136$N,NR)PKRY]TF]$M@0OZ_\LZH-T$8B..?R$S1;B,QOI@9'[9L2?<% M3CQ=LXI9@67[]BL#W,7 I4J'F[Y22.!W[7%'[_C+"&,P:DOK-JICLZW!"!+R M"2VLX(?]:]>-L,'(VTH_RB!PR=MV+% M*4,/P:5MEV[,PP-)7\8D*A6%/$6AEDT-YU#N)[-%@F]97GGQ3G>@ZX?WH-E! MM5369!(T/JZ^[^6GKRE]?L$',*^8SB!2VDX/"B[(^TD<%$=N@N$HJ!?GH(_= MW*]'-D[5W= M4]LZ%G_?F?T?M#SLM+,-(=!"86O?_GRMUX/#:]&Z,P0=$F&U#4LQ_4X>3>Z?8_^.'^X02-C M3FR,AH[AV80)U$-S(18G_?[CX^.N.74-9]=P[/Z4,LP,BJV>2_B2&L3MHUY/ MB[C@! O0!@VQ($C]G:#]O<%Q;V^_MW['_<'1SO?=X;'/UC;^]D M;R_"X+MO#8K\G:"#W8/=P^-/1[L'GP8'AQ'J>VS\P#."KH<1ZL/!YZ//T^-/ MT\ET\I'L'WX>'$TG1T>'!\=X,/AH'D?5=18K3F=S@=X9[Y6>8#]CQ++("EUI M2S^@FYN+771F6>A!$KOH@4CCB;D;\'+]O@-W,/>$ 0?//MV)=-_3A%N[#I_U M3<'[8K4@?2#J 17AU-C1[Y$M=!W^F#2Y][>H'!A R7")<;NS%GVY9VL!ESDB0EO931CF!INMB!U2S8YBC>A;$E5P!8B:8W'(\)OLH6$=S,\(!%V8\" M*?+V!+NAE*<4_>.!HAX<'Q_WU=U0(8]SB$UY&@5W,U0B3\8\NY&\DX57:N3@ MFQJ2?*#)L1"<3CQ!KAQN#\D4>Q;@PV,_/6S1*24F1%.+R%@8(XC<%IC/B/B* M;>(NL$$J R:KRZ"#!_T_;F_\,+P#406A+]1>.%P@/[S<.(:*K04.DM]Z&@L] M>:DWV =C=Y]<4)=E*IH'I/X6*FB@;*3"&F4;J:!'O93]*4]J=I@HE^?F#5?Y MH;<&8Z'R5S%(3/ ](DE7'VE@BZ%46H#770D]?60&V@33JCJ4]UHEIJ.-] @DN4%GWOK MC*^2%AEYX@9ZK#-4_V-=CZ0SW V4T/F*_-!;)RZ5%$CF.IN(U\L!]:DN&E*+ MB4 #S)@CE%CU75Y9+"B;.L%7N"#G_Q/N6&0,@QU1\W1G3.R%!0O*&Y50REO? M'J[+LZV^I.S'&]?+KOR3]8)4<6S%H4DK*^]),MDLP\EYAW M[!?U><%A2U-Q).TOWT0*9(9?LGF!N2 MMGA-T%]P9T&XH!#*(TL*Q6#.R?1T1RZ_>MJ-?X*%N^ W39(2$'>>,!R/^L1%X4[0<9X3[\B)F)?'8HPJ_> M!+!Q&-]\YMA^ MC:C2/06Y58+AQF$@:RX8/K6-2$Z^8YMF0M8C0G1+@1;]9I M5>;4@71JR!#)FG# $T69HH K\MEVOFW4M_<8%C!B3@2%KMK,T7$695[?W\CK MZ%U,ROL.!350\(UASZ1"N3#MRY#,O9O>P?RFC'4A3-]!;_,+QX9.F$,KNB0W MCIL9#)H54(:@@R2"0O%Y6%IK@)PI6NN@I@^E!8JI@:0>'<2:A]C=="0)&2D!+5(:+":B+<#S$DKL'I0FIS-SWW7,I(;+8IHRSSZZ%: M0X1,Y)8_5DX-,_R1(RORSG_)/ MP %'#H'U P^ M;K'P0._TIZZ6O>4:9(PG5I[#\XC+7/NI^GH$O?-Y=GYL*O\L<&AYJS+/ILM MA;EHY]UG#-9GIJD4QE;DX?V0"$RM+>)W$=CH=@3TSI?>86C+ M2"]/:)B>18+G/N=8%?SM!6&N,O;R27XD10C:DF<9?FK4L>2]0';X7*DG-_R8 M*"H?!0IT(&H*1$5NADGE.[8\=2DR@FL'JF>76@;$=&6M$(AEX)/S8JAB++9U M0>^9\7J%*9==#Q'JTEY8SHKX1'?JP95;"X75>)5@:S]=SBO"EI2IL*/"G!;K M-T&!X XLSPR6>X\;]Q:N%[=J,"R#3;JLN#%LM'0DQ7?@:0@\]YQ,">=R MXP3J9@2-7T YK"#45F95!)J/^6@ 97VB' MEY?!RP-Q!:>&T)'A$7/335S\!OK+&L\]X<3<2GGLQJBM:C:(_(XY5P^:MH%'-I,R:-1\G+"&1B"N0T73J @ZMH$E1Q5.9?BH5^77$KOI MY04+(OJ%E5<.O_($4%^[KB>3STV+(F4,2S!S4*]Z'RN,:-$($(-\X4A+[[#S M8OOSZ\:>IF64(2QK__#&N_J[8-4TX')W4-7'U4:LRN"3+O87[]#J /)2 /%# M_BWH:GOV&6,>MH+#]&QV0^2B&J]4P\U 4Y=]&9#2CP#*@!3,:8$*R-,9 M_]?N_]*/OAT2OL7?'ODE>#^W_W.INX@F-#^.^N/-VI1NN_QTR] M?_U$%NC9[%H06^JX@UQP%C3T9(M_<<=;:$(*)#O(_PQAFSKF6+$Q/?_P&JA M92XJWZ,FN >L<"!0?^_G&'C/'=,SU*PU"GY_X9;8$\*U504$OBG^SQ.*_:C.0:H?6.P$-3E:3!F2#DQA,,C%V*SU+]VW%.=I[L)B'V,57+]-_?N.)_RJO MTQV#$XBG&\+RWIM8U+B;3HF\4PENR29O"4:US,UL\6;:M],0Y=JE[-XV^Q57&;!BT!EU81+ZL*GR[%-Q3QXM6 M8_(DSBTP6??-MEQB*8G0UU\W'M[0GQXUY<[1;)OS[[?1FBK[Q!(99(T6;4LI M(Z/R B^HP)8_!^<^KE#G*E,NWII-&Y%0[=PB+-&(U'.="]9MUK(54^1H7;DE M_LGLT/1-FFY@OBE.YG"?&]Y$=>+S=,29&,_)+>8_B+C"!K4@@L4'?@%!V\;Y M5ZQ++KYD<-%O!%MBKI_JJ(QL_.C$+:S=K&UVRU*QI/N=BOF%YPK')OR&XHER MU@A;,D1!7%JOY&HT:$WF4I:R*B<]D"5A'KGRF!DN0+31!011([6&KQN68]#3 M%B0NOAG7Y&YRC(_#4K*VC;M.YV)FCNB3(*2JI?D-6V>[OX=,QHKP M@?CETX+Z?.4/O8;&5J",#4"X\KJ#S]=85ROBFB<<68&R;9Z+8.Q2_G M@*S( MQ,KD;;/S0OX>BDS*Y(1^!O?,M''%-*VS*+4 4<6UW/5'_L*EK%W#4XO_^Z&B M^9GE8D[)]!9H#&S!**0&X0D'YQ.TS;O7S/0,=4T=DZJ_1-^"0=OZ0BVL4Z^D M4&:-(?F!%=B5XR5<7:_-&[28+DEMBR-MVF:Q'W/^ QEMW*KT];9IGM/OLM@[ M4Z3GJS5)L"-'><5/%^0ZDWO^R__E#WR,YY@%QV^N[07(OYO>.J8_+?EZ%GG[ MV:2V[HG4B]K_.U')CGFV)!S/B%IRR5PU?.G$Z[BE@EK!:(&A @Y0HE_7;U\] M.8KOID%("HL0Z>M1Q%$FR(SP-PHY]<]WF'!A52 CV=9@23.,=I:ZU"XOR[I&H6 =73SI>/.>'(O69^%6KL0%[^@M&E5('6E)=*GEDFTMZ< M96P9U?],CG&+G]0>95L^AKA?;\K9&E'YC-\*4C8V/2S1Q0K*C;%K7_EY8].N MY99.M=0F/%6!;YIK:@J\=9B8MZ%V>*U^DP 67XFB[OB16,E57)T6;8M29PM. MK8BV5W0J"X3Z047D;!7X.3LP;\7BC?3'K6<)*@&JK:K7%^7-V]8/__8823_+ M^"K?*FI8GALYZWTZK%&6;>NO$5F(%!RT@3F!J%Z;MEE\#ZL:)I+GAH=KOOZ.MA*J]F5E\1.' MKLIVK-6#_SQ56J%-JT#X5G)V_Z'-:($-;$82:N[05W MEOIG_ +32NE:@]/21Y'YAX=3NR>KT;9LRV39[YM4,*[MFR'52)-C[,J!7%O. M8Z:L5LK *=F-?GH0-JX<1^!9(H/8I&7;ILVH#?)1J9SK(_GC;S!&80R5+$;=F.BU)^]:GVY4]9B2Y"Q=M122-)7K;/T-2VLE76$43 M&S_A.5_=^.?F@MI?#*%5F[P5EUY03CUW/ ><+@CH8[A@A,,706TOL6^K&G'; MPNAWZD*>P\0Y==2'U$'\ H*VV3+"MHLY'@5J0O\G:@2Y]UMGB?#,U2W$\I^NT/>W;99<<^I/"_UFV=C=D$LRW_.$[R:(OG"B@JDKVG? ME[YKS"'1_^6_4$L#!!0 ( %2$1TXG$:T0:PH "*# 5 ;VYV;RTR M,#$X,3(S,5]C86PN>&ULW5UK4^,X%OV^5?,?O)DO,[6;)S00"F8J3:"+JO2$ M"O0\/DTIMDRT;4M9R0[)_OJ]1'>1$4%01C'1TS]7K2CH6-[].?<^: M8"X(H[>59JU1L3"UF4/HZVTE%%4D;$(JO_[RPS]N_EFM6MV'9ZMC!V2"NT38 M'A,AQS\]?_W9^O/SH&?U"/T^1 );76:'/J:!5;5&03"^KM??WMYJCBML5K.9 M7W<)1=0FR*L*S"?$QJ)N5:O+0NXX1@'88W51@*WHZ]IJ-9KM:J-5;5R\-"^O MF^?7K?-:L]VX:C0O_]5H7#<::P"_S_E8:U_7UEGMK';1_G19._O4/+M82_V$ M[._H%5N/W;74%\VKRRNW_3MJAC!6C**/-G<]#G !!E/[AC MU,%48 <^".81!YX[GY$GZ^-YA'$@]I$; -[?!?"2#ESPLI%GAUY4G9)O(BF> M!AC G26 )**5>&02&.4Q.^%1 W*1&$:M"$:D5X3&4;EU[ 5B^23R5K71 M7#2F'Q>/_W[B>(R(54,W;![ G&Z0":@*S^L1S. M6G[[M!O6Q2X&%S@#.8W#3U)D1,P T3T<,AIP9 =_ MD&!T%XJ ^9CW"!H2CP2S DS4\/1/5#S$SK)<@@NU[]T@)> V=]S=7,%-.V]9556 M_LAY*Z]F8Z.B1LQS,!B=, M>6-.P<&F3!/!/8XL/'K;VEY&[A(D5=A+X?H55) M@/UE?I'Y+UKFVLF+BQL5P&<;6=R-@'QH9Q&3[(V%>.B9L5OVT+:;[^Z#O9BK68'8;JX[CE]CHF:%8>FGBNNCL]JI>FDM0K9E\PRKJI M;XCQWEEY^(VB$**C2("WK<1;)1-]MP]3<&2%6'*]8_Z8XQ'D(A/<8R*G2%%+ MT4?6,[XO)\V'0M@#S-2 JX%PT[UT&1(J)^;16&KBZG MV2Z>8(]%L6(!/GN M)^!B:#O?F',B3:L%T+X9^8Y>3ADH91 0!:Z<%C.D[O- MO-H;#; M3]VQ$T*SZ;!<8_-)C+[.;2@PQ&: Z!8.)XO=#B+VR(;3LI>A=4Z$"7'A#XQ# M^$CGD:<]>X'UAH!!1H;,U(E^6P30SG_">8>%\+SOYAS&=%F@NZGBH%@M;V34 MKWK9=&R12LJ$.>JB2H4@V^E]4R48.5GKZF.F"C?2.R_;,Q2;*M/8RS9CQC15 MJK&7\\X0IY THWH*E/<&3TPY1#55G9'+![L7&J8J-K("4';@RM%4%8>B3[9W M!PHI.$YA(-BY2<+4]G!,%7&H\-ZS_V:JC$.%NNI6ZL$RCM,Y8)!'H@\>>]-V MC+!5@#&'!;'ENQ:@VUZ23V3@Q#$2N(OG/Q_INC)&95&I!*-_DVRC^$R-4\[- MLWS0I5/=UK$=QB\-[QBDUB6)!S-*@I5.9W$6O.P4J6?"AW%4*Z%TXLNS_H-; M90)H)PWE4:[(]2+*4$?K+<6N2U'#T_W^IQ<9"=/:"''\&463G2\;<333%C@Y M4$74_NKWF&.;1&7"9P\O-N,Z/N,!^5_T/ \M-;S2#M>>D8?[;D* N5)?%CME MRT;4?W.)2X*\IP#KN70;B&91S/?".C9XAJ/MA;V@J8SLY6MQL+Y^8#Q]^BA2>_G+R!OHK/OS48A07I,'J\/X945H M*G\@'D4LRB%//E#-]77ONM@.^N[]U![!4(4'X-$^E>O?#<5T4B,/)B8?K*6$ M^&>^0SK?/$?>%\["L=Q3(L*.WFV&Y5 LQ\M3\Z=@K?ZC?8- M6O$C7=Q;2E^CVUYS+TOSH!Z'X/R\X;T)IJ(>A^!JJ_U="::BEG"S8>'^]H0Y M8<[V&FG1"]=[]KRWYU)BE&S9<;>UCU,-K%B;-%9,3AW:3-6:;>1W.8;U1/;TV]S.8P[Z@=V1>Z^,;<;J6LSRAT28ZY M?E$4U12Z4>D5-2E7H IZ/Z*XM=9VI=_1H<,R6D-+42WW>VS=[1+2F7@KT MKA-74D)]JC<%Q?_',^-6\("O ML^#C"/^U,"KIDH2HZ*1Q*T-"_ (3)T9N@'G2PXI7**B#EW4G1+9%[,B('^LD09B'72#A&/Q7"+U"JQBI>AS\9RF],(^$5^&G0+?!_H/(BGP91 M#0Q/Y25A1>)I5T4H5J&I*A']+EKOT::J/$KQTMI ;ZI.HPP_K84 I@HB2G%3 M'!J:*HO0[Z;U%&UL[5WK<^,XCO]^5?<_ MY'J_[-9=.G'ZW36S6^X\9G.5;GZEL6L'NEX__H#)5N4;3T( MB90@QUM36S-)! (@"8#$#^ O?WN:>P>/+ A=[O_Z8O3R^,4!\VWNN/[]KR_B M\- *;==]\;>__N=__/)?AX<'9QWHW3>]>LY.W[T?OIG?OWKU]]<$:C5X['_+L M\H=%X-[/HH,_VW])^ 3Y?9]Y'EL<7*PD_9^#JZO3EP=CSSNX%G\<'EPS(3QS M7BYI>2OMP93XX:\OC MHW]\OKJQ9VQN';I^& $K\BM!INB[T86[>'*6_A#\- MW8]A,M05MY/Y4Q#AH/0OQ'\=KO[L4/SH<'1R^&KT\BET7H"Z#@Y^L0([X!Z[ M9M.#A-V/T>*!_?HB=.[\:/DW1\D'1^88@K&8+U;SH<.F5NQ%./8*/N^&63ZW7+\QK\NO3;*: M#'$X9_,[%B#Y7/_4(),S(!'8\1T[S'2#8[60P))A56ZY_\B!I='[T4FZ_?YT MR^"OP#9?)39BDQDA%O!B^?PQM?:K;X\2EM8_WN!%G59D/7&?SQ-F'/*?0<$3OXEY)[KP!\XV9^%D^D$-).8J7#L.Y-HQH)3/G\(V$RH MZ9%=\3"LT\,U#/V'V:'7IV6I+=C*KN\* D*):W_)GB(&HSNK[X5VJ&@S81[8 M][A=M!V213RUPKMD)4/L<6]9#PF+1\R+PM5/DBDX/!XM?<&?EC_^XWS*R 3>)(.#\1U7RR0M<&'L]<+XZDGE+M><)S\6#U0\^Z M8UX2!K4:X5@R@-)V.1'CFG]DZ9I,Q[WT(Q; 3W"J+Z-AF/G?(&(4ZW/BP\'Y@8>)]YY, MQV'((M1JKR'4UQ(:WX51 )9$RU*2Q$P;Z_7AL9:G\'/C+C*,1(RU5!6*W^UO M#3-[PSR@>?\;&+C \F#DL3.'R%7,KKA#:F!^5"D:%DS6H(=;"8)M/?.'?$LKA9WL7=< \5-591,3X/C\R/V47 YW R28S&[VXT M.X7@!39D[&(R85YA'\<9"C5B+QAD<'L6_?W ;NW4LN_Y+&) :XE9=HI M0L 9?5Y>HR!<8/XSPRQ>P5(6'BE;UWAV2TF4LKY]TR!^\L?7@#NQ'>4WF3HW M=11P>@R#**=#^*]-_<&/BD8[6U[LU?-;0V!0[/YQ8I+A2; <;?SD*H4#Y=^: M#@=6%T:WUIV'<_L;7W;%Z)7KLTOX5U285?1UQK"\NQL']AI1" -6!)?7MXK9 MA_2;*3BI:AZ6@_%RM?+ 8<&O+T;'HU?'+X^/7QP\!"X/W&CQZPM8PG$('/$' MP;LEADTNJS_:X!C94W3N)81@=;%[\2_R]QX'S_CKBRB(F3$]%-YS5^IE?0GR MJETAM?*V7BN&!"S(X^3%JS4'7,%$23G?49!SS?9J$C,OY(?^A%Q/()5(6.&( M>+T_S^0\&0U:SMHH2@JJ8+,&(.A:="N%>T-1.)RWJ3UN2&G?4Y96]03&6QXD M,W6\?DU9'6J37W5)D GZKD<'JTO0FAN=3-;W.S"IJK=QF= ?3H8O]/8MZDJ\ MT?'Q\,4KO-26$I*VS&H2*N0=,GG[#/GKY55/Q^0#C.H,4B;Z*])[M9'HY>F_ M3.K7I+=P(ZDK4K92[!W8UZ5Y]4S*-Z1WLZ+U6H<[9+*]W8%XPA1T)5/2.](V M337^J$ W99*^)VW'U"2MA:-):7? ?#6%%V9*^*!LW7XY6H>0]@/"!=DB;O^8 MP1F0!>'YOV+@V0CDMFJ@00!L"P4PFP+Y&G#PG5A$3/XKPSD::>?#6SYV'#== MXE\MU[GT3ZT'-[*\9.^( A)'&$W0;^(AKADH$,)>MKR% //B:V?P^G?3O MEA>CTE/F><'FBI/U5E#$E)ZU\ P!%'C<,D(SBK,61VL\+*443 >[!7&5 WF MHIJ0^?JF.?>3O8!GO>!CTY5ER485RY7[$-NJH^%J" R2;3R(KSGL;(.!4!79 MITAH#_/;P_R2=.RQ C9HQV!^BEM$JJC':_5JS!_.:G %\R:%[A%M5 D U"MS M7N(>(8_U%\C5'HU7Q@A21)* 1[2(-1$<"L(\ ''+ FXI)VEDH/JTJA^22."4 MM4&H-!V,)79R!Q)_!364@$#!G$8N[^66.$! M9\+-9393RSN%OL\#$"3J7'G3FP'& MR%ZIV]%>7,01#"@L@^AMF@QS M"])\@A%^*">46X]C^I[2GC$G]E@1#.@+C]CO5B"*QL))D+:616E PR#=B;]$ M :X;NGS F#0G7BVXMGIH/%JW"BFP_"$<&>T$00;\0#BT\9-O8 ?TJTHS'SVL MJJ_60GB8\4\K<%919L)H/IP4;C-%&H,UF*<+0>]RT\9&SRK,;Y5NM88=N3-% M9=.9QF3%)F;L>9@6T/#J;0)V**24!>8INUE(:* ^[3M[Z=%\>Y+_N\6!!0'<3!5 M7ZPYPV?AS8R_5QIZ_ Z0#W)P)-)AX\-N _%/BU//"D,\S*&*C&D(DAAJ.?#V M25H%AE1,H&OD0[4<7%'9SP )H;!D>>E^&A ,HMB$;":5#)C&X: F>E'18$ 6 M1ETW5X[J!H+7,*TM=%!/O.%5"[^E_;@F544Z0=+$Q6NY#9#Z(;T%M>FGU1V3 MS,N3MNY-E:7Y4E/FZ4G#MEHM+>QMN4S.D\8N-#UQ8#(I,G5-&KU8JPH]:36I M#>6%83R!&\_G5K V5WPL%/7AHDKB2L^ QA\;V.00(V/1UYV\:+%LMXFZUEK_H:%^AIPFS$G%!9@%5U-IKF #".1 M K'NZJ;3$#*%@N*FI82$^6<-3ZUP!CI\=,&Q?UI\ WM[Z6==5I>'(J1GQ5#M MN*= KI#G#,)+&_%6Y$19 5..&W!]$C#?[^[>A]HYX<*@0-BR5NP2?3 ML9.>8O%2%'\_0*:[@!A((/T%#[ZPG[GC9P!GUAB\VKQ)LP4DX2&_J582!W^Q M5H?V,'*C.(+I_3NSO&BV%E_?_N1(3!>:;B^O/N9R7JO8[Y8O,U>P())JUE L M>CR:1]. >[44#-B!R6G!YZ=%$S24I@'-'T[$ -R_ *BT0!N! M9-5(FGXIE/OWMRR8K_*GXL#I)F'!*825]UQKW#M[N-1[BV8K>@9$O MY^S3HH0WK%EO/ 0VD!M'MS/VV0I^L.C"LI,;*V3(5D'!-#;7RC*N E$TF>9> M"&B HU:@MF,"=='@+KX+7<>U@D6.'71SNW(BZ";&,E-?GY]<*..\F]-&"Z"4 M5MU.T=CO%L99U."AQS<(/!_^M M[F]Y?;1# <;=Z:$BT.%0R)?WK:S"-$MN> MH6M?H"VX$:'02+$3&U5^WR55T"/VN+,W[VF6QJ"?2-^X!Z;P GRGKE;3-3^) M,B UQZLWDZ)'E>NI)*E,ZO$];5WF-4GZN* WZ\F;IKR)UZJA;?L:$$%62_7G MN#JU[$@LB=0/^:-3,_A-3C5EL"&I ^JG(2,J&$Q)825L;+T1O HR3TI-TDNT MO:=&PB^)]S?6I8UR6*U4 ,F2=GT*J(='$R^GU:4*# 2>>"-L;<:BK,9!RD\R M2-0EOT*ABFQV3?(J1-]*4"E"(M[YNQ-E%!2<96IYOY/.%%MH*-6QDY%642&H M[!R_D_ZBKOA6BK_CP52#*FFIFYUVI1OE\"NI1Z.=-(DKJ8L:%F2BTTR>Z!)= M4S\*J2WE[=']FQN;/3$WFQ:=/XE_9]V+2VE,%S*E_:Z8TYQSZDE M*QA,J2I%T\5[S(?3JS?VG;$SAZD.(W&6?63+\1N4]:D1[*7JH[%02N0,BY2^ M2"G?)%KV7L3CLFL([808'2#+2\;'8LLKR0SMD8CF;BNFZB;TIW)-K:[CL;OQAQP19LW(-"^B@NH%WN(B'V=D@\&KJ\6NM3"DS;" M1@JP?1/"*QX$)!R6Y&5'AWY+]40H-:9L('NX\*@ZLL.:R/I\Y]JN:NQAVQ4_ M]"Y--,M)()+^ M/-0M@72>?X\)9'EI?_O=A97WCT3Q;)/24O M&X-KC[G-,$GA(--$LM3D7? @]_;SB(3.2S@;JJ+SS>Y)Z'>=(6QQ>>FS$,B> M$+5T3/<;:OR:7L>/!^IBM(/[MM6 V NV]>_V[X;NX+NA:]M]TK!)9 61_0N> M])X]W;_?N7^_<_]^Y_[]SOW;E,-\;5'![0[D9I3:*YZTNT[0?<63Q#K/-$56:M\+!7(%A1BYH>C862W\')1KZ71LU5 E>]DJ'04T/GFXP=7;%) MM9&LO:.CMI*;7_F8+$F<.1W]U63(6TI/$=$@I=9\; (U3+U:^>XR_X MR 1;J=5#LK7^D0&VKL5[@^YTL>CM,X+4H;1],T+5KNKBG 8OI=ZAO!ETS]]YC"J\8U%,>7 MO#"T)5$16?M B(HT1!X.JNX57W06X85G,^((JSIAUL^_%&!/.N!BS:(5\]<> M))XZV2G];M[3R7[LI)$O@]5P=LCUWO49!%ID:G[[7/V?(7A0IEB:O;B)KM^F:+:5MD]&RDZO M>]1H[D4'DUUJ<,.00XLJLH_,E>6HGEH/;F1YR9;,\-TB- MAR*T19E4=YI=6I=4.ZWL5@OBV-D81[)M-;"#Q"RTXF']\?0X&::8'BN]!U7"M8Y)C!XA0JB& 7QRD+HN35!_%< M[!AVER-V&')]5!,QCJ-@O@4&]YL?0O /;&R];Z^$BR@E,FCV.VCGE'4273&! M7LW%!+ K.9=G/4_.*LQ?=QO(1:U,;X^+W.,B>X4@)B'29#IE(OALM>952!DV M)TDUJHB*W/2Y8[PQ+*,P4,8[,.&; V,M>/'W^X9<^X92^X9& M"$":K9@:(@!I-UQ2-!W*YVXI]N[8CYH[$1(]CM1\?_6U$%>\NY("4X50ZY,W M+RWIC5Q_9+U*;), MZ+#<6LRJ62LI-LDP,9[7P&#D)LB?5(_2 MOCG$)J6_Q,)@I9$SG)PD,I]_AUE4EKB.#-4F)$D_=.ZD9]]D189VX":ZAH4M MRA.Z:4^BQ =5):XF?QF1/,*>%L=M<%7)7^[MK;T/O$^9*WQ] M-VM0D1.JBJRUG=^3!NPKP]F)2M$\8 MTVN1V@AA>FSXK76/[_6HGX&V+KZQ4Q_PWL_>7TAEHK'YMYC"SFQZ$A2;"8D? MW/[P^:!0B6)VGSDXMF27)=VH4O-SX3XB]-. J &6>8S=F3BB_=CC'#.W,!QB M5AH2[E_,G]R(D))L[R).?"/SF"-K6,1EO(2'X])W89O)B1_]S]BU&0%<="LU\9HYK M6QY:O744#"^.6S<2Z #0EF@3%UO>[VXTNV9>8J+"F?MPR\_]"")T_%9$DWXV MHG9@E[8XPEJH$@*&V:YY3%B=_1I"?1_1V[PFK.,TWFA\PTHK?OA<0=J-#_>5 M6OM*K4V,Q+Y2"X'VW-A/Q$JT*A">Q18$TT6LD5T<2+&34:?$E5WO+A9*U01- M ^@$KQ8W5HE:'_+2[R!O6@OD.\^W/2OQ^@,M\7;U75G+MI<4Q&O^-"PDI8LG MV6U]][S)VB6A+#8A[T.*[D2WQ2KP"V^H^P6,9'FY2-OZXKOV^JBY.'\AA29M MWC4(G M<> [6XQHWD8T:P8QZO&R0'N;CE&?Y]^VMF,;%"RE"K MR=L&PF;BO2,="^)6AGZHLE0328N-6P4:D>]2+WO#@BN0R!XO>4WZJ1CSFE.L MUI'Z&K8=-E\@EFGJS8YT2#!:BYAIZ^VP>PTH5:]FPM)^C]&P&VM?G)SI\;WR M,:'[3@4W\7QN!8O)5*C'\AZLIKR6]4LP MVW8TF>:C2RU:I\GW8/=%=ILWD"V!X9?JI"B=YR&JD1T,"74%V>2+JI)WNT<( M=>6N>RX:RMWDB;:S).H+![PF=[,QB(&J4RUEIOM2NGTIW;Z4#C%%^U*Z?2D= M+7S9OI1N7TKW/$KI"&@+'7D-I':& +"D%+%V//#\?R_G/PD>'S87[#T#[_&@3T#)8GSG\GW MC#3R0 \3J$$VHKFK_;,J+>J2,CLQ#L-XGJZ/#-;-@OD(K3Y#7/2=9"J;^1SJ MOY.5MC9>9UGX2V&WDD8^3#XP:#[+7C)L9V)GEK$C>3?'([OHP=/PV(\N(#)* M'PG^&K@V6[&?OAG;Q690X8.J$I>UX>NN V9^Y9L[T6 ]$YUMMB4KX[F84:0> M3(U,?.UD85Q\EWF%ZZXV7RT/IA/O^'>[$4EY/'&J(=XRZI_$41A9O@-^=./0 M>,W$H1=^?LK]*+#L*+8\$76==!+[M6&/N,K/GUA@NZ$X"2C*U$VXW88]JBH? MZF-T/3N2;:X[\1U%PPY!16E@CM^EVL:EJJ3^H.N: .JE-V)(_&\MG>?TMDRO M#P_MVILQN_=BC-K34./[@"7_U>[]IRTRAK79''#>,51\-1QVMM>_VP/%]T#Q MS03H'BB. (JO;Z?AX,0+S4>!7 ,#>./Z]F\Y%PK [-[>..D1*4?E<0_:N/+. MWF0X(0WOZ^*-DQ/2.+$:*U=[F,W$?$5ZO9O';-6AUM\\<^QUX676KI22&+D. MEZO.E-@H&3F0AT&4E=@@!;XO-5+%1DA- M#=OUF0+>2/WLD/(%J:MG;J*57YK%D25&B%-FGGK6^46)U *W;IJ1K)&75%5]:W]Z=E#%M]J[A&E/*K M(G/JU<42<=46F+TNU5@XO&F5":\J[M.8.FSF7#ZX874MHU$\ZGCC0]/@6Q@KG$(P/?:=&Q8\ MNC:H:#*]<'W+MUW1CB%K!R+:(8;%OVH 0M8Z[EY)M>/^8;YNK6!P++BWE$1W M.-_&068;5'#;0:G:_NWK')/&_JH_=+)#F=NND&<%?-:TA[F"82*&F&93 M*_:B8@75V6=NSO-(+?6(]% "Z?:DI,$ U(W$0KPT_*4 :-?1:;R9^==_ZI'( M6=))19KZ+#QV9QI]33JS;TBC#:YVI,)(9W!I+L'"V\&!P+UI:E3YVGH@0,N> MM*PS]R*A9:3K>(AJ&IE+E,K>1U@=Y,@E)D?Y)-0]TF09A($ .+'#(,J)#/^U*2[\Z(\E M^EL]>57PD0FV8.+Q;*U_9("M:[&H<4RM?6**)=7DR\8'^\3HKN3\]AF_?6>? M?6>?74QPJ?1+&4K*:I^,V2=C^MLM&\&/[";4XVU^Y=XH#N]X05PI92%YC586 M.O/"N%T*0[)70)TPZVL]_LY"J[%9%.G0VDB<:),9G[Y M3*1HA>0^;A*__=D/;9=:^J(&[9!_+ 2M-W M9,JS(5)PDC #1<&5GPE[17I!FSEEMWE@0+UDU72._91[GG7' TOL9<$ZZ'5V MQAZ9QQ\2/?B@!=CJ(\[$ZY;*< 8PX#9C3BCZSB_9NF!B&=L, MV$=UZ*LEA4[06# QT::RSN(@48]Z4J:&C&F -0^CR?0WSAT96K+PAGLHY591 M,9Y)>F1^S,2TKH!#XJVYTSB,^)P%YT^V%XO"YW$8,O@'(KTG7'ZI 7GL4KIA M#U'B(_).6PPLW'931 >.J/$'L.?B^/\9%GL 9Y)PI4M\MJR.DO']LKT(P#>[ M<.(2($!8"?@TF#K-'1:N@^9]]:Q@4WJJ%+$&80S!EU>T;[]P/S$Y8FKTF0%?VR6D:D*Y:/BV:(%XT#=B-,Y$'E\9N99N$ M@;IW.,@ZL1WE#UKJ"[:&@#EV)\%R+$S%?O&WG0&GUIQ*/HL F@-_9)?\.LG5 MP*(6Y2XM$%3Z1C<>5K=F=/LR4RGXUCENYQ7A)K16"+32MY">$^)*^^;G53:- M/OJJUI;S6N]"'$&EYERY@M>G ( BLN0UAX+T:]?-!-MZ-)D_:PP$=J;W*,=U M'%Z)E^GWHKGZ.PP),"%I_,UJ3=^=UD!@#6;4J/* MUF0&A:[8Q,(YU<27[+Q, C!9]70,,CN(4D;!*S'O>G2#2@&L>7T,IC$W.B_. MU?$*LEDV22]DUDSC,"KR!7O21Q;3-WN-($E2=Z1?)#&MNRJ@VDI%H]?OGZ.* ME-"(F8[>/.ME5 LFS?3T5OD^USR:>CYWHY46A.4 &\%\VV5:0=-M!ND=&]V( M>P G/$DLN(11^AO4W\Q:B\$-,'6+F M,=0::35=2NE3,.<0$(+3P*FPD$!K5FXB*XC:,9,C81IU(F(SMCY+HMVE.+>G M01UND]=30Z/(,IN7D',FTRFXNIL'2ZT'8CV-1A.>MAH0LKG^T@J'=N ^H(HN M%"BAF8.CBP=N/[4&S78:X%R+/WX^+_\0?2?IN3Q(5+6DA>L2E;P\#L1]62XE M]G?P'0%S(.H_%SVV%Q<0D$ZFR;:'+7[SK]@*V 7GD871H:&!VXB>]@P'+EX\IJWEU8+6[!X2<*66-];.+)'YVIYZY:OH V4Z9 MFZW;&PKM#2OD;!YK*ER>20 QR0?)&LFN\>)3JH_NA#(U&,8&!0&F4;;7S ,;Y'P%^ZL56(NFVS.65IW?SMK#KK.$2=Y5$#'> MLBL;;I%#IX_G/!;OC$]S/\,)A"!KO-\2&#/8MQ<\8+85-F@)6T:A(\:_^>$# ML]VIRYP&3R"6$S'-?@1+0)CB%0O8E'8) 70?[<"=6\'B[_'<\D^9YZ6=[I>% MS]@73E5H81EH"R8_^N3R<+D*D&NH@@(: ^0& M;AS>SN"D^L#BR+7%BN3!P[*;#I(Q16H=1F%-FL-N?STPACL V96$I.&G1?XW M^ ZTZE0[ZRNJQE2+UJ&H ?J9U^WC?O/9O.JOBZ>R=(6=.5'SM+LH03T[A#?; M]0/"$S8PD25*&2*R4+?T@\$85CASC@N3!@(G5!"X(F"E@,CJSN05'B!(8'RJ M;5K5>8D7']9(/-A9::J00N5%(IF<+3UF\]J[!PJ/C':W"Q4:>[\FL14--_9^ M37(9*W?2K+@JE2*2Q!3@1"R[DI9"DHP/<$(JY0(H](#M_GQ4DKF1RB#1K+/B M+%"=N^)*Z;6!],>MSS(6B+N9"97(/Y+(MS:W*:A4MM0#271W.SV48A0D'HQ, M,[J;^"YD_XH%:NV1:7VVNP'EGJ$R&([-WM7FVQJN7H87 -KL,7G,9:T",>,/ M4V5CWS=DK"/?I,.]0"8XP)VXCT] M&IQD>/VQBT*F&;^5*SUWZ7E7MLP@V1J@B:P*%Q12ZC8W9[\&UL[;UK<^0VLBCX?2/V/^#Z;-R8B96Z6^T9V^US9FZH]?#1;G=+(:G' M=\)Q8X(B41*O64299*E;Y]"?[C[^&?S/][;-SV_>" #^P18(A/_[&7S_ZOM7/[S[ZX^OOO_KR?<_")^^B>+? MHT<(KLZ%3_]P\M.//ZW>_77UL'KX"WS[PT\G/ZX>?OSQA^_?12B>2B MS4N1/CY5X$_QGRF=>/UY#K,,OH#+>J5'X,.'LU?@-,O +?EP"6XA63Q,7G%8 M6^/A39*U0\OG[[YLWWK^L/?L<^^3/Y;X6/?]W[_)?OZ:=/ MWKU[]YK^M?EHF?9]$(,]>?T_/WZXBY_@.CI./6*>2#]$#S#"Y!/;/3P5<]7\O*XK6UP@)[P@))S\0$OZM#UKULL%&4Z;K M3889\GH.E9]@99;0+D"#M-[ (D7)16Z8M?U@C=-]5T6%85X/ 39(^SUV<] L MU?L@3=*+JB@S3.\>2#/T:BA#M4^BA.0S\@FR;_(/$6 C/I/BXAY: J_5C!/ M('>*!"R*]V@O,40*K83QJT?T_#J!*89Z\A/YX9C\QXLHN\+PO_Z_\*6-."-N'A7U+^EJ_O;=R)=?-Q22CY)M!G^)!!\P/_Y\ M)POG7]E#AZT%+-&VH'N0-!^KG;+_G:$!' ^@B #&]!^O*2TMJD^+N(4[*N(: M+?YQ C/_Q.L8X1US4QUGHHJL"K0>91]'BR9Y\WI($U#^C*BP3]YR49/?_*N. MV$[SA$&]RE>H6-,]_/2AQ CB2D;T"L"45$$:KAG52#@F"OJ[OS?Q+ Z+<XQKP@,#WI7+]G$6#' B!BYD, TUZN>8T1A(SJNZN\V5MJVW!L>@ M&1Z\I20T#^7;%_;S'DWR)B0^=]WD!(M-JNYE6L91]D\8%9?X-Z6J\NY]79NM M'4@6%9AA @05H+A\J_"0#) $A\+B=U>1)UEM7I69[P58-E7:.XU M E+I/EGT*O4>GT+C^X!BC['WG+!KD0 A0L?4Y(BR*M/T5HZK.W_KF9ZLPW&6G9SAP80 M/'YSFP-L1U-\"8C%F2IW_>:[V^1.IKI-6-C9MBA:09CBX7'X^\IJ, 3*O+5Q M3*VHT/WN6WC,LU@<891/*)"\5:L\U5-C]:"8FW/H%A MC<;OEM'/S,%SII3U(LU+!YQQ/]+@;Y43V=HO8ER1<\Z $*3L[W0K"EP MC0TP=(#C\ZO)XS)!DMP*C_^9#NL-%M6@]1KE=Q6*?[][BO "KK<5+;K%1*AI M_#@DW7*;$:#V:F\H4D"Q'@&&%PB(/9?BR$@,J3$Q6.ED@X*1D$N/E=1&LHK* M!XIJ6QX_1M&&60K,JK+^3==D^*__=5?A.(FD)*]734GU#2I3U?HD-7A* E(! M;51,#4)PO=H5G(,:YT@)C L3TI(@TF'G8,V;&14\+4M8E3K*UOVFEEJU@5BH MPZ#P?6K( (/1. ^"868F\E&M[LR4PK< MRYG0.-U6YYK7CM7Z+"J?3O.$_.OBCVWZ'&68B/*T.HN*X@7''O^(LJU4,ED1 MH)8PI&!;, .,CQ8FQ^0'N,/LTR+4!(>TF!BZD#)!/J0ZF?X@( 6G%:C1 HK7 MS581QVB+T=_"&&)2'C+X"5;NYL!*2%B(=C T6#SNLF(B,7I,*L M0&60==B_PP0PJGJK<6(+OY#K6F&I*OJ__UTM?G?!F-=SBB$0)1]D.)KB2$#, MS02^BNKK1&6O\F=L':AXP;:BHJ[M[VEQ4P1A7DT;Z$<@AWOF[U))>UF,QO@0 M"#NS#B>)/W6BE#<%W$1IMTHJ*K4N"T>"X!V;QFE3^2?E@&09%"#/LSUVTYSB#HT351=B M,#T]'P"@Q?!>6.8UG 6!@3CX<0$@*>:$QNQ,Y#,/91SK-<.J'FC/B@1MA=:A MA-3#L?3L(-I"].Q$SSZDT4.:I54*2QRKT+*J)Y0EV-N0L*5ZT;F^EX>IQ7!9 M\.8=KX"9IDU$W/_]WWYZ>_+COP-&@T]=5Q8ITN7M L27[4ONM",Y+C+7Y00" M23-*9<:@S!6/LZ(9 6<@AB-1/C/%J""YWV,.GJIIZAO7F^B%7%?-N//O0IAU MT]P&9O&>?\,0A7#)/R""GNO]/NX$Q^[NE3['X39='L?%%B;[YJRHX$- =)G> M#\^*FA-4S2V39S6?D 62YE&(?,_:+._Q[6[*(U%.MX]?T^KI;%M6: V+FI87 M#>V7@Z=7=R4P49'X[=<2GP-7W*R89+CV[']_5'/QL;A&-JZ'5E37H5H M2E*2&HVFC!B-?:F,Q52.K4/8!#7CJ?F;NZT(*KS(:2)D,A,KV0J2' 5'ZW5: MD0HX/R40Y*UD7L_WKSZLV;$[")"O!,\/T[P-\Z>L/^'Y2LEU6TK9Y0D?X73([ MRGYE='^-A0;B"=H9QYM;U!=4!3\@I(]%E+ZJQ% MF<-6"DE"^U!%V4V4)E?Y6;1)<<0L+%7I[ED"FMYEZ"1@"[?1#4Y 7M0=ISF( M&5JO]]+R D/J_ M:.-F>7 @^<)4#CK'5Y\_1FYDJ2G.87$1%CEUH>1K'V_4V M(X-]\9D^C5/%US/3T#3?=$P!ME+,4>, "4/B]U6-M*20.N."E@JWFQH=J/$! M443G_2)R=)B9=X@Q%C?;RC^5/4<7&.#11>[(8O2H8ON($L1[",V$Z@ L*P7T MME3_,%X_3*1K1S@:L+!Z;K\'7CFX/MS?1,5U0=OF)O0H= ,+VK59\[P_#&[N M.7 (LNVL0),.".3X/2FP_A/Y./O"%D[?N1UC!-<%8#C9*9Y,'F0MQUT;$>MS M?MJDAC2-9Q_,7+ET(=HVEKTD62!&,RB@?F/I9UN8PN@S#MYW_W10#&X,XHHF M/V<90PW"#.\9-$=&P%*_01E 1R!CRB^R*CSFCRC]52_;W2B\XF 6.3AFN&]U M*$NO_B._TUB4A#1F"?,FL;@3R(A-N![ #(#2[9_9",]Q( MD^ NP$K88Q2F9(%DN22Y8$I#=9[U=;*W6_.F\-S;Z>MLJ 5%$,8TW7NA[HJ M][$C&+YFDBR5T=.RJ 0=Q?_5U4_\*]*<+MG&%3[APN(YC>'IUU2J,&[XNTJ\ M' )CH_,!O#-.48J/\&5&U/7G+E9;\ MIH_RC[1.2D9KIR H\7$DBTL(E46 D.)[I8;MUCE_>7"=!:-[H]4*SD?7(,&I4 M4.-EZL-QCZN/NYO6<=^IO %G-J! L M@*()(ZVRS_R^U$J'-T$Q>C_%,L)C.R_(TS)Z?"S@(]U=KU>WK!N!3BIY$I3> MB^5QJ#;ZYE,$7I\BRDH%*?(I7 EP2VCC(K/3.3;7[[(XVDLLEKY&$Q=?XVQ+ M[GE(BVK\O^0^^JIB*UK@-4NRE3&9MRE6.!F"945,*N(5S/L-[!!X99FI#40MW$&:D*$ZDQ]G@ M19>UI 8X3FIH;:Q.;8ULB&3'Y3@5VQIUOZN]]8M@K+4P)7BHD81@%8.,1U.< M"8C)0E3%HJF+ <[:F:"W@<1B\D=6GO(S[2((W87&::W(#'_"B58+!B3)_0CEJ+ZX>UZV1V)4 IL7^2;BV1D9R M:?R)H_NS3\67EQ12YES(4N$F(F*KY5(/>G><\OTE2G-BH-?Y>5IN4)FR=+?Z M!,H)0'J7IV,P+=Q-8W3@3QE&^&> !00UWM?<@KL!AR-&_<.*[U43^>+>LY$A&'>=6/POA\#+;L=%UZH;NMV=HO2G@$[:)]!GN%G>)"I@^YFRB4_QR7T1YB<_'^!1P MFB?TOS*:RCM-_O>6!4YX!=(D6Q3HY>BL$&-KAG?\ @2\8(?8:V[5KD8A M-\(Z..VID\0TOF[1*/HT( M,@31_+[;%J/O'5A&)DB!4V'R/^MC/;<@QT90]R&N^_*]C\HT)G4V:;:MU%IT M38+2$L8$5//;(A$ 22,#?*8%,>]?1##33JEO__V!$,#JM1@)/NU%5GQ(D:'A MBHK;3M,_NVGM""@Z5KC5+Q@K!O0KWNJ>,++39UA$C_#3EKSINEY1DH3N2C/L M2A>#E@SUD)FWPIH.$#%"ZMYA6U*F3:9 8-^YI1FG?$GV.E-;D!E!+4XSLHY2 M,5/40EO,)^E,C?V<*NW7+! AI4F&:RS'1^L ME%!*B5/ I#;>@Q +(*>6.P5&+^M1"!"E&&"2Z5\WG&BP(53[:[AA4PN1;3$/ M-HA3,SG:RMF/Q MK6 AV;E6':;A_:@-WM,^LZ%$ ,2I"$Z11Z4KM1_TL=FDGS>K>;T@S?IEOWK' M_&WH:C@CU?GCN7PEZ?3&$B10A=!8<9WS\'9':'04M,SA3XZW*DN;HV3P R.2O; MEI9W9F63&>;UK.P0=%Y.5--SS&?;@@.Q9+T2$:>7.[62[O!I=?,8@F!D%K8U M@]@?>1V$)4R(8V0D^6S=M\EZKO3[H\?=[@@[H0^5.&KL#O) ]5R2+'R[1C)2 M+Z0T95L=[=2Y^R2I"CN07PX-F#X 2, 4 IX^I#3 !HB?%HI\QFVS'04 MNDD)CR!R9:A!;&CZ0IZVV$D>+TJ@TS;+MU-)HS51^>2S(K75Z@B31V(TTE4^ M%N;.2Y>A'I$ZU*.>0M1#XYJLYZ:6G!C@7'^ M7QRXT;+.I2Q0UM"5%:*CBHVTB4]VC@)IF2]X!=1$(R\# O:5WU+?QCFY9I!?DD%+:6 M6QBCQYQ"H?JI5K-@FQ;-^W6[9%DZLAQ3NH&]W[()1PJ'7$OP@)6K MJ?]HB"7Y])%RD!W)0*09-$0WXX6Y"Q3H9AN;$^]W4Z!56JEVA1._I27T'0![ M;3A\VG@/6]'PZH-@(==P!G:PG<\";\S8Y^O&"O_$>N3$.X3!JB=RCX MDWLXAZ500.R4SB'[]U7.)G-CYP/39R(+&3<@#4K]H=PT5"L/Y&JT(.%X2:>0 M1S:TO&A0^WL6IR WI,A)U;>7^W#/(0[7"XAWWERJLD,*C G5$2&Z4YN$8\6* MDU%T^-,R+1$C;5:[>[-[%I5/EQGZ4LY\JML#9^X+ MW3V0]A[F$E2 X@KO/>ZPA/J?X0ZPS;)*X=,(08Q5_3E-8/+^Y3,^$E[ES;BL MT[A*G_&I#VHIF@YTW;[3BH@L//K:*>.E,,V-C.%NL'MN JXK:C2?TXL2:[8[ MJE.IU@2 ]R^ D$ R*7WB=3TGJY6<(AF:/$XSV&K"?H\LVK<=_//S=(9(L?%D M;I>@JQ YNS$Z=\T>\6_)SS%1N[HGY&X*2=30^',P.6+3>C>4%S8JU /3L?[\ M;T,BZ$Q/('\,VK'M9KG=11D.NC&=F*KJA5R!TS80='BYBJN2A3AS]-P8B&-%'!W%1!>HUHUT2$]+@8OICJ6K%'NIA!TBP4<#T/L7 T<2JO:= YP*I MU1W>)XG QHASY4:0D;Z MO%Z$0+..+&N\[9-:T^7%[3%MGQFG<8RVRC?V:O ,R6T?M(T#6HU%N*FX-@O81 ",D^F<%/ 390F=>D- MC__Q.9OV_SFEJ<9Y-B*'P9#T9)#9L"J.MZ[V+VE2"=$62O[3M3.E/FJ&\@Q? MCH0E#+>6=TU&,V.=9*A8ZZS37KD[#MIOHA=S$7L#S'! R.%::4S'HK\-PQ"6 M$0[)2"I&;_$L9'E(1>]N"9$U$'M!6K(3B: MO2PXJQD2UI3A]'(N<,%,F \5E(#4DP6=D:T3S*UD,NH MJN[SA:JL783\LIWHE(H,?=H@R:V5UAX\C$(W*=,11/8?/#3(PW[P("/J:1.= MY/2BQ"ICLGWB=7WAC(_^=2N.^(]M6L!6Q>9IGFC5!JM U6N&((W 2KJ9-Q K M0ZH*UI DTF=HV%+KM+C@:&D'%X:X6R!,\L9NBX3%M[!-K72R)8X JM_[R$#3 M[3HR =C\-MA^$%U7X(=E;/+20^K,#%I264=(-%(1ZNXY2I<7,'M^Y2JO,+_2 MATS'E*:!F7%^7;C6=ZJT01B"!4G+;&R7ZN=AD/*9WI-V"%T:CWR$;.?<9CVP M=Y!#29M(/N@E%AE3+9/O!.M:\)L"C5\ !KM"%6/YR!_K+M#'9&&!\M9>>^! MHFF039H2B<.IR4F]QN_T<'$+Z63&>W0??26WC:3;)=:[2U3T/R'3.7.HXY@5 MZJJBLW%":3KW5]%72$K%4G()RH9@\M8=)7TNAP/B*F.-JK"N0S8"+$ZGP1Q MCM%6CY[CC9Y3;I/V,V=)R4!;'X2R,VT MJ/9F)>Y'X@23<+)ULE.B)%D9LICZ4W4>A[3)1Y)VSC?6 V"+N89-'?T^O(!5 M$_4&G6\8DZO68<;)(<;OX<6)'5ZL5C"NKE<77]D[]5N\ZU[GA$[R_^0B[#G* M6%B #U)IC/=D\@<<>[=_(7RRZ?=^SN]K?BG0=D.G1I6DU7N:;V'"BU2PXU&Q M[Q"HU=(Y_X2;W^[9FNA9=%L4,(]?$[/E@Q6P?Y&/GRK[_U"[9/; M3I^M)'SO:S'^7D"DO;Q8@TU]NJNBHA)N+B6]+8@J\ ?TSPG"HMC<09ML4[8 M0 "]D%!Y>8IJU/V:B'P/FMO=87"*3@&2OB=#[B"\34NGFL400O?6:Z_FI6Y+ MSQOVDMR,@MI4"%1/$& 0"6DX0-K'YB7*TH1>Q?$QA*!\@IXK1LUJFJFMPT!] M34!:9=39SRK#$9F#$75779U%1?&"G;/!F;]]OE4K5*RI=](:KR8+4F_2FAQT"RV[!<0T^,E0 MN2WHU3E5/4(($"CQVDE85:Q(D\'ABS#KD5ZOO#PT#T9K>$_JJ,AT=J,)AH3#VJS%50J\<7T+PE)3[7W6!KBW6G:(Y T9L6,PC0[(28 M!@VH\03B8R7D@N3997NJ=_J8IZLT)CTE]BBYAU^K]QCO[TH'4$F(>H<7*> V MCI_K=52\$"\JD !ZE-#KN5--F$B/K\$+KCYTC@L*_$;0 HK7S9GS@K[#T7'2 MW6_J59ZU@)BM F,OC,+POP-L1N.'6ZNI)%+!/M?KE V8 M)[>8DF-N1I54FH0984Y0*. P+L\%,G6T+=TN@081O>E)&LSAM.?@3 M*)J]EXQ#FJN:CG:,G4)&784,1/6DMX%IU@4KDQ[_X-.]WZ;E[\1B/V,Y%564 MYKH]G"8 :6$A)089]W[8M1D] 5)S1-R9OM@&7B: M5C\-VH8_%K!Z=L *HD(Z? M<+%F/1 #!Z-D_) LHRR?:G50:YW>S4,Q(CJ6*T*Z"A02%HS?N$TSJ00&3]LM/+^DG1M MIL!<@OC+"I+6DU% M&9C\[VU)4\9"B;'*IJ\.6[-WJ!H:*\^-6VB9UF.JP N,BI8!^.WZJBEK-)?9 M"Y(KMV**O&Z.LR??'7X@$* 7EWQ(_]BF25J]Z$88Q=#&2R]I"HTW[ M:^1T) :HT7O;- FBCP*"D7; +)B;/)0:3XD#R M7 J2]9G =;S]4$3>U/\B*DCC1=(0E5;YS["!25!ZSZ+&H9JW!M(Y.$-E23K/ ML7E-7E]+2^: H8S>7P@H29U>[QR[ 0:Q/U9:EW\1-,MF1@ M/'V+^/[EC&3_[J.'#*H8Y2@8O$#@>^TJTLMA M-,J%4+B9=1D)?B/ ';GLWIFF^S(;A;LE",&?,,KRS^ WAM;SFPH9:2$E#H8JF6Q/*"RVI+C +;@# MGP=E(E?:< ,+VOL7LYT::-^BY U!&:3Z=;P\="L%$0)Z\$ ]6M%K,?X*)30D MBC1Y&[[T6D._=[B/V68T8%=C7B[$169[ZP-:Z[-S[4;.P/ST_2'-X54%UVJ3 MO/H!Z-WX],&R<,]&S_U-)N W@@I07'X[>HR* DFQ*32V9\H.X6DI([DNU'S!8X^(F;DWP_18S*0BKD+' M#_OGFHNOY&>OV2?[>M:;D;4BOT/4J9YL<$TGX(2"X7-S0RSYWH[9=UV64%H!.E"+. M:Z=M="/D=(7ALHRJ3__-D3$)'8RJ]-U/#>;C6DH#&A*!0".@1(;GA9KM@"SA M!G/I"7^")!3=NJ199%A1NAD4.796-7$T#QRRRS*A:PK^:[8$#U.OE#S;F*H% M[>@>NB%M)YO4FK.YRR^=QE7ZG%8OQCR=83I,J*11DJS.JB!$1OD+ZY5>]N?E M0$T7?8 MF*^>1&<9+VF3(@7R$, M,6&E3I]0!7^-2/%*55X7M^GCT^Q$O#(2$T6N\OBL.@2.-31?H"GVX4IE578O M4<1#5S:)-6448=3DGFG!3/,+E$Q>66 M#("\PB2@A=*%\ '%+"BE(&4 MD^:O[,64@B"34EFH,G2'1#2[^*TH>D8'J G1K98)8L59SV(Y-2RR*7=KO]Q? MN_]HAA'T,;"A]9 >[HXOT^A>I-_QZL/6T$=U-'9T4BA5*^7TTV/;OCF"1W,YOR A#S[K MYA*^'A]X_C+VX#OHA?=E%F:NV5J/_31),5VDCP]/PZB^LAX!HMWJO1>>!:6, MA.I8W_WUQP6!I!D4(M-K@VBPT,910FV[PR?;N_615YG7*V%4BL8#; EH>@*9 M!'S(YB O(Z3.LJ#ED0FB:,R#/A_&_R7@E'U-/!"[GE;W3_!C5/P.J\LH3K.T M>E%\$3D"03U$&01F)=H\K8ZK)WB\IOC BB/T%T]."P/)\2DXQK=:G53'&-0583#S :($N\E9WK \H?[V&QKNO\=K-UW[^<115\1"3")0?: M^A.):BRGC4++IVIBLW ?P)&1S8^@:THIO?8(F2MO9(C3RY,M-UI" R!$[$IC M=V307E:UW*^[J1 ZG;&D8&NI7V M/10QK2$74->/3\>;6SALX:,D3Z3)V?!EEW7$=MH1FX#6;0!]4Z!D&VL85N>+ MFF.E!!AF&/T,BP>T:P7#$ 1A#/V<1J/<"(6KF1P[_6P*]?R)>\0?TY *@.H) M>\OW+SHM4@TAM..49' [W&X$RHYV@T J5+]KH@5DC+XC[RU=S6J2RF8E+[6E M:XW*1M?HR_U.7RX;?2&'4=>]:V"BBL'(!5=, &B)("HJ109\B4!$_TI=&U1?D[V9*5\YH#K,7(M/6V*6K M_P2-:?["7@IA=+,OM[PLC+N:'B6];I2TO=C1M=J9"=%,0B8UT",S991G1J@! MUIN"H(+#PD7L#CT-(T:'XG@=2Z$E9#2+T4L1:+8OR\LI6;H\79 @XWIUFB#Z M1EH]Y=;_?2WI]($R;U4TJL*[>(W'I^&,,A_)<"8P1F<"CZ]W/':\YS1V=5?A M\UI4).7G31)5$'_^AY.?U'5<$J">2Y*!;6%OV?F>!B]@B '!?'SR4Q ):C59 M(BV^ABZW;%)D#.?L*-;+JZ>^!@X3Q?,$(:6=$&Q=>!"--G,7D![C#/6,QNVY0!/HG[$BV18%A MVJ!?Z#Q%5C"#ZD^P(N3B:.\Y36#R_N5S"9.KO'F!R;N58*'/7,<[MHX\IIX"IGO).@[7AEA^*>@8:XZ:J5;)'RB(8N(=/#S?=DL* M$2DS-62![6[*F8P(NEW[B&O:(K)I/3'+&;!\]J]I]72&C[MH#8L/:?1 :[#/ M[#GH<[B"&#@9A_0,\^W>'8N=V3)CB[UEA.S:Z*NX!U7(>F-1E)#8N%&C*+#( M:AQ>I]/H"1/-X^=B!,<=2'-?17"#&CEHL(-:J+>#0I5MN#6R1O+DJKR%U;;( MY7M&*$#4Z9LD"=Q2NRPNE2]$*G$ME:R1"MF-2>@*W! M<+Q\C8EG: <+="&R?H%B!ARUGDN@]U?=BB.VO23,)5O2Y]EAV3N'6->:5 R<]$ MRFL-X7CXI+-924E&-S:DOHWXXFN<;0FFT[*$^'_)??35S+(VJ$RK]!G>CQZP M1O7?TAFYK,CL.TJ)VA&X]47-@Y( PT9OTK(B.2ZN_UX36_U\1J.\"(6GF"VUJ*:77$(=YL =,-(<;91EC'5U M6[#;*6&J5$;NE^ELX-TPI[J[\.E#26-@M4UU'B;-[6$.4L-;24T*OY<3IV)1 M:O@D9F%V5M/-^;>:)*\E6X:4!9F5SV".R70S?$.CP66[$%LF((PYZ?9;W9H? ME#[8$==9_DE MF<3PLW8)IH4JC&G#\-]#[>(KV=N@J?YI'7 &&PFT(%MN+I'LT(;7*J)?8I.- M('KX%[9TNC>RW28.'*7;9VV_P!P6489I.4W6:9Z2TRW)(6F;D21 +5%)P;9P M)4D M'/47#!,@K3P0Z6Q+S=P,@M;?C M1\^7VUQXF=(Z8,;D*4#!J]TJA#_)%L"+;'E+N>%G7$%E<(SIJFI>QXS<#UTO ME7- #=F T0V8-K<^0]^R8-H!)EY,$XEG23>Q8[KKPM?.Z("WXRN.O6^/$E/ MNB^+*UFV']Y!8E^BHR/NGZ(\J%!WDLBP-'Z*7O..^K/HHE5O7@["(4LKLI,X M6$H!OD6E=1LO"T#YM^FJ %F6TSAZX,)Z-\OG_Q3/HX"6%F==(UYV&(><2 M.V1MX@YQN&9$F/?U_J7ETCC1S+4!0C:@= .!<%!3#AI5);0OU^G] ^'3)NM5 M&8+;ZY(3CJJV*3/O^G;P#\[M#>B8;!^I/ MF3AW=7;5JNOC+$KK(%5(]&H/N9&.D[A.ES2WV[$>E>8]X:_=JVTVLYN..UP1/7TF>+W[10\Z:B(@ MG"/E;T&HF?KN]SF0TL!Q7P:#:FYG2L-Z69D8D>0C:E+E4I)F/0^Z_H/LGM"VC M/+E+OU80&GLN,@S9X'N%(23.GY0 3 FH20&<%J_/4&?*??(%RCCK%R-CT?63 MX=# SU,5NXN4>;RBI, RD5!95$(4A/^K&P'A7_WKEG@_V7>[G2\HZ5CKN^95 MYV.:I^OMVJO%]_,3]:[=-^^X1E*H,][ERNN8_+:V]Q4]7EGK@4: >U6O_9VB M=]'^V=96,MNN[&/TE;@ -47K?$F99ZWO6W!K#+QWM];/6S3(@Q#XF,FQT)S^ ML2U(4?_:7U+GF_C]P]U6^WF+!GD0 A\S.1:&=8_P0:<_G EL;K.K'^QU@9N? M-0VE[YM!)3*1N_]@H+M;* IC+,,^IBMA>1;YBC_N,0.KN&VH\E\F-$J@S?K; M(\"1+-(MZ6N@VWK MLZ.!CCVG*,AO0MO\>_1P>*&GC"*Z? 01 M6-AI7>ELN\Z!)Q'+C3E[)>(YXARE*5 EMA5M#GO. PL]9131J><,*^RTKG3> M/.>P'A_(@Y;V>(LF^,9,F+WJI16AMUGQB\PK"#N=Y#$L6!2\I2?E4WFZK9Y0 M03K_J&Q\4Y#T.J./ K70>;[&QYI_'8&2H@11@]-K2WHY82$U_@4KF*PK$U98 MR)"!TT&1.#.4ZVU55E&>I/GC7$MI@3(F$0&J.UM!.Z2A&4N?P":L98^%X0IG MW%ZNA\4B6>7_QS:M7NZB#%OZ(PY?R#Z*]_"TH/OMN60C#6E0&C7>DU#M%.Y3 MM* D>$%4(R9-(CEFNK%[G HA+S>DR,G7=GTN;3*(@[IU6M$G+*H3F/J_KV7 M?:#,NU3655% X].!CG(?R; F,$YG TQV.;FINSKU"4Y#$(PPV]9$IZ 5>WC" MTQA[@N/WL'K/F_Q$]X+K%8XI<.C0WA-47_-)@-+=]L>@VMSV$&8N*K0D X' Q=0YVGM3\;-W.EJN*VWGLG66'4MWM E*S8!BO8N MAGE4I$CU%#8 0.\FJ0^6C2X=#+K7.\51OB,IGH3&X_IJK<8 :A0NCV USL]Y MN8%QNDIAHGX*&P&BV61D )X]Y3X" C*_'62F!(*D&14B\[,VWT6VSSR;G<&B MPG"PHL+KU2FVJ$0C8AL'HAX%C,&S$IL)"$ESS:A&Z2\^DY(+DN97B#(0/4I' M V^V2&8_65D^RNXEEF!E9V))&U03F]MSJ)-6D49N[NYA24LGB&9_7:YK;8% MO"K+;93'4A_,JCA)E M"=CF"2P 9)),TK(JTH\'M4S(EA"+FDL4A/_(QUC@ 46<5K"\@CD ML#KB85F .\.0D*>WAEY^!R_0ZUT+%3$-O@50Y! M5ASK?5J1)ME7>4(F9&ZC3/6B: " EI7UPC*OX6.2^E62,F@S$AK'8N']IH + M5 @P;$%9BZ1,Q^Q(AJO+D=^([1'TH"73^UJFJ,U#$'C[#@$S,XAD6 #:X:.%!<2?!Z/@).R0')L"H[OKUQ M!@9UO=%&9L6>=]2 B#X*W^SH.6;3^HJ&(GYVV1*:_-G\?'U 9D2Q.-FW\B<[ MP;-N (QQZQ;P(XIN;D;__X%M,,T?55,UK:]I M<5F 8.$RDP'WJOJD\\4Y?+25^@A''8YPO0G+; F>V[U8; T)>*X;V8YP7\$. 4 MDQ!$W*$CY>D6;,.\7H9$,T&8O8W0:%PO(TM/IGG_!=DP30&L)4$V&/R9)GF) MM@S3W)>RDFEV>+T,B:J9YI@L?9DF1F=EWVP!MB7,'0Z/!DJ(6(J)]DA;S4B[ M'%^*9!4-=52FXE4H9O#5@*HG;E7@6\G3,P$QJXM% ;&L?<4%M,)X M_&7FM42+M%F\!#'*S:9K&1DA87:2W?U*U3S)Z"*-.9+T66$/UP!J10,;^%X= M":8B:$>R+UH%1])A\1+$J.-(2-;>@2,QO%)%1S*V2#E'PHI1_PDCU:AC_XOJ MFM2%8<7H>;GM"\;BSZ@'V8Q&61$*2T4#Y/PD*&8;F!UJ,WE"PQI]PIYE7N5E M55 -+FF_P/NG*.?M\#]AKL&R@LFGK:'3N0VBW,ZA4*7/O$4PN,+[S"BCLO#< MN<6Y%IH8?*(GS6]!XR9# ]G1)_SQMT _8'U)R0H 7P)HU@#8(HR>4PSP^&J] MB>+J>O41):PY"-GL9YYTK)%E+,BV1*'CTY:@J0\OS&GRSVVXIK(#&7_.*5T0<;]K84G!'>!LZ_S$$="JYGP+_G?#GH)645'Q??\]?$SS MG)0]/$09J9TD7=L8XB.P"PJ&7]P>JB-HU=KV6N>WS1_'6SD7P?4*B$M9^%&H M/1DLC)-0EZ; W&*;//.F3N'+^K[E'X,&--#)*:A/E-^ MCEVG&P)^%.\(\/" M7>8_:&@2ELOLTA28$K?)FZG$[Y@2Y_"1Y(:$^N-OQV<.J* 3G]DGRT-6-S\^ MDRUA*3X3GQ09X7NBN43%"J;D!J$\S9-=9T2U[E-.Z7*KS!HDVO"?9^3@G6&- M>TT:"1&\!^--YRBG"8^J+>%#5T33GA6O@/O//BHDWD*\N)@<;![HS88$W:%??3B:*1_4W0CXPA<-(K9J\-@WY/Y; MN4*1MSX_=RR2*FJ[-ZO]#<.(&PR+WL .F/*D>[DTJZD"G"QP4Z1^)T&$( I/ M!3;*;N>;U'!O93E[MD)72 JCF0EQ2[2O#1>R M2R@3'9@Y*=)OIW/9M[9)Z&JZAP*#96X27K3:("]DAU"@.S)!4 MB+?0-+BW*N);VBFTU-W)-J&N&=^\:CO>(,2*"VMIUL-+AJ]"%8:588%?1PCO4>!Q ,9-HOZU8S*O6[*J0?BF&XHWZ6UW4KDCW9LP. MK5F+S.M5W2IIJ@K0X.'M85H!'L84X)9LC24^F<;$ A_5SV+F"="//TW38EZC M3UNN:=-@\GXJLJ9'W4..'1D=FLZ(1Y 'N1/(0\\!A/VS'I? 2 4WHUJWP "B MU;!O-S>M%0$-UCPAL[=-1%\S\Z*0-T=') M"4".E8RY)>H8SE%J0%!#!ZL^]@66*++QG/$9%@^HTPUT_&AR!/)N@S:6AP@[ MH2_UK"FQJ!9MIFXGY(*4/)]8S?2^TE>D)>RN"U%:BQ@7M$E$(/2;2'+!B(6R<>'T'WG-"UD;L=Y>0 M4J]OSA[VGMYU&Z&4)@H>%LXDQR680I7EKDZ?KDN^(G]@,[S*DVT,=]>"CP6D M_Z4X &L*C+H9C4.TXOMW*.M*K1JI/TMTK50X)Y=\.CQQ4JF@*T$D?RR3:# #WCR+,D_78!20IW9\6[V4ZFF+:R8CR M. RML.1B&(EA>Q@>DUUO*[S-TA>A#H<7#R/W$CSOT6&KRVH=" L(C\!>Z]5% M^J%)?3)XZAJ0UR'ICO&SET"GW.C@,/Q3^US[2X%*-Y'0&/H #OB4$HL=#GNT M9LE>:4R+K&6#!!D=EL98SPL!2NPB_-/@+!L?66H)8KQHXB1=]B90[35;.C#/ M)J]_!OVZ:K:5.PR'6BHE MDYPY59-DV5%C!1>Z^-CG=B=\+1!NU,+.JKB4DU+^MO01P776FIFBQ?A M8.>FK4*)8V<2&F9.T+X9B(?Z6I'C_@SUDEVT$RUWFRG M-N&:YO ":D7*_,0P2D3:#*OA[CICR5[;CKJ:C*TU)/[-J*;Y"+M9A+[?/=1, M4?="3SISN>Q+OE!.'](D^;[5<7NB&+HF7/*F9%@Y[5PD!GH\<*J(5B\=%Q'N MRV]05WE5I'F9QN[F.4X3X?M^ITV/K3O&T\?'@M8B@08?:U=R^+>+ UIGYSZQ M3YJ'J&%6[PP[*KH(-[=W]*%]@?QY/#EZ?.[/HZ39RSL+19B#3G')GD])$QG;333Q,AS-AS];;/ZFTN:;>:\42%6XGIDT2 MY"YY$.[>8%??3 SBDQ3C0>J6Z/T?Y)S_@V0VH*.(#INXF.%W)QES"]=12LZ; M9P@O+(JK;921_MZ^?)\\>;X55Y92\]ZR2:E&/"%5U+A))YD:.9T=0-K3UMWT MX([V W&?RKILQZ^J:<*WI;<6/?%>7K99"A#60J<5+,-+#]\B#@GIK4LOK46> M%VW7H#08+XT">D[G29<->FEM3?BV]-:PEQY]>C+LI=\Z'F'R,?J:KK?KTS7: MYM4-+"[6FPR]0 >C288Q.QRQ,$1$H*-$UHQ<$%%ZR900 #G%"QP-,JE[LT=^ MC(OWM2LCN\&*\X1_*=^*QBP^AP;51AVH&6TXD7S,S@)-9T"C9AM,G_BHN*3C@DEW(5(U8Z/B?C=),*;D@)(.JZ#J M4H)HLRD0)@5L\P1_ZN+NYB;LD@D>']1AP=WVH9GR>!M5;LHD)FEP>TL]08[Y M'$&-"90"*E L==R K$J9*'B0DM4!JH^QP@9.+6AT4*07W [HX()/I*+AM5C6 MQR]8L[' 1%>'-8@/3:G,?.P:$&^[#PM8^)^+[$&?XR*WV%%'Z+4^8MS5]&[%!UN ME5&")/-.C8Z=75-L;"HPB"J0<$H6Z=14-,R$7Y,6VX%JDS'O5E,,",F T MJ8&::CHZV7E\:R,WWIKDUTYK'\3ZC&E%PQSM%M[!YGC;DY)[T[.'M%QC*E'S MJB9R$>-0SV&3H' 3X(CX'&\].]3F#44 3HYB&[R.988I/?I@)!SI,G_ALC<7 M7NPH\_',J7W&/'V.THQ4@EZB@C9DM#".G!T-=Y5[48V3S@QN[M(=W_EH#T"P&7>(0A?08O(/%]2R]O,=K+?O_=(Z( :O8AUF\6N(U M28(;2_0ZOMB*IB";XC@0K>">HB&,=LYL2",9UEY= 92\X3__QFATXV9^I35 MU4>H.DBH\T4MD;9@6'B(P,!CCC(,>QQU::7]C$:CS B%J5F+GX/L#.O,O-^M MU_-8R' &03H9_7AP@[+&-,E.6^RP1CHN:(BCD:&-4YP+;=I#[S!IC2Z4!]RN MMU6"J-T_.LR^YCV6&DQG;O-<=H/J"P(5)P'_!Z'!WRL^#9$B3>:&+[[6V83)KD$."': M;>+M:"XSQ&5E8RO"F$&-&C#IW2NLH!=+T0U3HB%D@1.(]E46E2V0U%R!],EM)5,$DD% MOU%BO5X,6%1!9%_"!Z5NF7M-DXM]3G'@G EN^C)=51#FY!4XUK0G@4A\L'PL M(,6O& S-PJ&^O U :!% 6A(F!UT>5]X)JZY%75Q4O1Y,,N#?=QF5?I/C+A&;]A[3<,WIL53 MJ"QZK=:A;L4%NB;T@!=,RLZAA>O"I!5APGW)26%A0A]P6Q3Y,95P8[W6?9:; M%4_[*TH'^*?BXN6 B:U'Y=R=7(C^<-CSE9AR]./;"9 M"Y(/:0SS4L'C#GQ1*T_<@F%>7SGX()X']/,9C?(B%)YF\4=D- M$(SBG)];F('>59*IK$E<4'1@0[.&LE&S17@ 6M2;M?K1?5P0'&.&DUL-:8%' M!?4 DU_3ZNEL6U9H#8OW49F6URM2^)7FCZK/\F4A:G;1E@%NH]DJPPN^8,2@ MQGP$*&[2@(1C]UH&J29*I,?5X,66=23VJR@Q+K#K1F N&P%,-4WBU0RRS)%@(XH>+'J. MU(J>"9& 4NDU.+"B:^9?6N MTI',%!CU76\9IFE197:]^02C9]9V# MY1W*#+7!Z4S::^7&-T/BB?*Z8]K$%!3 (RS/[V>GF9 M(34VJ@ZQOEZML";>;:(8A\7UQX)4!KJ,PG5COY0M* D>$&$ M$?.^[U2;0DAI*0@.*;)258:@XP$,6DKH&30*UHD 4*T!L M\$:UPPN2'6)_VB,O,J3&167=B?(D0T5R2FQZ6Y55G$I"& MYDS M*,X'"E84:Q8=PA:D IX/>J-K+B0$@M5M8;,B$^K.L]#KG_PQ@CS.(5J MZ5$%8.K:(P/7B@8)B&GR,A91^],=):$A928:U"'IKC:2@(SJCL'F'XO7F[W> M+PK,"U4HG='EC41(UKB%&FJI9O#,/0>* R ML_#^@T:E JHC.IK#ZS.0*7D@648%R/ML@.V4ZRY+*ON6J5Y$.0;%&/=M%4HN M1/>'*R&GF!6D!"8L0*ZX<2SQ0$ZCEZBXI7/[$C(RD"3%R'YR]\T9FI""8O%7 5)4M!1AT5-":D>+C@MH*3$X ]0:CRG+O2$CF:R?3D" MWO=[A C2CQSL[I N,=FDU$QX MF/V?VSPI8(+CWPO2%OKE,GV&YMV5&<3S=-T$#2YB7ON.EKB:D[\<_?#37]TZV'!XTN]^:_I:[2 M)Y'F!!B1@%!IV46?8H^0:!3S]W]94Y<[<"RZNZC&Y-E-#;$=3;(E)!;WG"EK M-+/LV JQ62^=LQV/N[L-A73HA_'*Z[#6)9<7-; D1_4WHIQNA1H;.OF&%M\$ MO@ ND%WA$$,'.#ZZ'0&.T4G*KK/NZ]4'6)80-AI2T0TR*^F+T;M- :/D.O]' M5*1DT[R-*J6Y# :0::6?9N,UK[UDH!(.-\7[+,APP> MAYZ,H)TSK@ GB3_/9D2!ZQS49 %"E[:'4AN;U?U\_K]\!92O^A0T:D R8@=,;E2$) M=.]2>MD3&+=; ?P. Z HM,\;3@K;6HI25[7UE+/5E6[1&FUGG*&TXLC1)_,4H@%@ M0!TX+&?* /,D-%7HRF-0$5J\4GY"TYN?>,]1F'F#M0?-U#NL#F"W;[$>=B?M M,!]D#0EQ_%%6+T]5M>HT25+"OBBCL!/A5"6M2Z,P--JM#H.SHC?L[BQJL';N M7,GU&E6H!/^T.\QZ[+8K(3(DR\L Q=/J;DL.VOT"T&Y::YM^'B/N\+ <00+$ M%(*C/ ')+[6]!XE6R710ULI,+6LP#4WS5#L%V-999*@K@KLT@K2 D#J_@A9& M*.G MA2GFUT>%,*D?83S&,XOM#F/P_ALMENBOGB#;N!>PCJEKV?>UE"3O9L?.\D\H M2\04'DONO7^A?[S"FT9.6G6I'>]E86J>^.7 VTL"$/R]R=R'%WZ?E-9$>$X, M* H7Z7)Y 8+<\\][4ISEF5TN)>NN0D1<9^??O_#HI4'NIIFV5C>#L6_K]69V M<+USOW^KX[4S]FAC@BG&!,7EK,7@L0LFB^\&\X3%00K)S D ,]ZJ=6#9+5_S M?I<]R/N]AX&]? F-SZW@FA0\\@#;8V'=Y;;:%O!CFJ?K[9HW^B_/M_!L6Y"8 M647952&;*)^:0&+>/"Y34A8'Z!!V2/?7CW10T_@PQ9 #CKV>=E$"C!]P D*RS*O\_@OZ)]8_I8!* [A-P>[PN#;1MV\6 M8*(],E:WTBZ/ER1/'5N]RNF\ TI%8 :+L4*+)BN MRSD!I-SL^TM]PO/;/-->]8K0+SCNEVN+PHD6H: M+J$B2+M-GRWNN@)TRT*N$3FWV^^78;=[8M:RVS:7%R527;LEO0:"L]O[)UC M:%6I3=S4 &Y3Q#L\%JX;&M@+,,\>::I;9Y>;2Y*8;#/::BB+*IC<1$7U(@ZU>__2^HML MN^V9"+0DJH7+PHA63@9KC$31 8JO/2SP_4OGKR,]HET9[#QU0$9$L3319U:D M;L7:Y7BCVF%;!:J6<.41V"@P$(3ETS0U9(?T6;@(.64](IJR-G=MO,4UJ[?O M[OOV;*'8:M<=I)$,-^<>8DE0_.U5[GD]N,_2(MV6Y+@6;>"V2N/R*H]1L4&L M3X5B@T5):!JS.V0 VYFJ0C$#$35HX?8X645)=DB=E4'+J=59<%](1T1*KX[F MMTITMZ)L<#%MC9O90O4?:1FG6,'?IXC^$,-2TEX-@N6FT+&LHX92QB_>D3/KQ.8LG 1_]"-$O&O M_O4!/D;915ZE\F>NWJ\I*40/!!LO51Y)H3#%X,/@QKB+1G@0!B>S?2;*'UR4 MM9 AD#^A[']'F6OBU\TKGU^UZV4G&EIW *S+1*[-/&'<1>LR*J([[CUQ)*,8 M;0P#4-_UAF!9B34X,E!C8R&IMV!C4A!(BDFA,;V59N<(,E-@9)M M7*E:FQ0L=7V0 &O%#CE>\$00@QAC/GZ@O8;^$E%J/ EQ0J;FV#0#0E- #/QF9&46'+BM%CGOX7 ME@]1Z9:ED7&1HZ.[W)G7E+"0-!-#%$S6E@E!TZH'3?>]FYT3SO:AA']L2;]5 M3$FE_HBB]_MZ,78/* MGFP8+H&B">-LP)@0DPZ' &)ZI\=J)9N/%J#X?& 1A MA-T+?S:QB@\J4].GGJO0)5B2)2#&SU$<9970 7$PQ M@Y*@%I?%?\:+_AW_-_XO_ .Y8?W[_P=02P,$% @ 5(1'3KON(F\3-P M)EP$ !4 !O;G9O+3(P,3@Q,C,Q7W!R92YX;6SM?>MSV[B2[_=;M?^#;_;+ M;MU-8COOU,QN*7[,\5XG>B=K%(0N]G]]UXB?SHY.7)(HI6GU^__OGSYRMG'MKX ME8V7K^>N;_FV:WDO0Q2L71N%KT]>OMP-G.0*_IQ,\R?WO\\F;5V]> MO?_T[L.K-^_.WKS/_?:=9?^PGM#)S67NM]^???SP/9A M_OCAP_LWGZRSL[?.ISR[>+4)W*=%=/)O]K\G?)+Y^S[R/+0YN=[-]#].;F\O M7IU,/._DGOYR>'*/Z.21\VI+R]NA1];(#W]]D4/N^3'P7N'@Z?7YZ>F;U[M? M?)'^YF?Z9\"O/Q_\_L\WR6^???KTZ77RM]FOAF[9+Q*R9Z__Y^OM@[U 2^NE MZ]/]8M,!0O=SF/SP%MO)&G+P=5+Y&_1/+W>_]I+^Z.79^0^<%@>SD MY)< >^@>S4_HO[_?WQ2&(W0L'Z_3+4?6Y>/9^9NSU_0W7\_0RWXTV*W(T0I?\#9GV:U%>(NL9^WBY29G:G9K= MOR>^<^5';K2Y\>$R'[UA->O'>0F@]'_2#!Y>7JVW2O_2G[T M9TK^ B^7V'^(L/WC86&1:4[C*)%V1 (6(?'H#L;![H>>]8B\7U_P4GJM@/>K M)0J>"/7? OPS6I#Q5Y:_@3%=04(%MP]+R_.^Q*'KHS"$<;GWJ0KNKET/!1?D M5#_A (CAWJ=RN;N(@X %JN_5X'B!1DJL+P;(@Z> M_R\"XGCPL0H.[]&3&Y)A_.B;M>1&L?Q;N?S- HN*BH?-\A%[O(SM?227HYTL M3C?/'0I<[%R3GW&?WAH"*CFEV[P%G[G/U7"9 @$\R!4?R^5P0D9P$B0\BUO] M[7VD!K,980(*5?I-)3^'QA+]R9]U%LCDD9Y_.^+A!$ L8S%O9TT"NS"*%=B[ M$ME]MD\P$L0>ULN'$2Y<:CYF$)V/PGP' M4;GISY :97H1J8-;'(-JE.D[J*IOY1E:;T:A7MQ8>VX6!M0HSHM [7G+,J#> MCD*]"%2%\Y,!-LKV/=E>Z^)FN&D0]+^\WG^3D//F\D ((HK.!28:S ^10_XC MQ)[KD)\[7RR//FP]+!"*,N]2[=.+ +V.7F @G-:Y>'8>GKD5/B;+&(%NY_L^WNV/_[SUK4>7<^-7!22/9ILMP7VR.8*K_Z*R7[B\;[PTZKU M5[6?3#OV.V#X'D4641W.E17XY%R'$YN(BY@^>#J7:.[:+I?W"T)-\80FCN.F M8N?.*AK0=B,J M&*D$(3(Q(OL8^3:1*%#@*\DHGD)." K*3N4L7F[-@7NJ@,B_W>@;]NWTF@3A MN9Z.\JWB)WOR#Y>8DW$886)@[D#?1P3^7UG;:Q'#XGQ7DI!^^$5T<%U5/1-H-2* M;SF=!IJJMU48'MS^&K;1]@O%C$VC!0K2L<245P4!Y1<8LG"N36X8%U:X$..\ MFH9BYN\"O$)!M+DCU^W$0T/VXHI:C=\0: +U=+3L:!'Y6/Q0.=9H1>YP5\\K MZNX@(.7VJP#S7.043^G&7Y-A<+ !;I?B=XJ9_(V^HX7WR$;NFJI!"*.'WVI2 M^FQ( E$+U5].1[4U2808O762?U%!L+:\Y!X:75A!L"'W4+@;@8^@3CDC8@-4 M$-#"MCB_VAC-7,+3>9:WG MB[W<&O<@R2>8,%B.,LB,BZ$ 0U:O2-DCI.$'CP.I0UN)H6-<#%=!U&UDXG!8[B< MKH.GPGN88?/!<$G=+''R8,B7PCT1-:)7,G[_/@/16.L:_(!2#F3U7>ZCL8** MX_&LY':R_\*7 ?7)6',)#%35,R[#:@CGD<=+P/5XOX/M[-18FPH&6TWT!L-J ME%N5$3H92&?R+:V>&!=M]")W:!;#<0BR'XQC?<@> V\(RJ"-<9;#2L&K@Q$' MMB8$EV$W!(T QH[G_G1F[H,.?*,5@^P91,9*,1A$/&D4&6CFON7 0.-)IF&@ M&2O'VDJN'$@*7GL,4)3-27,,0 U^QQ[D>MXE>"]0Y-I65IQ-5N)G*?'^9X$6 MV=:6\B94II./CKZ\O73PFS",V7H)\;\CH9OU21PMR('_NR7[>3+ZID!V[C1( M=KJ3V&=W*$C8$9Q*-;DQ/J\GCT%7(,+W$G';2>O#:YT)QVS M\BHC.JK>*;<\O_M63"["B95U:&YEOQ9.Y],5"A(NPEU %BU8$Z %^>^V&G>%C-L)*7>J&1[YL8G6Y1&(T_G,^L9:$Q6D]&1Y5G" M #T!US@@6\A/7P3MS2RP_)!(;2K ?2?YDY=J%.?_Q6&TC>X#SUX5!XJ!(P,Q M/B'SW?M0>4H@'8H LHWG_8)\-(<5\:DDH1IA(N)3,>T_I3QL&0"A74U$0S)F MNB?3<6]\8F&0G\"@KZ*A.DG3 /: ; MLIJ*\G58(S]&U^2F7!8_=/5L>S&UR:EX)/]W@*:4$'G5E9CVH[Q4X.>FB0(,QS"(62EPTJ(ELK273I0VZ:%ZY&G#F*WQKO82]N M3UQW8A@LQCW6-(H8W"CT&#H?#4:G1E_@9CW&:IN<#A:C1LN#@70^>) *UB0# M9H!BN>XFP(!Y;SPPA]-IZ_HYU>9 ]Z3"'T^:$J?;%2F+Q\5.APO<@/( MON5_Y,Q;Y?7OL@-(ZA."K?I!?@ Y?D*(U01@J$Q6.RHY5AEAHR+1ZE.*D$]O M%]O?/0:,]L*F,F04E) [JKVC*GPN ]C<0FN\UFE-="9#:>"&:F,H;H:4N;7" M^) 2#H&.I*TAM(I*'XA;Y.->_#QGYY[ZIUW MT).22/74.WJ'@T1>1%'@/L81=>#/,*U'1%VJ.''KB(3QRAE1$SQW 2:V)S2V M-/^5\HZN.VLEG.&*2B+)WGJTDJ.RI#9U%V@04[+7TCS#RSB@.RPAG!ZVN_C1<^WIG.@&SL,*IRF)X30[5RJ_ MI22EXON=R.?@BN@)O$$H4=X!L@F3R4?31#O?/WPG?W$7!_:"; E:'YOKG*D; M6^9Z=3/_5D/K4#952Y;C+;QZ1H'MAK $.!'JW4PX62-5\ZTCKGJZ4BV@T?:I M''&,[3[H3+>K_E7E H*'4@.(*L^4*!8[@\^EBH)RZ[34"!18BWI"^NKEP%DO M^5AU4GDB6>AVQ3XYAOQA\ T$=$F=O>%#WMAX3D)CH/S><&6^DI8UD[AZ2'=; MB 5:.K$BI/[4N*!6@=C-\H/&,#(_"*I69N%&TH4C*P@.AY8:VK_G4N/2#E*A."^4-9(VGSK5 2[6K\Y \_82.)Z\)0] MP0R@+[4XLNT>]QBTQD8EM]RT^^_!K/GN0.,>X2_^ VCGS*=6U$>#C,F()?%& M+/-PH$).39R9PHZBJ;U]Y1]/^D%EL")#2?J)+$>I+Z&YX71.&]=?>_BGLMKC M!P,<22AN@75-!7Z)7B9Z!O)X=?"IZM>W>$66C>)C>3MX;OPY#I;I>1=Y?^,E MJ;[ )A&L-MT8A(M\!U-(P$(5#=5O_60XVA*3_(MJC;7E)<\YT845!!LBZL!1 ML9P$-4QKCX4BQ(3%X@_RS IL1DD#]AF6S)Y(LX8M[[< QZOD0AK:24M5607(77+K%POVR^$WOTQM^V6_*? M)G;DKK?-P?F!@U!5GXID(^2$M*I5Z]AQ#F*JIV-MENF.2]Z>9YB8WK1(%[VQ M$V"O<98Z6W0.@68I/(9 M>0,3^HII*U!R;6'1;*0@_$',?@LGZ]CA #1WIPO MH782 M2[F7!:]$2V0"FEJND$SO#$)G(]H/5;B')P'ST$;VW"04RG?"0Z:CK? M5N9TUR+SX:"F>WT(!T2?1AOZG!71$F'DITG9N58+54.U-R=,HDBII=[-A+.Z M9E)%2BE5J%X[-+DOMT[;>\Y]QT5&?4GXO>'+RH+N6KUO(."#26N?ZL2V V** MYQK9MYM?&;TN)H5C>C&T-M L"PYBVJ=S%Z"5Y3J[0[&K)+;MQ@G77J(C:)\X ME<8^F4?K75D@U%[*)76ZR;W!1N2^R[G!N$EU=EI@\X'1TSZI3+]M8PD$&WUP M4U6=*NDEK"*G_$HJT)Z,EZ+JGE=H%2#;3<8D_^VA;H-SC"GN2ER(M6,/_0J0?Q7!(DWK2Y7 M))?GF<4>M$QI+:'3BTB=NAGB=HO$D@R,C65L<3*: O ,KA8M!30UHGX F0E* M=71I6?1ZDT1%YY3>%6;6!3J?>3N +!%=@/->DS+(WQDKUW5!#KEV,]B-E><" MOHU:,,O<,RK24GHGH\6 Y/;;,0SE"5U#,.1TS+*,'7DRU'@$^5SW*I*AC(?V MX.6'H6AL]I0"# _> P?0_DXVC W/Q@Q18PU^J=J[&%\P@.Z"Z5@"4D/9 U^S6_2RJF@^I"6JK+O$R'-30>J>H]G'/*HWI6(J2^XVYY1GEEOK9 M6P*.2D8*FZ7W:0,K@[FZ]!5#5E-Y/<.0[4BKRG]+[M-J004Y=Y6Z##]S'Y&A M10"++\C%>H497#K>.%75W:1GR<-A')";0V@';L+P=/XE#ET?L?2:VM*:G#0Z MJI[9Q)WB1" K(B-/YV)EI,J^5IS(,Z60;L.>6771-"3Z+K=8T_G6Z6)YK/"H M2,:/I &[E"IR,K" MR]%N%PR\82+B GMD 3$UL]:$9(@(NHM+M$8>3D+<"!RWKITD CP%*#7=@$*D MS1"=BQDAYE5WB<^Q-*'!'T_)N(QI(1D$(CO>QH9S&P-M#./$XW+IIIFJ]$4B M<;\^(5_@;L9!J0?"KII'U3(M&[FU&*NGI+HP?C6$C!VA/AR!*"FRI/G2YP>[=\$=K&<)#3W5W(S(N/3_?"2\! M[2\O6C:K@5"7DH)OCABZ,H;)AVV8\IT51'"[H_SCSN7#'ENJ&X5E@VUFQ'X- MR>ZB8JFEF "15=X+K9P7(8'12*M3F<$[4RRX4H9)CX?X,41_Q62(J[6 ]Z;J M\\XER %CJOLH%H<3\_-6$U'>!K(XLEC?QRH:W<:V-,P,<^%OW*GG>5M5^LY\ MI._-FMZ=OZ&?N;$#PG!,3-ODSIMPL$G_*21FX+15/R=9@4]8H4D;R>-*B[DU MDE+NX DCLH,L;[M3Q&911T6YI4A$7XQH6EY9+9@6DX)25CS1[R&:SJ_"R%T2 MVP\4?[;_);3/PZW[5^PZ1'<(@-E 0'F%<:+TTM2J>V1[5A@FL"&KQ3K#R=CJL["MMJ^"&4#&ID_# ((:6PQ 8VLMP "L M,\$SL,RM0P4#J_'6Q1 ;N* 7OX,S"#7H@"Z"CV>T]BW8U]1 IGNO4A6#P,M+ MKJK3M@QI:C@UVU#6Z?_+0"YXJ(3[Q!J3"[BP-[07Z#UCNEM192)4NDP3+= M"'*WFS0V.H8P?U3TH@8=61M0V7(2Q>+:J%S$;/OB))')M!?,D^_^3>:7>!FH MC=Y6P$MG0O4# _6K;/42L5W03826(.]U!0&H,Y5,/BD00"R !*XR:?85+1]1 MP&UZ0$@J?P4Y'/K^X3O_A#@)J3YKY;N9!>F'7S;E0B/YQXQ,D+I$B83]9BW1 M)5Y:+LBGKV9\U0[R;.AG%W2R]C[4:PA_V20'>P9MJUU+9DPCE)-&6(&1H%3D[">B2A>D#-GWIB*K5 .65DLKU?,,Z8\CTF)(@TU$ MUC;ZU%C,88*UPO1G0!FK@>IO3:6J6OK%< !MS 5@EN.S8-@:*U^E8=O*B\;Z MFAMK,H@"+=GERWIKOQV1EO .P3HX&QLB(H(G]'V+=1\>KK$@YZ%411_G?M;" M$'K9YZ;7^1-_,Z>Z/('IAOOJ^NXR7M*>HY:WJU%%MF/6/O.6]L*0\N+4:L"Q MUH9Z4=:VUH:DI1YD^MS$<=QT3KEBVIULO8#'R=+.A/0HY&< 17+TLL##B%S M+/M:2Q[>-@H:GGJ7?=AMMEVZ#6@'MY (57+IF5G/$E/NRLE#(P%^HU>%W4BQ M3^FE#C#NA_\:"E!F=C48$Y+<#.Q]!1VT#-M;UWIT/:+ADA#R>T24)U^5>RA% MY0>IAI/MFC'/)^RDP2AW.=&+7>\;2=/+Z"E/V&SH$ N9$0G?RS@5!5KLIHA2[D["P48M7%RS@IK'.)B*'G HL, M-5/3%@.VWP!+)/QKGX;JD\+7) UP;O@(0E4GWWW@T O7I$#!=+5E73]$EN]8 M@1-^7SED.Y/??W_V$1Y8R$E0\;3HJ_UT/G'2RSM\%N7?JUZ++!F9>BYJ,K' M 8 PPHJGF1BS\"4I? 8]SM^LW;4]C-PHCLCB_@-97K0H6-BSGQ@8&@RFJUXW M),/2OGNY:N\LV&5G_ BHRIY$LP7Z:@4_4'1MV8EW JB<:RBHSH&PLA@&&C0ZG>>JMPIDJW!0 MTU"'TW5<?B-,>BV/IJ44DM#@&I[*T/@V8 MZWP.(->E6<1AF$@>0A8+OY[#S4K9X&04F<=4V (K'N)SD_"590!SP=Q@X[." M2,8&2+>]8F&!6R.#U3AQ*D,Z5'L2BL?^K4G -;I><*,SR.!L/#X_&JYTZRG, MOUNCX!$?_9F3[.TM'M3W)FU%-8YX.4N0?X=@6]XX):/FB0B+/H09G!D)EKN% MITV67V><0I(I OT/NS+S&9+(0*RNOD,%F MWG.K+-@D5=Y@2&MPF'71EVN_R.Q^\;VK9_J?2*RPC9S1NB]KTW(>BJ.:TRJU MR"FOGKAE!13AS$E1=0,!*35Z#Z4$3P<"V4.KS@9%/@HL;^([$V?I^BZ-^Z:2 M;[M4 GFB? 0[R:\2GA07.<53NO&)R"$2A1PO.OCM=@?!\UD:"'4S#6@R2RV9 M8VM5)=Z<12H#RHN%[=1BXK3,U4-.'B823EC%Y%T109%$F[8C=?D8+@DEE;7K MC<_JT7/0,:^&B(JL94JN3K'$LL^Z^.FC_TSR M3'O@B/I&%AR%Y%PE;7C"&8XL+__W]&1^P]$_4<3.+*.4?I0D",P6EK_M=B+= M9:6&R3[X 45FEHK,:QQL?T1_[ZP7F%=P=JQ YSOX] +?(D,#:>I=V1H,6!&H MD8[J@FO"':LU]YK>#0?UBA:_&WNW&]B[O7"&IH+U56N(C*WGQ];S8^OYL?7\ M4#S[8^OY4H#&UO/'VA"=0\J@KGV@!J&'$W%-?DAF60&Y?*WA_( M*UX6&/;&)>+T!_OFE[1L&=YH,#2[>'*_MMP@J:"2"S_)"0%)#^F@47KX/,[' M?\0O+ZT(93.5ZOV5S9H.;_IC M\WP>]^>3L3@)PWB93HX&4= ;%:TL#'K,5LE%U\\151NBC/5[-_QQ'2!TXQ.1 M243\/=D+6G8G/S/'!.=N)_R./4(F*2C1):!5[!PCI)J@C\KJ43**GEX71]3*Z7DQS MO7RUGMUEO.R5!R;CZ>C!=?W^@;OCZ=C![16JQP5G^16T:U'0P)4! 'X;L<4(Z7+>W\ P.XQU4XG4K6O4[#^YSA)"T+-AJ MRF->;$UX:BP>E1Y38T+C'>#:Z85W6WP:47*X,3.)N *%Y\ MAY55*5_GR_")#"$'3YZCJJ/HPW-CK;@C6IO*",2WQD:Z'>WJ9*\TK#FDL0&\ MQ[M(N[=*UK+.V!#%(UBD^GC>LS-CXZR/=&T.9-S9V]%,Z-D2[4NXL_>CK0!? M(L61\614OT27C+^)(X6Y)S]S592="9Y2F/%52D55YM@'D#V MJAA(A5.E]:VT"\5"5/02^\JU"FR8'JH4S@D @[YR5"^LE1M97F+2T.9IP1K1 MXE?7<43XN2%V*JU%R1WS!2>L.DB)LD)'0\YE'-#>Z(EUEQZY;^AG\E>PH$]. MBJI[9C"DVVC%6C+=K$VR8V0NS3Y!W2N35QS,BWB)[X[H&-Z1UUZAW&[0S"]P[S&/X+I'>:F%G!* M5^[[-8/,N$,D:-M4>$R*(O>MD4#5.ILPES^,E14U]@@VNQ0QE^=3:[>;XSAZ MU9[KXO%[;R18C*H2,92!^EN][ZDUG #1-GJ! #S=@< M&?&=51K6^VD\@KP1@EFNS^EP5:1@U&@&W;FA;4#W&K^G[5#+NL'3GO(<3>-5 M!EEWP&L/([5UH@",4!#.C$MG=N,3[N+$E[C?D#=+B]NES25M?D&-,[KF$!KN M\2VF-\'T&DEN2BR!$_].5I%[QDUD^EHHF=9F^XJ=U&>5[,C0#MP$:[*Q:1:K MGA+*7'ST%<3=XF_MJ#4YT_1Z311=LEVU -C(0V_!P]NS?7#V">]SY%)+0<\> MY.2DKT VRL[?D_[M.\&I!5(P3U#Q+6*D?\=DGLFV='+5T3OTX_ =,#20#)[W^4AD M#"@^_' X8>D]#>(?>+1\A7!(:HJF4O/:70/P$2"J@&4<0T\FC&@W:B3'S(P, M!U@50<+=3_,G5C))1K;S*4Y])>N8(ZMXBELS#YZ8LO>A'C:A:2B%SU2;-PL7 MS:^>D1U'1#Q.YW/71@ YQD4&*FQO?">V$7/S<'A*@9*WQ0C@Y%B*S%?DN+;E M@>%MHJ!X<\S?8\OYPHT72EH5:X@MW-<-7?D3L=?A!!)/6/57H MH:T@H)CMLIUZ__ =?H ;"'5]AZTL0I_J'S)!^J0BW-M+S?B*06-# [?JWH=C M?N.8WSCF-PJ$/>Z=HP$D-I:+'$@!5B%!.H!\2*4:$'/K^3&7 M1-(R[^@A'(=I:L;JC'*O=K-U7>Z"9X 9JR8D )9[EAE (J0,P/*/=2P5LE26CL(]1:>[PPCYGYCF%Q.K9G)GGLQ&K<$20 M, T(/O%Z&.K'DN2,VQMJ:A6 ;-6#U#55( M@WBXAUYV?@K#U%B-TP-!NI\"E?6A?&MPSU#UN'-F\S&TI6NM0:'=E'Z:X?QN MK%>C.D^:83W8B72RO83.<4 M6LO?/)2\1D_LR%W3B#ZN8B*[WY94\$47@SVL\J)\ZD>?+\S1.#V_8IVG$C?R M^Z?GGGKGW8?!"T\U9[X>R>+ .#[:A2E>Y(YD;_(85-=@2HTI*+@AI<+&6#)A+)DP MEDP +%&')1.8 SWUD^\V2))!1O=,&(4'(3NA2(F%MB-U^= F":6QA,-8PF$L MX= ULF,)!U.0!INL \@'E]P2T-PLWAY$AU:&V9_*#Z1;I8VM(BN(C@'\3MPR M#/[AQM;I]R&R;-OA]L_L+A+]5&)XY*<4=1\]T5O1(' 7>N]AV,N+2Q\@]J)O MF@K;JZ9:]LH?%P#\G,_:DDHW.4?;1T(,#%L?8^^K/3@QX)BPL3-M+R,I!U#C MH ?+ @L^9FMBK&^S!VL"C]9GQ2\4:?Y]>ZR33"'ZDRU$]#ZP7'EX@])?O(L# M>T& IIY.E=V?)?+0QWP?";/K:5S.V(2V16V)3-Y,PC!>IOLC2Q9%P?(,#)\B M+KJ.1*E:^5P>LI:=5AA/6X3AC4^D0E+$F>@,_XD_ZE+)L-JFG4E&3?/='Z^W MFYYH&AS[T36QK[Y:P0\4W06NC7;L4T-&SV'@X:.O(&X+OQ55!UGYG6[6@F S M$]H.VY:5R9*N*! '52/W?.]D9ES\F&F%>UV'KY$'U9'&>+G$?F+!7E@K-[*\ M=/?>$SL[6".'&%]I+<$;8E30" A0%#*<>%]-O*W5/XVC,+)\A^C1OSV'_.H9!;8;TIL YYSTF-MMV.LKY/5%\C2 M6L] 7Q7)(==:=$?9L,< 46J8PT^IM''["E)W:7G0Y#NSTIPJ'7G W*9&.D-J M&=QI/VDY4QB['K>84$-^%%_'[\E3@)(_M6OK?4!&,9KBR72:T^!VPT%7N_C= MF 0W]@T>D\X$E\J8$D $EB\%Z4QYHLB$D>8U]>OF TM"GU]RT M-FUM3N7'(!D (7>KXW-C@U ;%$&CY6Z8C=Q4 M!58W8KBW9R7)+@H+QNP?NH5N_(CHOM"U$]'253;$ 1<]C[K.N76*K.L,P*YD MHN_=DHKKC\)"O][N\.3CI^>@]GMG]AZ^:H?Y;GO$F#:<);,6== -\RFLI:J=MS5,MKU,C3MJMKJA-UM=@A;74-L MK,SN/;0YM:ZQ>UWUX#V'*[?L^N$Z&%R714#]"_1A&SF7,7-1IYZI?(&YW=:' M)0 +4._Y+FE4>+W2OKV'LZC)?@MPJ*=80=WP/8>L7W)J;-C7BUQ(!0W[Y.\4 MEO,D_3VY7Q7O^[<:I8*.K8>Q$1/]6PD.G9VMRYG![5(4K(R M3%#0P! M:E77'98U9G2KFOZM2,E]/5N+M\:&?_5O';B=3VQUI"OOP1M3,OVO"I.-^I,K MT+]SU/)A8@ ]&GMXKH"/> K30\:C)>U-6V$4^6C220GKT!IN.JY.8P03ZSPH MW608O&DG)4*/]2 -%C"BSJ MBR*#ZXJ.(@#UQ?R-,:-CD..@9%%_X;H5Z5,D8S3%@&POC? &/7L?JNY30\8* MY^3.._&=!Q2L79OLF>G\VO4MWW:IXS",@C@QT6:$^;#\KP3Z]4@=5S%()4-# M&[Q4DM#7ZT78!F_3&:;MH&-LMIFQV?)VR+"ZX$@ZQ)A#,@V@?4Z38,>J%-8 M^O HL2QPI9TTK+X]\L6 #).:Q3Z;*XKEW7,TI2JIBD/O2PA&/U>D/EWIC;%A M2HI6HTUBS%N#$V/ZN?E+?;HJ.MF,ZR$I64E^:'^? HYZORJ\H?S2+PNC*I?\ M^,PB^D<36.\J":=>F'M?[.="@8.36'2_LJV;/<4/:=N> ]NU MGP9)S\*"E,C^,MS^;0@"37 /=.N:+7 /ZU] C"VPR#*L4S^M,\N^=&?VTY/ M_ $))1^I8(OL5SA;Q8\4L'5/SR*,J<(GJECBC3O8^V ,=AF#7085[%+9SAP6 MOG)(1O$44A-*),!D_\LNKS,5LR@/ #G$>%@A'95;=0S2&(,TQB"-(T.4\V#O MV6?%8WQN$C#EIBLNL9E9U4CCQ'[5E0*7WF<8$,8Y/)N *-XW&1#&2F"@(5#A M+V! &2M8N;M:"GJ*&(3&!N>H;\#:QD.IHI)MKPIM$"R7V$]^?D_&#M;(N<;! M=4R?PFAP$[&KD*07!/A0/7Q( $Q"L9>7,7)AK=S(\M+(LTJN0!Y@./$QEX\W ME^_PZ"3MT&]\)[911FGR%*#D3_P.3"XR4+:NR.'#&Y0>A:R7O6?YLY]XML!Q M:)%;FDN.'?*!G I0!C.?G-D;LD']R%WO$Y_]1-X:X% 'DU1\)NC8WZPE@CM_ M][_4Q"C49UO\;GPO&-\+^OQ>4"&#[E"01!H0B9&H"Z)#(V+P$_,S$7S??3<* M@3((0E(QTF5#WS]\AY^B!D*JGSCRNBB],,"G4$.D:^NH,OXM3< BDR/'6ER? MJ!E?,6AL:*!HV/MPS)8?L^7';/DQ6[ZS--D]>32 Y]=RT2TE(+Q.(0W@\56I M)8&Y;*4A/,AJ0KG!J#;X<5,7TN#[V !>Q?I0&L:H<(7^1!V=&RLHNHHZ.C:EA55"DIPD>"UKPUS@&FK$R MK &TIL=6AI"QA_!X"H"]-7:7JLG4%@@"45'?J,-PJ0OL>=8CICU.UXA.FRS) MXA*MD8=7"88^09"HEQ!E)U]B#K:BT3L/JI(]+\6Q"P&V$7+":W+BMFQ=(WH( M;$38!Q7A;R0%?EJVR,)$^V!=QFE37O[GY 8RJO.5<1A-Y[]A[+"[%PH?L <" MMXZ*\C?P-?)C1)=U%T'ZAQLM+N(PPDL47#W;7DSK54S"$)'_$W7W#'L9%R"O M?,UR9SBOX@GVW[!O5_QU%GK<'M(H2RRYO$]/5H5:Q M:, >C*CJZ")W2?V=7XE$"%S+"W<;#AX,T41)^08]/"G$_''#Z9R&VY/C H]R MX*?9^>2@(0V\%*$G9D(,0*]L8Y/#F@BN,&<#3.9SUW,3I5,XY\ #)75,Q2NY M5;KPX[7W(71=+HG-L2]STLN]PH61.RATRO\=^TCK=.4-V/;47;OSQ&\3>Y'[ M3S)B-JZ@RA*F+VDB._HYL+"P_FTUAOKHRA1(W\E?D)AALY/;,[Q]@R27\FFT M('=E^D@!5W&2!NPO+%\V(A%_D@;4HTS8]4=8K1R24% [B%R'G=B.\MZF$_Q)[KI&+?=^YR M#K+YF)7&E\K;/X,*-)5^Z'&=+#,XZ+11^.-&=61P MX"B?)L<<)L80XCZ5GD[)UNH NKD7B3D+$'^'C6 %VY5UPLXU)O<*FC3E!O M]@NQ8#7C]*-:Q.7Y& <0JJ1F">1ZM5GW(^,"$44MQ4-HQAW:2BRW>A!3V/BI M+ZN@QTKG?7(=0&P[\#T;!.*!*6UN;R5PS /F#]=@_8Z,TTMJA2\LO(>U*S+V MPJ=+NLH,%&/+8NR-4$E$7\$C(A#%R'#7$$]N)NYU<;$[>,_>2F^UND;!(S8: M8*[0Z0SA=^,&%MS C5'S&<;O-3P]Z4@Z62[=:(<@E95$*B+?=I'4W)(V@_0@ MA42(?<7A-\A*GK7N*0K>U3--Q *%3%004!WRC7S+CVZ6JP"OTX,+"O,N^1H: MY9?,FU99SI.YCNE^^;))_C)+XN6.Z@/1A#(\72$JS_RGA%#XE>R_A;>AV75T MZ0 K#Z$FA&JZE>YVG4HOB;J"05A*H#4K27/O=LSD2*@.JZ/V*"JN$BT/3R\P M/CCFAX<:.$PVDWD).6\1H2*6!F/CC)*1\9Q)PB(!P4W.3G@90_]+R[\'2D.V428"L[P2, M(%5E.WN87Q1RD%(=!%B4QM-Y>F S&R-*A5"8.-8>B-%C.5/_=RMPJ2?BGE.D M21Q,CNZ2I[=:Z:P:N^[PCM#$'Q\Q(=$V(50=@5R#\H^'T\&VI_U^RYH_-3!5 M^.18&NO6;6FJ76E%!QP'U#.=>\K^!U%OY,),SM 5;9NSN28V\W2>2"8BA1[^ MBJT 76,<61 ,%0W<9NII&R"B<>1/CI>T#GLA[X,1RA&JH]+!!*"Y/-4T)&HK M[G0)3D+*$XHK&6!.%Y$,!R#A;OV8(AA@[B4T./D =AHPSUDT.)^ 6Y@U #6 MY * XL(MU.X ,@\$$91CE;& :N."1\"B;VRR7-=DV;CPBK&W<,MNTZ-$KG(; M&5Q"&BQ5 0X_@PLCPWVHF-^7RW SKA>U$&X2??@L]\:X**$66Y+C+8C5FST; M@=N_+AX\[#&TI(?['25:G(^X+._(.%=$"]B:W^49;J/"8+E8=6$6++=J-$V* MXJPY9H;E]PS.Q]!P2BNBIAA@@_-' P#+8MX87(.[;4&O#0>ABPP[X]P:+;<: M;X0J2[\;;9!"VF*=O?9Q-',/WY .PLNUIAQVFCZ1=BO9>AHGOA];7E& [?H> MRTZI$!RXSVD6T"EI#=HL,)M8J/V0(%R)I'L'*O L3[,=T; MGSX[TII"H-@?$>J]F3". X439M3[,N$9&57A$N?)]V;*/['""6?$^S'=BS@( M$%]R@"CE,6Q.^3.F<-B%JG$ND UR9OXQ6C>N^7L3@W546RUAS8,I7UGAR/(T^ZSND6=% MM#-O$$FM\@&FV[G'B9]C;2T]BRQ!K/@:(LH;)&7#;7*%=B9+'),C-)WG?@:; M$(!L-U,\]("+S^N6(TM8SF0>;.1;1(1=XP#95BC0;K.*@B;&O_OA"MGNW$4. M/*&PAHAJ]G>M:'8L0),)*PB &SD'[M(*-O^(EY9_@3PO;=2^K94,S#OEH@5E M<%<;?@!KQ1[&RR&J701KNE'X^-S30V-JM:5FL96H'U0"Q%G\SU MQK>A2UM)H!:O< =8B.Q73WC]VD%NBA?YCWVHR(_^O"(F;;3A7\S#;^3R M+"\=@'?52C^#+MCOQ& C4$=?7!QN,0>N6 T% \@8)S6-UHU(%\_#K[LQQ\(OF_S?P/MN\E/5UDV1CZD6#1-! W2TKB*O M&LVTNBW_S3G3TB:%H#4SN!2 G.."Q43 (H&",C9"C '5#Z@1IMBF-H?0*4 M#K!JC#>#,YBEB;92$]S@0@!U-Q5<=DEB^9#&ZIV$U$D+"Q.@W'E@&(1G MM2\B^7YD-V$86^2:3@M1+)?8?XBP_0/R),)!3$,.RW:LAP4YLB%E@RT;;[9* M*0G53W+%/7$H-WA>W2II@)OP1+,%^FH%/U!T;=FN1P0/\.FYAH)J)"UJ%R0K M^,U:HH(J$HCGXJ"F86NXCDMN8CEFP,%=U43T[FR!<,!R GK9%FLO4$-$/_LB M6Z:4A&;6P<$'I=_K95HHIJ":1J=WK::9X2;HAQ B4+=G:P :4H^ )I%4#]. MGOB;54\U5 -ZW(>&UL4$L! A0#% @ M5(1'3HC>VYE@5@ .#P% !4 ( !CB4! &]N=F\M,C Q.#$R M,S%?;&%B+GAM;%!+ 0(4 Q0 ( %2$1TZ[[B)O$S< "9